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                                           Abstract 
 
1. Introduction  
The development of novel therapies for chronic hepatitis C virus (HCV) 
infection could potentially be streamlined by using patient-derived model 
systems in which drugs can be tested on patient derived viral strains prior to 
embarking upon clinical trials.  Such models have been hampered by 
difficulties in maintaining primary human hepatocytes (PHHs) from infected 
individuals in culture and by the lack of a replication model system for patient 
derived virus. Most in vitro models to date do not comprise individual patient 
virus from all strains of HCV and hence novel antivirals cannot be tested on 
them. The aim of this research was to develop novel models of replication of 
HCV that will allow new drugs to be tested against all viral genotypes. We 
have examined two models - an ex vivo liver biopsy model and an HCV 
monocyte-hepatocyte fusion model. 
2. Methods 
Liver biopsy fragments from patients with chronic HCV infection were studied 
to determine whether or not they could be used as a replication model. 
Biopsy fragments were incubated with DMEM alone or with antiviral drugs for 
24h and 48h and viral replication assayed by RT-PCR for HCV RNA.  Similar 
experiments were done with isolated primary human hepatocytes (PHHs) 
from patients with chronic HCV infection which were then compared with liver 
biopsy fragments. Various methods were used to extend the longevity of 
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PHHs. In later experiments we examined a novel model in which CD14 
positive monocytes derived from patients with active HCV infection were 
fused with different liver cell lines in order to observe HCV replication. In this 
later model viral replication was observed and drug validation experiments 
were performed examining the effect of telaprevir on infected hepatocytes 
from genotype 1 and genotype 3 patients. 
3. Results 
Viral replication was observed in both models. The mean viral RNA 
concentration in biopsies from patients with genotype 1 HCV was significantly 
lower after 24 hours’ incubation with telaprevir compared to unsupplemented 
medium (P=0.0015).  Telaprevir did not have an effect on HCV RNA levels in 
biopsies from patients with genotypes 2 or 3 HCV. Viability of PHHs was 
reduced compared to intact biopsy fragments.  
In the HCV-replication fusion model, HCV expression was higher in fused 
cells compared to unfused monocytes (p=0.0007). Optimal fusion conditions 
were achieved by using monocytes and Huh 7.5s in a 1:1 ratio and using 3 
minutes incubation in PEG with pH of 7.  HCV expression was highest during 
the first 7 days in fused cells and there was a significant decline in HCV RNA 
during subsequent days (p=0.002). Viral protein production was observed in 
fused cells by indirect immunofluorescence, which confirmed viral replication. 
HCV was successfully transferred to Huh7.5 cells using the monocyte 
‘capture-fusion’ approach. Telaprevir showed greater antiviral efficacy in 
fused/infected cells with genotype 1 compared to those with genotype 3 
strain of HCV. Interferon’s activity was compromised by transfecting Huh 7.5 
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cells with PIV5 plasmid. This however did not increase HCV expression in 
these cells after fusion with CD14 positive monocytes.  
4. Conclusion 
Fragments of tissue from human liver biopsies can be maintained in tissue 
culture for at least 24 hours. Our data demonstrates the principle that antiviral 
agents can be tested ex vivo using surplus liver biopsy material and that the 
results reflect the findings of clinical studies in that telaprevir has efficacy in 
genotype 1 but not genotype 2 or 3 HCV. Moreover, monocytes may act as 
sanctuary sites for HCV virions and could be used to transfer virus to 
hepatocytes in vitro. The HCV fusion model can be used to test drug 
sensitivities for different genotypes as well as individual patient sensitivity to 
antiviral agents. Further analysis of the clinical utility of these model systems 
is indicated. 
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1.1. Introduction to hepatitis C infection 
Infection with the hepatitis C virus (HCV) is emerging as a global health 
problem. It affects 130-185 million people worldwide and causes significant 
morbidity and mortality (Shepard, Finelli et al. 2005, Mohd Hanafiah, Groeger 
et al. 2013). It can lead to acute or chronic hepatitis, steatosis, cirrhosis, liver 
failure and hepatocellular carcinoma. In addition, HCV is implicated in 
extrahepatic sequelae like lymphoproliferative diseases and neurological 
defects (Ghinoi, Mascia et al. 2004, Monaco, Ferrari et al. 2012). Thus far 
there is no vaccine available to prevent HCV infection. Current therapy 
against hepatitis C1 is non-specific, costly, prolonged, not suitable for 
everyone, poorly tolerated and often ineffective with only 50-60% patients 
achieving a sustained virological response (SVR) at the end of this regime 
(D'Souza and Foster 2004). Out of the 6 major genotypes of the HCV, 
genotype 1, 2 and 3 are most prevalent globally (Simmonds, Alberti et al. 
1994). HCV genotype 1 is least responsive to interferon alfa and ribavirin 
therapy while genotype 3 has a higher relapse rate. Therefore, extensive 
research is underway to develop novel drugs against hepatitis C. Over the 
last few years two of these new agents, i.e.; telaprevir and boceprevir have 
been licensed and when combined with pegylated interferon and ribavirin 
they increase the proportion of people with genotype 1 HCV who respond to 
therapy. Other, more potent agents are at an advanced stage of 
development. The clinical introduction of new therapies for chronic HCV is 
hampered, at least in part, by the absence of a cell replication model for all 
                                                             
1
 At the time this work was initiated the standard of care for patients with hepatitis C was Pegylated interferon and ribavirin 
and here we describe conditions at the commencement of this work with updates of possible new agents listed where 
appropriate 
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viral strains of hepatitis C. The aim of this research was to develop novel 
replication models for HCV that will allow new drugs to be tested against all 
viral genotypes.  
1.2. Overview of hepatitis C virus 
1.2.1. Historical introduction 
It is difficult to identify the origin of HCV since there are no stored blood 
samples older than 50 years to test for the presence of the virus. Since blood 
to blood contact is the main source of transmission, there is a debate as to 
whether the viral transmission has increased in the past hundred years 
during which time the virus has spread and evolved (Smith, Pathirana et al. 
1997). However, it is unlikely that the origin of HCV will ever be formally 
proven and the historical transmission rates are likely to remain purely 
conjectural.  
In the post world war II years it was noted that the proportion of patients 
receiving a blood transfusion developed hepatitis that appeared to persist. 
The infection was not caused by hepatitis A or hepatitis B and was therefore 
named non-A non-B hepatitis (NANBH). A putative cause for NANBH was 
identified in 1989 by antibody screening of a phage display library and was 
given the name hepatitis C virus (Choo, Kuo et al. 1989). Subsequent studies 
showed that this virus was responsible for most cases of NANBH.  
Developments in diagnostics led to the evolution of effective tests and by 
1992 blood tests that effectively eliminated the chances of the presence of 
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HCV from the blood transfusion supplies were developed (Fujiyama, Kawano 
et al. 1992). However, accurate Identification of HCV was challenging 
because of genetic heterogeneity, low titres in blood and the natural history 
of infection which involved a lengthy asymptomatic stage (Feitelson MA 
(2006) Hepatitis C Virus From Laboratory to Clinic. Cambridge University 
Press.). Sequence comparison with the RNA viruses showed that HCV 
encodes a conserved serine-like protease domain, a RNA polymerase 
domain and a helicase domain (Choo et al. 1991) and was classed as a 
Flavivirus. 
 1.2.2. Taxonomy, structure and biology 
HCV is a positive-sense RNA virus classified in the Flaviviridae family and is 
the sole member of genus Hepacivirus (Simmonds, Alberti et al. 1994). It is 
detected in serum in cases of both acute and chronic infection and is closely 
related to yellow fever virus and dengue virus (Choo, Kuo et al. 1989). It is a 
hepatotropic, double-shelled, enveloped, virus, 50 to 60nm in diameter. It is 
believed to replicate mainly in the cytoplasm of hepatocytes while the 
replication in extrahepatic sites is hugely debated, (reviewed in Revie and 
Salahuddin 2011). It is transmitted from cell to cell and in the infected liver 
approximately 1010-1012 virus particles are produced which are not believed 
to be directly cytopathic (Choo, Kuo et al. 1989, Choo, Richman et al. 1991). 
1.2.2.1. Non-translated regions 
The hepatitis C viral genome is 9.6kb long. It contains highly structured and 
conserved 5’ and 3’ untranslated regions (5’ and 3’ UTRs) which regulate 
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genomic duplication and initiate translation and flank a larger open reading 
frame (ORF). The 5’ UTR is relatively conserved and is approximately 341 
nucleotides (nt) in length. It consists of four major structural domains. Domain 
I though not a part of IRES (internal ribosomal entry site) is important for 
replication (Tsukiyama-Kohara, Iizuka et al. 1992). Domain II and III are the 
secondary structures formed by the HCV IRES. They contain elements which 
are necessary for initiation of translation (Brown, Zhang et al. 1992). Domain 
IV contains the initiation codon (Hellen and Sarnow 2001). 3’ un-translated 
region varies in length from 200 to 235nt and has a variable region, a poly 
U/UC stretch and a 98nt long conserved region (Tanaka, Kato et al. 1995, 
reviewed in Shi and Lai 2006). 
1.2.2.2. Viral proteins (structural and non-structural) 
The ORF encodes a 3000-3030 amino acids long polyprotein which is 
cleaved co- and post-translationally into 10 distinct structural and non-
structural viral proteins. Structural proteins constitute the building blocks of 
the virus and are cleaved by the host proteases. They comprise core (C) and 
envelope proteins which are present at the amino-terminal. E1 (has 6 
glycosylation sites) and E2 (11 glycosylation sites) are glycoproteins which 
are anchored in a lipid bilayer surrounding the nucleocapsid formed by the 
core protein and genomic RNA. Both core and envelope proteins are 
required for virion formation (Vassilaki, Friebe et al. 2008). E2 engages CD81 
on host cell surface during viral entry process (Falkowska, Kajumo et al. 
2007). Wakita et al. incubated the cell culture adapted viral strain JFH-1 with 
Huh7.5 cells with and without CD81 antibodies and observed that after 48 
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hours CD81 antibodies reduced the number of infected cells and HCV RNA 
within the cells, hence confirming the role of CD81 as a viral entry receptor 
(reviewed in Wakita, Pietschmann et al. 2005). However, other viral receptors 
have subsequently been identified and have a role in the entry process 
(discussed in section 1.8.1.2). At the N-terminus extremity, E2 contains a 
highly variable region of HCV genome called the hypervariable region (HVR-
1) which is 27 amino acids in length (Weiner, Christopherson et al. 1991).  
A 16 KDa protein called ARFP, (alternative open reading frame protein), F 
(for frame-shift) or +1 Core (indicating its position) formed by the frame-shift 
of core protein through an open reading frame overlapping core gene at +1 
nucleotide, was identified for the first time in 1998 by Walewski et al. 
(Walewski, Keller et al. 2001). Antibodies against this protein have been 
identified and it is believed to be formed during the viral replication process 
but its exact role remains unclear. Furthermore, it is reported that this protein 
does not have a role in viral replication as halting its production does not 
have any negative effect on viral replication (Vassilaki and Mavromara 2009) 
and it is unclear whether this is an artefact or a viral protein of unknown 
function. 
P7 is a 63-residue peptide that does not form part of HCV virion and is also 
cleaved by the host proteases (Reed and Rice 1998). It has ionic channel 
activity within lipid bilayer membranes (Carrasco 1995). In addition, p7 has a 
role in the assembly, release and production of infectious hepatitis C virions 
from liver cells (Steinmann, Penin et al. 2007, Jones, Murray et al. 2007). 
Mutations in the specific p7 sequence led to the loss of ion channel activity 
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(Murray, Jones et al. 2007). Moreover, certain drugs can inhibit its activity 
and show antiviral function (Pavlovic, Neville et al. 2003). The junctions 
between these proteins (C/E1, E1/E2, E2/p7 and p7/NS2) are cleaved by 
endoplasmic reticulum (ER) resident host signal peptidases (Wu 2001). 
The non-structural region of hepatitis C virus comprises of proteins termed 
as NS2, NS3, NS4A, NS4B, NS5A and NS5B, which are cleaved from the 
polyprotein by the viral proteases (NS2/3 autoprotease and NS3/4A 
protease) and are functionally categorised as proteases (NS2, NS3 and 
NS4A), helicases (NS3) or RNA-dependent RNA polymerase (NS5B). This 
non-structural region plays a critical role in viral replication. NS2 and NS3 
carry out auto-catalytic cleavage and thereby separate the NS2 protein from 
NS3. The NS2/NS3 junction cleavage is carried out between the carboxy 
NS2 terminal end and the amino NS3 end and is independent of the NS3 
protease (Phan, Beran et al. 2009, Schregel, Jacobi et al. 2009).  
NS3 has a diverse set of functions. It has protease activity in conjunction with 
NS4A, as well as RNA helicase and nucleotide triphosphatase (NTPase) 
activity. It thus plays a key role in HCV replication and morphogenesis 
(Kwong, Kim et al. 2000, Locatelli, Gosselin et al. 2001). After being cleaved 
from NS2, NS3 in conjunction with NS4A (NS3/4A serine protease) mediates 
successive proteolysis of NS3/NS4A, NS4A/NS4B, NS4B/NS5A and 
NS5A/NS5B junctions and play an active role in HCV non-structural protein 
maturation (De Francesco and Steinkuhler 2000). NS3 is also proposed to 
interfere in some cellular signal pathways and over rides normal cellular 
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defence functions making the cell more vulnerable to infection (Jouan, 
Melancon et al. 2010).  
The main function of NS4 is to act as a co-factor for NS3 mediated 
proteolysis of non-structural viral polypeptide (reviewed in Tu, Ziemann et al. 
2010).  It also anchors NS3 to endoplasmic reticulum (ER) and  plays a 
pivotal role in formation of the membrane associated replication complex 
(Lundin, Monne et al. 2003).  
NS5 is processed into two proteins NS5A and NS5B. NS5A is a 
hyperphosphorylated protein and its role in determining sensitivity to IFN has 
been discussed through a region called interferon sensitivity determining 
region (reviewed in Gale, Korth et al. 1998, Lauer and Walker 2001). 
However, in a study of HCV-1b NS5A quasispecies no NS5A related 
sequence showed resistance or sensitivity to IFN (Pawlotsky, Germanidis et 
al. 1998). NS5A has been implicated in replication and is thought to act as an 
anchoring protein, locking the replication complex onto the endoplasmic 
reticulum (Enomoto, Sakuma et al. 1995). NS5B is a RNA-dependent RNA-
polymerase (RdRp) which does not have 3-5 exonuclease proofreading 
activity. This lack of proof reading activity renders HCV replication error 
prone and subject to mutations and hence evolution of different viral 
subtypes (Lohmann, Roos et al. 2000). The virions of HCV associate with 
serum low density and very low density lipoproteins. This association can 
create a wide range of viral particles with variable buoyant densities. Viruses 
with lowest density are most infective (Yamamoto, Aizaki et al. 2011). 
However, this variability has made it difficult to obtain precise structural 
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information about this virus (reviewed in Rice 2011). Host cells which permit 
HCVpp (pseudotype particles that display functional E1 E2 glycoprotein 
complexes) entry and are of hepatic origin express low density lipoprotein 
receptor (LDLr), CD81 and scavenger receptor class B type I (SR-BI). 
Though other cell types also express these receptors but are either not 
permissive or poorly permissive to HCVpp entry and infection. 
 
 
Figure 1.1: Open reading frame (of HCV genome) encoded proteins and their 
functions:  Consisting of two regions, 1. Structural (comprising of core (C) 
and envelop proteins E1 and E2) and 2. Non-structural region (composed of 
NS2, NS3, NS4A, NS4B, NS5A and NS5B). 
1.2.3. Life cycle of hepatitis C virus 
HCV interacts with a number of host factors for completion of its life cycle. 
The complete HCV life cycle was studied in detail after the advent of JFH1, a 
unique viral strain that infects and completes a full replication cycle in 
cultured hepatocytes (Lindenbach, Evans et al. 2005). During its replication 
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cycle HCV undergoes various stages which encompass viral attachment, 
ingress into host cells and fusion, viral RNA translation, post-translational 
processing, replication, and viral assembly and release. 
The early stages of viral life cycle involve attachment of HCV to the host cell 
surface receptors and ingress into the host cell through receptor mediated 
endocytosis. The viral and host factors which interact together to carry out 
this process are envelope glycoproteins E1 and E2 of HCV and host cellular 
molecules including glycosaminoglycans, tetraspanin CD81, scavenger 
receptor B type 1, claudin-1, dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin (DC-SIGN or CD209), liver/lymph node-
specific intercellular adhesion molecule-3 (ICAM-3)-grabbing integrin (L-
SIGN or CD209L), low density lipoprotein receptor and asialoglycoprotein 
receptor (reviewed in Pawlotsky, Chevaliez et al. 2007). The precise details 
of how receptor engagement leads to internalisation and release of viral 
nucleic acid remain elusive. It is suggested that HCV enters a cell by clathrin-
mediated endocytosis after which viral envelop uncoating and release of the 
single stranded HCV genome (messenger sense viral RNA) into host cell 
cytoplasm takes place. This is followed by translation of HCV proteins via the 
IRES locus at the 5'UTR region. Viral proteins and genomic RNA template 
form viral replication complexes which assemble in the membranous web 
formed by NS5B protein on endoplasmic reticulum (ER). NS5B protein then 
acts as an enzyme (RdRp) which produces anti-genomic strand which 
subsequently produces new genomic strands. Genomic strands either 
translate more viral proteins, form anti-genomic RNA or get packaged into 
new viral particles which egress out of the cell through the secretory pathway 
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(reviewed in Weber, Wagner et al. 2006). Egger et al. observed that HCV 
proteins induce distinct alterations to the ER membranes producing a 
membranous web which is vital for HCV proliferation (Egger, Wolk et al. 
2002). During HCV RNA replication double-stranded (ds) RNA intermediates 
are produced. The dsRNA acts as pathogen associated molecular patterns 
(PAMPs) which binds with many innate immune receptors called pathogen 
recognition receptors (PRRs) e.g.; RIG-1 and mda-5 (discussed later) 
(reviewed in Li and Lemon 2013). 
The virus genetic material is translated by host ribosomes encoding a long 
open reading frame and polyprotein formation which is then processed by 
host and viral proteases into the ten individual gene products (discussed 
earlier) and subsequent production of a replication complex. HCV genomic 
replication takes place through a full-length negative-stranded intermediate 
which serves as a template for de novo production of positive stranded RNA. 
The synthesis of these RNAs takes place by viral RdRp (NS5B) (reviewed in 
Penin, Dubuisson et al. 2004, Moradpour, Penin et al. 2007, Bartenschlager 
and Lohmann 2000). As discussed previously because of the lack of NS5B 
proofreading ability, there is a high rate of mutation in the HCV genome 
leading to production of quasispecies. 
The final stage of HCV life cycle is not well understood and it is thought that 
the structural part of HCV-core protein (C) and two envelope glycoproteins 
(E1 and E2) along with the non-structural components- P7, NS2, NS3 and 
NS5B are packaged together and contribute to the formation of infectious 
virions. These infectious virions are thought to egress through the cell after 
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budding into the ER lumen and are expelled through the host cell secretory 
system (reviewed in Pawlotsky, Chevaliez et al. 2007). Assembly and release 
of HCV is associated with the lipoprotein pathway (reviewed in Zeisel, Fofana 
et al. 2011). 
Several host factors are required for the infection and replication of HCV in 
the hepatocytes. Cyclophilins are family of proteins which have peptidyl prolyl 
isomerase activity leading to protein folding by isomerization of peptide 
bonds from trans to cis form at the proline residues. Cyclophylin A is a 
cytosolic protein implicated in replication of HCV (Kaul, Stauffer et al. 2009). 
It has been observed that cyclosporine; an immunosuppressant agent which 
is known to bind with cyclophilin inhibits HCV replication. In one study it was 
observed that cyclosporine inhibited incorporation of NS5B into the HCV 
replication complex and hence inhibited HCV replication by preventing 
formation of the replication complex (Liu, Yang et al. 2009). Moreover, 
variants of cyclophilin A did not allow infection and replication of HCV (von 
Hahn, Schiene-Fischer et al. 2012).  
MiR-122 is a microRNA which is known to assist in HCV replication. The 
exact mechanism as to how it exerts its pro-replication function is not fully 
elucidated. It binds with the 5' UTR region of the viral genome at two sites 
and promotes HCV RNA replication (Jopling, Yi et al. 2005). In one study, 
Shan et al. demonstrated that miR-122 triggers HCV replication by post-
transcriptional suppression of haeme oxygenase enzyme synthesis (Shan, 
Zheng et al. 2007). Furthermore, it was shown by Li et al. that miR-122 
protects HCV genome against degradation by the RNA exonuclease Xrn-1, in 
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the cytoplasm of host cells (Li, Masaki et al. 2013). However, it is suggested 
that this may not be the only way by which this microRNA promotes the HCV 
life cycle. Hence, miR-122 may have yet another function in HCV replication 
(reviewed in Garcia-Sastre and Evans 2013). 
1.3. Epidemiology and global burden of hepatitis C 
1.3.1. Prevalence and incidence estimates  
A large global population is already infected with HCV posing a major 
setback in controlling this infection. As the majority of those infected belong 
to the developing countries the global burden of disease and relative cost 
estimates are difficult. The latest figures from the WHO, revised in 2005, 
showed that 185 million people are positive for HCV antibody globally or 
2.8% of the world’s population is infected, in contrast to 1990 when estimates 
showed 122 million or 2.3% individuals being affected worldwide. 130-170 
million are thought to have chronic infection (Te and Jensen 2010, Mohd 
Hanafiah, Groeger et al. 2013). Most data on global HCV prevalence derives 
from hepatitis C seroprevalence studies which are generally cross-sectional 
in design and involve only selected groups e.g. patients with liver disease or 
blood donors which may not represent the whole community. As compared to 
developed countries, developing nations have a wide variation in their 
prevalence estimates and fewer data to support assumptions about disease 
burden in these regions making data on the prevalence in these countries 
much less accurate (Shepard, Finelli et al. 2005). Incidence rates of hepatitis 
C can give an estimation of the future burden of disease, however it is 
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difficult to distinguish the acute form of HCV infection from chronic or 
resolved infection (reviewed in Shepard, Finelli et al. 2005, Lavanchy 2009). 
Egypt has highest national prevalence rates and of those born before 1960, 
50% carry HCV, which was spread after a campaign to eradicate 
schistosomiasis intravenously to millions between1950 - 1980 (Frank, 
Mohamed et al. 2000, Strickland 2006). 
In the United States it was estimated that 3.9 million people were infected 
with HCV according to reports from National Health and Nutrition 
Examination Survey (NHANES) from blood collected during 1988-1994 from 
persons representing households (not including homeless people and 
prisoners) (Armstrong, Wasley et al. 2006). Ethnic minorities were shown to 
harbour HCV more often than the indigenous population. The HCV report by 
NHANES in 2000 suggests that in non-Hispanic blacks HCV prevalence was 
greater than in the ‘white’ population by 14%. The main risk factor for 
contracting HCV in developed nations is injecting drug use (IDU) (Williams, 
Bell et al. 2011) and most of the epidemiological estimates come from the 
developed world where chronic HCV is considered as a disease of drug 
users. Nonetheless, worldwide other risk factors clearly play a role in HCV 
transmission (see later) although injection drug use continues to play a major 
role even in the developing world - it has been estimated that out of 13.2 
million IVDUs, 10 million reside in developing nations and only 22% belong to 
developed nations (reviewed in Chu, Chiang et al. 2009). 
In the UK, general population studies have not been performed and most 
prevalence studies focus on certain groups such as IDUs. In England and 
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Wales in a study testing 1034 drug users for HCV by using dried blood spot 
for diagnosis, it was found that 32% had the disease (Hickman, McDonald et 
al. 2008), while in another study looking at 1949 IDUs in Glasgow, salivary 
antibodies against HCV were positive in 61% (Taylor, Goldberg et al. 2000). 
In a study looking at 4729 pregnant women at a London hospital between 
1997-1999, showed prevalence in that group of 0.8%. This was a relatively 
small scale study and chances of selection bias with women self presenting 
to the clinic was high. Moreover, pregnant women represent a low risk group 
and might not represent the whole population (Ward, Tudor-Williams et al. 
2000). In a study looking at prevalence of HCV in immigrants from South 
Asian countries, it was found that Pakistani born individuals had a prevalence 
of 2.7% while in Bangladeshis prevalence was 0.44% (Uddin, Shoeb et al. 
2010). In 2010, attempts were made to collate all the available data for 
England and Wales and showed that an estimated 191,000 (95% CI: 
124000-311000) people carried antibody against HCV, out of which 142,000 
(95% CI: 90000-231000) had chronic infection. However, the confidence 
intervals were broad and overall prevalence still remains unclear due to 
unavailability of data related to ethnic minorities (reviewed in De Angelis, 
Sweeting et al. 2009).  
In France, a screening study carried out within general practices involving 
11805 individuals showed a prevalence rate of 1.3% (Pradat, Caillat-Vallet et 
al. 2001). A study done in Southern Italy on 1352 persons showed a higher 
rate of 12.6% (Guadagnino, Stroffolini et al. 1997). In a selected population 
study in Germany with 2796 dialysis patients, a prevalence of 7% was seen 
(Hinrichsen, Leimenstoll et al. 2002) while in a multi-centric study involving 
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984 dialysis patients in France, 23.6% had HCV infection (Dussol, 
Berthezene et al. 1995). In Egypt overall prevalence rates vary from 15-20% 
(Frank, Mohamed et al. 2000). The prevalence in Pakistan is believed to be 
high - in the total population of 170 million in Pakistan it is estimated that 10 
million (6%) people harbour HCV infection (Waheed, Shafi et al. 2009). 
Nonetheless, a cross sectional study in healthy children showed a 
prevalence of 0.44% indicating that there could be variation of HCV infection 
among various age groups (Agboatwalla, Isomura et al. 1994).  
In summary, hepatitis C infection poses a considerable global health problem 
because it establishes persistent infection in its human host and infection 
cannot be prevented as a vaccine is not yet available. Neal et al. have 
demonstrated that HCV infected individuals have a three times higher death 
rate compared to uninfected people (Neal, Trent Hepatitis et al. 2007). 
Chronic HCV infection is currently believed to be responsible for considerable 
mortality worldwide with an estimated 1.4 million deaths per year, out of 
which 796,000 are due to cirrhosis and 616,000 are due to primary liver 
cancer (reviewed in Seeff 2002).- 
1.3.2. Genotypes and distribution  
Hepatitis C is a highly variable virus but it is now recognised that the viral 
variants can be classified into different genotypes. Six major genotypes of 
HCV were identified through phylogenetic analysis of genes encoding NS5 
proteins of HCV and comparison with the published sequence led to the 
identification of different types and subtypes of HCV which vary from each 
other by 33% over the whole genome (Simmonds, Holmes et al. 1993).  
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Knowing the epidemiology of genotypes is important in order to track HCV 
infection back to its source and to predict response to therapy. Genotype 1, 2 
and 3 are broadly distributed globally.  Genotypes 1a and 1b account for 60% 
of infections worldwide with genotype 1a most prevalent in north of Europe 
and America while genotype 1b predominates in south and east of Europe 
and in Japan. Genotype 2 is mostly found in Europe, Mediterranean 
countries and Far East and genotype 3 is common in South-East Asia.  The 
Middle-East, Egypt and Central Africa have been affected mostly by 
genotype 4 while genotype 5 has been reported in South Africa. Other 
genotypes are distributed mostly in Asian countries (reviewed in Hnatyszyn 
2005, Simmonds, Bukh et al. 2005) . 
Some studies report that there might be a relationship between the type of 
genotype affecting the host and the progression of disease (Gane, Portmann 
et al. 1996,Kao, Chen et al. 1995, Gonzalez-Michaca, Mercado et al. 2000). 
It has been suggested that genotype 1b leads to a more aggressive disease 
and is also associated with more severe graft injury in patients who undergo 
transplantation (Gane, Portmann et al. 1996). Moreover, HCV genotyping is 
of clinical significance as response to treatment varies among different 
strains and decisions about length of treatment is tailored according to the 
viral genotype (reviewed in Narahari, Juwle et al. 2009, Yu and Chuang 
2009). It is well established that patients infected with genotype 1 show the 
poorest response to conventional antiviral treatment with pegylated interferon 
(PEG-IFN) and ribavirin compared to infection with other genotypes (Cheng, 
Roberts et al. 2010).  
52 
 
1.4. Disease transmission patterns  
HCV is a blood borne hepatotrophic pathogen which is transmitted through 
blood to blood contact. In developed countries till 1980 the main source of 
HCV transmission was exposure to contaminated blood or blood products 
and injecting drug use. Following the introduction of routine screening of 
donor blood, blood products and organ transplants, illicit use of injectable 
drugs remains the main source of HCV transmission in the developed world 
(Donahue, Munoz et al. 1992). The acquisition of HCV infection is more 
frequent compared to HBV and HIV infection in injecting drug users 
(reviewed in Wasley and Alter 2000), perhaps because of effective 
vaccination programs for HBV and because HIV is much less infectious 
through this route compared to HCV (reviewed in Beltrami, Williams et al. 
2000). 
In developing nations unsafe use of therapeutic procedures and transfusion 
of unscreened blood or blood products is still a significant cause of HCV 
transmission. Needle reuse for therapeutic or preventive procedures is 
common in the Middle-East, South-East Asia and Western Pacific (Hutin and 
Chen 1999, Kane, Lloyd et al. 1999). Due to a lack of a nationwide system for 
blood screening in developing countries a significant number of individuals 
continue to be infected with HCV every year (Simonsen, Kane et al. 1999). 
Occupational exposure to HCV is seen in health-care workers who have 
sustained a contaminated needle stick injury and the observed attack rates in 
these cases are as low as 0.3%, although a few studies have estimated it to 
be higher, at around 3-7% (Martins, Almeida et al. 1996). HCV is less likely to 
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be transmitted through mucosal contact, making sexual transmission and 
vertical transmission relatively uncommon. However, in some cases 
transmissions have reported from patients who are co-infected with HIV 
(Matthews, Hellard et al. 2007, Polis, Shah et al. 2007) and this seems 
particularly common in men who have sex with men. Materno-foetal HCV 
transmission occurs in some 4-10% of cases and is common when the 
mother is co-infected with HIV, particularly in those delivered vaginally. 
(Paccagnini, Principi et al. 1995, (Zanetti, Tanzi et al. 1995, Polywka, Feucht 
et al. 1997, Granovsky, Minkoff et al. 1998).  
1.5. Natural history of hepatitis C infection  
1.5.1. Acute infection  
Hepatitis C infection has vast heterogeneity in its clinical course, progression 
and outcome (reviewed in Alberti, Vario et al. 2005). Early infection with HCV 
is mostly asymptomatic leading to an inability to precisely identify the time of 
acquisition of disease, but in a few cases severe acute infection takes place 
with a rise in serum transaminases and the appearance of jaundice. 
Occasionally acute hepatitis C may resolve spontaneously without long term 
sequelae. Epidemiological studies show that an estimated 15-20% of all 
infected persons resolve their infection without undergoing any treatment 
(reviewed in Katze, He et al. 2002, Sumpter, Loo et al. 2005). However, there 
are reports that suggest that resolution of the acute stage of HCV infection 
could range from 10 to 50% and that several cofactors predict the severity of 
liver disease secondary to HCV. Those exposed to low levels of HCV virus 
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may resolve without clinical signs of any disease and it is suggested that T 
cell immunity might develop even without anti-HCV seroconversion in such 
cases (reviewed in Alberti, Chemello et al. 1999). In a study looking at 60 
patients with acute HCV infection, 44% spontaneously cleared the virus 
(Gerlach, Diepolder et al. 2003). In a prospective study 24% of the 41 
patients followed for 6 years cleared the virus spontaneously (Barrera, 
Bruguera et al. 1995). Various host factors like increased age at the time of 
infection, male gender, co-infection with HIV or immunosuppressed 
individuals, IV drug use, ethnic background (such as African Americans), co-
morbidities (i.e. Haemochromatosis, NASH) contribute to progression to 
chronic disease (Thomas, Astemborski et al. 2000). However, all of the 
studies to-date examining the transition from acute to chronic infection have 
been relatively small and the precise factors that determine the outcome of 
acute infection remain unclear. 
About 20-30% of acutely infected individuals may become symptomatic 
within 3-12 weeks of infection (reviewed in Romero-Gomez, Del Mar Viloria 
et al. 2005). HCV RNA starts rising within 1-2 weeks of exposure to HCV with 
a subsequent rise in serum transaminase levels sometimes up to 10 times 
the upper limit of normal along with the appearance of clinical symptoms like 
malaise, anorexia, jaundice and weakness. Acute infection can very rarely 
progress to fulminant liver disease (reviewed in Romero-Gomez, Del Mar 
Viloria et al. 2005). 
In self-limited acute hepatitis C infection, symptoms can last for a few weeks 
after which there is a drop in serum transaminases and HCV RNA levels and 
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anti-HCV levels appear with clearance of infection. It is thought that the 
presence of jaundice increases the chance of spontaneous viral clearance 
(reviewed in Tillmann and Manns 1996, Lehmann, Meyer et al. 2004). 
1.5.2. Chronic infection  
Chronic HCV infection is characterised by the inability to clear HCV leading 
to raised aminotransferases or persistent viremia for more than 6 months. 
About 80% of exposed individuals are believed to develop a chronic infection 
(reviewed in Conry-Cantilena, VanRaden et al. 1996, Alter, Kruszon-Moran et 
al. 1999). Liver function tests and serum transaminases fluctuate 
considerably during the course of chronic hepatitis C thus they cannot be 
considered as reliable markers of disease progression. Liver biopsy is 
currently the gold standard for the staging and grading of chronic hepatitis C 
infection.  
In the patients persistently infected with hepatitis C initially the symptoms are 
usually mild and it takes decades before the serious consequences of 
chronic HCV infection become apparent. The long term complications of 
chronic HCV infection (either liver cancer or decompensation) may lead to 
indications for liver transplantation (Brown 2005). 
In the patients who develop chronic hepatitis C there is 15-20% progression 
to cirrhosis over 20 years (Alberti, Chemello et al. 1999, Hissar, Kumar et al. 
2009). The proportions of patients who will develop cirrhosis after longer 
periods of infection are unknown but probably substantially greater than 20%. 
One study, in a self-selected group of patients, suggested that up to 70% of 
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patients may develop cirrhosis after 70 years of persistent infection (D'Souza, 
Glynn et al. 2005). In a study done in Austria, 30 patients who contracted 
HCV in a plasmapheresis unit were followed for 18 years, variable rates of 
fibrosis progression were observed in different age groups and an average of 
20% patients progressed to cirrhosis. It was seen that increased age at the 
time of acquisition of HCV infection was an important host factor causing 
progression to cirrhosis (Datz, Cramp et al. 1999). A systematic review of 
111 studies including a total of 33121 individuals with chronic HCV infection 
has reported that 16% of the patients developed cirrhosis after 20 years of 
chronic infection (Thein, Yi et al. 2008).  
In the patients with cirrhosis every year approximately 4% develop 
hepatocellular carcinoma (HCC) and 1-3% develop decompensated liver 
disease while death occurs in 1.3-3.7% per year (reviewed in Hissar, Kumar 
et al. 2009). HCC is very common globally (it is the third most common cause 
of cancer related deaths worldwide) and currently it is estimated that chronic 
HCV infection is a major cause of this cancer with 40.1% of patients in one 
study being anti-HCV positive (Levrero 2006). For this reason it is 
recommended that patients with established cirrhosis should have 6 monthly 
ultrasonography and alpha-fetoprotein monitoring.  
Before the discovery of hepatitis C virus in 1980s there was a high incidence 
of infection through blood transfusions and injecting drug use and as chronic 
hepatitis C related morbidity takes decades to develop, it is highly expected 
that the burden of disease will dramatically rise in coming years (reviewed in 
Grebely and Dore 2011) 
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Figure 1.2: Natural history following infection with hepatitis C virus 
(Gupta, Bajpai et al. 2014) 
In the chronic HCV infected patients the course of disease is extremely 
variable and fibrosis progression can only be partially predicted by different 
cofactors like the age at infection, disease duration, ALT profile and stage of 
fibrosis and liver histology. 
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1.5.3. Single nucleotide polymorphisms on the IL28B locus 
In 2009, several genome wide association (GWAS) studies (used to identify 
genetic variants linked with complex traits) recognised two single nucleotide 
polymorphisms on the IL28B gene locus. These common variants are 
rs12979860 CC and rs8099917 TT (Thomas, Thio et al. 2009). It was found 
that these variants were linked with clearance of HCV, response to therapy 
and progression of disease course (Rauch, Kutalik et al. 2010). It was 
observed that patients with CC variant responded well to the standard of care 
(SOC) therapy which was PEG-IFN and ribavirin at that time. In contrast CT 
or TT variants responded less efficiently (Ge, Fellay et al. 2009, Tanaka, 
Nishida et al. 2009).   
1.5.4. Clinical features and extrahepatic manifestations 
HCV's major weapon is its silence, most patients remain asymptomatic for 
considerably long periods of time and even in the acute infection, jaundice 
appears in only 25-30%. Most symptoms such as low grade fever, anorexia, 
abdominal pain, fatigue, malaise, arthralgias and myalgias are non-specific. 
Acute symptomatic illness appearing in 20-30% can last for about 3-12 
weeks and displays elevated serum aminotransferases (reviewed in Alter and 
Seeff 2000, Thimme, Oldach et al. 2001, Chen and Morgan 2006). 
Symptoms of liver failure and decompensation only develop in chronic HCV 
infection after many years of apparently ‘asymptomatic’ infection and these 
symptoms involve the development of ascites, upper gastrointestinal 
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bleeding secondary to varices or gastropathy, hepatorenal syndrome and 
hepatic encephalopathy. 
Extrahepatic manifestations of hepatitis C are have been debated 
extensively. They can be the first sign of hepatitis C infection due to silent 
nature of the disease. EHMs can be seen in those with normal 
transaminases. Some studies suggest that between 40-74% of patients with 
hepatitis C infection develop at least one extrahepatic manifestation (EHM) 
during the disease course (Cacoub, Poynard et al. 1999, Cacoub, Renou et 
al. 2000). A decision about HCV therapy may be based on the presence of 
EHM (Galossi, Guarisco et al. 2007). 
An association between HCV and EHM was first illustrated by Pascual et al. 
in 1990 when he described two patients with mixed cryoglobulinemia (MC). 
MC is the most studied EHM of HCV infection. It is a systemic vasculitis 
involving kidneys, skin and nervous system (Pascual, Perrin et al. 1990). 
EHM could be secondary to the formation of immune complexes and 
autoimmune phenomenon (Agnello and De Rosa 2004). Moreover, 
lymphotropism of HCV is widely accepted and could explain the 
pathogenesis of some haematological EHMs (Ferri, Monti et al. 1993).   
Other common EHMs are Non-Hodgkin lymphoma, porphyria cutanea tarda, 
lichen planus, thyroid disease (usually hypothyroidism), rheumatology 
symptoms (arthritis, fibromyalgia, vasculitis and 'pseudo-Sjogren syndrome') 
etc (Galossi, Guarisco et al. 2007). It has also been observed that diabetes 
mellitus is more common in HCV patients compared to general population 
(Mason, Lau et al. 1999, Galossi, Guarisco et al. 2007) and is found to be 
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secondary to insulin resistance (Petit, Bour et al. 2001). Mason et al. 
suggested that HCV is a risk factor for DM which is unrelated to the severity 
of liver disease (Mason, Lau et al. 1999). However, some suggest that DM in 
HCV increases the risk of advanced fibrosis of the liver (Caronia, Taylor et al. 
1999).  
1.6. Hepatitis C management 
Liver biopsy is the gold standard test to look at the extent of hepatic fibrosis 
and grading and staging of liver disease in chronic HCV patients. Some 
alternative tests are fibro scan, fibro test and enhanced liver fibrosis (ELF) 
test. Standard of care (SOC) antiviral therapy for HCV at the time that this 
work was completed showed success in 50-80% of patients with clearance of 
HCV RNA from serum, often accompanied by normalizing of liver 
biochemical tests and improvement of liver histology (Lindsay 2002). A 
patient is considered to have achieved a sustained virological response 
(SVR) when the serum remains negative for HCV RNA for a period of 6 
months post-treatment (Lindsay 2002). The recurrence rate after gaining 
SVR is reported as 2% at 1 to 4 years after treatment ((Fujii, Itoh et al. 2010, 
Morgan, Ghany et al. 2010), but some of these ‘late relapses’ may represent 
new infections and most physicians regard an SVR as equivalent to a cure. 
Previous SOC antiviral treatment consists of combination therapy with 
pegylated Interferon alfa (2a or 2b) which is given once a week plus ribavirin 
which is taken daily (800mg for HCV genotypes 2 and 3 infected patients and 
1000/1200mg for HCV genotype 1, 4, 5 and 6) (Hadziyannis, Sette et al. 
2004, Fried, Shiffman et al. 2002). Response to therapy depends on both 
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viral- and host- associated factors. Various genotypes of HCV showed 
differences in response to this therapy when compared with each other thus 
genotypes are the most important predictors of response to therapy and 
determine the length of treatment duration and the dose of ribavirin. 
Genotype 2 and 3 are more responsive to therapy with almost 80% achieving 
an SVR while genotypes 1 achieve an SVR in no more than 40-50% of the 
treated patients (reviewed in Munir, Saleem et al. 2010, Cheng, Roberts et al. 
2010).  However, for patients with advanced disease these response rates 
may be considerably reduced – for example in patients with genotype 3 HCV 
who have cirrhosis, success rates with therapy may be less than 60% 
(Freshwater, O'Donnell et al. 2008, Sood, Midha et al. 2008, David, 
Rajasekar et al. 2010). The host factors which predict response to treatment 
include female gender, young age, low body mass index, low fibrosis score 
on biopsy and lack of co-morbidities  such as drug and alcohol use, renal 
disease, co-infection with HIV or HBV (reviewed in Feld and Hoofnagle 
2005). 
The primary aim of therapy is viral eradication and important secondary goals 
are increased longevity, reduced liver damage and fibrosis progression, 
normalized biochemical liver tests, decreased incidence of hepatocellular 
carcinoma and lower mortality and morbidity. Previous SOC therapy 
recommends continuing treatment for 24 weeks in HCV genotype 2 and 3 
patients and for 48 weeks in cases of HCV genotype 1, 4, 5 and 6 patients. It 
is recommended that treatment should be terminated if patients infected with 
HCV genotypes 1, 4, 5, and 6 do not show a two log10 drop in their HCV viral 
load by the twelfth week of treatment as it is highly unlikely that they will 
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achieve SVR if therapy is continued (Lukasiewicz, Gorfine et al. 2010). 
However, there is no recommendation for treatment discontinuation 
secondary to lack of such a drop in viral loads in patients with genotypes 2 
and 3 (Zeuzem, Rizzetto et al. 2009). For patients with HCV genotype 1 
infection responding very rapidly to therapy- rapid responders (defined as 
undetectable virus after 4 weeks of therapy) there are various studies which 
indicate that 24 weeks therapy may be sufficient to achieve an SVR, (Jensen, 
Morgan et al. 2006, reviewed in Poordad, Reddy et al. 2008). However, these 
are relatively small scale studies and no properly powered assessment of 
short duration therapy has been reported to-date. 
Interferon exerts its antiviral function through induction of interferon 
stimulated genes (ISGs) and establishes antiviral state in the cells. 
Interferons also stimulates T cell and NK cell activation, T cell proliferation 
and maturation of dendritic cells (reviewed in Feld and Hoofnagle 2005). The 
exact mechanism of action of ribavirin is still not clear, it is reported that 
ribavirin interacts with viral replication and increases the error frequency of 
NS5B mediated RNA transcription and hence leads to production of non-
viable viral genomes (Crotty, Maag et al. 2000). It is still not clear whether the 
treatment of HCV infection leads to successful elimination of HCV, or 
whether there is persistence of small quantities of viral RNA (Radkowski, 
Gallegos-Orozco et al. 2005) in some sanctuary sites - so called 'occult' 
HCV. 
There have been two recent advances over the last year in the treatment of 
chronic HCV infection and these have changed the optimal treatment of 
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genotype 1 HCV infection. Inhibitors of the NS3/4A serine protease i.e.; 
boceprevir and telaprevir have shown to be potent inhibitors of HCV 
genotype 1 replication and have improved SVR rates considerably both in 
patients who were not treated previously and those who previously failed to 
respond to pegylated interferon and ribavirin (Bacon, Gordon et al. 2011, 
Jacobson, McHutchison et al. 2011, Poordad, McCone et al. 2011, Zeuzem, 
Andreone et al. 2011). 
The recent treatment recommendations entail the use of boceprevir or 
telaprevir in combination with pegylated interferon alfa and ribavirin (triple 
therapy) and these drugs should not be used in isolation and are only 
effective and licensed for patients with genotype 1 HCV (Ghany, Nelson et al. 
2011). For treatment naïve patients, the dose of boceprevir is 800 mg three 
times a day together with pegylated interferon alfa and weight-based ribavirin 
(weight-based dose of ribavirin starts at 800 mg/day for patients weighing 
under 65 kg, and increased by 200 mg/day for  each additional 20 kg of 
weight up to a maximum dose of 1400 mg (Nunez, Miralles et al. 2007)) for 
24-44 weeks and this regimen is preceded by 4 weeks of lead-in treatment 
with PEG-IFN alfa and ribavirin alone (Kwo, Lawitz et al. 2010). In non 
cirrhotic patients shorter duration of treatment (28 weeks) can be considered 
if the HCV RNA level at the 8
th
 and 24
th
 week of therapy is undetectable while 
in cases where at the 12th week HCV RNA is >100 IU/ml treatment should be 
terminated as it is futile (reviewed in Poordad, McCone et al. 2011). The 
telaprevir treatment regimen consists of taking telaprevir 750 mg thrice daily 
with food (not low-fat) along with PEG-IFN alfa and weight-based ribavirin for 
12 weeks followed by an additional 12-36 weeks of PEG-IFN alfa and 
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ribavirin. An additional 12 weeks is used for non cirrhotic patients whose 
HCV RNA level at weeks 4 and 12 is undetectable. These patients are 
defined as showing an extended rapid virological response and require 
shorter treatment durations of a total of 24 weeks. All other patients should 
receive total treatment duration of 48 weeks. (Zeuzem, Andreone et al. 
2011). However, cirrhotic patients should be treated with telaprevir in 
combination with PEG-IFN and ribavirin for 12 weeks followed by a further 36 
weeks of PEG-IFN and ribavirin without telaprevir (Ghany, Nelson et al. 
2011) even if they have evidence of an early virological response. Similarly, 
treatment should be stopped if the HCV RNA level is >1,000 IU/ml at 4th or 
12th week of therapy and/or is detected at 24th week of treatment (Ghany, 
Nelson et al. 2011). In patients who have received treatment beforehand and 
have relapsed or responded partially to previous SOC therapy re-treatment 
with triple therapy (either telaprevir or boceprevir along with PEG-IFN alfa 
and ribavirin) is recommended (Bacon, Gordon et al. 2011, Zeuzem, 
Andreone et al. 2011). As for null responders this treatment might also be 
considered although response rates are low.  Furthermore, response guided 
therapy should not be considered in non responders to a previous course of 
therapy (Bacon, Gordon et al. 2011, Zeuzem, Andreone et al. 2011). 
Patients failing to have a virological response, those who experience 
virological breakthrough (>1 log increase in HCV RNA) or relapse on one 
protease inhibitor should not be re-treated with the other protease inhibitor 
because of the possibility of viral resistance (Sarrazin, Kieffer et al. 2007, 
Sarrazin and Zeuzem 2010).  IL28B genotype should be considered as a pre-
treatment predictor of SVR for both previous SOC and triple therapy in 
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patients infected with genotype 1 strain of HCV if the patient or provider 
wishes to have information on the probability of response to treatment or on 
the probable duration needed for the treatment as likelihood of viral 
clearance with antiviral therapy or spontaneous resolution of HCV viral 
infection depends upon the nucleotide sequence near the gene for IL28B 
(discussed above in section 1.5.3) (Ge, Fellay et al. 2009, Thomas, Thio et 
al. 2009). However, it was shown that not all patients with CC variant 
responded and those with CT or TT variants could also attain SVR. 
Moreover, 53% of patients with CC variant and 28% of patients with TT or CT 
variants respond to therapy according to one series (Thomas, Thio et al. 
2009). There have been reports that in the new SOC therapy using triple 
regimen (using protease inhibitors along with PEG-IFN and ribavirin), 
response could be predicted with IL28B status. However, the link is not as 
strong as with the previous SOC therapy (Akuta, Suzuki et al. 2010). Thus, it 
is highly debatable whether IL28B genotyping should be used to avoid 
unnecessary treatment with new SOC triple therapy or treatment should be 
given only depending upon the favourable IL28B genotype ignoring other 
variables like age, gender, ethnicity, fibrosis, viral genotype or compliance.  
1.7. Host immune responses to HCV infection  
Clearance of HCV infection relies on the T cell responses, innate immunity 
and on the direct antiviral effects of Interferon. The immune responses are 
orchestrated in a perfectly timed manner in order to clear the virus. 
Understanding of host immune responses to HCV infection and its evasion 
from these protective mechanisms demonstrate how the virus persists in its 
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host and may remain so even after treatment. Some of the strategies to 
escape the immune response by HCV are through retarding the interferon 
framework, suppression of antigen presentation, debilitating the T-cell 
response, development of peripheral tolerance, infection of immunologically 
privileged areas, down-regulation of HCV gene expression and viral 
mutations that abolish, anergise or antagonise antigen recognition by virus-
specific T cells. In short, it is the rapid virus dynamics which surpass the 
immune strategies of the host (Missale, Cariani et al. 2004).  
 
Figure 1.3:  Mechanisms of evasion of immune effectors of the host 
by HCV. 
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1.7.1. Role of innate immune response to HCV infection 
According to epidemiological estimates 20% of all infected persons resolve 
hepatitis C infection spontaneously without undergoing any treatment 
(reviewed in Sumpter, Loo et al. 2005). The precise mechanisms of viral 
clearance are not clear but probably involve a variety of different host 
defences. Innate immune response provides the primary line of defence 
against pathogens which are present in the host since birth and are antigen 
non-specific. Innate immune response ‘buys time’ for the host to set up 
adaptive immunity against the pathogen. Physical barriers like skin, mucous 
membranes, the complement system and cells such as granulocytes, 
macrophages, natural killer (NK) cells and antigen presenting cells like 
dendritic cells (DCs) and various molecules secreted by these cells, all 
constitute host innate immune responses (Beutler 2004). The major innate 
response to a viral infection is the production of Interferons (IFN) and 
inflammatory cytokines and chemokines.  IFN acts by inducing ISGs and 
either acts directly in infected cells or indirectly by protecting uninfected cells. 
It is also pivotal for activation of variety of immune cells which help in viral 
clearance and surveillance (Borden, Sen et al. 2007). Moreover, 
inflammatory cytokines and chemokines attract T cells into the liver in HCV 
infection (Wald, Weiss et al. 2007, Zeremski, Petrovic et al. 2007). Evidence 
shows that HCV disrupts signal pathways involved in the production of IFN 
and cytokines (discussed in section 1.7.5).  
IFN also has immunomodulatory function and up-regulates the expression of 
MHC class I and II molecules and in turn enhances cellular immune response 
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to viral infection in vivo. In some cases this might be seen later at the stage 
of recovery from viral infection rather than being an initial host defence 
mechanism. Other cells of the innate immune system like NK cells, natural 
killer T-cells and myeloid cells present in the liver are activated by HCV 
infection and produce IFN which not only attracts lymphoid cells to the 
infected area but also inhibits viral replication directly (reviewed in Lau 1994, 
Zhu, Zhao et al. 2003, Guidotti and Chisari 2006, Dustin and Rice 2007). 
1.7.2  Interferon (IFN) system  
Interferons (IFNs) are a group of secreted cytokines which together constitute 
the interferon induced innate immune response. They have antiviral, anti-
proliferative and immunomodulatory functions. They are classified into type I, 
II and III IFNs depending upon their different amino acid sequences. Type I 
interferon further constitutes several types of which α and β IFN genes are 
mainly induced in response to viruses. For this reason instead of type I IFN 
the term α/ β IFNs is more often used in relation to response to viruses 
(Randall and Goodbourn 2008). Type I Interferons are derived from 
intronless genes found on the short arm of human chromosome 9 (9.21p3) 
and they share the same receptor and have overlapping functions (Brideau-
Andersen, Huang et al. 2007, Randall and Goodbourn 2008). Multiple IFNα 
subtypes have been found in mammalian species. IFNα subtypes have 
approximately 80% amino acid sequence similarity (Randall and Goodbourn 
2008). Type 1 IFNs are produced by a broad range of cells in the body and 
induce an antiviral state in virus infected cells and surrounding tissue by 
setting in motion a complex signalling pathway that results in transcription of 
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hundreds of ISGs which have strong antiviral activity (reviewed in Katze, He 
et al. 2002, Biron 2001).   
Type III IFNs were recently described and consist of IFN λ1 (IL-29), λ2 (IL-
28A) and λ3 (IL-28B) (Meager, Visvalingam et al. 2005, Zhou, Hamming et 
al. 2007). Their receptors have mainly an epithelial distribution (reviewed in 
Borden, Sen et al. 2007). These are also induced in direct response to 
viruses and induce a similar group of antiviral genes as IFNs α/ β (Onoguchi, 
Yoneyama et al. 2007).Type II IFNs are also called IFN-γ and they are not 
secreted in direct response to viruses but are produced by the subsets of T 
cells and NK cells in response to viral infection (Randall and Goodbourn 
2008). IFNs α/β act on heterodimeric receptors broadly distributed in tissues 
to activate a signal transduction pathway which results in transcription of 
ISGs (Valarcher, Furze et al. 2003, reviewed in Galligan, Murooka et al. 
2006). These genes are also induced directly by viral infection but the 
response is less effective compared to that induced by IFNs (reviewed in 
Randall and Goodbourn 2008). Type III IFNs are known to elicit similar 
response as that induced by Type I IFNs but their receptors are not widely 
distributed and their exact role in the antiviral response is under investigation 
(Meager, Visvalingam et al. 2005, Mennechet and Uze 2006, Zhou, 
Hamming et al. 2007). Marukian et al, has shown in a recent study that HCV 
infection of human foetal liver cells led to induction of type III IFN and ISGs 
suggesting that type III IFN may play a very important role in inducing innate 
immune response to HCV in liver cells (Marukian, Andrus et al. 2011). 
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Figure 1.4: Different types and sub-types of Interferon 
1.7.2.1. Induction of interferons (IFNs) 
Type 1 interferon can be induced by Toll like receptor (TLR) dependent and 
TLR independent pathways.  TLR dependent pathways are present primarily 
in cells of the myeloid lineage such as antigen presenting cells (APC) – 
including plasmacytoid dendritic cells and myeloid dendritic cells. This 
induction pathway involves TLRs which recognize and bind to the motifs 
present on different pathogens and leads to a wide variety of inflammatory 
responses as well as activation of dendritic cells and generation of specific T 
cell responses (Yonkers, Rodriguez et al. 2007). A number of viral motifs, 
including double stranded RNA (dsRNA), GU rich single stranded RNA 
(ssRNA) or endosomal DNA interact with TLRs (specifically TLR3, TLR7 and 
TLR9 respectively) which are found either extracellularly or intracellularly 
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(reviewed in Randall and Goodbourn 2008).  This interaction leads to 
β 
IFNs and other pro-inflammatory cytokines.  An alternative pathway for IFN 
induction involves the TLR-independent pathway that is activated after 
cytoplasmic molecules interact with viral RNA (chiefly replicating, dsRNA). 
This pathway may be more ubiquitous than the TLR induction pathways and 
is probably important in non-myeloid cells (reviewed in Randall and 
Goodbourn 2008). The RNA recognition molecules are RNA helicases 
variously named melanoma differentiation-associated gene 5 (mda-5) or 
retinoid-inducible gene I (RIG-I) (Staeheli and Haller 1987, Zhou, Hassel et 
al. 1993). dsRNA and 5’triphosphate RNA produced by both DNA and RNA 
viruses are known to induce IFNs by binding to these intracellular detectors, 
(Mda5 and RIG-I) (reviewed in Marcus and Sekellick 1977, Marcus 1983) as 
shown in figure 1.5.  
The downstream events that follow the activation of interferon inducers are 
less well established but activation of NFkβ and IRF-3 have a role in 
induction of IFN-β (Honda and Taniguchi 2006). Upon receipt of appropriate 
signals IRF-3 and NFkβ are translocated to the nucleus and bind to the IFN-β 
promoter leading to induction of IFN-β (Murray 2007). The mechanism of 
induction of IFN-α is less well defined (Meurs, Chong et al. 1990). It is 
thought that production of primary IFN i.e. IFN-β may lead to the induction of 
other transcription factors i.e. IRF-1, IRF-7 and IRF-9 which play a role in the 
induction of secondary IFN genes i.e. IFN-α genes (Morin, Braganca et al. 
2002, Cebulla, Miller et al. 1999).  In the context of HCV infection in 
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hepatocytes it is thought that TLR-independent pathway is induced after an 
HCV specific PAMP is recognised by the host receptor, specifically RIG-I, 
which leads to the production of IRF-3 which in turn mediates IFN and 
interferon stimulated genes (ISGs) induction and induces an innate antiviral 
defence response within days of HCV exposure limiting host cell 
permissiveness. RIG-I recognises blunted end dsRNA or ssRNA rich in 
polyuridine runs or bearing 5' triphosphates (Kato, Takahasi et al. 2011). 
Although RIG-I in Huh-7 cells recognises PAMP and responds to HCV RNA, 
Huh-7.5 cell line, which is a derivative of Huh-7 cell line, has defective RIG-I 
signalling which leads to blunted innate immune response, part of the reason 
why this cell line is so permissive to HCV infection in culture. In one study it 
was found that restoration of RIG-I signalling rendered Huh-7.5 cells non-
permissive to HCV infection (Sumpter, Loo et al. 2005). 
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Figure 1.5: Mda5 and RIG-I dependent pathway for IFN-β induction 
(TLR-independent pathway): Viral dsRNA activates both mda5 and RIG-I 
and their specific domains recruit Cardif/VISA/MAVS/IPS-1, which in 
turn recruits signalling molecules which feed into NFкβ and IRF-3 
pathway and thus lead to IFN-β production.  
1.7.2.2. Interferon induced signalling 
Pioneering studies using mutagenised cells that were selected for the loss of 
the cellular response to interferon have confirmed the pivotal role of the JAK-
STAT signal transduction pathway in the cellular response to type I IFN. The 
JAK-STAT pathway is comprised of Janus kinases (JAK, a tyrosine kinase 
which is recruited to many receptor types after binding of ligands) and signal 
transducer and activators of transcription (STATs) (Stark, Kerr et al. 1998, 
Platanias 2005, Stark 2007). STATs are phosphorylated by JAKs and bind to 
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DNA (Murray 2007). IFNs α/ β binds to their heterodimeric cognate receptor 
composed of IFNAR1 and IFNAR2. IFNAR1 is linked to tyrosine kinase 2 
(Tyk2) while IFNAR2 is linked to JAK1. Following binding of IFN to the 
receptor the JAKs are phosphorylated and then bind both STAT1 and STAT2 
which in turn are phosphorylated by JAK1 and Tyk2 respectively. On 
phosphorylation STAT1 and STAT2 dimerise and this complex then binds to 
IRF-9 before translocating into the nucleus where it binds with Interferon 
stimulated response elements (ISRE) which are present in the promoters of 
all ISGs. The above signal transduction leads to the activation of ISGs which 
create the antiviral state in the cell (figure 1.6). Similar signalling is observed 
in response to IFN II in which IFN-γ binds to its cognate receptors leading to 
phosphorylation of STAT1 and its homodimerization to form gamma-
activated factor (GAF) complex which activates the transcription of IFN-γ 
responsive genes (reviewed in Randall and Goodbourn 2008, Platanias 
2005), Murray 2007, Gunji, Kato et al. 1994). 
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Figure 1.6: Signalling pathway activated by IFNs α/ β leading to the 
production of ISGs: phosphorylated JAKs phosphorylate/dimerise 
STAT1 and STAT2 into a complex which binds with IRF-9 and 
translocates into the nucleus to produce ISGs. 
1.7.3. Interferon stimulated genes (ISGs) 
ISGs are the proteins which are induced by IFNs, many of which have known 
antiviral activity. There are hundreds of different ISGs and the function of the 
majority is unknown. The most well studied examples include; protein kinase 
R (PKR), myxovirus resistance protein A (MxA) GTPases and group of 2’5’ 
oligoadenylate synthetases (2’5’ OAS). 
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1.7.3.1. Functions of antiviral interferon stimulated genes  
A) Protein kinase R (PKR) 
PKR is a dsRNA-dependent protein kinase. It is a 68Kd protein containing a 
serine/threonine kinase and a dsRNA binding domain. The protein is present 
at low levels in all cells and levels increase after exposure to type I IFN. The 
kinase is generated in an inactive form but binding to conserved motifs in 
dsRNA leads to its activation which then phosphorylates the eukaryotic 
translation initiation factor 2 (eIF-2) and by doing so it prevents the recycling 
of initiation factors and hence halts the protein translation. In addition the 
kinase has a variety of other roles including promotion of apoptosis and 
activation of the NFкβ transcription factor which is needed for IFN β synthesis 
and which reduces viral spread to neighbouring cells (reviewed in Meurs, 
Chong et al. 1990, Gale and Katze 1998).  
B) Myxovirus resistance protein A (MxA) 
Myxovirus resistance proteins are IFN-inducible GTPases. MxA were 
originally discovered as IFN-induced proteins that are capable of blocking the 
replication of influenza virus. They interfere with viral replication by inhibiting 
the activity of the viral polymerase (Staeheli and Haller 1987).  
C) 2’5’ Oligoadenylate synthases (2’5’OAS) 
2’5’ Oligoadenylate synthases (2’5’ OAS) are a family of enzymes that are 
activated by dsRNA to synthesize 2’5’-linked oligoadenylates. The 2’5’ OAS 
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bind to an endoribonuclease L (RNase L). RNase L catalyses the cleavage of 
single stranded RNA resulting in the inhibition of protein synthesis. They 
cleave ribosomal RNA in a site-specific manner leading to the inhibition of 
protein synthesis (reviewed in Tan and Katze 2001, Zhou, Hassel et al. 1993) 
and help prevent viral replication. 
 
Figure 1.7: The mechanism of action of 2’5’ OligoA synthetase: 2’5’OAS 
is activated on binding with viral dsRNA. Activated 2’5’OAS further 
activates RNase L which destroys viral mRNA and prevents the 
translation and replication of HCV.  
1.7.4. Role of adaptive immune response to HCV infection 
The adaptive immune response is acquired after birth and sets in motion 
either simultaneously or soon after the activation of the innate immune 
response to virus infection. It has a very important role in the control of 
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infection. B cells are involved in providing antibody mediated immunity 
against HCV while functional CD4+ and CD8+ T cells with antigen specificity 
are required for induction and maintenance of effective antiviral immunity 
(Heydtmann, Shields et al. 2001).  
Antibodies produced in response to activation of B cells can act in different 
ways to provide immunity. They can bind to the pathogen and act as 
opsonins for antigen presentation or label infected cells to act as the 
substrate for the complement mediated killing. Alternatively, bound antibody 
can present infected cells to T cells, may directly block viral entry into the 
cells or bind to the virions and remove them from the circulation (Heydtmann, 
Shields et al. 2001).  
CD4+T cells act as helper cells and provide effectors like IL-2, IL-4 and IFN-γ 
which mediate immune responses either by activating B cells and CD8+ T 
cells or by recruitment and activation of NK cells and macrophages (reviewed 
in Sen 2001). CD4+ T cells have a crucial role in activating CD8+ T cells and 
without these cells CD8+ T cells cannot assume their antiviral function 
appropriately. They also activate APCs and up-regulate MHC (major 
histocompatibility molecules) to promote antigen presentation to CD8+ T 
cells (reviewed in Guidotti and Chisari 2006, Randall and Goodbourn 2008, 
Brideau-Andersen, Huang et al. 2007, Onoguchi, Yoneyama et al. 2007). 
There are two ways by which CD8+ T cells act, either by lysis of the infected 
cell or by production of IFN-γ (reviewed in Doly, Civas et al. 1998) and TNF-α 
which controls viral replication directly by induction of antiviral state or 
indirectly by recruitment of cytolytic NK cells (reviewed in Guidotti and Chisari 
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2006, Randall and Goodbourn 2008, Brideau-Andersen, Huang et al. 2007, 
Onoguchi, Yoneyama et al. 2007.  
 
Figure 1.8: Adaptive immune responses to hepatitis C virus: Role of 
Th1 CD4+ T cells in activation of cytotoxic CD8+ T lymphocytes (CTL) 
and production of IFN-γ and TNF-α in the early stage of infection and 
Th2 CD4+ T cells in the production of antibodies in late stage of the 
disease. 
Earlier studies have shown that patients who spontaneously clear their HCV 
infection show a wide specific and rapidly developing cellular immune 
response (Cooper, Erickson et al. 1999, Lechner, Wong et al. 2000), while in 
chronic HCV infection CD8+ T cells in peripheral blood are relatively low in 
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frequency (He, Rehermann et al. 1999). Similarly the CD4 T cell response is 
more efficient in those who clear HCV associated viremia (Gerlach, Diepolder 
et al. 1999). Sustained help from CD4+ T cells is required by CD8+ T cells, 
presumably in order to keep pace with viral replication and mutation (Lauer, 
Barnes et al. 2004, Burton, Klarquist et al. 2008). In order to resolve HCV 
infection rapid CD8+ T cells responses targeting multiple epitopes are 
pivotal.  In chronic infection T cell responses as seen in the acute stage but 
are lost leading to a decrease in quantity and function of CD8+ T cells (Cox, 
Mosbruger et al. 2005). It is evident that in chronically infected patients 
despite persistent viremia and HCV sequence variation, new epitope 
specificity does not develop, as is seen in acute, self limiting infection. In 
cases where there are abundant CD8+ T cells and the patient slips into 
chronic infection, it is observed that these T cells are defective in function 
and could be referred to as 'stunned T cells'. Stunned T cells have limited 
ability to produce IFN, low proliferation rate and lose their lytic function (Cox, 
Mosbruger et al. 2005). 
1.7.5. Effect of parainfluenza virus 5 (PIV5) on interferon 
induced antiviral state  
Many viruses encode proteins that inhibit both the production of and the 
response to interferons by modulating the interferon signalling pathway and 
inhibiting cellular proteins participating in this cascade.  They can interfere 
with components participating in the expression of ISGs including STAT1, 
STAT2, JAK1, or TYK2 (Cebulla, Miller et al. 1999). Here we illustrate this 
with reference to the PIV5 protein. 
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 1. Structure of parainfluenza virus 5 (PIV5) 
PIV5 previously known as simian virus 5 (SV5) is a non-segmental, single 
stranded and enveloped, negative sense RNA virus (reviewed in Goodbourn 
and Randall 2009) belonging to genus Rubulavrius of family Paramyxovirida 
(Chatziandreou, Stock et al. 2004). In PIV5 a P gene encodes P and V 
proteins which have unique C-terminal domains but the same N-terminal 
domains. The V mRNA is a faithful transcript of the P gene while P mRNA 
has two non-template G residues in its transcript that alter its reading frame 
(Andrejeva, Young et al. 2002, Young, Didcock et al. 2000). The V mRNA is 
implicated in degradation of STAT1.  
2. Mechanisms by which PIV5 circumvents interferon 
responses 
A.  Targeting signal transducer and activator of transcription 1  
As discussed previously in section 1.7.3.2 STAT1 and STAT2 are critical for 
the IFN induced antiviral state as they are the transcription factors which 
transduce IFN signalling.  The V protein of PIV5 forms either direct or indirect 
complexes with STAT1 and is known to block IFN signalling by targeting 
STAT1 for proteasome-mediated degradation (Young, Didcock et al. 2000, 
Carlos, Young et al. 2009). PIV5 infected cells are known to be defective in 
both phosphorylated and non-phosphorylated forms of STAT1 and formation 
of ISGF3 complexes is largely hampered by their absence (Andrejeva, Young 
et al. 2002, Precious, Young et al. 2005). This helps the virus to block both 
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IFN I and IFN II signalling and circumvent the immune responses of the host. 
Blocking IFN signalling prevents the appropriate antiviral response to be 
generated by the host. PIV5 infected cells do not show IFN induced 
responses and the production of ISGs is hampered (Carlos, Young et al. 
2007). 
 
Figure 1.9: PIV5 targeting STAT1 for proteasomal-mediated 
degradation: Inhibition of signalling pathway by PIV5 V protein by 
targeting STAT1 and preventing the activation and production of ISGs. 
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 B. Targeting melanoma differentiation associated gene 5 
 It is also thought that the V protein of PIV5 binds with and inhibits the action 
of IFN-inducible RNA helicase, called melanoma differentiation-associated 
gene 5 (mda-5) that recognises dsRNA and is an activator of IFN-induction 
cascade (Young, Didcock et al. 2000). It has also been debated whether 
PIV5-V does not degrade mda-5 but inhibits the helicase domain of mda-5 
and prevents binding of dsRNA with mda-5 and prevents its activation and 
hence the IFN induction (Andrejeva, Childs et al. 2004, Childs, Andrejeva et 
al. 2009). 
 
Figure 1.10: Inhibition of IFN Induction pathway by PIV5: Mda-5 is 
targeted by V protein of PIV5 and inhibits the signalling of mda-5 and 
Targeted by 
V protein of 
PIV5 
84 
 
RIG-I dependent pathway for the IFN-β induction. Viral dsRNA activates 
both mda-5 and RIG-I which have domains that recruit 
Cardif/VISA/MAVS/IPS-1 which in turn recruits signalling molecules 
which feed into the NFкβ and IRF-3 pathways and lead to the IFN-β 
production.  
1.7.6. Evasion of host immune responses 
As discussed above HCV has the potential to cause both acute and chronic 
infections, however the exact mechanism of its host immune response 
modulation is unclear. The unusual ability of HCV to establish a persistent 
infection may, at least in part, be attributed to its potential to counteract host 
antiviral immune responses particularly the interferon induced defences and 
the cell-mediated acquired immune responses. These properties of the virus 
enable it to maintain chronic infectivity in the hepatitis C patients in 50-80% of 
infections.  
Many viruses have developed mechanisms to block the IFN induced 
pathways at different levels; (Cebulla, Miller et al. 1999) by disruption of 
dsRNA and IFN receptor/JAK-STAT signalling events, inhibition of NFкβ 
functions and by various other mechanisms (reviewed in Levy and Garcia-
Sastre 2001, Cebulla, Miller et al. 1999). For example, parainfluenza virus 5 
(previously called simian virus 5) is known to inhibit immune responses by 
degrading STAT1 and inactivating mda-5 (Precious, Carlos et al. 2007) 
(described in detail above) and  dengue virus is known to act on STAT2 and 
inhibits interferon signalling by degrading it (Ashour, Morrison et al. 2010).  
Some viruses inhibit ISGs for example influenza virus, herpes simplex virus, 
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epstein bar virus and HIV have developed mechanisms to inhibit PKR 
(Kaufman 1999, Cai, Carpick et al. 2000, reviewed in Katze, He et al. 2002). 
It is therefore not surprising to find that HCV has been implicated in immune 
system invasion at numerous levels. 
1.7.6.1. Evasion of innate immune responses by HCV 
The relation between Hepatitis C and interferon (IFN) has been extensively 
studied (reviewed in Tan and Katze 2001, He and Katze 2002, Taylor 2001). 
This is due to its use as therapy against HCV and its intrinsic role as a critical 
component of the host innate immune response. The interaction between 
HCV and IFN is difficult to evaluate as there are very few animal and tissue 
culture models that allow replication of HCV (Bartenschlager and Lohmann 
2001, Gale and Beard 2001). Resistance of HCV to IFN (defined as 
persistence of HCV RNA in patient’s serum after treatment) (Pawlotsky 2000) 
clearly plays an important role in determining the outcome of therapy, thus 
understanding the mechanisms underlying resistance will be of great 
importance in improving responses to therapy.  
Different HCV viral genotype isolates show different levels of sensitivity to 
IFN with genotypes 2 and 3 being more responsive clinically. However, it is 
unclear why these genotypes are more responsive and the lack of a tissue 
culture model for the different viral genotypes precludes a formal analysis of 
viral sensitivity to IFN. For patients with genotype 1 HCV some 
patients/viruses appear to be more sensitive to therapy than others. Some of 
these differences may be due to differences in the host response perhaps 
mediated by IL-28 genotypes but viral variation may also play a role. Some 
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studies have shown that the NS5A region of HCV contains a region – the 
Interferon sensitivity determining region (ISDR) which confers IFN resistance, 
perhaps by interfering with dsRNA activation of PKR. However, not all 
studies support the association between ISDR sequence and the response to 
antiviral therapy (reviewed in Kittlesen, Chianese-Bullock et al. 2000, 
Wertheimer, Miner et al. 2003). 
HCV is also implicated in blocking IFN through interfering with the IFN 
production pathway and attenuating the ISG expression and function. HCV 
infected cells show reduced production of type I IFNs and the NS3/4A 
protease of HCV is believed to play a major role in this phenomenon as 
blocking NS3/4A with an active site inhibitor leads to the restoration of RIG-I 
function and the IFN production in cells infected with HCV (Tasaka, 
Sakamoto et al. 2007). In few studies NS3/4A was shown to interfere with 
IRF-3 (activated by RIG-I) accumulation secondary to Sendai viral infection 
(Breiman, Grandvaux et al. 2005, Karayiannis 2005) and this protease is 
believed to degrade this molecule. As noted previously RIG-I is involved in 
the signal transduction cascade which leads to the IFN production and in a 
hepatoma cell line HCV expression was unable to transduce pathway 
involved in IFN production through RIG-I (Karayiannis 2005). The destruction 
of RIG-I by the HCV protease may play an important role in establishing 
chronic HCV infection and helps explain the mechanism of protease 
inhibitors in controlling infection.  
HCV circulates in plasma in association with lipoproteins and resembles low 
density lipoprotein (LDL) particles. This phenomenon could disguise HCV 
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from the host immunity (Syed, Amako et al. 2010). Moreover, HCV replicates 
in host cells within a membranous web which might compartmentalise HCV 
from cellular nucleases, proteinases and RLRs (RIG-I like receptors) (Gosert, 
Egger et al. 2003).  
Studies suggest that patients who do not respond to PEG-IFN and ribavirin 
therapy have an up-regulation of ISGs before therapy compared to those 
who respond to therapy. In one study, chimpanzees who had chronic HCV 
infection already had ISGs induced maximally and there was no further 
increase in ISGs after IFN therapy (Lanford, Guerra et al. 2007). In contrast, 
patients who respond to therapy show an impressive up-regulation of the 
ISGs after treatment (Honda, Sakai et al. 2010). The reason why this is the 
case is still an enigma but perhaps host induction of ISGs forces the 
development of viral variants that evade type I interferons. 
1.7.6.2. Evasion of acquired immune responses by HCV 
Persistence of HCV infection has been linked with the impairment of the 
acquired immune response (Takaki, Wiese et al. 2000). A number of different 
ways by which HCV kinetics outpace the acquired immune system have 
been described and these are outlined below. 
 A) Immune escape variants evade anti-HCV antibodies  
Chronic infection with HCV is associated with the production of anti-HCV 
antibodies. One possible explanation of why HCV persists despite these 
antibodies is the heterogeneity in the HCV genome produced due to the 
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development of mutations at a very high rate. These mutations are due to the 
infidelity of the NS5B, the RdRp which during viral replication causes 
mutations in the HCV genome. These mutations accumulate successively 
resulting in the emergence of the quasispecies (different but related viral 
genomes) populations (Bukh, Miller et al. 1995) so that the virus has 
considerable heterogeneity and therefore it is hypothesised that the restricted 
antibody repertoire is unable to neutralise all viral variants  in the 
quasispecies gene pool.  Another explanation is that under antiviral 
pressures from the host, HCV undergoes adaptive mutations in the envelope 
gene (HVR-1 in E2) thereby constantly changing the antibody binding domain 
and preventing effective neutralisation of the viral antigen. 
High variability in viral particles is due to the combination of several factors. It 
is partly due to the lack of proof reading activity of viral RNA polymerase 
(reviewed in Moradpour, Cerny et al. 2001), as well as co-evolution of HCV 
along with human populations for millions of years (reviewed in Pybus, 
Charleston et al. 2001) and due to the very high viral replication rates and 
rapid viral life cycle resulting in billions of viral particles produced every day in 
the HCV infected patients (reviewed in Neumann, Lam et al. 1998). 
A number of other mechanisms have been implicated in HCV’s evasion of 
humoral immune responses. These include HCV bound with lipoprotein while 
circulating in host blood mimicing the host molecules and this might protect it 
from host antibodies. HCV glycoproteins have been shown to interact with 
the high density lipoproteins (HDLs) and SR-BI in order to enter the host cell 
and thereby may evade neutralising antibodies (Logvinoff, Major et al. 2004). 
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Moreover, E2 glycans present on the surface of HCV modulate the viral entry 
and non-neutralising antibodies binding or direct cell-cell transfer of HCV may 
be implicated in avoidance of antibody neutralisation (Falkowska, Kajumo et 
al. 2007, Zhang, Wu et al. 2007, Brimacombe, Grove et al. 2011).  
B) Impaired immune effectors 
The immune response to HCV is polygenic with enormous expansion of T 
cells, as is the case with most pathogens. Given this huge expansion and 
mutation of the host response it seems unlikely that viral mutation in a single 
epitope is the only mechanism involved in the persistence of HCV infection. 
This raises the argument that there are mechanisms other than the evolution 
of immune escape variants which are implicated in the chronicity of hepatitis 
C infection (Eisen-Vandervelde, Yao et al. 2004).  
Acute resolving HCV infection is associated with a rapid immune response 
leading to the generation of immune subsets i.e. CD4+ T cells and CD8+T 
cells which target multiple viral epitopes (Wertheimer, Miner et al. 2003). 
Conversely, in chronic infection this response is not seen and comparisons 
show that in chronic infection there was a delay in the formation of 
antibodies, markedly decreased IFN-γ production and lack of rapid expansion 
of immune subsets which only targeted a few epitopes and were insufficient 
to eradicate HCV (Takaki, Wiese et al. 2000). These hypotheses are 
supported by the studies done by Wertheimer et al (2003) who showed that 
people who recovered from the acute HCV infection showed a wide CD4+ 
and CD8+ T-cell response to specific epitopes which was not present in 
those who were chronically infected (Wertheimer, Miner et al. 2003). T cell 
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epitopes on APCs specific to class I and II MHC molecules can get mutated 
leading to a defect in antigen processing and presentation, T cell activation, 
antibody production and viral clearance (Eckels, Wang et al. 2000). In order 
to escape a multicentre cellular immune response, it is thought that multiple 
epitopes need to be altered. In one study, CD4+ T cells were inhibited in 
chimpanzees (previously resolved HCV infection) prior to re-infection. It was 
seen that despite memory CD8+ T cells being present HCV infection 
persisted due to epitope escape mutations in the viral sequence (Grakoui, 
Shoukry et al. 2003). However, epitope substitution was not actively seen in 
chronic infection in one study which suggested that epitope escape is 
characteristic of early infection (Chang, Rehermann et al. 1997). It was found 
that the mutations in the T cell epitopes, caused by replacement with viral 
amino acids, was a median of 16.7 fold higher in patients with persistent 
infection compared to the mutations at other sites and led to an impaired T 
cell recognition (Burke and Cox 2010). In chronic hepatitis C cases where the 
T cell epitopes alteration doesn't affect antigen processing or presentation, 
other factors such as the alterations in T cell receptor (TCR) affecting their 
engagement could be imperative in the mutant selection (Wolfl, 
Rutebemberwa et al. 2008). CD8+T cells reside in the  liver for many years 
and could contribute to the pathogenesis of progressive liver disease 
(Claassen, Janssen et al. 2013). 
In one study, T cell inhibitory programmed death receptor-1 (PD-1) was up-
regulated in those patients who were unable to clear HCV infection (Urbani, 
Amadei et al. 2006). Other reports have shown the presence of these 
receptors in CD8+ and CD4+ T cells. Blocking of signalling through PD-1 
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receptors led to the restoration of activated T cell function (Urbani, Amadei et 
al. 2006, Radziewicz, Ibegbu et al. 2007). However, in another study PD-1 
expression on T cells was also seen in patients with resolved infection and 
there are speculations that PD-1 expression might not be responsible for 
HCV persistence on its own and may need other factors in order to contribute 
to chronic viremia (Kasprowicz, Schulze Zur Wiesch et al. 2008). In settings 
where PD-1 expressions were low despite high HCV RNA, T cell escape 
substitutions were seen. High PD-1 expressions were linked with antigen 
preservation in the chronic infection (Rutebemberwa, Ray et al. 2008). Hence 
PD-1 expression may play a role in the development of chronic infection but 
further studies will be needed to confirm or refute this and the availability of 
monoclonal antibodies targeting these receptors in humans may allow their 
function to be assessed. 
Viral sequence mutations leading to formation of quasispecies, may also 
pose selection advantages by increasing viral replication and evading host 
immunity. Furthermore, viral proteins have been implicated in conferring 
resistance to host defences and in the development of immunomodulatory 
strategies against host defences. There is some evidence suggesting that the 
HCV core protein can interfere with the activation and expansion of T cells by 
interacting with T cells receptors (TCRs) directly. Various researchers have 
shown that the core protein can hinder the magnitude and frequency of T cell 
response (Kittlesen, Chianese-Bullock et al. 2000, Yao, Takasawa et al. 
2001, Yao, Nguyen et al. 2001). Kittlesen et al (2000) studied the 
complement receptor gC1qR which is involved in the activation of the 
complement system and can be inhibited by the core protein directly 
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(Kittlesen, Chianese-Bullock et al. 2000, Yao, Takasawa et al. 2001, Yao, 
Nguyen et al. 2001). Nevertheless, studies have demonstrated the indirect 
effect of core protein in inhibiting the T cell activation and proliferation by 
modulating the cytokines secreted by macrophages and DCs to activate T 
cells (Large, Kittlesen et al. 1999, Lai, Gong et al. 2000, Bain and Inchauspe 
2001, Sarobe, Lasarte et al. 2002, Soguero, Joo et al. 2002).  
HCV E2 protein is considered as another viral component that may be 
responsible for causing immune dysfunction. It has been suggested that it 
may play a role in cross linking CD81 molecules and thereby reducing 
cellular activation (Tseng and Klimpel 2002, Crotta, Stilla et al. 2002) . In one 
study cross linking CD81 molecules by monoclonal antibodies had the similar 
effect on NK cell function as that seen when cells were exposed to the E2 
protein of HCV (Tseng and Klimpel 2002, Crotta, Stilla et al. 2002).  It was 
further observed that E2 not only inhibited the cytotoxicity of NK cells but also 
attenuated the IFN production by NK cells in response to cytokines (Tseng 
and Klimpel 2002). DCs are antigen presenting cells which secrete cytokines 
like TNF-α/IL-12 (myeloid DCs) and IFN-α (plasmacytoid DCs) which derive 
CD4+ T cells towards Th1 and Th2 phenotypes. In one study, where DCs 
from healthy donor were stimulated with HCV core and E1 proteins it was 
seen that DCs became defective in orchestrating the T cell response 
(Sarobe, Lasarte et al. 2002). The data on the effects of different HCV 
proteins have, in the main, been developed by in vitro models in which HCV 
proteins have been presented to immunocytes under carefully regulated 
conditions. It is unclear whether these effects play a major role in chronic 
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HCV infection or whether such effects are laboratory artefacts of dubious 
significance. 
A large body of evidence suggest that Immune responses can also be 
attenuated by the regulatory T cells (Tregs) in chronic HCV infection. 
CD4+CD25+ T cells were found to be in abundance in chronically infected 
individuals compared to those who resolved their infection. These cells not 
only prevent effective CD8+ T cell replication but also prevent secretion of 
IFN- -specific CD8+ T cells (Sugimoto, Ikeda et al. 2003, 
Cabrera, Tu et al. 2004, Boettler, Spangenberg et al. 2005). Furthermore, 
studies on human tissue determine that CD4+FOXP3+ cells are the main 
type of Tregs present in the livers of HCV infected individuals and their 
activity may be protective against hepatic fibrosis (Ward, Fox et al. 2007, 
Sturm, Thelu et al. 2010).  
 
 
 
94 
 
  
Figure 1.11: Viral evasion from the adaptive immune responses: the 
constraints placed on the virus due to the immune pressures of the 
host lead to the clearance or the selection for mutations that 
successfully evade the immune response. nAb = neutralizing antibody. 
TCR = T cell receptor (Burke and Cox 2010). 
In summary, spontaneous or therapeutic HCV eradication requires an 
efficient and multi-centric immune response, while the chronicity of HCV is 
associated with a muted cellular immune response. The mechanisms 
underlying this immunological decline are yet to be fully elucidated. Multiple 
defects in the immune response secondary to HCV infection have been 
debated, some are described above. It is not evident which the most 
dominant phenomenon is or whether they all have equal part in the process. 
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1.8. Hepatitis C infection models 
The lack of robust culture models for HCV has been a major hurdle in 
developing a full understanding of the virus and its replication. In the past 
decade there has been enormous progress in the development of various in 
vitro cell culture systems and in vivo small animal models. These model 
systems have furthered our knowledge of HCV infection, replication and have 
allowed preclinical testing of numerous novel antiviral compounds for the 
treatment of chronic HCV infection and are essential tools to develop more 
effective antiviral compounds. However these systems may be poorly 
representative of the viral replication in patients. 
1.8.1. Cell based in vitro HCV systems 
For years HCV researchers have strived for the development of a suitable 
cell culture system to study the viral replication, life cycle and host invasion 
and to test putative novel therapies. A number of groups tried to propagate 
HCV from patients’ sera into primary cell lines from humans and 
chimpanzees with limited success (reviewed in Bartenschlager and Lohmann 
2000) and earlier studies with HCV failed to generate replication competent 
viral clones. One explanation for this failure was the possibility that mutations 
occurring in the quasispecies gene pool rendered virus non-functional and 
this was enhanced during polymerase chain reaction amplification that led to 
the generation of molecular clones of HCV that were non-viable and could 
not be propagated in the in vitro cultures. However, development of so-called 
‘consensus genomes’ with a master sequence representing the majority of 
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viral genomes circumvented this problem by terminating unsolicited, non-
functional mutations. This led to the construction of a full-length functional 
clone of HCV complementary DNA from a genotype 1a strain (H77) and in 
1997, this was shown to replicate in chimpanzee model. Hence, its RNA 
transcripts were found to be infectious (Kolykhalov, Agapov et al. 1997, 
Yanagi, Purcell et al. 1997). However, consensus genomes constructed 
successively thereafter from genotypes 1 and 2 did not effectively replicate in 
vitro (Bartenschlager and Sparacio 2007). 
1.8.1.1. HCV (sub-) genomic replicon systems  
Sub-genomic viral replicons for other flaviviruses, especially Yellow Fever 
were developed many years ago (Molenkamp, Kooi et al. 2003, Jones, 
Patkar et al. 2005). The success of this approach for a flavivirus, closely 
relating to HCV, led to attempts to generate an HCV replicon. Professor 
Bartenschlager’s group was the first to successfully develop an HCV replicon 
from Con 1 strain (genotype 1b) by generating a bicistronic replicon construct 
engineered by replacing the structural protein-coding region of HCV along 
with P7 with a Neomycin phosphotransferase gene (Neo®) and 
encephalomyocarditis virus IRES element (EMCV IRES) (Lohmann, Korner 
et al. 1999).  EMCV IRES promotes the translation of non-structural protein-
coding sequences crucial for the viral replication. Upon transfection of RNA 
the constructs, manipulated in this way into a permissive cell line (Huh-7), 
drug-resistant (i.e. neomycin-resistant) cell colonies were isolated which had 
high levels of viral replication within them.  These replicons self-amplified 
through synthesis of negative-strand intermediates. Subsequent analysis 
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confirmed that these HCV replicons were indeed capable of self-amplification 
through synthesis of a negative-strand replication intermediate and remained 
stable in cell culture for many years (Lohmann, Korner et al. 1999, 
Pietschmann, Lohmann et al. 2001).  
A much more permissive cell line was generated by treating the replicon 
infected cell line Huh-7 with Interferon alpha (IFN α) and eliminating the virus. 
Retransfection  of this cell line with replicon RNA resulted in much higher 
replication rates (reviewed in Krieger, Lohmann et al. 2001, Lohmann, Korner 
et al. 2001, Lohmann, Hoffmann et al. 2003, Blight, Kolykhalov et al. 2000, 
Blight, McKeating et al. 2003).  The exact mechanism for the enhanced 
replication seen in Huh-7 derived cells is unknown (reviewed in Sumpter, Loo 
et al. 2005) but several such lines were later developed such as Huh-7.5 and 
Huh7-Lunet cells which were permissive to the viral replication (Blight, 
McKeating et al. 2002). Although the mechanism of the adaptation in Huh-7.5 
that allows HCV replication to occur is unknown it seems probable that some 
significant change in gene expression has occurred that allow HCV to 
replicate in these cells. In the replicon itself adaptive mutations have been 
reported along the full length of the non-structural protein encoding region 
and the replicon depends upon these tissue-culture-adaptive mutations in 
order to replicate effectively in host cell lines. These mutations mostly cluster 
in the NS3 and NS5A regions. Although the mechanism by which these 
mutations enhance replication is largely unknown, these may modify the 
activity of viral replicases to enhance RNA replication or alter the 
phosphorylation state of the NS5A protein and affect interaction with VAP-A 
(vesicle-associated membrane protein-associated protein A) of the host 
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Krieger, Lohmann et al. 2001, Abe, Ikeda et al. 2007, Yi, Ma et al. 2007, 
Jones, Patkar et al. 2005, Liu, Ansari et al. 2006, Sarobe, Lasarte et al. 2002, 
Lohmann, Korner et al. 2001, Lohmann, Hoffmann et al. 2003, Blight, 
Kolykhalov et al. 2000, Blight, McKeating et al. 2003, Evans, Rice et al. 
2004). VAP-A is considered to be a host factor vital for HCV replication and 
binds to both NS5A and NS5B. Novel antiviral compounds have been tested 
effectively on the replicon to inhibit the action of proteases like NS3 or the 
polymerase activity of NS5 (reviewed in Bartenschlager 2005) and many 
drugs have been successfully developed using this system. 
There are a number of limitations of the replicon system which are due to the 
failure of the replicon to generate infectious virions and the presence of 
tissue culture adaptive mutations. The later problem is a source of great 
concern as these mutations are not found in naturally occurring isolates and 
when transferred into virus and used to infect chimpanzees the mutations 
showed an attenuated phenotype with defected viral packaging and 
secretion. The relevance of the replicon system to viral replication in humans 
is unclear but there are clear differences with uncertain effects (reviewed in 
Bukh, Pietschmann et al. 2002).  
1.8.1.2. HCV pseudotype particle (HCVpp) system  
To study HCV entry into cells, clearly not possible with replicons, a novel 
pseudotype particle system has been developed. The HCVpp system was 
constructed by packaging HCV envelope glycoproteins, E1 and E2 into a 
retrovirus and lentivirus core protein to study the mode of viral binding and 
entry into the cells (Bartosch, Dubuisson et al. 2003). The exact role of the 
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envelope proteins remain to be unravelled though evidence suggests that E2 
possesses receptor-binding properties and establishes covalent binding with 
the viral entry receptors (Pileri, Uematsu et al. 1998, Bertaux and Dragic 
2006). The infectious HCVpp has allowed the identification of many viral 
entry receptors such as CD81 receptor which is necessary but not entirely 
sufficient for HCV entry (Bartosch, Dubuisson et al. 2003, Cormier, Tsamis et 
al. 2004, Lindenbach, Evans et al. 2005, Wakita, Pietschmann et al. 2005, 
Zhong, Gastaminza et al. 2005) and needs the assistance of other receptors 
such as low density lipoprotein receptors, dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN), liver-specific 
intercellular adhesion molecule-3-grabbing non-integrin (L-SIGN) , claudin-1, 
claudin-6, claudin-9 and scavenger receptor class B type1 (SR-BI) (Jia, Du et 
al. 2008, Regeard, Trotard et al. 2008, Stamataki, Grove et al. 2008, von 
Hahn and Rice 2008). Occludin was identified as another critical factor in the 
establishment of HCV entry into the host cells by the use of HCVpp system 
(Ploss, Evans et al. 2009). Moreover, E1 and E2 neutralizing agents 
prevented HCVpp entry into hepatoma cells (Hsu, Zhang et al. 2003, 
Bartosch, Dubuisson et al. 2003, Lagging, Meyer et al. 1998). Hence, HCVpp 
continues to provide understanding of HCV binding, attachment, and 
internalization processes. 
1.8.1.3. Infectious HCV in cell-culture (HCVcc)  
Studies of the release of infectious virion from the replicon system are not 
possible as the replicon does not contain the structural genes. Moreover, 
there has been limited success in attempts to generate full length replicons 
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that contain viral envelopes and release viral particles (Blight, McKeating et 
al. 2002, Pietschmann, Lohmann et al. 2002). In this context, the emergence 
of a genotype 2a consensus genome called JFH-1, isolated from a Japanese 
patient with fulminant hepatitis C, was a major turning point (Kato, Date et al. 
2003).  Replication of in vitro transcribed JFH-1 was 20-fold higher than non-
JFH-1 replicon and it did not require adaptive mutations for replication (Kato, 
Date et al. 2003, Zhong, Gastaminza et al. 2005, Wakita, Pietschmann et al. 
2005). HCVcc has enabled the study of full viral life cycle in vitro. 
Furthermore, this virus is able to infect Huh-7.5 cells directly. The in vitro 
transcribed full-length JFH-1 clone and a genetically engineered chimeric 
genome (another genotype 2a isolate- J6) both produce viral particles that 
are infectious in tissue cultured cells, in chimpanzees and in chimeric mice 
transplanted with human hepatocytes (reviewed in Friebe, Boudet et al. 
2005, Evans, Rice et al. 2004, Lindenbach, Evans et al. 2005, Yi, Ma et al. 
2007). Similarly, HCVcc replicating system from genotype 1a virus (H77-S) 
produces infectious virions in tissue culture on being transfected into the 
permissive Huh 7 cell line but is not as efficient as JFH-1 (Yi, Villanueva et al. 
2006). It has also been possible to produce infectious particles in cell culture 
by Con 1 strain, but again it is not as efficient as JFH-1 and infection is 
marginal (Pietschmann, Zayas et al. 2009). 
Since its discovery seven known HCV genotype envelopes have been 
engineered into JFH-1 but these inter-genotypic variants result in lower 
infectious virion production than wild-type JFH-1 (Yi, Ma et al. 2007, 
Pietschmann, Kaul et al. 2006, Gottwein, Scheel et al. 2009). These 
envelope hybrids do not contain replication enzymes from any strain other 
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than JFH-1 and although success in introducing protease enzymes from 
other genotypes has been achieved (like Jc1-pFK JFH1, J6/C-846 clones 
which contain proteases and NS4A coding sequences from the major 
genotypes) hybrid virions containing other replication enzymes have not yet 
been produced (Imhof and Simmonds 2010).  
In summary, it seems probable that some viral proteins may be transferred 
successfully into replicons and JFH-1 and there have been recent successful 
attempts to generate JFH-1 virions which contain protease domains from 
other viral genotypes. However, to-date it has proven difficult to generate 
replicons or JFH-1 chimeras containing multiple domains from different 
genotypes. This has adversely affected study of combination antiviral therapy 
(Imhof and Simmonds 2010). A number of groups have managed to create 
JFH-1 clones with protease or NS5A or NS5B domains from other viruses (Li, 
Ramirez et al. 2012). They have, however not been able to transfer two 
domains so they cannot study combination therapy – hence HCV replicating 
model with heterogeneous patient genotypes is critical in the new direct 
acting anti-viral combination era.  
1.8.1.4. Primary human hepatocytes (PHHs) cell culture  
The lack of efficient HCV propagation in PHHs through sera of infected 
patients has been a major hurdle in the development of in vitro culture 
systems for HCV. This could be attributed to the loss of differentiated 
phenotype, minimum cell division, lack of reproducibility and low level of HCV 
replication in hepatocytes outside human body. HCV specific antibodies in 
the serum of infected patients might be the cause of impaired replication in 
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vitro (reviewed in Gondeau, Pichard-Garcia et al. 2009, Bartenschlager and 
Lohmann 2001). Moreover, it is well known that the liver has a highly 
specialised and heterogeneous structure and the in vitro systems with similar 
level of complexity have proven problematic.  
Primary human hepatocytes (PHH) are closest to the physiological liver cells 
in vivo. However, it has not been possible to infect PHH with serum derived 
HCV. Moreover, their life span decreases due to the loss of differentiation 
phenotype. Various groups have tried different techniques to increase the 
longevity of hepatocytes and to maintain their specific functionality by 
growing them with other cells to create co-cultures, by creating 3D 
environment for cell-to-cell interaction i.e.; matrigel embedded liver cell lines 
and by growing in the extracellular matrix etc (reviewed in Bhatia, Balis et al. 
1999, Sivaraman, Leach et al. 2005, Khetani and Bhatia 2008). In one study, 
Ploss et al. have described a robust but relatively cumbersome technique 
using a stensil (microscale) to grow hepatocytes and fibroblasts in spheroids 
in order to maintain hepatocyte phenotype, polarity and cell-to- cell contact.  
This procedure was referred to as micropatterned co-culture technique. It 
was used to demonstrate all stages of HCV life cycle and could maintain 
HCV infection for weeks (Ploss, Khetani et al. 2010). Complex polarity of 
hepatocytes could not be maintained within most in vitro models. However, 
co-cultured primary human hepatocytes exhibit polarised membranes with 
HCV entry factors localised at sites similar to human liver cells. These co-
cultures generated proto-bile canalicules suggestive of cellular polarity and 
hence, maintain HCV replication for longer (Ploss, Khetani et al. 2010). The 
co-culture model could be used as a platform to test antiviral therapeutics. 
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However, this system is not widely available and has not been replicated 
outside the inventor's laboratory.  
Many groups have tried using other cell types which resemble the in vivo 
phenotypic, function and physiology of hepatocytes. The hepatocytes derived 
from pluripotent stem-cells were used successfully to recapitulate hepatocyte 
biology, metabolic activity and non-transformed differentiated phenotype. 
These cells were engineered to mimic hepatocytes and were either obtained 
from embryonic cell line or induced by reprogramming with various agents. 
Various phases of HCV life cycle have been successfully studied using this 
approach. These cells bear receptors for HCV entry process, demonstrate 
HCV replication and possess ability to release progeny infectious viral 
particles (Yoshida, Takayama et al. 2011, Roelandt, Obeid et al. 2012, Si-
Tayeb, Duclos-Vallee et al. 2012, Wu, Robotham et al. 2012). In one study, 
infection with the virus led to the release of ISGs (reviewed in Marukian, 
Andrus et al. 2011). Moreover, viral replication cessation was carried out by 
the use of specific inhibitors. Though not hepatocytes per se this cell line is 
the closest to the ideal model containing hepatocytes which retain their 
biology and is a major breakthrough in the field of hepatitis C. Important 
stages of HCV signalling pathways can be studied in a greater detail by using 
this system. 
Non-transformed human foetal liver cells (HFLCs) were used in a few studies 
when HCV virions were secreted into the culture for almost 2 months after 
infection and the virus was also reported to induce interferon gene 
expression secondary to established HCV infection. Hence, HFLCs are 
effective prototypes of hepatocytes in vivo and induce HCV genome 
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expression in vitro (Lazaro, Chang et al. 2007, Andrus, Marukian et al. 2011). 
It was however noticed that different donor foetal cells expressed different 
types of ISGs which might not simulate the inflammatory response of in vivo 
hepatocytes (reviewed in Marukian, Andrus et al. 2011).  
1.8.1.5. Immortalised hepatocytes and hepatoma cell lines 
In the light of the above mentioned issues with using primary human 
hepatocytes in vitro, various research groups have generated immortalised 
liver cell lines such as PH5CH and HuS-E cells. Hepatocytes in these cell 
lines were immortalized by using T antigen of simian virus 40 and E6/E7 
genes of the human papillomavirus (Ikeda, Sugiyama et al. 1998, Aly, 
Watashi et al. 2007). However, HCV replication was restricted in these cells 
and the production of viral particles was not observed, which makes them 
unsuitable for long term studies.  
Certain hepatoma cell lines used to evaluate HCV life cycle have served as 
solid platforms for HCV research. As discussed above prolonged interferon-
alfa treatment of Huh-7s (hepatoma cells) after infection with HCV sub-
genomic replicon led to development of highly permissive cell lines. Re-
transfection of clonal subpopulations with HCV replicon led to increased 
replication especially in one cellular clone which was referred as Huh-7.5 
cells (Blight, McKeating et al. 2002).  
Higher viral replication in Huh-7.5 cells is accounted by the defect in RIG-I 
pathway which is an important substrate in imparting immune response 
against HCV (Lanford, Guerra et al. 2003, Sumpter, Loo et al. 2005). 
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Furthermore, HCVpp and HCVcc were able to infect, replicate and release 
infectious particles in Huh-7 and related cell lines for considerably long time. 
These cell lines have contributed to the significant amount of knowledge into 
the biology of HCV. However, as these cells are derived from the human 
hepatocellular carcinoma they have reduced differentiation, abnormal 
proliferation, atypical gene regulation and deviant signalling pathways 
(Durantel and Zoulim 2007). Various groups have used different ways to 
reduce proliferation and improve differentiation of these cell lines. DMSO was 
reported to inhibit cell growth and enhance cytogenetic differentiation of 
hepatocytes by increasing differentiation markers along with supporting HCV 
infection (Sainz and Chisari 2006).  
Hep3B is a hepatoma cell line which shows high level of HCV entry, but low 
level of replication (Sainz, Barretto et al. 2012). Huh-6 cell line derived from 
hepatoblastoma, expresses low levels of claudin-1, affecting the entry 
process of HCV (Haid, Windisch et al. 2010). In one series, the PLC/PRF/5 
cell line taken from a primary liver carcinoma showed three fold higher 
HCVpp entry. However, this cell line did not support HCVcc infection in the 
same series (Blanchard, Belouzard et al. 2006, Benedicto, Molina-Jimenez et 
al. 2009). After comparing different hepatoma cell lines for different aspects 
of viral life cycle it was observed that Huh-7 cells were more supportive of 
HCV replication compared to other cell lines which supported HCVpp entry 
step, but were deficit in maintaining later stages of HCV life cycle (Sainz, 
Barretto et al. 2012). Many factors could be imperative in increasing the 
permissiveness of Huh-7 cells. It is speculated that other cell lines might 
have stronger immune response leading to reduced viral replication. Huh-7 
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cells are thought to express the microRNA-122 (miR-122) gene in higher 
proportions compared to the other cell lines. MiR-122 is a microRNA 
(miRNA) present in abundance in the liver tissue and it paradoxically 
increases HCV RNA replication (Jopling, Yi et al. 2005, Girard, Jacquemin et 
al. 2008). In order to increase our understanding of HCV life cycle it would be 
beneficial to explore other cell lines with greater permissiveness to HCV 
infection as well as examine factors which are responsible for increasing 
HCV replication.  
1.8.1.6. Liver slices 
Lagaye and colleagues (2012) used adult human liver tissue slices to study 
HCV infection in which they showed effective HCV infection and production 
of infectious particles. Liver tissue dissections were obtained from liver 
resections carried out because of the liver metastasis which did not have any 
underlying hepatic disease. Nonetheless, HCV entry into the liver slices was 
inhibited by using neutralising antibodies against CD81 and E2 protein in a 
dose dependent fashion (Lagaye, Shen et al. 2012). This model very closely 
resembles the hepatic microenvironment and dynamics of HCV infection in 
the hepatic parenchyma can be studied by using this model. Limited 
availability and short life of the liver tissue are two major drawbacks of using 
this assay. 
1.8.2. The chimpanzee model for HCV infection 
There are many features in chimpanzees which are similar to humans, most 
likely owing to the close genetic relationship. Chimpanzees are one of the 
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most recognized models for the study of hepatitis C. They played a critical 
role in the discovery of hepatitis C (Choo, Kuo et al. 1989) and continue to 
play a very important role in facilitating our knowledge of HCV infection. They 
have provided us with a platform for the study of natural history, morphology, 
transmission, genetic drift, factors involved in viral clearance, cloning of HCV 
nucleic acid, clinical course of infection, the role of immune responses, virus-
host interaction, intrahepatic responses following infection, immunogenicity, 
efficacy of vaccine and immunopathogenesis (Prince and Brotman 1994), 
(Bukh, Kim et al. 1998, Walker 1997, Bukh 2004, Lanford, Bigger et al. 
2001). Chimpanzees respond differently to drugs as compared to humans 
and mostly show close resemblance to non-responders to interferon and 
ribavirin therapy. In spite of this chimpanzees are important for pre-clinical 
drug testing and to study the pharmacological effects of drugs (Lanford, 
Guerra et al. 2006, Lanford, Guerra et al. 2007, Chen, He et al. 2007, Carroll, 
Ludmerer et al. 2009).  Research on chimpanzees however is increasingly 
limited owing to the ethical constraints and economic issues.  For this reason 
much attention has been focused on the development of small animal 
models. 
1.8.3. Small animal models for HCV infection  
Small animal models like rodents are easily maintained compared to 
chimpanzees because they are small, have short gestational period, are 
routinely used in experimental work, are readily available, are not in the 
category of endangered species, like chimpanzees, and are highly cost 
effective. Most of these rodent models have been rendered immunodeficient 
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by the genetic manipulations and numerous inbred strains can be produced 
to achieve these genetic and immune deficiencies. Furthermore, transgenic 
mice over-expressing HCV proteins have been developed and used over 
many years to study the effects on liver pathology (Kremsdorf and Brezillon 
2007, Barth, Robinet et al. 2008). However, replication in these models 
requires complex manipulations including grafting of human hepatocytes and 
an environment of immune deficiency (Wu, Konishi et al. 2005). 
Almost two decades ago a transgenic strain of mice over expressing the 
urokinase plasminogen activator (uPA) enzyme in hepatocytes was 
developed which exhibited severe liver toxicity (Heckel, Sandgren et al. 
1990) and liver failure. The damaged liver could be repopulated with 
hepatocytes from mice, woodchucks or humans after rendering these mice 
immunodeficient (chimeric human liver uPA/SCID mouse model). These 
grafted cells were integrated in the murine liver and formed an organized 
structure (Meuleman, Libbrecht et al. 2005). Inoculating these models with 
serum from HCV infected donors showed high viral titres, replication was 
observed and infection lasted for months without hepatic damage 
(Meuleman, Libbrecht et al. 2005). In some models HCV replication was 
detected after inoculation with HCV positive patients’ sera for 3 generations 
with the release of infectious particles (Mercer, Schiller et al. 2001). It was 
also noticed that the models containing hepatic cells from different donors 
exhibited different responses. This proved that host factors play an important 
role in overcoming viral infection (Walters, Joyce et al. 2006).  This model is 
by far the closest in physiology to the human infection and has been useful 
for determining antiviral drug efficiency (Hiraga, Imamura et al. 2007, 
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Vanwolleghem, Meuleman et al. 2007, Kneteman, Howe et al. 2009). Some 
of the shortcomings of this model are that the immune deficiency required for 
the successful xeno-grafting restricts studies on the adaptive immune 
responses, the immunopathology and the development of vaccines. 
Additionally, generation of these chimeras is not easy because of the 
requirement of high quality donor hepatocytes. Furthermore, intrasplenic 
transplantation of fresh or frozen human liver cells was to be carried out 
within first 2 weeks of life leading to high mortality rates (Mercer, Schiller et 
al. 2001). The technical difficulties and high costs of this approach restrain its 
widespread use. Hence, this model is not widely accessible and is only 
available in a very small number of centres  (Boonstra, van der Laan et al. 
2009). 
An alternative approach has been tried in a rat model of infection involving 
immunological tolerance to allow the generation of small animal models with 
functional immune cells. The principal underlying the development of an 
immunologically tolerized rat model was to expose foetal rat during the 
immune development stage inside the gravid uterus to human hepatoma 
cells so that the rat immune system would be tolerized to human hepatocytes 
and would not reject transplanted human liver cells after birth. HCV 
inoculated into the spleen of such mice showed 62% infectivity but viraemia 
remained low in this model. Later immune-mediated liver damage did 
eventually take place making this model suboptimal for antiviral drug testing 
(Wu, Konishi et al. 2005). Moreover, the benefit of functional rat immune cells 
was masked by their lack of genuine immune response as seen in humans. 
This muted immune response was due to the lack of recognition of HCV 
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antigens in the presence of human hepatocytes by the rat major 
histocompatibility complex.  
Alternative mouse models with heterotopic human liver grafts have been 
created by implanting human liver fragments under the kidney capsule or 
behind the ear pinna of mice. However, they are subject to progressive loss 
of architecture because of lack of portal circulation and bile drainage (Galun, 
Burakova et al. 1995, Maeda, Watanabe et al. 2004). The loss of heterotopic 
liver graft is a major confounding factor in the interpretation of viraemia and 
low viral replication limits the utility of this model. 
Dorner et al, attempted murine humanisation using genetic approach. In one 
study, two human genes required for HCV entry (CD81 and Occludin) were 
genetically engineered to create a transgenic mouse model. This model was 
used to recapitulate initial steps of HCV entry process. However, there was a 
loss of HCV signal after 72 hours indicating lack of suitable machinery 
required for HCV replication and strong antiviral immunity observed by 
increase in NK cells (Dorner, Horwitz et al. 2011).  
1.9. Genomic diversity of HCV quasispecies  
In an infected individual HCV is present as a heterogeneous mixture of 
closely related but genetically divergent variants, which are known as the 
'quasispecies'. These variants continuously emerge due to accumulation of 
errors caused by the infidelity of RNA dependent RNA polymerase (RdRp) 
and rapid replication rate of HCV producing 1012 virions per day in an 
infected individual (reviewed in Pawlotsky 2003). Their emergence is 
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secondary to the survival response against the host immune system and the 
concomitant antiviral treatment and leads to mutant selection which replicate 
against unfavourable conditions in the host. Changes within the quasispecies 
could be reflected in the resistance to treatment (reviewed in Pawlotsky 
2006).  
Some regions of HCV genome are more prone to nucleotide mutation than 
others depending upon the viral protein function and specificity to the 
immune response. NS3, NS3 helicase, NS5A and NS5B are fairly conserved 
regions. HVR-1 present at the N-terminal end of E2 viral protein is the most 
variable region among quasispecies (reviewed in Pawlotsky 2006). This 
genetic heterogeneity is either spontaneous or is thought to be due to 
immune pressures from the host and neutralising antibodies leading to 
formation of mutants which escape the immune response (Bukh, Miller et al. 
1995). Quasispecies differ from genotypes which show major genetic 
differences amongst them, whereas quasispecies represent minor genetic 
change. Also quasispecies continue to evolve over time, while genotypes 
remain stable.  
Quasispecies analysis has not been directly introduced into HCV 
management. However, it is a major research target. Chronic HCV patients 
tend to have a greater diversity amongst the quasispecies variants compared 
to the patients with acute or self limiting infection (Farci, Shimoda et al. 
2000). The kinetics of quasispecies emergence during acute infection may 
indicate the later course of infection. Quasispecies have epidemiological 
importance and can be used to link infection to its source (Gretch 1997). 
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According to one study, quasispecies variability decreased in responders of 
treatment with interferon and ribavirin compared to non responders, in which 
it either increased or remained stable (Puig-Basagoiti, Forns et al. 2005). 
Quasispecies might vary within the same host among different tissue types 
like liver, extra-hepatic sites like PBMCs, serum and nervous tissue etc 
(Roque Afonso, Jiang et al. 1999). Laskus et al. studied PBMCs and 
autopsies from a broad range of HCV positive immunocompetent subjects 
and found variations in the 5'UTR within the quasispecies found in PBMCs 
which were not found in other tissues. Moreover, results also suggested the 
ability of PBMCs to adsorb quasispecies with different E2 related nucleotide 
sequences compared to the liver and serum (Laskus, Radkowski et al. 2000). 
As PBMCs have limited life span, the formation of unique quasispecies 
variants could be explained by replication of viral RNA within these cells 
(Roque-Afonso, Ducoulombier et al. 2005). 
1.10. Peripheral blood mononuclear cells as reservoir for 
HCV 
Hepatitis C is usually classified as a hepatotropic virus but many studies 
show that it may also undergo productive replication in other cells types. 
Numerous publications suggest that HCV can persist in peripheral blood 
mononuclear cells (PBMCs) as quiescent virus. However, whether 
persistence of HCV RNA and viral proteins indicate significant viral 
replication remains controversial. A number of studies have reported that 
cells belonging to the T and B cell lineage and monocytes/macrophages can 
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sustain HCV RNA even after treatment and this persistence of HCV 
replication in PBMCs could have a role in the late recurrence of HCV even 
after apparently successful treatment and may indicate a possible role of 
monocytes/macrophages acting as sanctuary sites for HCV (Sansonno, 
Iacobelli et al. 1996, Laskus, Radkowski et al. 2000, Bain, Fatmi et al. 2001). 
In one study HCV RNA was detected in monocytes and B cells of HCV 
patients (HBsAg negative and HIV seronegative patients). Moreover, as 
discussed above, PBMCs containing unique variants with nucleotide 
sequence that differed from HCV in other sites have been identified, 
suggesting that either viral replication and persistence may take place in 
these cells or that the cells differentially take up different HCV quasispecies 
(Ducoulombier, Roque-Afonso et al. 2004). Additionally, many other RNA 
and DNA viruses are also lymphotropic (Oldstone 1996) and these immune 
cells clearly demonstrate abnormal functions when infected with hepatitis C 
infection (Ducoulombier, Roque-Afonso et al. 2004).  
Replication is evident in PBMCs when negative (anti-genomic, minus, anti-
sense) stranded HCV RNA intermediates are generated but there is a lot of 
controversy about the assays used to detect negative strand RNA. The 
demonstration of HCV negative strand RNA is regarded as the hall mark of 
viral replication since viral proteins and HCV positive strand RNA may be 
present in the cells as a consequence of engulfment rather than replication. 
Moreover, it has been suggested in a few studies that the presence of HCV 
RNA in mononuclear cells could be from viral genomes trapped inside cells 
or adsorbed onto the cell surface (Lanford, Chavez et al. 1995, Laskus, 
Radkowski et al. 1997, Meier, Mihm et al. 2001). In previous studies 
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detection of negative strand has been performed by reverse transcriptase 
polymerase chain reaction which detects HCV RNA (Kao, Chen et al. 1997) 
and which uses a positive strand primer to specifically bind to negative strand 
RNA and initiate the amplification of negative strand. It is well known that the 
specificity of the product is critically dependent upon the specificity of the 
initiating primer. Various studies have debated that strand specificity could be 
an issue and considered the possibility that positive strand RNA could act as 
a template and lead to false priming of ‘wrong’ strands (Gunji, Kato et al. 
1994, Lanford, Sureau et al. 1994). Furthermore, it was speculated that non-
strand specific self-priming, because of strong secondary structures or 
contamination of nucleic acid, could lead to random priming and non-specific 
structures formation (Gunji, Kato et al. 1994, Lanford, Sureau et al. 1994). 
Various measures have been taken to eliminate these issues which include 
blocking 3 prime end of RNA chemically which allows only the relevant 
primer to be elongated by RNA polymerase (Gunji, Kato et al. 1994). This 
was undertaken by using tagged RT PCR in which a non-HCV tag is 
attached to the cDNA during its synthesis leading to the amplification of only 
the tagged cDNA by using a primer specific to the tag attached concurrently 
with the HCV oligonucleotide containing primer (Lanford, Sureau et al. 1994). 
Moreover, steps can be taken to limit contamination by doing both reverse 
transcription step and amplification step of PCR in the same tube. These 
steps have reduced but probably not eliminated the possibility of false 
positive results. However, detection of low level HCV replication remains 
problematic with no consensus on whether or not minuscule amounts of 
negative strand HCV RNA can be reliably detected or not.   
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Recent advancements to enhance the sensitivity of strand specific detection 
of anti-genomic HCV RNA by RT PCR have successfully demonstrated the 
presence of negative strand of HCV in PBMCs (reviewed in Sidorkiewicz, 
Grek et al. 2013). Carreňo et al, showed that 5 out of 12 HCV RNA serum 
negative and anti-HCV positive patients had replicating HCV RNA in PBMCs, 
detected by strand specific real time RT PCR. However, it was observed that 
the occurrence of genomic positive strand was higher than the negative 
strand in PBMCs of all 5 patients. (Carreno, Pardo et al. 2006). MacParland 
et al. assessed infectivity of low level replicating HCV by exposing naive 
lymphocytes to the PBMCs from 9 subjects who had apparently achieved 
SVR. Negative strand was demonstrated in 4 out of 11 cultures through HCV 
RNA negative strand specific nested RT PCR combined with southern blot 
hybridization analysis of the subsequent amplicons while positive strand was 
seen in 11 out of 12 cultures. NS5A protein was seen by confocal 
immunofluorescence microscopy in the de novo infected cells. Additionally, it 
was found that the HCV variants found in T lymphocytes were different from 
those found in plasma indicating HCV replication or selective uptake of 
different quasispecies (see earlier) in them (MacParland, Pham et al. 2009). 
Most recently Keyvani at al. found occult HCV infection in 8.9% of the 
subjects by nested RT PCR from a cohort of 45 Iranian patients with 
cryptogenic cirrhosis selected for liver transplantation (Keyvani, Bokharaei-
Salim et al. 2013).  
Hypocholesterolemia is linked with chronic hepatitis C infection and HCV 
particle circulates in blood attached to lipoprotein. It has been shown that 
cholesterol and lipoproteins are essential for HCV uptake and replication 
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(Alvisi, Madan et al. 2011, Felmlee, Hafirassou et al. 2013). Sidorkiewicz et 
al, recently identified that intracellular cholesterol in PBMCs was low in the 
case of chronic hepatitis C patients who had anti-sense HCV RNA in their 
PBMCs. This suggests that hypocholesterolemia could be a harbinger of 
HCV persistence after SVR (Sidorkiewicz, Grek et al. 2013). 
In one recent study, 55 patients undergoing treatment with PEG-IFN and 
ribavirin were studied for the relationship between anti-genomic HCV RNA in 
PBMCs (detected through strand specific RT PCR) and SVR/relapse. Out of 
15 subjects who relapsed, 2 had negative strand before treatment and the 
proportion remained the same at the treatment end point which is in 
conformity with previously reported studies (Radkowski, Gallegos-Orozco et 
al. 2005, Mohamad, El-Bab et al. 2011). This suggests that HCV persists in 
PBMCs of the patients who relapse (Inglot, Pawlowski et al. 2013). 
Surprisingly, it was found that the rate of SVR was higher in individuals who 
had negative strands in PBMCs before treatment (10 out of 33 patients who 
achieved SVR) while none of the patients who achieved SVR had negative 
strand HCV in PBMCs after treatment (0 out of 33 patients). The exact 
reason, why more patients with replicating HCV in PBMCs before treatment 
showed SVR is a paradox. One of the suggestions is that the PBMC linked 
HCV variants might attenuate the immune response. Suppression of HCV 
replication in PBMCs by antiviral therapy might antagonise this negative 
effect on the immune system (Inglot, Pawlowski et al. 2013).  
As discussed in the previous section, HCV exists in its host in the form of 
mutated quasispecies which help it to adapt to the host immune responses 
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by producing immune escape mutants. These quasispecies are found to 
differ from each other in their genomic sequences. It is mostly the hyper 
variable region (HVR1) which is more prone to mutations, perhaps in 
response to subjective pressures from humoral and cellular immunity (Bukh, 
Miller et al. 1995). It has been shown that the quasispecies present in 
PBMCs are different from those present in the serum and the liver of the 
same patient (Okuda, Hino et al. 1999). This has been used as supporting 
evidence for the notion that HCV replicates in PBMCs as the formation of 
quasispecies can only occur in presence of replication (Laskus, Radkowski et 
al. 1998, Lerat, Rumin et al. 1998, Navas, Martin et al. 1998, Laskus, 
Radkowski et al. 2000, Roque-Afonso, Ducoulombier et al. 2005, Di Liberto, 
Roque-Afonso et al. 2006). However, it is possible that PBMCs are infected 
by an entry mode that differs from that seen in hepatocytes and therefore it is 
plausible that differential uptake into PBMCs may be responsible for the 
varying quasispecies distribution rather than replication within monocytes per 
se. Nevertheless, the hypothesis that HCV does replicate in PBMCs has 
been supported by the data showing that HCV can be detected in PBMCs 
through in situ hybridization techniques in which only negative strands are 
detected (Sansonno, Iacobelli et al. 1996). Again the specificity of the 
technique is not beyond question and it remains controversial as to whether 
HCV does or does not replicate in non-hepatic reservoirs. Despite these 
reservations the extrahepatic persistence of HCV RNA has been put forward 
as a possible cause of the relapse of HCV after treatment.  
Revie et al, looked at 75 RT PCR studies done to evaluate the presence of 
replicating HCV RNA in the liver and other human cells. 85% of the studies 
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tested positive in either one or more samples for negative strand intermediate 
in cells other than hepatocytes. The review also evaluated studies which 
looked at the viral replication through other methods like 
immunofluorescence, immunohistochemistry, in situ hybridisation and 
quasispecies analysis. These other methods also demonstrated that HCV 
RNA replicates in the extrahepatic cells (reviewed in Revie and Salahuddin 
2011). The evidence that HCV causes a number of lymphoproliferative 
diseases (mixed cryoglobulinemia, non-hodgkin's lymphoma etc) apart the 
from liver infection, indicates that HCV also interacts with cells other than 
hepatocytes (Ferri, Greco et al. 1991, Pozzato, Mazzaro et al. 1994, Zignego, 
Ferri et al. 1997, Giannini, Petrarca et al. 2008). Apart from the negative 
strand, presence of NS proteins also signifies replication as they are not 
found in the viral particles and are formed during the replication process.  
In order to replicate HCV should first bind and then enter the cell. In one 
study the binding of soluble form of HCV E2 (sE2) protein with different types 
of PBMCs was analysed. It was found that sE2 binding was parallel to 
expression of CD81. However, monocytes, B cells and dendritic cells had 
some independent factors which supported binding (Yamada, Montoya et al. 
2005). Another study that looked at the binding and internalising of antibody 
bound core and E1 into PBMCs found that in one hour these proteins were 
found on the surface of the cells while after 24 hours surface staining was 
absent and 28% cells showed intracellular staining. This was further 
confirmed by the presence of negative strand on RT PCR (el-Awady, Tabll et 
al. 2005). Marino et al, showed that stimulating monocyte (U937 and 
monomac-6) and T lymphocyte (MOLT-4 and jurkat) cell lines by IFN-γ and 
119 
 
phorbal myristate (PMA) to up-regulate Fc receptor expression enabled the 
immune complex bound HCV entry into the monocytic but not the 
lymphocytic cell lines. Furthermore, anti-genomic strands were detected for 7 
days in permissive cell lines (Marino, Deibis et al. 2005). 
As discussed above, HCV replication in host cells entails conversion of viral 
genome into anti-genomic strand and then back into positive strand. 
Therefore, negative strand within the cell signifies replication process. Initially 
many investigators showed that PBMCs contain negative strands by using 
regular PCR (Bouffard, Hayashi et al. 1992, Henin, Makris et al. 1994, 
Manzin, Candela et al. 1994, Muller, Kallinowski et al. 1994, Willems, 
Peerlinck et al. 1994, Lohr, Goergen et al. 1995, Ounanian, Gueddah et al. 
1995, Crovatto, Pozzato et al. 2000, Karavattathayyil, Kalkeri et al. 2000, 
Goutagny, Fatmi et al. 2003, Natarajan, Kottilil et al. 2010). Bone marrow 
cells, brain and oral tissues were also found to contain negative strands 
(Fong, Shindo et al. 1991, Horiike, Nonaka et al. 1993). PCR is a sensitive 
technique in which viral RNA is converted into DNA by reverse transcriptase 
(RT). Previously nested PCR was used to acquire amplicons from a specific 
region of genome. The main issues with regular PCR are the formation of 
false positives due to self-priming or priming with contaminated RNA or DNA 
in the reaction mix. Steps to improve the efficiency and accuracy of PCR 
were tested, e.g.; inactivation of reverse transcriptase (RT) by either 
proteinase K or extended heating, RNase mediated removal of RNA and 
dilution of RT. These steps reduced the chances of false positives 
considerably. Some studies used tagged primers (additional sequence at 5' 
end which was not related to the amplicon) for RT step and rTth polymerase 
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(functions at high temperature i.e.; 70-74ºC, to reduce chances of false 
positives). The need to perform nested PCRs is also reduced due to 
availability of systems which can detect very low level of RNA (Sangar and 
Carroll 1998).  
Revie et al, evaluated studies which used PCRs with either one or more 
modifications discussed above. Almost all studies reported the existence of 
replicating intermediate (minus-sense RNA) in PBMCs (Takehara, Hayashi et 
al. 1992, Wang, Sheu et al. 1992, Gunji, Kato et al. 1994, Navas, Castillo et 
al. 1994, Shindo, Di Bisceglie et al. 1994, Yun, Sonnerborg et al. 1994, Artini, 
Nisini et al. 1995, Lanford, Chavez et al. 1995, Muratori, Giostra et al. 1995, 
Taliani, Badolato et al. 1995, Chang, Young et al. 1996, Lerat, Berby et al. 
1996, Mihm, Hartmann et al. 1996, Kao, Chen et al. 1997, Laskus, 
Radkowski et al. 1998, Lerat, Rumin et al. 1998, Mellor, Haydon et al. 1998, 
Laskus, Radkowski et al. 2000, Lin, Fevery et al. 2002, Authier, Bassez et al. 
2003, Gong, Lai et al. 2003, Fournillier, Freida et al. 2004, Nielsen, 
Bassendine et al. 2004, Pham, MacParland et al. 2004, Blackard, Smeaton 
et al. 2005, Carreno, Pardo et al. 2006, Sansonno, Tucci et al. 2007, Pham, 
King et al. 2008, Inokuchi, Ito et al. 2009, Lin, Libbrecht et al. 2009). 
However, despite numerous studies suggesting the presence of replicating 
virus in PBMCs, this subject remains controversial. The fact that the ratio of 
positive to negative strand in extrahepatic cells is 10 to 1 respectively and  
the negative strands in extrahepatic sites are one tenth of the amount of 
negative strands in hepatocytes, proves that the ratio of negative strand in 
hepatocytes and PBMCs will be 1 to 1000 respectively (Fong, Shindo et al. 
1991, Laskus, Radkowski et al. 1998). Moreover, the studies which found 
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replicating RNA in the extrahepatic cells did not consistently find it in all 
patient samples, the reason for this is not clear.  
In one series, mothers containing anti-sense viral RNA in their PBMCs 
transmitted HCV infection to their babies compared to those without 
replicating anti-sense viral genome in their PBMCs (Azzari, Resti et al. 2000). 
However, the confounding factor could be difference in concentration or 
some indeterminate factor as not all mothers who transmitted infection had 
negative strand in their PBMCs. In another series, it was found that HCV 
positive individuals who used intravenous drugs were more likely to have 
negative strands in their PBMCs compared to non-IVDU HCV positive 
subjects (Resti, Azzari et al. 2002). IVDU might lower the immune response 
to the virus but this could also be due to prolong time after infection. These 
studies suggest that negative strands are present in PBMCs at varying 
amounts and different factors affect the likelihood of them getting detected. 
In situ hybridisation (ISH) technique was used to detect negative strand in 
PBMCs in various studies. It is three times less sensitive than RT PCR. In 
addition negative strand concentration is much less than the positive strand 
(Agnello, Abel et al. 1998). Moreover, detection of single stranded RNA could 
be impaired due to the formation of double strand by negative and positive 
strands. This problem is however tackled by denaturing tissue RNA at 95ºC 
before probe is added but there is a potential of underestimating the 
presence of infection in cells by this technique. Many studies done to detect 
viral replication by ISH have provided evidence of the presence of replicating 
intermediates in PBMCs (Moldvay, Deny et al. 1994, Tian, Yang et al. 1998, 
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Rodriguez-Inigo, Casqueiro et al. 2000, Castillo, Rodriguez-Inigo et al. 2005). 
HCV positive strand was detected in 18 patients with occult HCV infection in 
one study by using RT PCR and flourescent ISH. Negative strand was 
detected in 61% of those with concordant results between the two methods 
(Castillo, Rodriguez-Inigo et al. 2005).  
Another way of analysing HCV replication is by the analysis of viral protein 
through immunostaining. Viral protein formation is an essential step in HCV 
replication as discussed previously. The disadvantages of using this 
approach are that low level HCV might make viral protein detection 
problematic. Also antibodies against NS proteins might not react with NS 
proteins in every sample which makes it essential to test various antibodies 
before choosing the one which gives accurate results (reviewed in Revie and 
Salahuddin 2011). The majority of immunohistochemistry and 
immunofluorescence studies have demonstrated the presence of viral 
proteins in PBMCs. Various antibodies against NS3, NS4, NS5 and core 
protein have been used and detected HCV proteins in PBMCs (Blight, 
Lesniewski et al. 1994, Sansonno, Cornacchiulo et al. 1995, Gong, Lai et al. 
2003, Benkoel, Biagini et al. 2004, Pal, Sullivan et al. 2006, Pham, King et al. 
2008, Coquillard and Patterson 2009, Sir and Kim 2010).  
Quasispecies analysis of HCV in the extrahepatic cells has been performed 
by the single-strand conformational polymorphism analysis (SSCP) and by 
the cloned sequence variants. 5'UTR and HVR1 have been looked at most 
frequently in many studies. In SSCP bands from different tissues are 
sequenced, however one band could contain more than one variant leading 
123 
 
to underestimation of the results. Various studies have compared liver 
variants with the other tissues and found differences between variants 
present in different sites (Maggi, Fornai et al. 1997, Navas, Martin et al. 1998, 
Radkowski, Wang et al. 1998, Okuda, Hino et al. 1999, Roque Afonso, Jiang 
et al. 1999, Bain, Fatmi et al. 2001, Laskus, Radkowski et al. 2002, 
Radkowski, Gallegos-Orozco et al. 2005, Pal, Sullivan et al. 2006, Blackard, 
Hiasa et al. 2007, Ramirez, Perez-Del-Pulgar et al. 2009, Bokharaei Salim, 
Keyvani et al. 2010, Li, Sullivan et al. 2010, Ramirez, Perez-del-Pulgar et al. 
2010). Revie et al, examined 44 studies, out of which 43 studies showed 
large differences in the quasispecies variants among different tissue types 
while only one study showed just a small difference among variants 
(reviewed in Revie and Salahuddin 2011). Many studies found quasispecies 
difference in HVR1 and 5'UTR among the liver, serum and extrahepatic cells 
(Maggi, Fornai et al. 1997, Forton, Karayiannis et al. 2004, Vera-Otarola, 
Barria et al. 2009, Li, Sullivan et al. 2010). It was also found that some 
variants had higher replicative capacity compared to the others and some 
tissues like brain resided variants showing lower translation frequency 
(Forton, Karayiannis et al. 2004). These studies suggest that the 
quasispecies difference affects the replicative capacity of HCV in different 
tissues. It was observed that in some patients there was considerably high 
quasispecies variability between two type of cells and this variability 
increased with time, hence longer the time of infection, higher the 
quasispecies variability amongst different tissues (Cabot, Esteban et al. 
1997, Cabot, Martell et al. 2000, Cabot, Martell et al. 2001). In a study 
following 4 patients for quasispecies diversity during a course of 18 years, it 
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was observed that HCV evolved through four stages in which it established 
an infection, variants evolved into subpopulations, diversification of variant 
subpopulations took place and new subpopulations emerged and in the last 
stage negative selection took place leading to adaptation to the host 
environment. However, the major drawback of this study was a small sample 
size (Ramachandran, Campo et al. 2011). This variation in quasispecies 
gene pool could either be due to the ability of HCV to adapt to different 
environments in different tissues or due to different binding capacities of 
different tissues selecting some variants and rejecting the other.  
By infecting significant proportion of PBMCs, such as B and T lymphocytes, 
monocytes, macrophages and dendritic cells, HCV could interfere with both 
the innate and adaptive immune responses of an individual (Blackard, 
Smeaton et al. 2005, Blackard, Hiasa et al. 2007). By infecting immune cells 
and interfering with their ability to mount an immune response HCV persists 
in the host. The pathogenesis of extrahepatic disease could be explained by 
the ability of HCV to infect lymphocytes. Furthermore, if PBMCs are 
reservoirs of HCV RNA, they could contribute to re-infection of a graft after 
transplantation. Reports that PBMCs could be detected in the individuals 
whose serum HCV RNA disappeared after treatment could be the reason 
why  the viral relapse took place in these patients (Marukian, Jones et al. 
2008). 
1.10.1. Role of monocytes/macrophages in harbouring HCV  
Replication of HCV in extrahepatic sites has been under research for more 
than a decade and as discussed in previous section, one of the 
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compartments thought to house HCV is the PBMCs. However, due to the low 
level viral replication this remains a controversial issue. Monocytes and 
macrophages are known to house many replicating viruses. They are 
permissive to a wide range of viruses including other flaviviruses (Mogensen 
1979). Monocytes/Macrophages are thought to harbour sanctuary sites for 
HCV viral persistence even after treatment with standard HCV antiviral 
therapy and may act as Trojan horses for ' occult' HCV infection. They might 
have a role in the relapse after treatment and re-infection of the graft after 
transplantation. 
'Occult' HCV infection is described as the presence of HCV RNA in the liver 
tissue and PBMCs (detected in 70% of the cases with occult infection), after 
clearance of HCV RNA and anti-HCV antibodies from the serum of an 
individual in response to anti-HCV therapy. Occult infection can be identified 
in 87% cases after combining the results of HCV RNA detected in PBMCs 
and ultracentrifuge serum samples. This could be a step towards detecting 
occult infection without the need for liver biopsy (Bartolome, Lopez-Alcorocho 
et al. 2007). Infection in PBMCs has also been reported to have a link with 
the presence of anti-HCV antibodies and normal ALT levels years after 
resolution of infection (Pham, MacParland et al. 2004, Radkowski, Gallegos-
Orozco et al. 2005, Radkowski, Horban et al. 2005).  
Replicating forms of HCV RNA have also been reported in the 
monocytes/macrophages from HCV and HIV co-infected individuals (Laskus, 
Radkowski et al. 2000). Naïve human monocytes/macrophages are reported 
to be susceptible to infection with HCV in tissue culture and it has been 
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shown that the concomitant HIV infection facilitates the HCV infection in vitro 
(Laskus, Radkowski et al. 2004). Numerous studies have shown evidence of 
active HCV RNA replication in HIV and HCV co-infected patients (Laskus, 
Operskalski et al. 2007, Laskus, Radkowski et al. 2004, Laskus, Radkowski 
et al. 1998, Laskus, Radkowski et al. 2000). Human immunodeficiency virus 
has been shown to facilitate HCV replication in monocytes/macrophages of 
the host and this may help to explain why mothers co-infected with HIV and 
HCV are more prone to transmit HCV infection to their off springs 
(Granovsky, Minkoff et al. 1998, Thomas, Newell et al. 1998). Furthermore, it 
is thought that the viral dormancy in PBMCs, even after treatment induced 
clearance of HCV from serum, can lead to the reactivation of infection 
especially under conditions of immune suppression and this might have a 
role in the extrahepatic manifestations of HCV infection (Ferri, Monti et al. 
1993). Various studies have confirmed the relationship between the viral 
relapse and the presence of replicative intermediate in the extrahepatic sites 
especially PBMCs (Xu, Xie et al. 2005, Majda-Stanislawska, Bednarek et al. 
2006, de Felipe, Leal et al. 2009). However, testing extrahepatic cells for 
HCV replication is not done routinely in order to assess the treatment 
outcome. Moreover, it is not known whether HCV negative strands in PBMCs 
effects the treatment response. 
HCV infection in monocytes was first reported in the 
monocytes/macrophages of HIV and HCV co-infected patients (Laskus, 
Radkowski et al. 2000). Laskus et al. found that two out of seven cultures of 
purified monocytes/macrophages had negative strands isolated for 21 days. 
Radkowski et al. isolated fresh macrophages from healthy subjects and 
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subjected them to the sera of HCV positive patients. 16 out of 25 cultures 
produced HCV negative strands for 14-21 days. SSCP and sequence 
analysis of the 5'UTR region showed that 4 cultures had different sequence 
variants compared to the initial sera. Moreover, the infected cultures had 
larger quantities of IL-8 and TNF-α compared to the uninfected cultures 
(Radkowski, Bednarska et al. 2004). The same group then looked at the 
infection of healthy monocyte/macrophages first with HIV and later with HCV. 
It was found that all cultures which were infected with HIV showed HCV 
replication where as HCV infected cultures showed infection only in 50%, 
concluding that HIV might facilitate HCV infection in macrophages (Laskus, 
Radkowski et al. 2004). Similarly, studies with immature- and mature- 
dendritic cells showed positive strands for 10 and 5 days respectively while 
negative strand was seen for 1-2 days in both types (Navas, Fuchs et al. 
2002). 
The JFH-1 genome from a patient with fulminant hepatitis contains a virulent 
strain of HCV and is able to produce infection in Huh 7.5 cells; however 
studies have failed to demonstrate the infection of in vitro monocytes, 
macrophages, DC cells, B-cells and T-cells through JFH-1 (Marukian, Jones 
et al. 2008). Though able to infect a permissive cell line (Huh 7.5 cells), this 
could be one of the setbacks of the in vitro derived HCV which may not mimic 
the HCV infection of PBMCs in vivo. Also Huh 7.5 cells are hepatoma derived 
cells with defective HFE protein (human haemochromatosis protein) (Vecchi, 
Montosi et al. 2010) and RIG-I (RNA helicases) (Sumpter, Loo et al. 2005). 
Therefore, synthetic models should be approached with caution as they 
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might not truly replicate in vivo results. Furthermore, the unusual genome 
(JFH-1) could behave differently to typical HCV infections.  
Caussin-Schwemling et al. infected monocytes/macrophages obtained from 
healthy donors by subjecting them to sera of genotype 1b positive HCV 
patients. Low level viral replication was seen on RT PCR. Sequence analysis 
of HVR1 showed distinct variant tropism to monocytes/macrophages  
(Caussin-Schwemling, Schmitt et al. 2001).  
Cultures containing HCV infection within PBMCs have been produced by 
many investigators, however HCV levels start dropping after 3 weeks which 
is most likely due to the maturation of macrophages after 2 weeks of 
culturing, thus releasing cytokines that inhibit other cell types (Salahuddin, 
Markham et al. 1982). Revie et al. developed a culture system by infecting 
macrophages obtained from umbilical cord blood with the plasma or serum of 
HCV infected individuals and its supernatant was used to infect other cell 
types such as B and T cells, lymphoid cells and neuronal cells (Revie, Braich 
et al. 2005). It has been speculated that macrophages might modify the HCV 
virus by up-regulating certain factors which promote its infection or select 
variants which could be replicated in PBMCs. As infection of Huh 7.5s has 
not been carried out through this system, it is not known whether the HCV 
variants selected through macrophages would infect hepatocytes. In another 
series from the same group it was reported that the cord blood macrophages 
were not susceptible to infection by genotype 3 strain of HCV and it was 
presumed that these macrophages might preferentially select genotype 1 
HCV (Revie, Alberti et al. 2010). It is not clear how HCV infects monocytes 
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and macrophages and whether HCV uses the Fc receptor to internalise into 
macrophages or not. Few in vitro studies with macrophages suggest that 
genotype 1 HCV might preferentially proliferate in macrophages (Revie and 
Salahuddin 2011) and it is suggested that this may explain the resistance of 
this genotype to interferon based therapies.  
Coquillard et al. used simultaneous ultra-sensitive subpopulation 
staining/hybridization in situ (SUSHI) to assess HCV infection in different 
subsets of monocytes acquired from HCV infected individuals, with and 
without HIV co-infection. It was determined that CD14++/CD16++ and 
CD14+/CD16++ monocytes showed HCV infection while CD14++/CD16- 
monocytes did not. This selective monocyte tropism was analysed further 
and it was found that permissive subsets had up-regulation of CD81 
receptors on their surfaces. Nonetheless, this study only looked at infection 
from genotype 1 strain of HCV and the findings cannot be reciprocated with 
other genotypes (Coquillard and Patterson 2009). 
In summary, the work to-date on HCV entry and replication in PBMCs is 
inconclusive. There is a potential for artefacts in the studies of PBMCs' 
compartmentalisation due to sampling error induced by low copy numbers 
and cloning or SSCP approaches. However the overall weight of the 
evidence is for some entry of HCV into PBMCs and, on balance, it seems 
probable that low level viral replication does take place within some of the 
cells. Replication may be enhanced by the presence of HIV. 
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 1.11. Fusion 
Fusion is an important cellular process in which cells with single nucleus 
come close together and make multinuclear cell through a complex process 
preceded by membrane fusion. Although the process of viral fusion to cells is 
well understood, the exact mechanism by which cell-to-cell fusion takes place 
is still largely unknown. It involves different pathways and co-factors which 
orchestrate a process of cell fusion.  This mechanism is seen in different 
physiological processes in the body such as the differentiation of bone, 
muscles and trophoblast cells, during embryogenesis, and during 
morphogenesis.  It is well recognised that biological fusion of cellular 
membranes has a role in cell and molecular trafficking, endocytosis/ 
exocytosis and viral entry. Cell membranes have intracellular pockets which 
undergo fusion and fission to perform these roles (Chen, Grote et al. 2007). 
Cell-to-cell fusion is a specialised type of membrane fusion. Recent years 
have put more emphasis on understanding of the diverse role of cell-to-cell 
fusion in the field of development, regeneration and homeostatic regulation of 
an organism. Viruses contain membrane fusion glycoproteins which enable 
their fusion with host cell membrane and mediate transmission of viral 
particles into the host cells. These attachment proteins create initial contact 
between the viruses and cells and mixing of two membrane bilayers occur 
(Skehel and Wiley 2000, Kielian 2006). It is well known that both monocytes 
derived dendritic cells and those residing in the tissues bear receptors for 
virus envelope glycoproteins. They may enable dissemination of viruses to 
lymphoid cells through these receptors. One such example is dendritic cell 
mediated transmission of HIV to T lymphocytes through the cell surface 
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receptors (i.e. DC-SIGN) (Zoeteweij and Blauvelt 1998, Engering, Van Vliet 
et al. 2002, Geijtenbeek and van Kooyk 2003). 
 1.11.1. Mechanism of cellular fusion 
There are various molecular hypotheses about how cell-to-cell fusion takes 
place but the exact mechanism remains an enigma. It is said to be an 
important cellular event which plays a major role in many physiological and 
pathological processes. Molecular events which orchestrate the fusion 
process are thought to be cell type and species specific but are known to 
share some similarities (Chen, Grote et al. 2007).  One hypothesis is that 
cells enter a pre-fusion stage prior to fusion under the action of pre-fusion 
signals and cell membranes undergo modulation and orient in a specific 
fashion to mediate adhesive interactions between two cells via specialised 
transmembrane proteins. These interactions can either stabilise the 
membranes for fusion or directly initiate the fusion process (Chen, Grote et 
al. 2007).  
1.11.2. Biological role of cell-to-cell fusion  
Multicellular organisms exhibit cellular fusion in a broad range of 
physiological and pathological processes. Some cells are thought to be 
fusion-competent and exhibit properties which trigger the process while 
others acquire these characteristics secondary to specialised signals 
(Helming and Gordon 2009). Fertilization of sperm and ovum resulting in 
formation of zygote demonstrates fusion in which two haploid genomes come 
together in one single hybrid which has properties different to its parent cells. 
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Myoblast fusion contributes to excessive muscle mass by increasing the 
myofibre size and diameter and hence therapy based upon myoblast fusion 
may be used to treat muscular dystrophies (Skehel and Wiley 2000, Chen, 
Grote et al. 2007). Similarly fusion of monocyte/macrophages in the 
development of osteoclast and fusion of trophoblasts in the placenta are 
good examples of the physiological roles of fusion. Genetic reprogramming of 
somatic cells can take place after fusion with stem cells and may contribute 
to tissue regeneration. Transplanted cells incorporate in regenerating organs 
by fusion and contribute to tissue mass (Chen, Grote et al. 2007, Lluis and 
Cosma 2010). Pathologically, during inflammation fusion of macrophages 
can lead to multinucleated giant cell formation and aberrant fusion process 
can contribute to cancer formation and progression (Chen, Grote et al. 2007, 
Duelli and Lazebnik 2007, Oren-Suissa and Podbilewicz 2007, Podbilewicz 
2006). Additionally, disruption of normal fusion process can lead to 
osteopetrosis (Chen, Grote et al. 2007). Cellular fusion has also been 
implicated in the metastasis of cancer cells. The initial theory dates back to 
1871 when it was proposed that fusion between immortalized cancer cells 
and leukocytes potentiate the hybrid cells to settle in distant areas in the 
body (Pawelek and Chakraborty 2008). This information has driven research 
in this area in order to derive therapeutics to counteract fusion process to 
prevent tumour progression.  
1.11.3. Characteristics of fused (hybrid) cells 
New hybrids are formed after cell-to-cell fusion and are thought to have 
different characteristics compared to their mono-nuclear predecessors. This 
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is thought to be due to reprogramming of cells. Studies have shown that if a 
somatic cell is fused with a stem cell a hybrid with characteristics specific to 
stem-cell might emerge due to reprogramming (Lluis and Cosma 2010, Duelli 
and Lazebnik 2007, Oren-Suissa and Podbilewicz 2007, Podbilewicz 2006, 
Sapir, Avinoam et al. 2008).  When cells from two different lineages fuse they 
result in the formation of a heterokaryons or synkaryon.  Heterokaryon is a 
hybrid cell which is of heterologous nature because it contains two nuclei 
which have not fused. Synkaryon is a fused cell in which nuclei fuse 
(karyogamy) and contain double the normal genetic material i.e.; hybridoma 
cells formed after fusion of murine myeloma cells with B cells of an 
immunised mouse (Lluis and Cosma 2010). 
1.12. Rationale for the studies in this thesis 
There is currently no model system whereby HCV replication from patients 
infected with diverse genotypes can be readily studied. The heterogeneity of 
HCV and the lack of a readily available HCV replication culture containing 
patients’ isolates have contributed to the failure to develop effective direct 
acting antiviral drugs against HCV genotypes other than genotype 1. 
Furthermore, the development of vaccine against HCV and the study of 
neutralizing antibodies have also been hampered. With therapeutic 
advancements in the development of novel antivirals for HCV it will be 
increasingly important to examine the replication of HCV from individual 
patients to assess the drug sensitivity and to determine which combination of 
antiviral agents is most suitable. We speculate that a novel replication system 
for HCV will have widespread clinical and academic uses and the goal of this 
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thesis is to examine different approaches to develop such a system. We have 
adopted two different approaches to develop a new model for HCV infection:  
one involves an ex vivo liver biopsy model using liver tissue from patients 
with chronic HCV infection and the second involves a cell fusion model in 
which monocytes from patients with hepatitis C, which are known to harbour 
virus, are fused with a liver cell line (Huh 7.5s) to generate hybrid, putatively 
infected cells. Here I will describe the experiments and results of these 
studies with emphasis on their technical creation, extent of HCV viraemia, 
infectivity rate and validation by the evaluation of antiviral strategies. 
1.13. Aims and background 
As discussed earlier hepatitis C infection is a global health problem with an 
estimated 130-170 million (3% of global population) infected worldwide. Out 
of the six main genotypes of HCV, viral genotypes 1, 2 and 3 are most 
prevalent in the UK. Therapy with PEG-IFN and ribavirin cures no more than 
50% of patients infected with genotype 1 HCV although response rates are 
increased with other genotypes. New antiviral drugs specifically targeted to 
HCV have the potential to be effective in greater proportions of individuals 
and result in fewer adverse effects and the first wave of direct acting antiviral 
agents are currently widely used for patients with genotype 1 infection.  
The prospects of preclinical drug testing is hampered by the lack of a cell 
culture system which harbours naturally occurring hepatitis C virus derived 
from the hepatitis C patients. To optimally assess the efficacy of new drugs 
and to identify the drug resistance we need HCV cultures for different viral 
strains derived purely from infected individuals. Hepatitis C virus shows poor 
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replication in vitro and currently novel ant-viral drug testing entails reliance on 
the viral replicons which are derived from single viral isolates. Recent 
advances have allowed HCV clones to be propagated in the human 
hepatoma cell line but these viral derivatives (replicons) depend on tissue 
culture adaptive mutations and subsequently lead to the alteration of 
function. Some culture systems are limited to the non-structural gene of a 
single HCV genotype 2a genome (unique strain - JFH-1) derived from a 
single patient. A robust infectious system with clinical isolates of 
heterogeneous nature representing naturally occurring virus does not exist.  
The aim of the work described in this thesis is to develop models which allow 
diverse genotypes and patient derived virions to be cultured thus enabling 
novel drug testing to discover the effect of new drug therapies, individual 
genotype drug response and sensitivities. This was carried out by developing 
two models, an ex vivo liver biopsy model and an in vitro HCV fusion 
replication model. 
Hypotheses to be tested:- 
1.  Fragments of liver tissue from patients with chronic HCV can be cultured 
in vitro and will contain replicating HCV that will be sustained for sufficient 
time to assess the replication of HCV.  
To examine this a short term ex vivo culture system of liver fragments, 
isolated from the biopsies performed on HCV patients, was developed. The 
liver biopsy culture system was tested for hepatocyte viability in tissue culture 
and for the response to different antiviral drugs on heterogeneous genomes 
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of clinically relevant genotypes. As primary human hepatocytes do not 
survive for long in tissue culture we looked at a variety of ways to maintain 
hepatocytes phenotype and to prolong their survival. Furthermore, we 
assessed replication of HCV and monitored its inhibition with a variety of 
antiviral agents, specifically telaprevir and the experimental compound 
NA808. 
2. Replication of HCV in monocytes can be amplified by fusion with 
hepatocyte cell lines.  
As discussed above monocytes of HCV patients are said to harbour HCV, it 
is however not clear whether HCV replicates in these cells or is adsorbed on 
the cell surface. Work in this thesis was based on speculation that fusion of 
monocytes from HCV patients belonging to diverse genotypes with 
immortalised liver cells (Huh 7.5s) would enhance or maintain HCV 
replication. 
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         Chapter Two 
 
               Materials and Methods 
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2.1. Materials  
2.1.1. Liver biopsy culture system 
 A) Liver biopsy samples  
Samples of infected liver tissue were obtained from surplus tissue excised 
from routine liver biopsy samples or from non-malignant tissue from liver 
cancer resection margins at the Royal London Hospital. Approval for this 
study was obtained from The East London and City Research Ethics 
Committee and informed consent was obtained in accordance with the 
Declaration of Helsinki. Samples were processed immediately within an hour. 
All experiment with samples obtained from hepatitis C patients were carried 
out in the containment level 3 laboratory.  
 B) Cell culture consumables 
All tissue culture consumables (tissue culture flasks, pipettes, micropipette 
tips, culture plates) were purchased from VWR International Ltd UK, unless 
stated otherwise.  
 C) Cell culture reagents 
Dulbecco’s modified Eagle Medium (DMEM), foetal calf serum (FCS), non-
essential amino acids, L-glutamine, penicillin-streptomycin, trypsin, 
Dulbecco’s phosphate buffer saline (PBS), and all other chemicals were 
supplied by Sigma-Aldrich Ltd-UK, unless otherwise stated. CellTiter-Glo® 
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Luminescent Cell Viability Assay from Promega Ltd-UK was used to assess 
viability of liver fragments.   
D) Drugs used in experiments 
 
                   Drugs  
  
       Suppliers 
 
 Concentration  
 
Interferon-Alpha 2a 
Telaprevir  Vx950  
(Protease Inhibitor) 
 
NA808 (Serine  
Palmytoiltransferase  
Inhibitor) 
 
Roferon,Roche UK  
Virgil European  
Consortium 
Drug Pharma team 
Chugai Pharma 
Co. Ltd. Japan  
 
500IU/ml 
14.7nM 
 
 
50nM 
500nM 
Table 2.1: Drugs used on HCV infected liver biopsy samples; 
interferon-alpha, telaprevir, NA808 and their suppliers.  
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   E) Reagents used in RNA extraction and cDNA formation 
          
           Products  
 
   Suppliers 
 
TriZOL®  
Propanol for molecular  
biology minimum 99% 
Chloroform minimum 99% 
RQ 1( RNA Quantified) 
RNase-free DNase 
RQ 110X reaction buffer   
(Tris-HCL, MgSO4
, CaCl2) 
      
RQ 1 DNase Stop 
solution (EGTA) 
Oligo (dt) 15 primer  
M-MLV  
Reverse transcriptase  
             
                 Invitrogen UK 
                 Sigma-Aldrich Ltd UK 
             
                 Sigma-Aldrich Ltd UK 
                 Promega UK 
               
                 Promega UK 
 
Promega UK 
 
Promega UK 
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M-MLV RT 5X Buffer 
dNTP  RNasin RNase 
inhibitor 
Promega UK 
Promega UK 
 
Table 2.2: Reagents used in both RNA extraction and formation of 
cDNA.  
 F) Reagents used in PCR reaction 
Primers for HCV-NTR (p1-2, p3-4), B-actin, MxA and 2 5’ OAS were 
purchased from Sigma-Aldrich Ltd UK and 2x Quantitect SYBR green mix 
was supplied by Qiagen UK. 
G) Hepatocyte supplement medium 
Hepatocyte supplement medium contains Dulbecco’s modified eagle medium 
(DMEM) with high glucose, 10% foetal calf serum, L-glutamine, 0.5U/ml 
insulin, 7ng/ml glucagon, 7.5 µg/ml hydrocortisone (insulin, glucagon and 
hydrocortisone were purchased from Sigma Aldrich UK) and 1%penicillin-
streptomycin.  
 H) Collagen type 1  
Collagen type 1 was used to coat the bottom of wells used for growing the 
hepatocytes. It was purchased from (Invitrogen UK). 
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I) Fibroblast culture medium  
Fibroblast culture medium contains Dulbecco's modified eagle medium 
(DMEM) with high glucose, 10% foetal calf serum, L-glutamine and 1% 
penicillin-streptomycin.  
J) Primary human hepatocytes 
Primary human hepatocytes (PHHs) were isolated from surplus liver biopsy 
tissues from HCV patients by the technique described below.  
K) 3T3 murine embryonic fibroblasts 
3T3 Murine embryonic fibroblasts were a kind gift from the Centre for 
Cutaneous Research, Blizard Institute of Cell and Molecular Science. These 
fibroblasts were irradiated by transferring them into 15 ml falcon tubes in 10 
ml DMEM (2x10-6 cells per ml) and gamma-irradiated at 5000 rads for 20-30 
minutes. Fibroblasts were then incubated with hepatocyte supplement 
medium after being 60-70% confluent in DMEM (10% FCS). Hydrocortisone 
and insulin in hepatocyte supplement medium were meant to prevent cell 
division and avoid over-confluence of fibroblasts. 
L) Isolation of primary human hepatocytes  
A few different approaches to separating hepatocytes from the liver biopsy 
fragments were tried. Both mechanical and enzymatic (Collagenases) 
separation techniques were tested. Optimal mechanical dissociation 
143 
 
approach was adopted for all the biopsies. Enzymatic technique using 
collagenases did not give a higher yield of PHHs from liver biopsies 
compared to mechanical dissociation. Cells were gently scraped from the 
biopsy tissue using small cell scraper (18 mm blade) and pipetted up and 
down gently to dissociate them from fibrous tissue. Fibrous tissue was 
separated out using a cell strainer and cells were centrifuged at 500 rpm for 
5mins at 4⁰C to separate them from medium. Hepatocytes were assessed for 
viability using trypan blue selection (75-90%). 
 M) Pure hepatocyte culture  
For pure hepatocyte cultures, PHHs were seeded in wells of polystyrene 
omnitrays which were uniformly coated with rat tail collagen type 1 (From 
Invitrogen UK). 
 N) Co-culture technique 
Type 1 collagen solution (90-100µg/ml) made in distilled water was incubated 
in wells of 12 and 24 well tissue-culture polystyrene omnitrays (Nunc from 
Sigma-Aldrich, UK) for 1 hour at 37⁰C. Any excess collagen was aspirated 
from these wells. Either irradiated or non-irradiated 3T3 fibroblasts were 
grown in these wells for 1 day to reach 40-50% confluence. They were 
incubated in fibroblast culture medium (see above).  PHHs were seeded over 
fibroblasts after 1 day and fibroblast supplement medium was replaced by 
hepatocyte supplement medium (300 µl and 800 µl for 24 and 12 well plate 
respectively). Fibroblast over growth was prevented by the presence of 
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hydrocortisone and insulin present in the hepatocyte supplement medium – 
as these drugs reduce the proliferation of fibroblasts. Hepatocyte to fibroblast 
ratio was estimated to be 4:1. Haemocytometer was used to count cells. 
2.1.2. Materials used for hepatocyte fusion model 
2.1.2.1. Cell lines 
 A) Monocytes from hepatitis C patients 
40-50mls of Blood was obtained from treatment naïve patients with active 
hepatitis C at Royal London Hospital. Ethical approval for the study was 
obtained from Moorefield and Whittington Research Ethics Committee in 
London. Patients were consented in accordance to the declaration of 
Helsinki. Monocytes were extracted from the patients’ blood as described in 
section 2.2.2.2 and 5-10 million monocytes were used in each experiment. All 
samples obtained from hepatitis C patients were handled in the containment 
level 3 laboratory.  
B) Huh 7.5 cell line (human hepatoma cell line) 
Huh 7.5 cell line was obtained from Dr Michael McGarvey, from Imperial 
College London and was originally developed by Dr Keril Blight who obtained 
this cell line from a subpopulation of Huh 7 cell line after eliminating replicon 
from the most permissive Huh 7 cells. Replicon-containing Huh 7 cells were 
first obtained by growing them in non-selective medium for a week and 
subsequently treating with IFN-α for 3 to 4 days to eliminate replicon.  This 
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led to formation of Huh 7.5 cells which is the most viral replication permissive 
‘cured’ sub-line (Blight, McKeating et al. 2002). Before fusion 1x106 Huh 7.5 
were grown in 75 mm3 flasks until 70-80% confluent so that they were in the 
exponential growth phase before fusion. 
C) Replicon cell line 
Replicon cell line was a kind gift from Dr Michael McGarvey from Imperial 
College, London and originally came from Professor Dr. Ralf Bartenschlager. 
It was used as a positive control and contains replicating plasmid construct 
with HCV non-structural proteins NS3-NS5B (explained in Chapter 1, section 
1.2.2.2). These cells were grown in selective medium containing 750 µg/ml of 
G418 (selective antibiotic for neomycin resistance gene) (Blight, McKeating 
et al. 2002). All experiments using replicon cells were carried in the 
containment level 3 laboratories.  
D) Huh 7-J20 cell line  
Huh7-J20 cell line is a secreted alkaline phosphatase (SEAP) reporter cell 
line which was developed by Dr Michaela Iro et al. (Iro, Witteveldt et al. 2009) 
It stably expresses the enhanced green fluorescent protein (EGFP) fused in-
frame with secreted alkaline phosphatase via a recognition sequence of the 
hepatitis C viral NS3/4A serine protease.  
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E) THP-1 cell line 
Human acute monocytic leukaemia cell line (THP-1 cell line) was grown in 
25- or 75- cm3 tissue culture flasks containing Dulbecco's modified eagle 
medium supplemented with 10% foetal bovine serum. 
2.1.2.2. Reagents and other materials  
A) Magnetic-activated cell separation columns and CD14 
microbeads  
MACS separation columns, CD14 microbeads and MACS magnetic 
separator were purchased from Miltenyl Biostech Ltd UK. 
B) MACS buffer 
This buffer was formed by adding 0.2mM EDTA and 0.5% heat inactivated 
foetal calf serum in 500 ml of PBS. 
C) Polyethylene glycol 1500  
Polyethylene Glycol 1500 was purchased from Roche Biosciences Ltd UK. 
D) Primary and secondary antibodies  
HCV-NS5A was stained with a polyclonal sheep anti-NS5A serum (used at 
1/5000 concentration) a kind gift from Professor Mark Harris. Alexa-fluor 488 
nm-conjugated IgG goat anti-sheep (from Invitrogen Molecular Probes UK) 
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was used as secondary antibody against anti-NS5A. Hepatocytes were 
stained with polyclonal rabbit anti-albumin from DAKO (used at 1/500 
concentration) to differentiate them from monocytes. The secondary 
antibodies were PE-conjugated and alexa-fluor 568 nm-conjugated IgG 
mouse anti-rabbit (from Invitrogen Molecular Probes UK). 
2.2. Methods 
2.2.1. Liver biopsy culture model 
                      Overview of experimental steps 
                                       Liver biopsy culture system (A) 
 
                                    Drug treatment and incubation (B) 
 
                                    RNA extraction from liver biopsy (C) 
 
                                          Standardization of samples (D) 
 
                                                 DNase treatment (E) 
 
                                               Reverse transcription (G) 
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                                                    Real-time qPCR  (H) 
 
                                                    Quantification (I) 
2.2.1.1. Liver biopsy culture system 
Tiny fragments of tissue – approximately 1mm3 excised from the end of the 
specimen were processed immediately. The fragments were incubated in 
500 µl DMEM containing 10% Foetal Calf Serum and 200U/ml penicillin 
and 100µg/ml streptomycin (Invitrogen UK) along with the appropriate 
drugs (NA808 at the concentration of 50nM and 500nM, telaprevir at the 
concentration of 14.7nM (10µg/ml) and IFN-α 2a at the concentration of 
500IU/ml). Samples were incubated for 24 and 48 hours at 37˚C and 5% 
CO2.   At the conclusion of incubation cells were isolated from the liver 
biopsy fragments and were lysed by adding Trizol reagent (Invitrogen) and 
then stored at -80°C to be analysed later.  
2.2.1.2. Cell viability  
Cell viability was assessed by an ATP detection assay and by histology at 
different time points after incubation. Trypan blue dye exclusion method was 
used as a crude way to determine the number of viable cells in the cell 
suspension. 
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a) ATP detection assay  
Liver biopsy fragments were dissected and hepatocytes separated out 
according to the method discussed below. The cells were then used in an 
ATP detection assay using CellTiter-Glo® Luminescent Cell Viability Assay 
kit (purchased from Promega. UK) which detects metabolically active, viable 
cells by quantifying amounts of ATP emitted after addition of a single reagent 
(CellTiter-Glo® Reagent) directly to cells cultured in serum containing 
medium after cell lysis. Viable cells are detected within 10 minutes and 
amount of ATP is directly proportional to the number of cells present in the 
culture and is detected as luminescent signal (half-life more than 5 hours). 
Cell viability of primary human hepatocytes was checked after 24 and 48 
hours incubation. Around 1000 hepatocytes in 100μl of culture medium per 
well were seeded in opaque-walled 96-well plates. 96-well plates were 
compatible with the luminometer use. Control wells contained medium 
without cells to obtain a value for background luminescence. 
The plate and its contents were equilibrated at room temperature for 
approximately 30 minutes and a volume of CellTiter-Glo® Reagent equal to 
the volume of cell culture medium present in each well was added. (i.e.; 
100μl of reagent to 100μl of medium containing cells). Contents were mixed 
for 2 minutes on an orbital shaker to induce cell lysis and the plate was 
allowed to stand at room temperature for 10 minutes to stabilize luminescent 
signal. Luminescence was recorded on micro-plate reader - FLUOstar 
Optima plate reader (BMG Labtech, Aylesbury, UK) with integration time of 1 
second per well. 
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b) Histology of liver biopsy fragments 
In experiments performed by Dr Linda Hibbert liver biopsy samples were 
incubated for 24 hours in DMEM (10% FCS) medium, sectioned in paraffin 
and stained with haematoxylin and eosin and then analysed histologically.  
2.2.1.3. RNA extraction from liver biopsy samples 
 a) Isolating cells from liver biopsy fragments  
Liver biopsy fragments were broken down mechanically by using the plunger 
of a syringe and pipetting the samples up and down several times. The 
resulting cell suspension was then passed through a cell strainer to separate 
out fibrous tissue. Cells were then centrifuged at 500 rpm for 5mins to 
separate them out from medium and the cell pellet was then homogenised.   
The cell density of the cell suspension (in DMEM) was determined using 
haemocytometer. 0.1 ml of 0.4% trypan blue solution in phosphate buffered 
saline (PBS) was added to 1 ml of cell suspension and examined under the 
microscope using haemocytometer. The number of blue staining cells and 
the number of total cells were counted. Percentage of live cells with intact cell 
membrane per millilitre was calculated by using the formula: 
% live cells = [1.00 – (Number of blue cells / Number of total cells)] × 100 
Number of live cells per millilitre was calculated as:  
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 Number of live cells × 104 × 1.1 = cells/mL culture. 
 b) Homogenisation 
 Cell culture medium was discarded, and cells lysed directly by adding 1ml of 
TriZOL® (trizol) to each well. Trizol is a mono-phasic solution of phenol and 
guanidine isothiocyanate, it acts by selectively disrupting cells and cell 
components whilst preserving the integrity of nucleic acids (Wong, Lo et al. 
2004). The homogenised cells from each well were transferred to individually 
labelled eppendorf tubes and stored at 80oC. 
c) Phase separation 
To each thawed sample 200µl of chloroform was added; the mixture was 
then centrifuged at 13000g for 15 minutes at a temperature of 4oC. Total 
RNA remains in the aqueous phase, protein in the organic phase and the 
DNA forms a layer between the two.  The aqueous phase was transferred to 
a new tube, and the organic phase stored at 80oC. 
d) RNA precipitation 
RNA was then recovered from the aqueous phase by addition of 500 µl of 
cold (-20oC) isopropanol. Each tube was vortexed and then centrifuged at 
13000g for 15 minutes at 4⁰C. This precipitates the RNA in the form of a 
visible pellet. The isopropanol was removed, and the pellet washed with 1 ml 
of 75% ethanol, the water component dissolving any remaining salt. The 
sample was then vortexed and centrifuged at 7500g for 5 minutes at 4⁰C to 
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re-precipitate the pellet. The ethanol was then removed and the pellet was 
allowed to air-dry for approximately 10-20 minutes, the pellet was then 
dissolved in 40 µl water and warmed at 65⁰C for 5 minutes for adequate re-
suspension. 
e) RNA quantification 
In order to determine the concentration and the purity of the RNA, a 
spectrophotometer with full spectrum i.e.; 220-750nm (NanoDrop ND-1000 
supplied by Labtech UK) was used. The NanoDrop reader was cleaned with 
water to prevent contamination and set up to specifically measure RNA. For 
each sample 2 µl of RNA was placed in the reader and the spectral 
absorbance at 260 and 280nm was recorded. The RNA yield was noted as a 
separate reading in ng/μl for every sample. Purity is determined by the ratio 
of absorbance at 260 and 280nm. Pure RNA is expected to have a ratio of 
1.6-1.8 (in DEPC-diethylpyrocarbonate treated water). If the ratio is lower, 
this indicates protein contamination. 
 2.2.1.4. Standardisation of samples 
The amount of RNA was standardised to 3μg in all samples and genomic 
DNA was removed by DNase treatment (see below) before the reverse 
transcriptase (RT) reaction. We standardised all of our samples so that 3μg 
of total RNA was added to each RT reaction.  
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 2.2.1.5. DNase treatment 
Prior to reverse transcription any contaminating genomic DNA was removed 
by DNase treatment.  3μg samples of RNA were incubated with 4 μl of 
DNase buffer, and 3 μl of DNase. Samples were incubated for 30 minutes at 
37⁰C in a heating block. After that 4 μl of DNase stop solution was added to 
each sample and heated at 65oC for 10 minutes to stop the reaction. 
 2.2.1.6. Principles of reverse transcription 
Reverse transcription is the process whereby mRNA is converted into 
complementary DNA. The reaction is started when oligonucleotide 
deoxythyamine repeats (oligo dt’s) bind specifically to mRNA at the poly-
adenylated 3-prime tail. Reverse transcriptase, an RNA-dependent DNA-
polymerase, then adds specific bases to generate a length of complementary 
DNA (cDNA). RNAsin is an enzyme which breaks down environmental 
RNase and prevents degradation of mRNA. 
 2.2.1.7. Reverse transcription 
In the reverse transcription reaction 2 μl of oligo dT15 (from Promega) were 
added to DNase treated mRNA, and heated at 65oC for 5 minutes. A master-
mix was prepared containing the reagents shown in (table 2.3). To each of 
the sample tubes 24 µl of this master-mix was added. The tubes were placed 
into a heating block for 60 minutes at 42oC.  The cDNA was then stored at -
20°C, until the PCR was run. 
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            Constituents of reverse transcriptase master mix 
Reagent  Amount 
added(µl) 
           5X1st Strand Buffer  14 
dNTP mix (10mM each dNTP) 2.0 
M-MLV Reverse Transcriptase  1.0 
RNAsin  1.0 
Molecular biology grade H20 6.0  
Table 2.3: Constituents added in the reverse transcriptase 
master-mix. 
2.2.1.8. Real time quantitative polymerase chain reaction 
a) Introduction 
Polymerase chain reaction (PCR) uses a DNA-polymerase to amplify a piece 
of DNA by in vitro enzymatic replication.  As PCR progresses, the DNA 
generated is itself used as a template for replication. This sets in motion a 
chain reaction in which the DNA template is exponentially amplified. With 
PCR it is possible to amplify a single or few copies of a piece of DNA across 
several orders of magnitude, generating millions more copies of the DNA 
piece. 
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Real time qPCR is a highly sensitive and specific technique which enables the 
amplification and quantification of a specific nucleic acid sequence with 
detection of the PCR product in real time.   
b) Principles of real time qPCR with SYBR® green 
During real time PCR either genomic or complementary DNA is incubated 
with a primer specific for the gene of interest, a florescent reporter dye, the 
DNA-polymerase and single base nucleotides. The reaction mixture is placed 
into a thermal cycler, in our case the Corbett rotor-gene 6000 (discussed 
below). The sample is initially heated to 95oC to denature the cDNA and 
primers ensuring they are single stranded; the temperature is then reduced to 
the annealing temperature (usually between 50-60oC) allowing the primer to 
optimally bind the cDNA template; finally the temperature is subsequently 
increased to 72oC to extend the primer and form the new copy of DNA. This 
cycle is repeated 45 times and the PCR product accumulates exponentially. 
 c) SYBR® green    
A number of different chemical agents are commercially available to detect 
newly formed cDNA. SYBR® green is a fluorescent dye that binds double 
stranded DNA. It emits fluorescent signals of a specific wavelength on 
binding and excitation with light. Its excitation and emission maxima are 
494nm and 521nm, respectively. Detection takes place during extension of 
PCR product. The signal intensity increases with increasing number of cycles 
due to accumulation of product.  (Illustrated in figure 2.1) 
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QuantiTect SYBR green PCR master mix (from Qiagen UK) was used for the 
second step of qPCR, (Constituents of SYBR green master mix are 
hotStarTaq® DNA Polymerase, QuantiTect SYBR green PCR buffer, dNTP 
mix, including dUTP, SYBR Green I and 5mM MgCl2).  
Figure 2.1:  Detection of DNA amplification in real time PCR: SYBR® 
green binds with double stranded DNA and emits fluorescent signal 
of specific wave length on excitation with light.  
 d) Corbett rotor-gene 6000 
The rotor-gene 6000 (purchased from Qiagen UK) is a real-time cycler that 
enables highly sensitive real time PCR. It links optical system to thermal 
cycler and signal is captured at every step of the reaction and provides direct 
electronic results.  Samples spin continuously during a qPCR run at 400 rpm 
(heating or cooling). High-speed data collection is achieved with all samples 
read in one revolution (0.15 sec). G-force keeps reagent at the base of tube 
 3’  5’ 
3’ 5’ 
Emission 
SYBR green 
 3’ 5’ 
Primer  
Primer extension 
 
Excitation 
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which removes bubbles and prevents pellet formation. The rotor-gene can be 
used in gene expression analysis, pathogen detection, DNA methylation 
analysis, genotyping, gene scanning and miRNA research. 
 e) Cycle threshold (Ct) 
Signal intensity increases with increase in cycle number because of 
accumulation of the product. Data is recorded by the rotor gene 6000, and 
fluorescence plotted against cycle number (illustrated in figure 2.2). For the 
first 3-15 cycles the fluorescence level is too low to be detected (baseline), 
once detected the fluorescence increases through the log-linear phase. As all 
the primer is bound the amount of fluorescence plateaus. The threshold is 
arbitrarily set to a value above the background and significantly below the 
plateau of amplification. The cycle threshold (CT) is the cycle at which the 
amplification plot crosses the threshold, i.e. at which there is a significant 
detectable increase in fluorescence. Non-PCR products and primer dimers 
will also contribute to fluorescence signal. High PCR primer specificity is 
required when using SYBR® green.  
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Figure 2.2: Cycle threshold is shown where the amplification plot 
crosses the threshold, i.e.; at point where there is detectable increase 
in fluorescence. 
 f) Polymerase chain reaction 
Into each reaction tube the reagents (shown in table 2.4) were added.  
A pipetting robot (CAS-1200, Corbett Research) was used to make the 
master-mixes for the real time qPCR reactions. 72 reaction mixtures could be 
run at any one time in the rotor-gene.  
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             Constituents of Polymerase Chain Reaction 
                  Reagents Amount (µl) 
2x Quantitect SyBr green mix (Qiagen, UK) 12.5 
RNase free H20 (Qiagen, UK) 9.5 
Primer mix containing forward and reverse primers 
(12.5pmol each primer; Sigma-Aldrich) 
1 
      cDNA 2 
    Table 2.4: Constituents used in polymerase chain reaction 
The genes to be amplified were HCV NTR (p1-2 and p3-4), β-actin and MxA. 
g) Primers  
Primers were obtained from Sigma-Aldrich, sequences and cycling conditions 
were used according to previously published work (Andonov and Chaudhary 
1995, Wehkamp, Harder et al. 2003, Foster, Masri et al. 2004, Thomson, 
Nastouli et al. 2009) . Sequences and cycling conditions are shown in table 
2.5. 
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 Target  
  Gene 
               Primer sequence 
 
 
Hold 
15min 
 
  
 Denaturation 
     15sec 
 
 
Annealing 
   30sec 
 
  
Extension 
   20sec  
β-actin 
 Sense 
 5’CTGGAACGGTGAAGGTGACA 3’  
Antisense 
5′ AAGGGACTTCCTGTAACAATGC 3’ 
 
95 
 
95 
   
58 
 
72 
HCV 
NTR 
(p1-2) 
 Sense 
 5’ AGCGTCTAGCCATGGCGT 3’ 
Antisense 
5’ GCACGGTCTACGAGACCT 3’ 
 
95 
 
95 
  
58 
 
72 
HCV 
NTR  
(p3-4) 
 Sense  
 5’ GTGGTCTGCGGAACCGG 3’ 
Antisense 
5’ GGGCACTCGCAAGCACCC 3’ 
 
95 
 
95 
  
58 
 
72 
MxA 
Sense  
5’ AACAACCTGTGCAGCCAGTA 3’ 
Antisense 
5’ AAGGGCAACTCCTGAGAGTG 3’ 
 
95 
 
95 
  
58 
 
72 
                Temperature (°C) 
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2’ 5’ OAS 
 Sense  
 
 5’ AACTGCTTCCGACAATCAAC 3’ 
 
 Antisense 
 
 5’ CCTCCTTCTCCCTCCAAA 3’ 
 
 
95 
 
95 
  
58 
 
72 
Table 2.5: Sequences and cyclic conditions of primers: HCV NTR (p1-2) (Chen, 
Lee et al. 2012) and HCV NTR (p3-4) (Harris and Teo 2001), β-actin (Mitsuyoshi, 
Yasui et al. 2013), MxA (Jones, Davidson et al. 2005) and 2'5' OAS (Dondi, 
Rogge et al. 2003).   
h) Melt curve analysis 
Real time confirmation of the specificity of the amplified product is achieved 
by performing a melt curve analysis. In brief at the end of each PCR run the 
temperature was increased slowly from a 72oC to 95oC. At low temperatures, 
all PCR products are double stranded, so SYBR® green binds to them and 
fluorescence is high, whereas at high temperatures, PCR products are 
denatured, resulting in rapid decrease in fluorescence. The fluorescence is 
measured continuously as the temperature is increased and plotted against 
temperature. A melt curve is produced, because fluorescence decreases 
slightly through the lower end of the temperature range, but decreases much 
more rapidly at higher temperatures as the melting temperatures of non-
specific and specific PCR products are reached. The detection systems 
calculate the first derivatives of the curves, resulting in curves with peaks at 
the respective melt temperatures Tm. Curves with peaks at a Tm lower than 
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that of the specific PCR product indicate the formation of primer dimers, while 
diverse peaks with different Tms or plateaus indicate production of non-
specific products. Samples with primer-dimers and non specific products 
were excluded from subsequent analysis. 
 i) Samples and controls 
In each PCR run samples were run in duplicate, with a no template control; a 
control reaction that contains all the essential components of the 
amplification reaction with the template substituted with water, enabling the 
detection of contamination. In addition a RT minus control was included 
enabling the detection of amplified genomic DNA. Lastly a positive control 
sample known to express the genes of interest was included.    
 j) Quantification of real time qPCR 
 1) Absolute quantification method using plasmid standards 
for standard curve generation 
In this method, a standard curve was first generated from DNA (obtained 
from replicon cells) of known concentration for all the genes (β-actin, HCV 
P1-2, HCV P3-4, MxA and 2’5’OAS) by serial dilution, amplification and 
cloning into a standard vector. PCR products were generated by using Go-
taq ® DNA polymerase (each reaction containing 0.125ul) along with 5xGo-
taq buffer (5ul), MgCl2 (2.5ul), dNTP (0.5ul), cDNA or RNase free water in 
case of negative control (2ul), RNase free water (14.88ul), specific primer 
(2ul). Template sizes identified through agarose gel electrophoresis are;  
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 β-actin = 218bp 
 HCVP1-2 = 265bp 
 HCVp3-4 = 174bp 
 MxA = 171bp 
 2’5’OAS = 185bp 
PCR products were purified from dNTPs, enzymes and other reaction 
products using QIAquick PCR purification kit, according to the manufacturer’s 
instructions. 
PCR product was cloned into standard vector (pGEM®-T vector – size 
3000bp, from Promega) according to the protocol given with pGEM® -T Easy 
vector system. These plasmids were later transformed into the bacteria 
(DH5a E.Coli cells) and  the bacterial colonies grown on agar plates at 37  C. 
Colonies were then picked up and added to reaction tubes containing Go-taq 
® DNA polymerase (each reaction containing 0.125 µl) along with 5xGo-taq 
green buffer (5 µl), MgCl2 (2.5ul), dNTP (0.5ul, RNase free water (14.88 µl), 
specific primers (2 µl) and agarose gel electrophoresis was performed to 
chose the colonies containing cloned plasmids. Colonies with appropriate 
bands on gel electrophoresis were grown overnight and plasmid DNA was 
purified from overnight culture of E.Coli in LB (Luria-Bertani) medium by 
using QIAprep spin miniprep kit according to the manufacturer’s instructions 
(some of these cultured samples were mixed with 50% glycerol and stocked 
in -80  C prior to purification). Purified plasmid products were amplified by 
PCR and sent for sequence analysis to Geneservice Ltd UK. Further plasmid 
containing bacterial colonies from glycerol stocks were grown overnight in 
500 ml and further purified by using Qiagen plasmid midi and maxi kits 
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according to protocol provided with the kit. These samples were then diluted 
in 1:1000 to form DNA standards. 
Spectrophotometric measurements at 260/280 nm were used to assess the 
concentration of these DNAs, which were then converted to a copy number 
value based on the molecular weight of the sample used.  The following 
formula was used: 
 
Xg/ µl DNA / [plasmid length in base pairs x 660] x 6.022 x 1023 = Y 
molecules/ µl 
cDNA plasmids are the preferred standards for standard curve quantitation. 
However, since cDNA plasmids don’t control for variations in the efficiency of 
the reverse transcription step, this method only provides information on 
relative changes in mRNA expression. This, and variation introduced due to 
variable RNA inputs, was corrected by normalization to a housekeeping gene 
(β-actin).  
After calculating the number plasmid molecules with the target viral gene in a 
microlitre, a series of dilutions was made to generate a PCR standard curve. 
Though a time consuming process, the use of absolutely quantified DNA 
standards helps to generate absolute copy number data from unknown 
samples. 
2) Comparative CT method 
 
 'Comparative CT method’ to quantify HCV RNA was also used parallel to the 
above method. This method involved comparing the CT values of the 
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samples of interest with a reference or calibrator such as a non-treated 
sample in our case. The CT values of both the calibrator and the samples of 
interest were normalized to an appropriate endogenous housekeeping gene 
(β-actin). 
k) Agarose gel electrophoresis  
This method was carried out to confirm that the amplified product was of the 
expected size. A ladder of fragments of DNA of a known size was used as a 
marker. 3 g of agarose was mixed with 200 ml 0.5X TBE (Tris borate EDTA) 
buffer. This mixture was micro-waved until the agarose had fully dissolved. 
Once cooled, 3 µl of ethidium bromide was added and gently mixed. The 
agarose was poured into the gel tray and the comb positioned. This was 
allowed to set. 5 µl 6X PCR loading buffer (Promega) was added to each 
PCR reaction tube. The comb was removed and the gel was placed into a 
tank of 0.5X TBE running buffer. The wells were washed with the running 
buffer to remove any extra agarose. 20 µl of the sample / buffer mix were 
loaded into the wells. 5 µl of the 100bp DNA marker (Promega; also 
premixed with loading buffer) was added to one well. The electrodes were 
attached and the gel was run at 100 volts until the bromophenol blue dye was 
approximately 4cm from the bottom of the gel. The PCR bands were 
visualized by placing the gel on an ultraviolet light box. 
 l) Statistical analysis 
Each sample was run in duplicate during PCR and the averages calculated. 
Differences in gene expression between treated and non treated samples 
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were analysed using the Wilcoxon matched pair test. The statistical software 
package Prism 5, was used to prepare graphs and perform the statistical 
analyses.  
 2.2.2. Cell-to-cell fusion experiments  
 All experiments were carried out in containment level 3 laboratories. 
2.2.2.1. Separation of PBMCs from blood (density gradient 
separation) 
Blood from the patients (within 4 hours of venesection) was taken into 
preservative free heparin-100 units per 10 ml of blood, and diluted with equal 
amount of Dulbecco's modified eagle medium. 15 ml of ficoll-Paque™ PLUS 
(GE Healthcare, Buckinghamshire, UK) and ficoll was mixed thoroughly 
before use and was added to 50 ml conical tube and 35 ml diluted blood was 
layered carefully on ficoll. After layering the blood over ficoll the tube was 
spun in a bench centrifuge at 2000 rpm for 20 minutes at 20˚C, with brakes 
off. The upper plasma layer was removed and discarded without disturbing 
the plasma-ficoll interface.  Mononuclear cells make a layer at the interface 
between the two liquids and red cells (and majority of polymorphs) go to the 
bottom of the tube. The mononuclear cell layer was transferred into a fresh 
tube, taking this entire layer but with the minimum of the ficoll and tissue 
culture medium layers. The mononuclear cells were diluted with tissue 
culture medium and spun at 1500 rpm for 10 minutes. The medium was 
removed from the cell pellet and the cells were washed twice. These cells 
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were resuspended in a known volume before the last wash and taking a 
small aliquot for counting using a haemocytometer.  The cells were then 
plated over night onto a 75 cm3 flask to allow adherence. Adherent cells were 
separated out from the 75 cm3 flask using a cell scraper, the following day. 
Note: Ficoll, blood and medium were kept at room temperature (15 - 25°C) 
for optimum results. Principle of separation-- Differences in cell density is 
exploited to separate granulocytes and erythrocytes from mononuclear cells. 
Granulocytes and erythrocytes have a higher density at the osmotic pressure 
of ficoll, and they sediment through the ficoll layer during centrifugation. 
Ficoll-paque™ PLUS also enhances erythrocyte aggregation to increase 
erythrocyte sedimentation through the ficoll layer. Mononuclear cells, with 
lower densities, remain at the plasma-ficoll interface. 
2.2.2.2. Magnetic-activated cell separation (MACS) of 
monocytes 
1. Principle: positive selection 
Cells are magnetically labelled with CD14 microbeads (purchased from 
Miltenyl Biotech Ltd, Surrey, UK) and separated on a column which is placed 
in the magnetic field of a MACS separator. The magnetically labelled CD14+ 
cells are retained in the column and the unlabelled CD14 -ve cells run 
through as they are depleted of CD14 +ve cells. After removal of the column 
from the magnetic field, the magnetically retained CD14 +ve cells are eluted 
as positively selected cell fraction. 
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2. Steps of MACS separation 
A) Magnetic labelling 
Monocytes were magnetically labelled with  
CD14  microbeads 
B) Magnetic separation 
 Cells are separated in a MACS column placed  
in a MACS separator. The flow-through fraction  
can be collected as negative fraction depleted 
 of labelled cells. 
C) Elution of the labelled cell fraction  
The column is removed from the separator.  
The retained cells are eluted as the enriched  
positively selected cell fraction. 
D) Sample preparation 
Platelets are removed after density-gradient 
 separation by resuspending the cells in MACS  
buffer and rotating in a centrifuge at 1500 rpm  
Figure 2.3: Steps to 
separate monocytes by 
MACS separation method 
   Magnetic Labelling 
Magnetic separation 
Elution of the labeled cells 
  
cell fraction 
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for 10-15 minutes at 20˚C. 
a) Magnetic labelling (using CD14 microbeads) 
  The PBMCs were kept on ice to prevent capping of antibodies on the cell 
surface and non-specific labelling with CD14 microbeads (Miltenyl Biotech, 
UK) which occurs at higher temperature. PBMCs isolated from 40mls of 
blood usually yielded 2.5 x 10-7 ± 0.5 x 10-7. They were resuspended in 
MACS buffer (PBS containing 0.5% FCS + 2mM EDTA—kept at 2-8˚C) at a 
ratio of 80 µl of buffer per 10-7 cells. 20 µl of CD14 microbeads were added 
per 10-7 cells, mixed well and incubated for 15 minutes in the refrigerator (2-
8˚C). Cells were then washed by adding 1-2 ml of MACS buffer per 10-7 cells 
and centrifuged at 1500 rpm for 10 minutes. Supernatant was aspirated 
completely and cells were resuspended in 500µl of MACS buffer.  
b) Magnetic separation by MS columns 
For the above number of PBMCs, MS column (Miltenyl Biotech Ltd UK) was 
selected. The column was placed in magnetic field of MiniMACS Separator 
(Miltenyl Biotech UK). MS column was prepared by rinsing with 500 µl of 
MACS buffer and cell suspension applied onto the column. Unlabelled cells 
passing through were discarded and the column washed three times with 500 
µl of MACS buffer. Column was removed from the separator and placed on a 
15 ml conical tube. 1 ml of buffer was poured onto the column and 
magnetically labelled CD14 +ve monocytes were immediately flushed out by 
firmly pushing the plunger into the column. Monocytes were counted using 
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haemocytometer. A total of 6 x 10-6 monocytes were isolated from 40 ml 
blood.  
2.2.2.3. PEG fusion of Huh 7.5s and monocytes  
1) Aims of fusion experiments 
  To determine optimal fusion conditions.  
   To estimate the percentage of infected fused cells and whether HCV 
could be propagated into the Huh 7.5 cells after fusing them with HCV 
infected monocytes. 
  To determine how long the Hepatitis C virus can be detected in the 
fused cells.  
2) Use of dye labelled monocytes and Huh 7.5 
A small proportion of cells were labelled with colour dyes (VybrantTM cell 
labelling solutions—Dil-PE and DiO-FITC (purchased from Invitrogen 
Molecular Probes) before fusion. The Dil-PE dye generates red fluorescence 
in the FACs scanner whilst the DiO-FITC dye fluoresces green. Separate 
cells can therefore be distinguished from fused cells by simple colour 
analysis. Some Huh 7.5s were labelled with DiO and some were labelled with 
Dil dye and left unfused to act as controls for flowcytometry. Other Huh 7.5s 
were labelled with DiO and fused with Dil labelled monocytes to estimate the 
degree and amount of fusion which was done by colour sorting 
(Flowcytometry). This labelling was done so that fusion could be analysed by 
Flowcytometry (FACS). Cells were washed thrice, centrifuged at 1200 rpm 
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for 10 min each time and fixed with 4% paraformaldehyde. Cells were 
reconstituted in FACS buffer (1%BSA/10%FCS in PBS). FACS sorting was 
carried out by the flowcytomter, BD LSR II analyser (BD Biosciences). Data 
were analysed using FlowJo software, version 7.6.5 (TreeStar, Ashland, OR).  
a) Method used for dye labelling  
2 x 10-6 to 4 x 10-6 of monocytes (depending upon the numbers isolated) and 
Huh7.5 cells each were suspended in 1 ml of serum free medium in two 
eppendorf tubes. 5 µl of vybrant DiI-labelling solution were added to 1 ml of 
monocyte containing medium and 5 µl of vybrant DiO-labelling solution were 
added to 1 ml of huh 7.5 containing medium. Gentle pipetting was done for 
even distribution of dyes. Tubes were then kept at 37°C for 20 minutes to 
allow efficient cell labelling. After 20 minutes the two tubes with labelled cells 
were centrifuged at 1200 rpm for 5 minutes and washed thrice with serum 
free medium. Both cell populations were transferred to a 15 ml conical tube 
and centrifuged so that they pelleted together at the bottom of tube. The 
supernatant was discarded and tube spun again and extra medium 
discarded.  
b) Fusion of dye labelled fused cells 
The dye labelled cells were treated with 500 µl of polyethylene glycol (PEG-
1500 from Roche Diagnostics, Burgess Hill, UK) already incubated at 37˚C 
and stirred for even distribution and kept in the incubator. After 3 minutes this 
mixture was treated with tissue culture medium (37˚C). Note that the time 
taken from the addition of PEG to the addition of medium was kept to a 
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maximum of 3 minutes. This time is important to bring the cell membranes 
together and allows fusion to occur without significant cell damage from the 
exposure of PEG. While putting the medium, first millilitre was added drop by 
drop in 1 minute so that the cell hybrids were not disrupted and rest of the 4 
ml were added slowly in 2 min.  These cells were then centrifuged at 1500 
rpm for 5 min and were harvested in 4% paraformaldehyde to be analysed by 
flowcytometry and percentage of fusion was assessed. Fusion efficiency was 
checked at different days too. Some fused cells were grown on 24 well plates 
and isolated on later days with CD14 microbeads and again analysed with 
flowcytometry after fixing with 4% paraformaldehyde. This was done to see 
whether fusion persisted afterwards in these cells or not. These dye labelled 
fused cells were also used in our experiments to optimize the method of 
fusion.  
c) Use of dye labelled cells in optimizing fusion 
We looked at few things to optimize our method of fusion. We looked at the 
amount of time needed to keep the cells in PEG 1500 for more efficient 
fusion to take place and to see how maximum number of cells can fuse 
together without too much cell death due to PEG 1500 toxicity. In order to 
find out what ratio of both monocytes and Huh 7.5 cells will give us the 
maximum numbers of fused cells we tried different proportions of monocytes 
and Huh 7.5 cells to find out optimal ratio. Dye labelled cells were used 
(explained above) in these experiments.  
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To determine the optimal time required for effective fusion isolated 
monocytes were labelled with DiI and mixed with equal numbers of DiO 
labelled Huh 7.5 cells (Huh 7.5 cells were labelled with DiO and DiI 
separately to be used as controls during the flowcytometry analysis). The 
mixture was separated in three tubes. In each tube fusion was done in the 
same way with PEG 1500 but the only difference was time in the incubator 
before adding the tissue culture medium. Cells were grown and fixed after 24 
hours with 4 % paraformaldehyde and analysed with flowcytometry to check 
which time was most favourable for fusion.  Some cells were extracted at day 
3 to be tested by real time PCR for HCV expression. To estimate the optimal 
ratios of both monocytes and Huh 7.5 cells to be used in fusion we fused 
different ratios of both monocytes and Huh 7.5 cells i.e. 1:2. 1:1 and 2:1. We 
used PEG 1500 with different pHs to determine the relationship between the 
amount of fusion with the pH of PEG 1500.  
d) Unlabelled fused cells  
Having established an optimal procedure for fusing hepatocytes and CD14 
bead separated monocytes, we proceeded to experiments in which we fused 
monocytes from treatment naïve chronic hepatitis C patients with Huh 7.5 
cells and looked at the HCV expression in fused cells at different times. Cells 
were fused without labelling with colour dyes and grown for different time 
periods. The fused cells were seeded into 6 well plates at a density of 
5x105cells/mL and maintained at 37˚C. Real time polymerase chain reaction 
and indirect immunofluorescence (both confocal and non-confocal) 
microscopy were used for HCV detection and replication analysis.  
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2.2.2.4. Fusion for HCV detection and replication 
2 x 10-6 to 4 x 10-6 monocytes and huh 7.5 cells, both in 1:1 ratio and 
unlabeled were fused by PEG 1500 in the same way as mentioned above 
and the time taken from the addition of PEG 1500 to the addition of medium 
was 3 minutes. Fused cells were resuspended in 5 ml of medium added 
slowly as mentioned above. 500 µl of this suspension was incubated in each 
well of a 12 well plate and grown for the indicated time points, ideally 3, 5 and 
7 days, although longer time periods were tried to determine the extent of 
HCV replication. The cells were passaged when they became confluent. 
Fused cells were processed – RNA was extracted in trizol reagent as 
previously described. Real time PCR was used to detect HCV expression.  In 
few fusion experiments the fused cells were bead selected for CD14 at 
different time periods and were grown on cover slips for immunofluorescence 
microscopy to confirm HCV replication in fused cells.  
2.2.2.5. CD14 microbeads separation of fused cells 
Cells were CD14 microbead separated to analyse subpopulations of Huh 7.5 
cells fused with monocytes and to select out cells which are more likely to 
express HCV RNA. These cells were stained with anti-NS5A antibody to 
detect HCV. The cells were also labelled with anti-albumin stain to localise 
HCV replication in Huh 7.5 cells. Albumin expression is a feature of 
hepatocytes and hepatic cell lines.  
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Figure 2.4: This figure shows the steps used for PEG 1500 fusion and 
then CD14 bead separation to isolate CD14 labelled cells.  
2.2.2.6. Capture transfer assay  
Monocytes were isolated from blood of a healthy donor and incubated with 
serum of a hepatitis C infected patient containing high titres of HCV for 24 
hours before fusion. PEG 1500 mediated fusion was done with Huh 7.5s in 
the similar way mentioned above. The cells were grown on cover slips after 
CD14 bead separation and stained to look for the presence of HCV 
replication in fused cell.  
 
CD14 bead selected 
cells  
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Figure 2.5: Monocytes isolated from healthy donor were fused with Huh 
7.5 cells after incubating them in HCV patient’s serum for 24 hours and 
CD14 bead separated. 
2.2.2.7. Quantification of HCV expression  
HCV expression was quantified by real-time quantitative polymerase chain 
reaction. (See chapter 2 for method) 
2.2.2.8. Indirect immunofluorescence microscopy  
13 mm Cover slips were first coated with polyethylineimine for 1 hour at room 
temperature and rinsed well with sterile water thrice each for 5 minutes. 
Cover slips were allowed to dry completely and sterilized under UV light for 4 
hours. Cells were grown on glass cover slips and rinsed briefly in phosphate-
buffered saline (PBS). 
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a) Fixation 
Cells were fixed in ice-cold methanol, acetone (1-10 minutes) or in 3-4% 
paraformaldehyde in PBS with pH of 7.4 for 15-20 min at room temperature 
and washed thrice with ice cold PBS (5mins/wash).  
b) Permeabilization 
Cells were then permeabilized (Note: acetone fixed samples do not require 
permeabilization). Samples were incubated for 10 minutes with PBS 
containing 0.25% Triton X-100 (Note: Triton X-100 is the most popular 
detergent for increasing penetration of the antibody. However, it is not 
appropriate to be used for membrane associated antigens since it destroys 
membranes). Cells were washed in PBS three times for 5 min. 
c) Blocking and incubation 
Cells were incubated with 10% Foetal Bovine Serum or in some cases 10% 
serum from the specie that the secondary antibody was raised in, for 30 
minutes to block unspecific binding of the antibodies. Anti-NS5A was added 
in the above blocking buffer in humidified chamber for 1 hr at room 
temperature (in dark) / or overnight at 4˚C. Cells were then washed with PBS 
Tween20 0.02% thrice for 5 minutes each wash in dark. The secondary 
antibody was used in similar way. Anti-albumin staining was then done in the 
similar way with secondary antibody following the primary antibody.  
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d) Counter staining and mounting  
Cells were mounted with Vector shield with DAPI – hard set purchased from 
Vectral Laboratories ltd UK and left for 30 minutes at room temperature in 
dark and looked at under an immunofluorescence microscope.  
e) Immunofluorescence microscopy 
Labelled fused cells with replicon containing cells taken as positive control 
and unfused Huh 7.5 cells as negative control were viewed on a Leica 
DM5000 automated epifluorescence microscope (Leica Microsystems, Milton 
Keynes, UK, www.Leicamicrosystems.com) and camera used to capture 
images was MM Leica – QIClick Qimaging 12 bit Monochrome, 1.4 
Megapixels. Images were viewed under oil-immersion lenses x40 and x63 to 
detect NS5A and albumin staining.  
f) Confocal microscopy  
Confocal immunofluorescence microscopy enables the reconstruction of 
three dimensional structures. By the mean of a confocal pinhole, the 
microscope is efficient at rejecting 'out of focus' fluorescent light resulting in 
image coming from a thin section of the sample and it scans thin sections 
through the sample resulting in formation of a very clean three dimensional 
image of the sample. 
For confocal microscopy fused cells along with negative and positive controls 
were viewed under Andor Technology Revolution DSD Spinning disk (Andor 
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Technology, Belfast, UK www.andor.com) and Zeiss LSM510 inverted 
microscope META detector laser (Carl Zeiss, Welwyn Garden City, UK 
www.zeiss.com) confocal microscope under an oil-immersion lens of x63 
objective with numerical aperture of 1.40. Alexa-fluor 488 antibody was 
excited using an argon laser fitted with 488 nm filter in Zeiss 510 META and 
488 nm 30mW laser lines in Spinning disk. Alexa-fluor 568 antibody was 
excited using the argon laser which was fitted with 561 nm 30mW filter in 
Spinning disk. Vybrant dye DiI (orange—red-fluorescent dye, which is 
spectrally similar to PE) was excited with the 543 helium / neon laser line 
while vybrant dye DiO (green-fluorescent dye, which is spectrally similar to 
FITC) was excited with the 488 nm argon laser line in Zeiss 510 META. DAPI 
was excited with 405 filters in both Zeiss 510 META and Spinning disk. 
Images are given in the result section and are displayed as single optical 
sections of 40 µm thickness.  
2.2.2.9. Fusion with SEAP reported cell line  
As mentioned earlier SEAP reporter cell line expresses the enhanced green 
fluorescent protein (EGFP) fused in-frame with secreted alkaline 
phosphatase via a recognition sequence of the hepatitis C viral NS3/4A 
serine protease. The main principle of SEAP reporter cell line is that it 
secretes alkaline phosphatase in culture medium if it gets infected with 
hepatitis C virus because of cleavage at NS3/4A serine protease site by the 
virus leading to secretion of alkaline phosphatase fused with EGFP. This 
leads to production of luminescence which can be detected by luminometer. 
We fused 4 patients’ monocytes (infected with different genotypes strain of 
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virus) with SEAP reporter cell line (Huh 7.5 J20 cells) and grew fused cells 
for 1 to 4 days. We incubated some cells with telaprevir while others were 
kept as untreated controls. At day 1 and day 4 we took off medium from the 
top of these cells and used this medium to detect for the presence of alkaline 
phosphatase by using Great EscAPe TM SEAP Chemiluminescence Kit 2.0 as 
per manufacturer's instructions (placental alkaline phosphatase was used in 
different dilutions, i.e. 1:10 and 1:100, as positive control and was provided 
with the kit) and detected luminescence by using a 96-well micro-plate reader 
(FLUOstar OPTIMA micro-plate reader with integration time of 1 second) to 
detect and record SEAP signal.  
2.2.3. Formation of immunosuppressed cell line  
2.2.3.1. Plasmid construction - 'pEF PIV5-V IRES.neo' 
As discussed in Chapter 1, section 1.7.5, V protein of parainfluenza virus 5 
(PIV5) forms either direct or indirect complexes with STAT1 and is known to 
block IFN signalling by targeting STAT1 for proteasome mediated 
degradation and inhibits the action of IFN. We speculated HCV replication 
will increase in absence of IFN induced host cellular response and 
transfected Huh 7.5 cells with PIV5 plasmid to impair IFN induced signalling 
and ISGs production. 
Plasmid construct 'pEF PIV5-V IRES.neo' was a kind gift from Professor 
Richard Randall, University of St. Andrews. It is a 7556 bases containing 
plasmid with EcoR1 site at position 1 destroyed, rendering a unique site in 
the multiple cloning sites. The construct 'pEF.PIV5-V' has been cloned in 
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'pEF.IRES.neo' (6374bp) between NcoI and NotI sites. Other elements 
included in plasmid are residual SV40 fragment (at 16-99bp), EF-1 promoter 
(at 99 to 1291bp), R-globin 5’UTR (at 1291-1349bp), Polio IRES (at 1405-
2044bp), Neomycin resistance (at 2044-2954bp), R-globin 3’UTR/polyA (at 
2954-3730bp), ampicillin resistance ORF (at 5385-6780bp). NcoI sites are at 
1350bp, 2981bp and 3835bp. NotI site is at 2530bp. Restriction enzymes 
NcoI and NotI were purchased from Promega UK.  
2.2.3.2. Transformation of bacteria 
E.Coli DH5α bacterial cells (purchased from Invitrogen UK) were used for 
transformation. About 10-20 µg of each plasmid DNA was used per 30-50 µl 
DH5α competent cells (thawed on ice) for cloning. After mixing plasmid DNA 
and bacterial competent cells and incubating them on ice for 30 minutes they 
were heat shocked at 42⁰C for 50 seconds and left on ice for 2 minutes. 
250µl S.O.C medium (purchased from Invitrogen UK) was added in the 
above mixture and incubated for 1hour at 37⁰C. 50µl from the above mixture 
was then spread on plates containing Lysogeny broth (LB) agar (mixed with 
ampicillin). It was then allowed to dry for 10 minutes and incubated at 37⁰C 
(plates inverted) overnight. Ampicillin selected colonies were grown 
overnight.  
 2.2.3.3. Plasmid purification  
The plasmid purification from bacterial cells was carried out using EndoFree 
Plasmid Maxi Kit (Purchased from Qiagen UK). Single colony was picked up 
from every plate and a starter culture of 2-5ml Lysogeny Broth (LB) medium 
182 
 
containing ampicillin was inoculated for every plasmid and incubated for 8 
hours at 37⁰C with vigorous shaking (at the rate of 300 rpm).  This culture 
was diluted to 100 ml and grown at 37⁰C for 12-16h with vigorous shaking.  If 
the culture showed a considerable growth, bacterial cells were harvested by 
centrifugation at 6000xg for 15 minutes at 4⁰C. The pelleted cells were 
separated out after supernatant was removed and were resuspended 
completely by vortexing in 10 ml RNase A containing Buffer P1 (50mM 
Tris·Cl, pH 8.0, 10mM EDTA;) until no cell clumps remained. 10ml Buffer P2 
(200mM NaOH, 1% SDS (w/v)) was added and mixed gently but thoroughly 
by inverting 4-6 times, and incubated at room temperature for 5 minutes. 
During this time QIAfilter Maxi Cartridge was prepared by screwing a cap 
onto the outlet nozzle and placing it into a 50ml Falcon tube. 10ml chilled 
Buffer P3 (3.0 M potassium acetate, pH 5.5) was added to above lysate and 
mixed immediately but gently by inverting 4-6 times and poured into the 
barrel of QIAfilter Maxi Cartridge and incubated at room temperature for 10 
minutes. The cap from the QIAfilter Maxi Cartridge outlet nozzle was 
removed and plunger was inserted gently into the QIAfilter Maxi Cartridge 
and cell lysate was filtered into 50ml tubes. Buffer ER (Composition not 
given) was added to the above filtered lysate and mixed by inverting the tube 
approximately 10 times and incubated on ice for 30 minutes. QIAGEN-tip 500 
was equilibrated by applying 10ml Buffer QBT (750 mM NaCl; 50 mM MOPS, 
pH 7.0; 15% isopropanol (v/v); 0.15% Triton® X-100 (v/v)) and allowed to 
empty by gravity flow. Filtered lysate was applied to the equilibrated 
QIAGEN-tip and allowed to enter the resin by gravity flow and QIAGEN-tip 
washed with 30 ml Buffer QC (1.0 M NaCl; 50 mM MOPS, pH 7.0; 15% 
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isopropanol (v/v)) twice) and DNA eluded with 15 ml Buffer QN (1.6 M NaCl; 
50 mM MOPS, pH 7.0; 15% isopropanol (v/v)).  DNA was precipitated by 
adding 10.5 ml isopropanol at room temperature to eluded DNA and 
centrifuged immediately at 15000xg for 30 minutes at 4⁰C. Supernatant was 
carefully decanted off. DNA pellets were washed with 70% ethanol and 
centrifuged at 15000xg for 10 minutes and supernatant was carefully 
decanted off and pellet was air dried for 5-10 minutes and dissolved in 500 µl 
endotoxin-free water supplied with the kit. 
 2.2.3.4. Quantification of plasmid DNA 
In order to determine the concentration and the purity of the plasmid, a 
spectrophotometer with full spectrum i.e.; 220-750nm (NanoDrop ND-1000 
supplied by Labtech UK) was used.  The NanoDrop reader was cleaned with 
water to prevent contamination and set up to specifically measure DNA. For 
each sample 2 µl of DNA was placed in the reader and the spectral 
absorbance at 260 and 280nm was recorded. The DNA yield was noted as a 
separate reading in ng/μl for every plasmid. Purity is determined by the ratio 
of absorbance at 260 and 280nm. Pure DNA is expected to have a ratio of 
1.6-1.8 (In DEPC-diethylpyrocarbonate treated water). If the ratio is lower, 
this indicates protein or phenol contamination.  
2.2.3.5. Restriction enzyme digestion of plasmid  
pCI-PuroR and pCI-B14R plasmids were digested with EcoR-1 and Xba-1 
restriction endonucleases separately to get controls and also with both 
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enzymes together to calculate appropriate band size. PIV5-V-IRES.neo 
plasmid was digested with Nco-1 and Not-1 enzymes separately and also 
with both restriction enzymes together.  The enzymes digestion mixes 
contained 3 µl buffer (NEBuffer 4 was used for Ecor-1 and Xba-1 and 
NEBuffer 3 was used for Nco-1 and Not-1) (New England Biolab, UK), 1 µl 
restriction enzymes (New England Biolab, UK), 0.5 µl BSA, 1µg plasmid DNA 
and diluted in DEPC treated water to make up to 30 µl in total. 
2.2.3.6. Agarose gel electrophoresis to detect band size  
After restriction enzyme digestion of plasmids we detected the band sizes with 
agarose gel electrophoresis. The plasmids with right inserts were sent for 
sequencing to Gene Service UK. 
2.2.3.7. Transfection in Huh 7.5 cells  
Cells were plated out at a density of 0.5x106 /well of a 6 well plate 6 hours 
before the transfection. This was to ensure that cells are in log phase of their 
growth when the transfection was done. Two concentrations of DNA were 
used for transfections - 5 and 10 µg. Cells were either transfected with single 
plasmid or with two plasmids together as shown in figure 2.6. Plasmid DNA 
was diluted with OptiMEM (Invitrogen UK) to 100 µl for each well.  At the 
same time 5 µl Fugene (Invitrogen UK) was diluted to 100 µl with OptiMEM 
for each well. These two mixes were then left at room temperature for 40 
minutes and then mixed together for 15 minutes at room temperature. Wells 
of 6 well plates were washed with OptiMEM twice and 600 µl was added in 
each well.  Above transfection mixes was added in each well and incubated 
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at 37⁰C for 1.5 hours. 3 ml DMEM (10% FCS) was added in the above 
mixture and incubated for 24 hours. 3 ml of G418 400 µg/ml containing 
DMEM (10% FCS) was added after 24 hours in each well and cells were left 
to grow for 4-6 weeks and antibody selection medium was changed after 2-3 
days. After 4-6 weeks cells started growing in PIV5-IRES.neo (5 µg) plasmid 
containing well. The cells were then shifted in a 75 mm3 flask when 
confluent. At all subsequent passages antibody selected medium was used.  
Figure 2.6: Transfections in 6 well plate with the plasmid (PIV5-V 
IRES.neo) at 5 and 10µg concentrations. 
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3.1. Introduction 
Development of in vitro systems such as sub-genomic replicating HCV (HCV 
replicon) or models involving unusual strains of genotype 2 HCV (JFH-1) 
have facilitated our understanding of the dynamics of chronic HCV infection 
(Lohmann, Korner et al. 1999). However, these replicon cell lines display 
deregulated gene expression, abnormal proliferation, aberrant signalling and 
endocytic function. The HCV replicon depends on tissue culture adaptive 
mutations exists only for a few genotypes and may not represent human 
virus. Moreover, JFH-1 has unusual features (reviewed in Bartenschlager 
and Sparacio 2007) and is limited to the non-structural gene of a genotype 2a 
HCV strain derived from a single patient. These issues with in vitro models 
necessitate the use of animal models, either chimpanzees or mice with 
engrafted human livers, to study more typical strains of HCV. A robust ex 
vivo or in vitro infectious system with clinical isolates of heterogeneous HCV 
genomes in a given patient does not exist and alternative systems allowing 
preclinical efficacy testing of novel antiviral compounds are required.  
Many drugs inhibit viral replication by interacting with viral enzymes. 
Telaprevir is one such drug, which is now licensed for clinical use. It inhibits 
the viral protease (HCV NS3-4A protease) which is involved in cleavage of 
nascent proteins used for final assembly of new virions. In one study 
chimpanzees infected by HCV clones with defective NS3-4A function did not 
show HCV infectivity and it is thought that NS3-4A protease has a role in 
HCV polyprotein cleavage, maturation and viral replication (reviewed in 
Kolykhalov, Mihalik et al. 2000). NS3-4A protease is also implicated in 
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evasion of host immune responses through down regulation of signalling 
molecules involved in production of IFNs (Foy, Li et al. 2003, Li, Foy et al. 
2005). Drugs such as telaprevir (VX-950) and NA808 are used to evaluate 
HCV replication in the liver biopsy model in this chapter. Studies have shown 
that telaprevir is more potent against the genotype 1 strain of HCV (Reesink, 
Zeuzem et al. 2006) and lowers HCV RNA during the initial 2 days of 
monotherapy. However, emergence of resistant mutants is a significant 
problem in later days if the drug is used in isolation (Forestier, Reesink et al. 
2007). NA808 is an exploratory drug developed by 'Chugai Pharmaceuticals' 
by screening a drug library using genotype 1 replicon cells. This agent is 
considered a potent inhibitor of HCV replication and appears to act on 
cellular targets; although the precise mechanism of its antiviral effect is 
unknown at this time experiments by the company involving HCV patients 
suggested that the drug was safe. However, when experiments in man were 
initiated, it showed no evidence of antiviral activity at concentrations that 
were non toxic and this compound was therefore withdrawn from further 
development. 
A previous study suggests that incubating liver biopsies with interferon allows 
a prediction of therapeutic responses (Chang, Sung et al. 2009). Preliminary 
work in our lab by Dr Linda Hibbert suggested that fragments of human liver 
biopsies could be used to support HCV replication for a short period of time 
and this work extends these studies to see if a model system could be 
developed and whether pre-clinical drug testing could be possible with this 
model. Thus, to allow drug testing on naturally occurring virus isolated from 
patients an ex vivo culture assay of liver fragments isolated from biopsies 
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performed routinely on chronic HCV patients was used. This might allow 
testing of novel antiviral compounds on diverse HCV genomes of clinically 
relevant genotypes and might be used to analyse dynamic changes in HCV 
gene expression after exposure to drugs. 
The liver is a heterogeneous organ containing hepatocytes, fibroblasts, 
endothelial cells, stellate cells and Kuffer cells (Cho, Park et al. 2010). There 
are cell-to-cell and cell-matrix interactions which provide adequate conditions 
and cell signalling for tissue modulation, cell-migration, differentiation and 
growth (Cho, Berthiaume et al. 2008, van Poll, Parekkadan et al. 2008, Cho, 
Park et al. 2010). This microenvironment and external stimuli are crucial in 
the proper function, autonomy and survival of cells. The microenvironment 
includes adjacent cells, extracellular matrix, growth factors, local forces and 
soluble stimuli (Ploss, Khetani et al. 2010). Primary hepatocytes in ‘blocks’ of 
tissue (as in our intact liver biopsy fragment model) have advantages over 
other human liver models as they retain the integrity of their cytoarchitecture 
(Sivaraman, Leach et al. 2005, Hewitt, Lechon et al. 2007, Khetani and 
Bhatia 2008). In contrast, when hepatocytes are cultured alone they 
disintegrate, undergo karyolysis and lose cytoskeleton structure. (Bhatia, 
Balis et al. 1999). Experiments (outlined below in section 3.3.2) show that cell 
viability is rapidly reduced in hepatocytes that have been extracted from their 
surrounding matrix.  
To improve the in vitro environment of liver cells attempts have been made to 
co-culture them with other cells to provide some of the matrix/cellular 
interactions that may be important for maintaining hepatocyte function. These 
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co-culturing techniques are used to provide a favourable microenvironment 
for adequate cell functioning and to achieve maximum benefits by controlling 
and modulating the degree of contact (Bhatia, Balis et al. 1999, Khetani and 
Bhatia 2008, Ploss, Khetani et al. 2010). 
In recent years micro-patterning techniques have been used to provide 
organotypic cultures. Studies have shown that hepatocyte survival and 
function improve if they are grown in a specific 2 dimensional, co-planar 
format with 3T3-J2 embryonic fibroblasts (Bhatia, Balis et al. 1999, Khetani 
and Bhatia 2008, Ploss, Khetani et al. 2010).  This co-culture technique has 
recently gained popularity and has a central role in monitoring drug response, 
metabolism and toxicity. This provides a platform for cell-to-cell interaction. 
The model described in these studies involves a miniaturized model with 
spherical islands of primary human hepatocytes co-cultivated with 3T3-J2 
murine embryonic fibroblasts to induce heterotypic and homotypic synergy of 
cells. This interdependence is vital for preservation of hepatocyte phenotype 
and function over prolonged periods as cells make polarized layers with 
optimized dimensions crucial for maintaining viability and liver specific 
function. The micro-patterning model to maintain hepatocyte functions 
involving 3T3-J2 murine embryonic fibroblasts has allowed hepatocytes to 
maintain albumin production, urea synthesis, glycogen storage and E-
cadherin expression over many weeks. They retain inducibility of cytochrome 
P450 and phase II enzymes and, importantly, have been shown to support 
HCV replication, albeit in a very transient, low level infection system (Bhatia, 
Balis et al. 1999, Khetani and Bhatia 2008, Ploss, Khetani et al. 2010).  The 
micro-patterning approach may provide an optimal environment for 
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maintaining hepatocytes in culture. However, the system is technically very 
challenging and has not been reproduced outside the initiator's laboratory. 
Real time quantitative PCR analysis for quantification of HCV RNA in liver 
biopsy model was used as our primary approach for HCV RNA quantification. 
RNA extracted from liver tissue was subjected to reverse transcription (RT) 
and specific domains in UTR region of cDNA obtained from RT were 
amplified. RNA was measured by UV absorbance at 260 nm and 280 nm and 
this is based on RNA being absorbed at 260nm and proteins at 280 nm. RNA 
purity is tested as the 260 nm/280 nm ratio while lower ratios indicate 
contamination. In order to stabilise RNA it is reconstituted in DEPC (Diethyl-
pyrocarbonate) treated water or in Tris solution (2-amino-2-hydroxymethyl-
1,3-propandiol). In one study, RNA isolated from mouse liver, was tested for 
influence of dissolving in both solutions discussed above. It was found that 
260/280 absorbance ratio of RNA dissolved in distilled water was around 
1.82+/-0.01 (n=5) while that dissolved in DEPC-treated water and Tris were 
1.52+/-0.01 (n=5) and >2.17 (n=5) respectively. DEPC-treated water did not 
seem to affect the absorbance at 260 nm, but elevated absorbance at 280 
nm while Tris-HCl (1 M, pH 7.0 or 10.0) lowered the absorbance at 260 nm 
and even more at 280 nm thus, the 260 nm/280nm ratio was elevated.  
These results demonstrate that the measuring solution has an impact on the 
overall absorbance ratio of RNA. RNA absorbed in Tris might falsely show 
increased RNA purity and DEPC treated water might under represent the 
purity of RNA. If 260/280 absorbance ratio of RNA is 1.6 to 1.8 when 
reconstituted in DEPC treated water, it is acceptable because DEPC treated 
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water has PH of 5 and will give a lower absorbance ratio (Wilfinger, Mackey 
et al. 1997).  
 
Moreover, in another study RNA Absorbance at 260/280 was different at 
different pH. At higher pH of solvent RNA absorbance ratio rises over-
representing the RNA purity while at lower pH RNA absorbance appears 
lower even if RNA is free of protein and may under-represents the ratio by 
0.2-0.3 (Wilfinger, Mackey et al. 1997, Okamoto and Okabe 2000).  
 
The sample preparation method and time taken to extract RNA from time of 
sample collection can impact on RNA quality and concentration and liver 
biopsy fragments are processed after 24-48h of collection. DEPC water was 
used to prevent contamination with RNases (degrade RNA). DEPC 
inactivates RNase through covalent modification. In our experiments we used 
RNase free 0.1%DEPC treated water/autoclaved. There is no RNA extraction 
method which yields RNA completely free of genomic DNA so enzymatic 
DNA removal of RNA sample is recommended. RNA was decontaminated 
from genomic DNA by DNase treatment. In order to prevent sample 
degradation extensive freeze/thaw cycle was avoided by aliquoting samples. 
Filtered pipette tips were used to minimise contamination between samples. 
RNA was stored in siliconized tubes to avoid adsorption of RNA with the 
walls of tubes.  
 
For PCR primers amplifying short products are known to give higher PCR 
efficiency. Therefore, the primers chosen for our experiments had lengths 
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between 18-30 nts. GC contents was between 45-60%, (GC content of 30% 
is minimum, 50% is optimal and 80% is maximum) (D'Haene, Vandesompele 
et al. 2010). Primers not containing runs of >3 G or C nucleotides were used. 
Sequence complementarities between forward and reverse primers were 
avoided and a BLAST search was performed to ensure specificity, 
amplification efficiencies were calculated based upon the generation of 
standard curves using plasmid DNA dilution series. Melt curve analysis and 
gel electrophoresis was used to gauge specificity of PCR reactions. In order 
to prevent secondary structures G/C rich areas and palindromes were 
avoided. 
3.2. Aims and background  
Development of novel therapies for chronic hepatitis C virus (HCV) infection 
can potentially be streamlined by using patient-derived model systems in 
which drugs can be tested prior to establishing clinical trials. Such models 
have been hampered by difficulties in maintaining primary human 
hepatocytes from infected individuals in culture. This chapter looks at the use 
of surplus tissue fragments of routine biopsy samples from patients with HCV 
to develop an ex vivo system for antiviral drug testing by incubating these 
samples for a definite time in laboratory and allowing estimation of HCV gene 
expression in response to antiviral drugs. 
To improve the value of the assay it was speculated that separating the 
hepatocytes from the biopsy fragment and culturing as isolated cells may 
reduce sample to sample variability, by increasing the homogeneity of the 
cells. It was postulated that growing the PHHs in contact with other stromal 
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cells (such as 3T3 cells) might allow survival of the cells for sufficient length 
of time to allow assessment of antiviral drugs. The aim of this research was 
to develop simple, easy to use culture conditions that could be used to 
maintain differentiated hepatocytes in culture for several days to allow 
studies on HCV replication to be completed. These experiments are based 
upon the micro-patterning model but in view of the complexity of this 
technique aim was to develop a simpler system, but at the expense of lesser 
robustness, that would facilitate future studies of HCV replication. 
3.3. Results 
3.3.1. Set up experiments for HCV detection  
A) Developing a PCR based assay for HCV RNA detection – 
assay involving ‘replicon’ containing cells.  
Different numbers of replicon cells i.e.; 3x10-6, 2x10-6, 1x10-6, 0.5x10-6, 
0.25x10-6 and 0.1x10-6 cells were used to obtain different concentrations of 
mRNA (determined using the Nanodrop reader (see Methods)). mRNA 
concentrations extracted from these cells were 3355.8ng/µl (1.87), 
2824.3ng/µl (1.95), 805.6ng/µl (1.95), 508.3ng/µl (1.87), 152.2ng/µl (1.82), 
and 84ng/µl (1.70) respectively (with absorbance ratios at 260/280 in 
brackets) were obtained. A total amount of RNA of 3µg was taken from each 
sample, using larger aliquots from samples with lower RNA concentrations 
compared to samples with higher concentrations, to generate equal amounts 
of cDNA from all samples. Real time quantitative PCR was used to detect 
gene expression of β-actin and HCV p1-2. CT values of all samples were 
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within 3-4 cycles for both β-actin and HCV p1-2 (real time qPCR plots with 
melt curves are shown in figure 3.1 and 3.2 for β-actin and HCV p1-2 
respectively).  
 
 
Figure 3.1: Real time qPCR plot and melt curve analysis of β-actin: A) 
PCR plot with CT values (for β-actin) of each sample ran in duplicate 
and difference of no more than 3 cycle lengths between two different 
samples (range of CT between samples is 18.93 - 21.85). B)  elt curve of 
β-actin shows a melt temperature-Tm in range of   - 1  C. 
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Figure 3.2: Real time PCR plot and melt curve analysis of HCVp1-2: A) 
PCR plot with CT values (HCVp1-2) of each sample ran in duplicate and 
difference of no more than 4 cycle lengths between two different 
samples (range of CT between samples is 24.4  - 2 .25).  )  elt curve of 
HCVp1-2 shows a melt temperature-Tm in range of   -    C. 
These experiments show that the real time qPCR assay robustly detects 
HCV RNA from different cell numbers in a replication system with little 
variability. These studies indicate that the difference in the initial cell number 
should not affect the results. Hence, the HCV/ β-actin ratio is the same 
whatever the starting number of cells.  
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B) Limit of detection of HCV gene expression 
In order to estimate the limit of detection of HCV RNA gene expression 
measured through real time qPCR, serial dilutions of replicon cells were 
achieved by using Huh 7.5 cells to obtain different ratios of infected and 
uninfected cells. Total 1X10-6 cells were used in each sample with different 
concentrations of both Huh 7.5 cells and replicon cells. The number of 
replicon cells in the dilution series were 1x10-6, 0.5x10-6, 0.25x10-6, 0.12x10-6, 
62500, 31250 cells respectively. HCV RNA gene expression was analysed 
by real time qPCR and relative quantification technique (discussed in chapter 
2 section 2.2.1.8). HCV gene expression (normalised to β-actin) was 
calculated in all samples. The average HCV expression (expressed as 2^-
T) was 0.005 (range 0.01 to 0.003, n=1) and all samples were positive. 
This study showed that HCV RNA could be detected in infected cell counts 
as small as 31250 cells (2^- T = 0.003). As the average number of cells 
obtained from the liver biopsy fragments was around 50000 cells in each 
sample with a high probability of many cells being infected we speculated 
that our assay had a reasonable chance of detecting HCV RNA in human 
liver.  
C) Polymerase chain reaction efficiency  
i) Primers                                                                          
Tm values of primers were calculated by using this formula: (2  C x (A T)   4 
 C x (G+C). Melt curve analysis was carried out as discussed above, to 
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prevent non–specific PCR products or primer dimerisation (5%DMSO added 
to prevent primer dimer formation).  
ii) Standard curve for primer efficiency 
1x10-6 Replicon cells were used to extract cDNA and DNA plasmid standards 
were generated through technique discussed in chapter 2 section 2.2.1.8. 
After spectrophotometric determination of plasmid DNA concentration, the 
copy number of standard DNA molecule was calculated using the formula: 
Copy numbers of DNA molecule = (x g/µl DNA/ [plasmid length in base pairs 
x 660]) x 6.022 x 1023 = Y molecules/µl 
Plasmid length = vector (pGEM® T vector) length + template size  
Template sizes are given in chapter 2, section 2.2.1.8. Plasmid DNA 
concentrations were: β-actin = 213ng/µl, HCVp1-2 = 440ng/µl, HCVp3-4 = 
265.5ng/µl, MxA = 329ng/µl, 2’5’OAS = 222ng/µl. Copy numbers of DNA 
plasmid standards after 1:1000 dilutions were calculated as: β-actin = 6.04 x 
107, HCVp1-2 = 1.23 x 108, HCVp3-4 = 7.61 x 107, MxA = 9.46 x 107, 
2’5’OAS = 6.64 x 107. 
The efficiency of PCR was evaluated by performing a dilution series 
experiment using the target assay and creating a standard curve (using 
plasmid DNA standards) using different genes (primers: β-actin, HCVp1-2, 
HCVp3-4, MxA and 2’5’OAS). Real time qPCR with SYBR® green was used 
to detect gene expression. Rotorgene 6000 software was used to generate 
standard curves. The slopes (M) of the standard curves were translated into 
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efficiency value (Efficiency (E) = 10-1/M -1). Standard curves with slopes, 
efficiencies and R^2 values are shown in Figure 3.3. 
 
Standard curve for β-actin  
 
 
 
Standard curve for HCVP1-2 
 
 
 
Standard curve for HCVP3-4 
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Standard curve for MxA 
 
 
 
Standard curve for 2’5’OAS  
 
 
Figure 3.3: Standard curves created from dilution series of the plasmid 
DNA: The R^2 value is a measure of the fit of the data points to the 
regressed line. The slope (M in the equation) is an indication of the PCR 
efficiency. A slope of –3.3 indicates 100% PCR efficiency (i.e., the 
number of copies of amplification product is doubled at each cycle). 
The y intercept (b in the equation) is defined as the y value (Ct) when x 
(log concentration) equals 0. 
 
If a standard curve has a correlation coefficient (R^2 value) <0.99, the data 
accuracy becomes less predictable. Rotor gene 6000 software was used to 
perform a linear regression to the standard dilution series data and to 
calculate the equation for the best-fit line (the standard curve). The equation 
is in the form of y = Mx + B, where x = log concentration and y = CT. 
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Therefore, B gives the CT for the 1ng/μl standard if concentrations are 
defined as (log10 (1) = 0). The slope M is indicative of the PCR efficiency. A 
slope of –3.3 indicates 100% (1.00) PCR efficiency (i.e., the number of 
copies of amplification product is doubled at each cycle).  
The slopes created by our standard curves range from -3.2 (efficiency 1.06) 
to -3.5 (efficiency 0.93). 
iii) Amplification plots 
Dilution series of plasmid standards with known target were used to form 
amplification plots.  
 
Figure 3.4: Dilution series (1:10) of the target gene - β-actin, amplified in 
duplicate. 
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Figure 3.5: Dilution series (1:10) of the target gene - HCVp1-2, amplified 
in duplicate. 
During the initial set up of real time qPCR it was essential to include identical 
replicates for each input cDNA. The use of these replicates helps in gauging 
the accuracy of the results especially at lower CT values. If identical 
replicates have a CT value of >0.3 and/or a standard curve has a correlation 
coefficient (R^2 value) <0.99 then results are less precise. However, it is 
important to know that at higher CT values (34-40) with low fold change in 
target there could be increased CT variation among replicates due to 
statistical distribution and this unavoidably gives rise to poorer precision. 
Thus the difference between CT values of identical replicates was less than 
0.3 at lower CT values while at values above 34-40 difference was less than 
0.5. 
iv) RNA quantification 
Quality and yield of RNAs obtained from all liver biopsy samples studied 
were estimated by spectrophotometer with full spectrum i.e.; 220-750nm 
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(NanoDrop ND-1000 supplied by Labtech UK, discussed in Chapter 2 
method section 2.2.1.3). 
Nanodrop readings (RNA concentration expressed in ng/µl and absorbance 
at 260/280) for all samples derived from liver biopsies were accumulated and 
plotted as histograms. The RNA yield was plotted in ng/μl for every sample 
(see figure 3.6). 
 
Figure 3.6: RNA concentration measured by the nanodrop 
(spectrophotometer): The RNA concentration was more than 100ng/ul in 
more than 89% of samples. 
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Figure 3.7: RNA quality determined by comparing ratio of spectral 
absorbance at 260nm and 280nm: More than 71% samples had 260/280 
absorbance ratio in range of 1.8-2.0. RNA samples in DEPC treated 
water could give lower 260/280 absorbance ratio due to acidic pH of 
DEPC treated water (Wilfinger, Mackey et al. 1997, Okamoto and 
Okabe 2000). 
v) Quantification of polymerase chain reaction 
Target nucleic acid quantification can be carried out using two techniques; 
absolute quantification and relative quantification. Absolute quantification is 
carried out by using set standards with known concentration or copy number. 
These standards contain the same sequence as that of the target sequence 
or differ only slightly from target nucleic acid. A standard curve is a measure 
of plot of CT values divided by crossing points of different dilutions against 
the log of the amount of the standard and is generated by using a dilution 
series of the standards. The initial amount of target used for PCR 
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amplification is quantified against the known standards by its comparing CT 
value with known standards. Relative quantification calculates the ratio 
between the amounts of target nucleic acid with a reference gene (i.e.; 
housekeeping gene) in the same sample and this normalised value is used to 
compare gene expressions in difference samples. Relative quantification of 
gene expression quantifies differences in the expression level of a specific 
target (gene) between different samples. The data output is expressed as a 
fold-change or a fold-difference of the expression levels. In absolute 
quantification a reference standard containing target gene into a plasmid was 
constructed and a calibrated curve was created by using known amount of 
plasmid and amount of target was calculated against this as an absolute term 
as number of copies (Li and Wang, 2000). Absolute quantification however 
relies on highly accurate dsDNA quantification and construction of reliable 
standard curves. It requires adequate pipetting as standard curve requires 
dilution over several orders of magnitude. qPCR results were analyzed by 
two types of relative quantification methods. In one method HCV infection 
was expressed as gene expression calibrated to β-actin while the other 
method was delta-delta CT method in which we calibrated HCV gene 
expression against β-actin and normalized with the positive control (cells 
containing HCV replicon). It was observed that the trend was exactly the 
same with both the methods. Results here are given by the first method and 
expressed as HCV/ β-actin ratio.   
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 vi) Validation of housekeeping gene 
Previous experiments performed in our laboratory by Dr Linda Hibbert 
compared HCV RNA to β-actin (HKG used in mRNA levels with HCV RNA to 
GAPDH mRNA levels and HCV RNA to transthyretin mRNA (a hepatocyte 
specific gene) in order to determine whether alternative ‘normalising’ mRNAs 
were associated with different results in RNA from four different patients (two 
genotype 1, one genotype 3 and one genotype 4). No significant changes in 
sample to sample variation were seen when the data was normalised to 
housekeeping genes other than β-actin (personal communication Dr Linda 
Hibbert). Endogenous housekeeping genes are used to normalize 
differences in the amount of cDNA that is used into a PCR reaction. 
Endogenous control expression levels must be the same in all samples under 
all conditions in both control and experimental group. Real time qPCR can be 
used to test uniform expression of endogenous controls by comparing their 
C
T 
levels in control and experimental groups by using equivalent volumes of 
the cDNA for PCR reactions. HKG expression level must not change under 
experimental conditions. In order to perform the comparative CT method (also 
known as the ΔΔC
T 
method) the target and endogenous control should have 
relatively equivalent PCR efficiencies.  
3.3.2. Viability of liver biopsy fragments 
Viability of liver biopsies was assessed by different methods. 
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3.3.2.1. Histology of liver biopsy fragments 
In experiments performed by Dr Linda Hibbert liver biopsy samples were 
incubated for 24 hours in the medium and then analysed histologically. 
Figure 3.8 shows results from these experiments and indicates that liver 
morphology is maintained in the biopsy fragments after 24 hours incubation. 
 A                                            B 
 
Figure 3.8: Histological demonstration of the tissue viability:  (A&B) 
Haematoxylin and eosin stained sections from the same liver biopsy 
specimen at (A) baseline and (B) after 24h culture in DMEM (10% FCS).  
At 24h there are moderate architectural changes (sinusoidal expansion) 
with a degree of hepatocyte loss. 
3.3.2.2. Cell viability assay 
Morphology is a relatively crude method of assessing cell viability. To assess 
cell viability in a quantitative fashion a cell viability assay based on a 
commercial system was used (discussed in Chapter 2 Methods, section 
2.2.1.2). A normalisation experiment was performed with different ratios of 
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viable and dead Huh 7.5 cells at different percentages (ratio of viable and 
dead cells; 100:0, 80:20, 60:40, 40:60, 20:80, 0:100 respectively). Dead cells 
were obtained by incubating them at 80ºC for 10 minutes. Figure 3.9 shows 
effect on cell luminescence at different ratios of viable and dead cells. 
 
Figure 3.9: Normalisation of the cell viability assay: Viable and dead 
cells at different percentages starting from 100% viable cells (with 0% 
dead cells) to 0% viable cells (with 100% dead cells). Experiment was 
performed to see ATP luminescence (RLU) in different percentages 
of viable cells.  
Cell viability was assessed in cells isolated directly from liver biopsy 
fragments after they were maintained in normal medium (DMEM + 10% FCS) 
for 24 and 48 hours. The results are shown in the figure 3.10 (1000 cells) and 
3.11 (500 cells) which show the viability of intact liver biopsy fragments after 
incubating them for 24 and 48 hours and then isolating cells for assessments. 
In experiments where isolated primary human hepatocytes were incubated in 
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the medium for 24 and 48 hours and then assessed for viability are 
discussed in the section 3.3.4.2 
                       
 
Figure 3.10: Cell viability after 24 and 48 hours in liver biopsy fragments 
incubated for 24 and 48 hours and is expressed as mean ATP 
luminescence (RLU). Total number of cells isolated from the intact 
fragment for assessment was 1000. 
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Figure 3.11: Cell viability after 24 and 48 hours in liver biopsy fragments 
incubated for 24 and 48 hours and is expressed as mean ATP 
luminescence (RLU). Total number of cells isolated from the intact 
fragment for assessment was 500. 
In intact liver biopsies the mean luminescence fell to 62.8% (3626.5 RLUs to 
2384.5 RLUs) after 24 hours and 35.2% (3626.5 RLUs to 1336.5 RLUs) after 
48 hours when measured in 1000 cells after extraction. The mean 
luminescence fell to 53.8% (2860 RLUs to 1538.5 RLUs) after 24 hours and 
29.3% (2860 RLUs to 838.75 RLUs) after 48 hours when measured in 500 
cells after extraction. These data indicate that although cell viability is 
impaired after 24 hours a significant proportion of cells remain viable. 
The same experiment was repeated after isolating the hepatocytes from the 
liver biopsy fragments and incubating these isolated primary human 
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hepatocytes for 24 and 48 hours in plates matted with type 1 collagen. These 
results are expressed later in this chapter in section 3.3.4.2. 
3.3.2.3. Telaprevir concentration  
Serum trough levels of telaprevir approximating 1.47nM are associated with 
marked inhibition of HCV replication in genotype 1 patients and in vitro 
studies show IC50 values for telaprevir ranging from 7nM (genotype 1) to 300 
nM (genotype 3) (Perni, Almquist et al. 2006).  Based on these data we 
chose a concentration of 14.7nM (10µg/ml) to evaluate the effects of 
telaprevir – i.e. concentrations in the non-trough range of those seen in 
patients treated with current dosing regimes. Though some data was 
obtained from a small number of samples, a full analysis of additional 
telaprevir concentrations was not possible due to limiting amounts of patient 
material. Lower concentrations of telaprevir (3.0nM) were tested on liver 
biopsies of four patients with genotype 1 HCV by Dr Linda Hibbert in a 
previous study in our laboratory. There was similar response at 3.0nM when 
compared to 14.7nM in one biopsy, two patients biopsies responded less well 
at a concentration of 3.0nM whereas one biopsy that did not respond at 
14.7nM did not respond to 3.0nM either (data not shown). Attempts to use 
higher concentrations of telaprevir (37.0nM) were met with tissue death 
(identified from poor mRNA yields with low levels of β-actin) and this may 
reflect toxicity from the telaprevir solvent (100% DMSO).   
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3.3.2.4. NA808 concentration 
Two different concentrations of NA808 (50nM and 500nM) were tested 
initially to examine the effects on HCV replication on three different chronic 
HCV patients (shown in figure 3.19). A concentration of 500nM was chosen 
for experiments because no significant conclusion could be drawn from using 
either 50nM or 500nM of NA808. This concentration was also used by 
'Chugai Pharmaceuticals' in their prior experiments performed on replicon 
cells. 
3.3.3. Experiments on liver biopsy fragments 
3.3.3.1. Effect of telaprevir on liver biopsy fragments from 
chronic HCV patients 
Given that liver biopsy fragments after 24 hours incubation have reasonable 
cell viability (arbitrarily defined as >50% survival) and maintain their 
morphology we addressed the question of whether they can be used to 
assess the efficacy of direct acting antiviral drugs. We chose the well studied 
protease inhibitor (telaprevir) at its effective concentration - 10µg/ml (14.7nM) 
and assessed its effects on HCV RNA expressions in biopsies of chronic 
HCV patients belonging to different genotypes. We reasoned that this rapidly 
acting antiviral agent should have activity in our assay and should reduce 
HCV replication, at least in patients with genotype 1 HCV. Liver biopsy 
fragments from thirty two patients belonging to major genotypes (1-3) were 
used to assess the effect of telaprevir after 24 hours. Patients' details are 
shown in the table 3.1. 
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No 
 
 
Age 
 
Genotype  
 
        Viral load 
 
 
Fibrosis                     
 
 
Fold
change  
 
 
   1 
 
 
36 
 
1 
 
             NA 
 
2 
 
-1.85 
   
   2 
 
 
29 
 
1b 
 
6.04 log IU (1092400 
IU)+ 
 
2 
 
1.5 
 
   3 
 
35 
 
1b 
 
6.69 log IU (4931750 
IU) 
 
3 
 
 
-3.54 
   
   4 
 
46 
 
1b 
  
              NA 
 
 
1 
 
 
-4.88 
 
   5 
 
53 
 
1 
 
5.57 log IU (372577 IU) 
 
3 
 
 
-9.26 
 
   6 
 
26 
 
1b 
 
6.16 log IU (1446841 
IU) 
 
1 
 
 
-1.29 
 
   7 
 
 
31 
 
1b 
 
7.09 log IU (12332603 
IU) 
 
1 
 
-1.19 
 
   8 
 
 
41 
 
1 
 
               NA 
 
 
6 
 
-1.02 
 
   9 
 
 
48 
 
1b 
 
6.29 log IU (1946623 
IU) 
 
1 
 
-137 
 
10 
 
 
49 
 
1a/1b 
 
6.64 log IU (4381228 
IU) 
 
3 
 
1.027 
 
11 
 
 
56 
 
1a 
  
6.75 log IU (5671859 
IU) 
 
4 
 
-1.1 
 
12 
 
 
55 
 
1a 
  
               NA 
 
1 
 
-3.16 
 
13 
 
 
41 
 
1 
 
3.51 log IU (3237 IU) 
 
4 
 
-1.56 
 
14 
 
 
33 
 
1a 
 
6.8 log IU (6296858 IU) 
 
3 
 
2.4 
 
15 
 
 
30 
 
1a 
 
4.88 log IU (75457 IU) 
 
1 
 
-18.14 
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No 
 
 
 
Age 
 
 
Genotype 
 
        
             Viral load 
 
 
Fibrosis 
 
 
 
Fold 
Change 
 
16 
 
 
38 
 
1b 
 
5.39 log IU (245227 IU) 
 
2 
 
-16 
 
17 
 
 
64 
 
1 
 
6.19 log IU (1555694 
IU) 
 
1 
 
-1.19 
 
18 
 
 
37 
 
3 
 
5.33 log IU (212095 IU) 
 
3 
 
1.68 
 
19 
 
 
43 
 
3a 
 
6.85 log IU (7034135 
IU) 
 
3 
 
-1.39 
 
20 
 
 
53 
 
3 
 
6.91 log IU (8133832 
IU) 
 
3 
 
-2.51 
 
21 
 
 
70 
 
3 
 
4.73 log IU (53093 IU) 
 
1 
 
1.83 
 
22 
 
 
39 
 
3 
 
6.89 log IU (7788994 
IU) 
 
1 
 
1.79 
 
23 
 
 
45 
 
3a 
 
6.06 log IU (1155192 
IU) 
 
1  
 
1.84 
 
24 
 
 
72 
 
3 
 
                 NA 
 
2 4.95 
 
 
25 
 
 
25 
 
3 
 
4.87 log IU (74573 IU) 
 
2 3.01 
 
 
26 
 
 
38 
 
3a 
 
6.21 log IU (1619920 
IU) 
 
3 6.33 
 
 
27 
 
 
34 
 
3 
 
4.68 log IU (47395 IU) 
 
1 1.84 
 
 
28 
 
 
50 
 
2 
 
                 NA 
 
1 
 
1.84 
 
29 
 
 
43 
 
2 
 
5.99 log IU (978981 IU) 
 
3 
 
-3.04 
 
30 
 
 
27 
 
2 
 
4.86 log IU (71775 IU) 
  
      1 
 
1 
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Table 3.1: Details of the patients whose liver biopsy samples were used in the 
experiments to look at HCV RNA gene expression after 24 hours of telaprevir 
treatment. The table shows age, genotype and subtype (if available), fibrosis 
score (Ishak scoring), viral load and fold change in HCV RNA after incubating 
these biopsy fragments in telaprevir compared to untreated samples from 
each patient. NA = no contemporary sample available for testing at the time of 
liver biopsy  
Seventeen genotype 1 patients' biopsies were treated with telaprevir; 
untreated samples were taken as controls. Two control and two telaprevir 
treated samples were isolated for each patient and HCV RNA was quantified 
after real time qPCR. Figure 3.12 summarizes the results obtained after 
telaprevir treatment of biopsy fragments obtained from chronic HCV patients 
with genotype 1.  
                                          
 
 
 
No 
 
 
 
Age 
 
 
Genotype 
 
         
           Viral load 
 
 
 
Fibrosis 
 
Fold 
Change 
 
31 
 
 
41 
 
2 
 
4.82 log IU (66109 IU) 
 
1 
 
-2.10 
 
32 
 
 
56 
 
2 
 
6.65 log IU (4417016 
IU) 
 
2 
 
-1.30 
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A) 
B) 
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Figure 3.12:  Ex Vivo drug testing using the liver biopsy fragments from 
patients with chronic HCV genotype 1 strain: A) The biopsy fragments 
were incubated with the medium alone or with telaprevir (10 µg/ml) for 
24 hours and the effects of telaprevir on HCV RNA expression was 
assessed by examining HCV RNA expression with real time quantitative 
PCR. (n=17, *p-value = 0.0138, using Wilcoxon matched pair test). Each 
point represents a mean of two samples taken from the same patient 
and is independent. B) The control and telaprevir treated samples are 
linked in this figure. C) Shows fold change in HCV expression in each 
patient's biopsy after treating with telaprevir. HCV expression 
represents the HCV RNA: β-actin ratio (calculated by the relative 
quantification method).  
The mean viral RNA concentration in biopsies from patients with genotype 1 
HCV (n=17) was significantly lower after 24 hours’ incubation with telaprevir 
compared to unsupplemented medium (without telaprevir). 
C) 
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Ten genotype 3 patients' biopsies were treated with telaprevir, untreated 
samples were taken as controls. Two control and two telaprevir treated 
samples were isolated for each patient and HCV RNA was quantified after 
real time qPCR. Figure 3.13 summarizes the results obtained after telaprevir 
treatment of biopsy fragments from chronic HCV patients with genotype 3 
strain.  
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n/s 
A) 
B) 
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Figure 3.13:  Ex Vivo drug testing using the liver biopsy fragments from 
patients with chronic HCV genotype 3 strain: A) The biopsy fragments 
were incubated with the medium alone or with telaprevir (10 µg/ml) for 
24 hours and the effects of telaprevir on HCV RNA expression was 
assessed by examining HCV RNA expression with real time quantitative 
PCR. (n=10, p-value >0.05, using Wilcoxon matched pair test). Each 
point represents a mean of two samples taken from the same patient 
and is independent. B) The control and telaprevir treated samples are 
linked in this figure. C) Shows fold change in HCV expression in each 
patient's biopsy after treating with telaprevir. HCV expression 
represents the HCV RNA: β-actin ratio (calculated by the relative 
quantification method). 
Five genotype 2 patients' biopsies were treated with telaprevir and untreated 
samples were taken as controls. Two control and two telaprevir treated 
samples were isolated for each patient and HCV RNA was quantified after 
real time qPCR. Figure 3.14, summarizes the results obtained after telaprevir 
C) 
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treatment of biopsy fragments from chronic HCV patients with genotype 2 
strain.  
 
           
                                           
n/s 
A) 
B) 
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Figure 3.14:  Ex Vivo drug testing using the liver biopsy fragments from 
patients with chronic HCV genotype 2 strain: A) The biopsy fragments 
were incubated with the medium alone or with telaprevir (10µg/ml) for 
24 hours and the effects of telaprevir on HCV RNA expression was 
assessed by examining HCV RNA expression with real time quantitative 
PCR. (n=5, p-value >0.05, using Wilcoxon matched pair test). Each point 
represents a mean of two samples taken from the same patient and is 
independent. B) The control and telaprevir treated samples are linked in 
this figure. C) Shows fold change in HCV expression in each patient's 
biopsy after treating with telaprevir. HCV expression represents the 
HCV RNA: β-actin ratio (calculated by the relative quantification 
method) 
These data show that telaprevir did not have any significant effect on HCV 
RNA levels in biopsies from patients with genotypes 2 or 3 HCV. Relatively 
few patients with genotype 2 strain of HCV were studied and therefore 
meaningful conclusions could not be drawn. For genotype 1 HCV there was a 
significant reduction in HCV RNA with telaprevir. However, the majority of 
biopsies showed a modest change in HCV RNA levels and the significant 
C) 
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effects of telaprevir may have been dominated by the very large changes 
seen in a small number of samples. For patients with genotype 3 HCV the 
changes with telaprevir were not statistically significant. Taken together these 
data suggest that telaprevir is more active against genotype 1 HCV 
compared to genotype 3. These data are compatible with data from clinical 
trials with telaprevir, suggesting that our liver biopsy model may be useful in 
examining the genotype sensitivity of different therapeutic agents. However, 
the changes seen in most liver biopsies were modest and large numbers of 
samples need to be analysed in order to examine the effects of the drug and 
to derive a statistically significant result. Furthermore, the need for multiple 
samples and statistical analysis detracts from the value of the assay – the 
data presented above indicate that it will be difficult to adapt this assay to 
determine the drug sensitivity of an individual patient. We speculate that the 
poor sensitivity of the assay may be related, at least in part, to the differences 
in HCV RNA expression in different fragments taken from the same biopsy. 
Data from initial co-experiments with Dr Linda Hibbert (shown below) 
indicated that there was a considerable sample to sample variation in 
untreated samples, suggesting that this may be a limiting factor with this 
approach.  Figure 3.15 shows a summary of all experiments performed with 
liver biopsy fragments and includes data from 14 patients anlaysed by Dr 
Linda Hibbert merged with my experimental data.  
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Figure 3.15: Effect of telaprevir on HCV expression in genotype 1 and 3: 
The controls are samples from same liver biopsy fragments incubated 
in the absence of telaprevir. **p=0.0054 (Wilcoxon matched pair test). 
Results are expressed as fold change. HCV expression represents the 
HCV RNA: β-actin ratio (calculated by the relative quantification 
method).  
3.3.3.2. Effect of NA808 on liver biopsy fragments from 
chronic HCV patients 
In order to examine the potential value of our biopsy fragment based 
approach we studied a second antiviral compound – NA808. NA808 is an 
experimental drug developed by Chughai Pharmaceutical Co. Ltd and is 
known to inhibit HCV replication in the genomic replicon system after 7 days 
incubation. It is a serine palmitoyl transferase inhibitor. Serine 
palmitoyltransferase (SPT) is an enzyme of the sphingolipid biosynthetic 
pathway. NA808 is thought to inhibit SPT activity because of its structural 
similarity to sphingosine which results in decreased intercellular 
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sphingomyelin and its intermediates. As sphingomyelin is one of the major 
components of the assembly of HCV this drug targets the assembly step of 
HCV (Lingwood, Kaiser et al. 2009, Simons and Ikonen 1997). 
The two different concentrations of NA808 (50nM and 500nM) were tested 
initially to examine the effects on HCV replication on three different chronic 
HCV patients (illustrated in the figure 3.16) 
 
Figure 3.16: HCV RNA concentration in copy numbers evaluated by real 
time qPCR after using two different doses of NA808 (50nM and 500nM) 
and result obtained by absolute quantification method. (n=3). G = 
genotype.  
Liver biopsy fragments from twenty five patients were used to assess the 
effect of NA808 after 24 and 48 hours. Details of these patients are 
discussed in tables 3.2 (patients whose liver biopsies were incubated with 
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NA808 for 24 hours) and 3.3 (patients whose liver biopsies were incubated 
with NA808 for 48 hours). 
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No 
 
 
Age 
 
Genotype  
 
                 Viral load 
 
Fibrosis 
 
 
Fold 
Change 
 
 
   1 
 
 
26 
 
1b 
 
6.16 log IU (1446841 IU) 
 
1 
 
   6.50 
   
   2 
 
 
31 
 
1b 
 
7.09 log IU (12332603 IU) 
 
1 
 
   1.46 
 
   3 
 
48 
 
1b 
 
6.28 log IU (1946623 IU) 
 
1 
 
 
   1.40 
   
   4 
 
41 
 
1 
 
NA 
 
6 
 
 
  -1.08 
 
   5 
 
49 
 
1a/1b 
 
6.64 log IU (4381228 IU) 
 
3 
 
 
  -2.49 
 
   6 
 
56 
 
1a 
 
6.75 log IU (5671859 IU) 
 
4 
 
 
  -1.48 
 
   7 
 
 
55 
 
1a 
 
NA 
 
1 
 
  -1.16 
 
   8 
 
 
41 
 
1 
 
3.51 log IU (3237 IU) 
 
4 
 
   3.79 
 
   9 
 
 
27 
 
2 
 
4.85 log IU (71775 IU) 
 
1 
 
   1.06 
 
10 
 
 
48 
 
2 
 
4.62 log IU (42068 IU) 
 
1 
 
   2.16 
 
11 
 
 
41 
 
2 
 
4.82 log IU (66109 IU) 
 
1 
   
   1.02 
 
12 
 
 
45 
 
3a 
 
6.06 log IU (1155192 IU) 
 
1 
 
  -5.19 
 
13 
 
 
72 
 
3 
 
NA 
 
2 
 
  -6.02 
 
14 
 
 
25 
 
3 
 
        4.87 log IU (74573 IU) 
 
2 
 
 
  -1.22 
 
15 
 
 
32 
 
4 
 
3.76 log IU (5853 IU) 
 
2 
 
   6.50 
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Table 3.2: Details of the patients whose liver biopsy samples were used in the 
experiments to look at HCV RNA gene expression after 24 hours of NA808 
treatment. The table shows age, genotype and subtype (if available), fibrosis 
score (Ishak scoring) viral load and fold change in HCV RNA after incubating 
these biopsy fragments in NA808 compared to untreated samples from each 
patient. NA = no sample available for viral load testing at the time of liver 
biopsy. 
 
 
 
 
 
 
 
 
 
 
No 
 
 
Age 
 
Genotype  
 
                 Viral load 
 
Fibrosis 
 
 
Fold 
Change 
 
 
16 
 
 
46 
 
6a 
 
5.89 log IU (788749 IU) 
 
1 
 
  1.46 
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T
able 3.3: Details of the patients whose liver biopsy samples were used in the 
experiments to look at HCV RNA gene expression after 48 hours of NA808 
treatment. The table shows age, genotype and subtype (if available), fibrosis 
 
No 
 
 
Age 
 
Genotype  
 
        Viral load 
 
 
Fibrosis 
 
 
 
Fold 
Change 
 
   1 
 
 
48 
 
1 
 
NA 
 
3 
 
   1.17 
   
   2 
 
 
33 
 
1 
 
NA 
 
2 
 
   1.66 
 
   3 
 
55 
 
 
1 
 
6.06 log IU (1164672 IU) 
 
 
1 
 
   2.15 
   
   4 
 
59 
 
 
1 
 
NA 
 
 
3 
 
   177 
 
   5 
 
33 
 
1a 
 
6.79 log IU (6296858 IU) 
 
3 
 
 
  -6.94 
 
   6 
 
30 
 
1a 
 
4.87 log IU (75457 IU) 
 
1 
 
 
  11.55 
 
   7 
 
 
38 
 
1b 
 
5.19 log IU (157792 IU) 
 
2 
 
  -1.4 
 
   8 
 
 
56 
 
3a 
 
6.60 log IU (3994255 IU) 
 
4 
 
  -1.21 
 
   9 
 
 
61 
 
3a 
 
6.62 log IU (4233360 IU) 
 
4 
 
  -47.27 
 
10 
 
 
38 
 
3a 
 
6.2 log IU (1619920 IU) 
 
3 
 
  -3.92 
 
11 
 
 
34 
 
3 
 
4.67 log IU (47395 IU) 
 
1 
 
  -66.77 
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score (Ishak scoring) and viral load from each patient. NA = no sample available 
for viral load testing at the time of liver biopsy 
Figure 3.17, shows the effect of NA808 on genotype 1 strain of HCV after 24 
hours incubations with the fragments of liver tissue (four from each patient-two 
controls and two NA808 treated).  
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A) 
B) 
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Figure 3.17: Ex vivo NA808 treatment of the infected liver tissues for 24 
hours: A) This figure shows mean viral RNA concentrations after 24 
hours incubation in NA808 compared to controls in genotype 1 strain 
infected liver biopsy fragments. Each point represents a mean of two 
samples taken from the same patient and is independent. B) The 
control and NA808 treated samples are linked in this figure. C) Shows 
fold change in HCV expression in each patient's biopsy after treating 
with NA808. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method) 
 
 
 
 
 
C) 
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Figure 3.18, shows the effect of NA808 on genotype 3 strain of HCV after 24 
hours incubations with the fragments of liver tissue (four from each patient-
two controls and two NA808 treated).  
 
       
 
B) 
A) 
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Figure 3.18: Ex vivo NA808 treatment of the infected liver tissues for 24 
hours: A) This figure shows mean viral RNA concentrations after 24 
hours incubation in NA808 compared to controls in genotype 3 strain 
infected liver biopsy fragments. Each point represents a mean of two 
samples taken from the same patient and is independent. B) The 
control and NA808 treated samples are linked in this figure. C) Shows 
fold change in HCV expression in each patient's biopsy after treating 
with NA808. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method) 
 
 
 
 
C) 
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Figure 3.19, shows the effect of NA808 on genotype 2 strain of HCV after 24 
hours incubations with the fragments of liver tissue (four from each patient-
two controls and two NA808 treated).  
    
         
A) 
B) 
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Figure 3.19: Ex vivo NA808 treatment of the infected liver tissues for 24 
hours: A) This figure shows mean viral RNA concentrations after 24 
hours incubation in NA808 compared to controls in genotype 2 strain 
infected liver biopsy fragments. Each point represents a mean of two 
samples taken from the same patient and is independent. B) The 
control and NA808 treated samples are linked in this figure. C) Shows 
fold change in HCV expression in each patient's biopsy after treating 
with NA808. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method). 
This was a limited study with a small sample size and relatively short 
incubation period. Since in the genomic replicon system longer duration of 
exposure (>5 days) was required for NA808 to have an effect (unpublished 
data from Chughai pharmaceuticals), we tried extending the duration of 
incubation.  To examine the effects of NA808 after 48 hours several liver 
biopsies were exposed to NA808 for 48 hours and HCV replication assessed 
further.   
C) 
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Figure 3.20, shows the effect of NA808 on genotype 1 strain of HCV after 48 
hours incubations with the fragments of liver tissue (four from each patient-
two controls and two NA808 treated).  
              
               
A) 
B) 
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Figure 3.20: Ex vivo NA808 treatment of the infected liver tissues for 48 
hours: A) This figure shows mean viral RNA concentrations after 48 
hours incubation in NA808 compared to controls in genotype 1 strain 
infected liver biopsy fragments. Each point represents a mean of two 
samples taken from the same patient and is independent. B) The 
control and NA808 treated samples are linked in this figure. C) Shows 
fold change in HCV expression in each patient's biopsy after treating 
with NA808. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method). 
Figure 3.21, shows the effect of NA808 on genotype 3 strain of HCV after 48 
hours incubations with the fragments of liver tissue (four from each patient-
two controls and two NA808 treated).  
C) 
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A) 
B) 
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Figure 3.21: Ex vivo NA808 treatment of the infected liver tissues for 48 
hours: A) This figure shows mean viral RNA concentrations after 48 
hours incubation in NA808 compared to controls in genotype 3 strain 
infected liver biopsy fragments. Each point represents a mean of two 
samples taken from the same patient and is independent. B) The 
control and NA808 treated samples are linked in this figure. C) Shows 
fold change in HCV expression in each patient's biopsy after treating 
with NA808. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method). 
Extending the duration of incubation to 48 hours gave us similar results to 
those seen after 24 hours. However, there are several limitations to this study 
– the tissue samples begin to die after 24 hours and tissue viability is 
markedly reduced; the sample size was very small and data from the replicon 
model suggests that NA808 may take several days to exert its antiviral 
effects. In next section we will discuss the measures we have taken to modify 
the assay to overcome these limitations.   
C) 
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 3.3.4. Experiments on isolated hepatocytes 
3.3.4.1. Isolated hepatocytes 
In the above section we discussed drug testing on intact liver biopsy 
fragments.  In this section we will discuss the work with hepatocytes isolated 
from the liver biopsy fragments. In intact liver biopsy fragments each 
fragment will contain a variable amount of liver tissue and stromal tissue 
(including fibrous tissue) and the proportion of infected cells will vary. We 
speculate that this fragment to fragment variability increased the sample to 
sample variability that adversely impacted our ability to identify drug induced 
effects. To overcome this limitation we speculated that isolated hepatocytes 
might allow homogenous cultures to be developed that can be used to assay 
drug activity.  Here we describe our attempts to develop such a system. 
3.3.4.2. Cell viability of isolated hepatocytes  
After extraction from the liver biopsy, cell viability of isolated hepatocytes was 
assessed after 0, 24 and 48 hours using the ATP cell viability assay and cell 
viability was measured in relative luminescence units (RLU).  Two different 
cell counts were used i.e.; 1000 and 500 cells. Figure 3.22 and figure 3.23 
show the cell viability in 1000 and 500 cells at 0, 24 and 48 hours, 
respectively. Note that these experiments differ from the experiments 
outlined in above section when the viability of intact liver biopsy fragments 
was assessed.   
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Figure 3.22: Cell viability after 24 and 48 hours in cells separated from 
liver biopsy fragments and incubated for the indicated times (using 
1000 cells). The mean ATP luminescence is used to assess viability of 
these cells. Control is plain medium with no cells.  
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Figure 3.23: Cell viability after 24 and 48 hours in cells separated from 
liver biopsy fragments and incubated for the indicated times (using 500 
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cells). The mean ATP luminescence is used to assess viability of these 
cells. Control is plain medium with no cells.  
In isolated cells the cell viability decreased to 44.8% (from 3626.5 RLUs to 
1626.8 RLUs) after 24 hours and to 26.8% (3626.5 RLUs to 973.8 RLUs) 
after 48 hours in 1000 hepatocytes. In 500 hepatocytes cell viability came 
down to 50% (from 1737 RLUs to 872.7 RLUs) after 24 hours and to 38% 
(1737RLUs to 666.75 RLUs) after 48 hours indicating that maintaining the 
integrity of the sample may improve cell viability while isolating the cells from 
their extracellular matrix causes them to die more quickly. Note that these 
pilot experiments were not performed in parallel and direct comparison of the 
data from these experiments and the experiments described in above section 
is not possible.  
Nevertheless the data shown above indicates that isolated human 
hepatocytes have poor viability under standard culture conditions and 
indicates that examining the impact of drugs on isolated hepatocytes is 
unlikely to be productive. In these experiments we did not assess hepatocyte 
specific cell markers but others have shown that expression of hepatocyte 
specific markers is markedly reduced with simple culture of hepatocytes 
(Bhatia, Balis et al. 1999, Khetani and Bhatia 2008).  
Table 3.4 shows the details of all the patients whose liver biopsy samples 
were tested for cells viability. This includes both those which were kept intact 
in culture and those isolated and then incubated for 24 and 48 hours. 
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Table 3.4: Details of the patients whose liver biopsy samples were 
used in the experiments to look at cell viability at 24 and 48 hours. The 
table shows age, genotype and subtype (if available), fibrosis score 
(Ishak scoring) and viral load from each patient.  
3.3.4.3. Pure hepatocyte culture versus co-culture 
There are multiple assays to assess hepatocyte function including simple 
viability assays (used in our preliminary experiments), morphology, 
expression and activity of hepatocyte specific proteins, enzymes and soluble 
factors including albumin expression, urea production, cytochrome P450, 
phase II enzymes and glutamine synthetase activity (Bhatia, Balis et al. 1999, 
Khetani and Bhatia 2008). Since our aim was to develop a culture system to 
facilitate analysis of HCV replication we chose to monitor 
viability/differentiation by examining HCV RNA replication. The aim was that 
once an approach allowing HCV replication to be maintained for reasonable 
 
 No 
 
 
Age 
 
Genotype  
 
           Viral load  
 
 Fibrosis 
 
1 
 
53 
     
      1 
 
5.13 log IU (134139 IU) 
   
    3 
 
 
2 
 
45 
       
      1 
 
5.73 log IU (546020 IU) 
    
    4 
 
 
3 
 
 
77 
      
      1b 
 
6.19 log IU (1573715 IU) 
   
    4 
 
4 
 
52 
     
      3a 
 
6.4 log IU (2533182 IU) 
    
    2 
 
 
5 
 
49 
      
      3 
 
5.32 log IU (208503 IU) 
    
    1 
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periods of time was developed we planned to monitor hepatocyte status 
further using some of the assays outlined above. 
A) HCV RNA expression in pure hepatocytes compared to co-
cultures of hepatocytes and 3T3 embryonic fibroblasts (24 
and 48 hours) 
As noted above others have shown that the co-culture of hepatocytes with 
3T3 murine embryonic fibroblasts grown in micro-patterns allows very 
prolonged culture of differentiated hepatocytes that can be infected with 
HCV. However, the micro-patterning technique is technically complex, allows 
only tiny clusters of hepatocytes to be grown and permits very limited 
replication of HCV. We suspect that such a complex procedure with the 
potential for significant sample to sample variation will prove difficult to 
develop for studies of individual drug sensitivity. Furthermore the micro-
patterning technique is optimized to allow hepatocyte differentiation over 
many weeks. We speculate that if a simple, easy to use hepatocyte culture 
technique could be developed that would maintain hepatocytes in a 
sufficiently differentiated state to support HCV replication for a period of 48-
72 hours then assessment of the effects of different antiviral agents would be 
possible. We therefore attempted to develop an ‘adequate’, rather than a 
‘perfect’ hepatocyte culture.  
Liver biopsies from ten patients with HCV were used to analyse the effects of 
co-culture with fibroblasts on HCV expression after 24 and 48 hours. Around 
2x105 to 4x105 hepatocytes were separated from each biopsy and then 
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plated in 4 wells (collagen type 1 coated to provide an extracellular matrix 
component to hepatocytes). Two wells contained pure culture with only 
primary human hepatocytes (PHHs) and the other two wells contained co-
culture of PHHs and murine 3T3 embryonic fibroblasts at a ratio of 1:4 before 
incubation. All wells contained equal number of hepatocytes. After 24 and 48 
hours incubation we compared expression of HCV RNA by real time qPCR 
(discussed in chapter 2). HCV RNA expression in pure PHHs culture was 
analysed against co-culture of fibroblast and hepatocytes from each liver 
biopsy sample from chronic HCV infected individuals. Table 3.5 and 3.6 show 
details of patients whose liver biopsy samples were used in the experiments 
to look at HCV RNA gene expression in co-cultured cells after a 24 and 48 
hours respectively.  
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Table 3.5: Details of the patients whose liver biopsy samples were used 
in the experiments to look at HCV RNA gene expression in co-cultured 
cells after 24 hours. The table shows age, genotype and subtype (if 
available), fibrosis score (Ishak scoring), viral load (done closest to the 
time when liver biopsy was taken from each patient) and fold change in 
HCV RNA gene expression in co-cultured cells compared to pure 
primary human hepatocyte cultures in biopsies of different HCV 
positive individuals.  
 
 
 
 No 
 
 Age 
 
 Genotype 
            
          Viral load  
 
 Fibrosis 
 
Fold 
 Change 
 
1 34 
 
 
      3 
 
5.49 logIU(312241 IU) 
 
    1 
 
2.40 
 
2 
 
45 
 
      3a 
 
5.25 logIU (179052 IU) 
 
    1 
 
4.33 
 
3 
 
48 
 
      2b 
 
6.69 logIU (4855028 IU) 
 
    2 
 
3.93 
 
4 
 
34 
 
      4 
 
5.22 logIU (165896 IU) 
 
    3 
 
5.87 
 
5 
 
49 
 
      2b 
 
4.43 logIU (27202 IU) 
 
    2 
 
16.8 
 
6 
 
57 
 
      1a 
 
6.50 logIU (3189531 IU) 
 
    3 
 
1.5 
 
7 
 
38 
 
      3a 
 
6.55 logIU (3547273 IU) 
 
    2 
 
 -1.058 
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Table 3.6: Details of the patients whose liver biopsy samples were used 
in the experiments to look at HCV RNA gene expression in co-cultured 
cells after 48 hours. The table shows age, genotype and subtype (if 
available), fibrosis score (Ishak scoring), viral load (done closest to the 
time when liver biopsy was taken from each patient) and fold change in 
HCV RNA gene expression in co-cultured cells compared to pure 
primary human hepatocyte cultures in biopsies of different HCV positive 
individuals. NA = no sample available for viral load testing at the time of 
liver biopsy 
Figures 3.24 and 3.25 show HCV RNA gene expression in co-cultured 
3T3 and PHHs cells verses pure PHHs (24 hours and 48 hours 
respectively).         
 
 
 
No 
 
Age 
 
Genotype 
            
          Viral load  
 
 Fibrosis 
 
Fold 
Change  
 
1 
 
 63 
 
    3a 
 
NA 
 
   4 
 
  3.462 
 
2 
 
 47 
 
    1 
 
  
6.29 log IU (1929423 IU) 
 
   3 
 
-5.40 
 
3 
 
 43 
 
    3b 
 
5.09 logIU (116418 IU) 
 
 
   5  3.09 
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Figure 3.24 : Figure shows the HCV RNA concentration after 24 hours in 
pure primary human hepatocytes (PHHs) culture compared to that in 
the co-culture of PHHs and 3T3 fibroblasts (p-value = n/s, using 
Wilcoxon matched pair test). A) Shows the comparison of HCV 
expression among pure primary human hepatocytes cultures and co-
cultures of fibroblast and hepatocytes. B) Shows the fold change in 
expression of HCV RNA after co-culturing relative to pure cultures. 
250 
 
Each point represents mean of duplicate wells from each pure- and co-
culture. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method). 
  
 
Figure 3.25: This figure shows the HCV RNA concentration after 48 
hours in pure primary human hepatocytes (PHHs) culture compared to 
that in the co-culture of PHHs and 3T3 fibroblasts (p-value = n/s using 
Wilcoxon matched pair test). A) Shows the comparison of HCV 
expression among pure primary human hepatocytes cultures and co-
n/s 
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cultures of fibroblast and hepatocytes. B) Shows the change in 
expression of HCV RNA after co-culturing relative to pure cultures. 
Each point represents mean of duplicate wells from each pure- and co-
culture. HCV expression represents the HCV RNA: β-actin ratio 
(calculated by the relative quantification method). 
Although the small number (n=10) of samples studied did not allow a 
statistically significant difference in HCV expression to be detected between 
the two different culture approaches there was a clear trend towards 
increased HCV RNA expression in hepatocytes co-cultured with murine 
fibroblasts. The ease of this technique coupled with previous reports of the 
success of co-cultures (mentioned above) and the indication of an 
improvement in HCV RNA expression led us to try and refine this model 
further. 
B) HCV RNA expression in co-cultures of PHH and 3T3 
embryonic fibroblasts (48hours) using hepatocyte 
supplement medium  
Liver biopsies from six patients with HCV were used to analyse the effect of 
hepatocyte supplement medium on co-culture of 3T3 fibroblasts and 
hepatocytes after 48 hours of incubation.  Again around 2x105 to 4x105 
hepatocytes were separated from each biopsy (as noted above) and then 
plated in 4 wells (collagen type 1 coated to provide extracellular matrix 
component to hepatocytes).  Two wells contained co-culture of fibroblast with 
hepatocytes without hepatocyte supplement medium and the other two wells 
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contained co-cultures of primary human hepatocytes and murine 3T3 
embryonic fibroblasts with hepatocyte supplement medium. After 48 hours 
incubation we compared expression of HCV RNA in the wells containing 
hepatocyte supplement medium with those containing none using real time 
qPCR (discussed in chapter 2 Methods). Table 3.7 shows details of patients 
whose liver biopsy samples were used in the experiments to look at HCV 
RNA gene expression in co-cultured cells with and without hepatocyte 
supplement medium.  
  
 
 
 
 
 
 
 
Table 3.7: Details of the patients whose liver biopsy samples were used 
in the experiments to look at HCV RNA gene expression in co-cultured 
cells with and without hepatocyte supplement medium after 48 hours. 
The table shows age, genotype and subtype (if available), fibrosis score 
(Ishak scoring), viral load (done closest to the time when liver biopsy 
 
No 
 
 Age 
 
Genotype 
 
            
      Viral load  
 
 Fibrosis 
 
Fold  
Change 
 
1 59 
 
 3b 
 
 
4.80 logIU (63324 IU) 
 
    3 
 
5.25 
 
2 
 
43 
 
 3 
 
NA 
 
   3 
 
13.4 
 
3 
 
47 
 
 2  
 
6.32 logIU (1700056 IU) 
 
   2 
 
4.1 
 
4 
 
57 
 
 1 
 
           NA 
 
   3 
 
6.27 
 
5 
 
43 
 
 1a 
 
6.89 logIU (7754868 IU) 
 
   2 
 
57.0 
 
6 
 
63 
 
3a 
 
6.45 logIU (2829228 IU) 
 
   2 
 
1.13 
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was taken from each patient) and fold change in HCV RNA gene 
expression in co-cultured cells with and without hepatocyte 
supplement medium in different HCV positive individuals. NA = no 
sample available for viral load testing at the time of liver biopsy. 
Figures 3.26, shows HCV RNA gene expression in co-cultured 3T3 and 
PHHs cells with and without hepatocyte supplement medium (incubated for 
48 hours).        
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Figure 3.26: HCV RNA concentration after 48 hours in the co-culture of 
PHHs and 3T3 fibroblasts with and without hepatocyte supplement 
medium (HSM) (*p-value = 0.03 using Wilcoxon matched pair test). A) 
Shows the comparison of HCV expression among co-cultures of 
fibroblast and hepatocytes with and without hepatocyte supplement 
medium. B) Shows the change in expression of HCV RNA after co-
culturing with and without HSM. Each point represents mean of 
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duplicate wells from each pure- and co-culture. HCV expression 
represents the HCV RNA: β-actin ratio (calculated by the relative 
quantification method). 
Although the sample size studied in this experiment was small (n=6) there 
was a statistically significant increase in HCV RNA expression in co-cultures 
with hepatocyte supplement medium (HSM) compared to those without HSM 
(p=0.03). This may be because HSM supports the viability of hepatocytes 
and is required for their maintenance in cell culture or because it provides an 
optimized environment for hepatocytes and permits differentiation to a level 
that allows HCV replication to persist.   
3.3.4.4. Drug validation experiment  
A. Effect of telaprevir on HCV expression in co-culture model 
Liver biopsies from seven patients (belonging to different genotypes) were 
used to isolate PHHs. These PHHs were co-cultured with 3T3 embryonic 
fibroblasts cells to produce a co-culture liver biopsy model for drug testing. 
Telaprevir was used at the concentrations discussed above - i.e.; 10µg/ml 
(14.7nM) and the effect on HCV RNA expression was observed after 48 
hours of incubation with telaprevir. Table 3.8 shows details of patients whose 
liver biopsy samples were used in experiments to look at HCV RNA gene 
expression in co-cultured cells with and without telaprevir. 
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Table 3.8: Details of the patients whose liver biopsy samples were used 
in the experiments to look at HCV RNA gene expression in co-cultured 
cells treated with and without telaprevir after 48 hours. The table shows 
age, genotype and subtype (if available), fibrosis score (Ishak scoring), 
viral load (done closest to the time when liver biopsy was taken from 
each patient) and fold change in HCV RNA gene expression in co-
cultures incubated with and without telaprevir from different HCV 
positive individuals.  NA = no sample available for viral load testing at 
the time of liver biopsy. 
 
 
 
 No 
 
  
Age 
 
  
Genotype 
 
            
 
        Viral load  
 
  
Fibrosis 
 
 
Fold  
Change 
 
1 
   
  41 
 
  1 
 
NA  
 
  3 
 
 
 1.85 
 
2 
 
  48 
 
  2 
 
6.66 logIU (4560203 IU) 
 
3 
 
 
 1.24 
 
3 
 
  48 
 
  1 
 
6.34 logIU (2193653 IU) 
 
3 
 
 
-1.05 
 
4 
 
  35 
 
  1 
 
                   NA 
 
0 
 
 
4.5 
 
5 
 
  43 
    3 
6.64 logIU (4367581 IU) 
 
1 
 
 
 1.55 
 
6   80 
 
  2b 
 
6.68logIU (4807015 IU) 
 
 
2 
 
 
 1.77 
 
7 
 
  57 
 
  1a 
 
7.3 logIU (20000000 IU) 
 
2 
 
 
 1.29 
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The HCV expression (HCV/β-actin ratio) in response to telaprevir 
treatment is illustrated in figure 3.27. For each biopsy obtained from a 
single patient four samples were taken; two controls and two experimental 
samples (telaprevir treated). Controls contained plain medium without 
telaprevir and were incubated for 48 hours before extraction.  
        
Figure 3.27: Effect of telaprevir on HCV RNA expression in the co-
culture model containing different genotypes of HCV after 48 hours: 
Each point represents mean of two samples each of isolated PHHs 
treated and untreated (controls) with telaprevir, p-value = n/s and 
experiment shows high sample to sample variability (represented by 
standard error of mean). HCV expression represents the HCV RNA: β-
actin ratio (calculated by the relative quantification method). 
 
n/s 
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There was significant sample to sample variability observed between the 
samples of isolated human hepatocytes co-cultured with fibroblasts from 
each biopsy taken - two control and two experimental samples. It was 
observed that there was no significant difference in control and experimental 
samples (telaprevir treated) of co-culture model. This shows that attempts at 
extending the life of PHHs for 48 hours by co-culturing with fibroblast did not 
increase the likelihood of a better assessment of the effects of the antiviral 
agent telaprevir. This may be due to either co-culturing isolated PHH with 
3T3 embryonic fibroblasts in a random manner doesn't enhance the ability of 
the cells to permit HCV replication or the distribution of HCV within liver cells 
is not homogeneous generating high levels of variability between different 
wells. Notwithstanding, the sample number was too small to derive any 
conclusion about the effect of telaprevir on different genotypes in an 
aggregated patient cohort. Likewise, it was decided to abandon this line of 
investigation due to above mentioned problems with this approach. 
3.4. Discussion 
Fragments of tissue from human liver biopsies can be maintained in tissue 
culture for up to 48 hours. However, the viability of the tissue is markedly 
reduced after incubation periods of greater than 24 hours. Data from intact 
liver biopsy fragments provides proof of the principal data showing that direct 
acting antiviral agents can be tested ex vivo using surplus liver biopsy 
material but it requires use of aggregated patient cohorts to observe the 
effect of telaprevir on different genotypes. Experiments with telaprevir reflect 
the findings of clinical studies indicating that telaprevir has efficacy in 
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genotype 1 but not genotype 3 HCV. Our data were unable to confirm reports 
showing that telaprevir is active against genotype 2 HCV as too few samples 
were available for testing.  Although results described in this chapter indicate 
the viability of this approach there are significant problems with the assay as 
it now stands, in particular the large fragment to fragment variation and the 
heterogeneity of the response preclude an assessment of the individual 
response to telaprevir, significantly reducing the value of this approach. 
To extend work with telaprevir a second antiviral agent was examined i.e; 
NA808. This is an experimental drug whose efficacy in patients is still under 
evaluation. However, data from the manufacturer show that the drug is a 
potent antiviral agent against HCV in replicon cells although prolonged 
incubation with the drug is required before antiviral activity is detected 
(suggested by data from Chughai Pharmaceuticals). In our studies, a 
considerable decline of HCV RNA was observed in biopsies infected with 
genotype 3 HCV after incubation with NA808 for 24 or 48 hours. However, 
we detected minimal response in biopsy samples from patients with genotype 
1 HCV. It remains unclear whether the absence of an effect in patients with 
genotype 1 HCV is due to a slower onset of action of NA808 in this genotype 
or due to an absence of effect on this viral strain.  To reach a firm conclusion 
regarding the significance of the effect of NA808 on genotype 3 viral strains 
increasing the sample size and extending the duration of incubation would 
have provided us with more accurate estimation of the effect of this drug. 
Although, reduced sample size is an issue here, it would be worth noting that 
NA808 affects lipid metabolism by inhibiting the sphingolipid biosynthesis. 
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HCV genotype 3 is associated with unique interactions with host lipid 
metabolism. There are multiple mechanisms by which HCV genotype 3 up-
regulates lipogenesis and steatosis. It activates a mediator of steatosis called 
sterol regulatory element-binding protein in its host (Kim, Hong et al. 2007). 
Moreover, HCV genotype 3 core proteins down-regulate components which 
suppress lipid droplet formation (Clement, Peyrou et al. 2011). Steatosis has 
also been linked to higher levels of viremia in those infected with HCV 
genotype 3 strains and successful eradication of virus led to reduction in liver 
steatosis (Kumar, Farrell et al. 2002, Lonardo, Loria et al. 2006). Additionally, 
in HCV genotype 3 infections, steatosis is linked with increased viral relapse 
(Shah, Patel et al. 2011). NA808 can be studied further for its link with lipid 
metabolism and effect on different HCV genotypes.  
Because of the inability to keep considerable numbers of PHHs viable 
beyond 24 hours and toxicity in man at concentrations which were effective in 
vitro, we did not study NA808 further. Moreover, experiments with intact 
fragments of human liver biopsies indicate that the tissue is viable for no 
longer than 48 hours and that there is considerable intra-assay variation, 
leading to a requirement for multiple analyses to derive significant results. 
This detracts us from the main aim which was to evaluate drug sensitivity in 
individual patient. 
The results obtained from co-cultured hepatocytes replicate the studies 
performed by others suggesting that murine embryonic 3T3 cells facilitate the 
culture of human hepatocytes and suggest that hepatocytes show 
conservation of their functions and express soluble and insoluble proteins 
and enzymes in a more functionally stable and structurally conserved micro-
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environment (discussed in Introduction 3.1). Although the sample number 
used in our comparative study of co-culture versus pure culture was small 
(n=10) and though results did not show significance regarding the rise in 
HCV expression there was an indication that HCV RNA expression improved 
in co-cultured samples and there was significant enhancement of HCV 
expressions in co-cultures treated with hepatocyte supplement medium.  
Taken together these data persuaded us that further studies in this area were 
worthwhile and characterizing the differentiation of hepatocytes using 
expression of liver specific markers as well as examining the effects of 
antiviral agents on HCV replication would be a useful future intervention. We 
speculated that co-culture techniques coupled with using collagen coated 
plates and special medium (HSM) to keep hepatocyte metabolically active, 
will provide an easy to use model for drug testing in HCV infected patients. 
However, our experiments with telaprevir did not prove to be a model which 
could be replicated for drug testing. This model showed significant sample to 
sample variability between two samples plated out in duplicates as controls 
(untreated with telaprevir) and telaprevir treated. Moreover, work to prolong 
the viability of primary hepatocytes in culture did not provide acceptable 
results because of even wider sample to sample variation in PHHs co-
cultured with fibroblasts without using the micro-patterning technique.  It was 
not possible to perform micro-patterning and as discussed earlier micro-
pattern co-culture experiments have not been possible outside the originators 
laboratory because of the unavailability of the stensil used in these studies 
(discussed in introduction section of this chapter). 
 
262 
 
 
 
 
 
 
 
Chapter Four 
 
       HCV Fusion Model 
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4.1. Introduction  
4.1.1. Polyethylene glycol mediated forced cell-to-cell fusion  
Artificial forced cell-to-cell fusion is used in various biotechnical research 
experiments and it can be carried out in vitro by using different methods 
which involve chemical, electrical and laser induced fusion. Chemical fusion 
by polyethylene glycol (PEG) was used as a method to induce cell-to-cell 
fusion in experiments performed in this thesis. PEG is a highly hydrated 
compound that brings cellular membranes to near molecular contact, 
making water between them thermodynamically unfavourable. This 
disrupted repacking of contacting layers of cellular membranes is 
necessary to induce fusion. It starts with the mixing of outer leaflet lipids, 
forming transient intermediate containing pores which join to form fusing 
compartments. The first intermediate transforms in a second intermediate 
in 1-3 minutes which then ‘pops’ to form a proper fusion pore with inner 
leaflet mixing followed by cell contents mixing. These sequence of events 
and activation energies correlate well to the process of cell fusion (Lentz 
and Lee 1999).  
Cellular fusion is a common physiological process (discussed in chapter 1 
section 1.10). We used artificial fusion in an attempt to transfer HCV from 
monocytes to replication competent hepatoma cells. In this chapter I describe 
my studies on PEG 1500 forced fusion with monocytes from HCV patients 
and a hepatoma cell line in an effort to create a model for the understanding 
of HCV replication. 
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4.1.2. Cell-based fusion assay for in vitro studies of HCV 
As discussed in Chapter 1 Introduction, section 1.9, HCV is known to infect 
monocytes (Laskus, Radkowski et al. 2004) and HCV transfer from B cells to 
hepatocytes is established (Ducoulombier, Roque-Afonso et al. 2004). In one 
study umbilical cord derived macrophages were infected with HCV from 
patients' plasma or serum and the supernatant derived from HCV infected 
macrophage culture was used to infect other cell lines like B and T cell, 
lymphoid and neuronal cells. As hepatocytes infection was not tried by this 
method it is not know whether infection of hepatocytes would take place 
using this approach (Revie, Alberti et al. 2010). Moreover, HCV from patients' 
serum has not been propagated in hepatocytes in previous studies 
(Gondeau, Pichard-Garcia et al. 2009). The reasons for the failure of patient 
derived HCV to propagate and replicate in cultured human hepatocytes are 
not known but work in this thesis speculates that poor entry (perhaps 
because of poor expression of receptors) may play a role and rectifying this 
hurdle might overcome this issue. Thus, transfer of monocyte incorporated 
HCV might be possible by avoiding the HCV entry step. Moreover, it is 
proposed that if large amounts of virus can be delivered through this may 
overcome host inhibitors of replication. These speculations raised the 
question of whether fusion of HCV containing monocytes to hepatocytes 
might allow HCV propagation and replication to become established and this 
will be demonstrated in experiments explained in this chapter. 
Polyethylene glycol was used to induce forced fusion of CD14 bead 
separated monocytes obtained from chronic HCV patients (with active viral 
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infection) and Huh 7.5 cell line (details explained in Chapter 2 Materials and 
Methods section 2.2.2) in an effort to make a hybrid cell line which contains 
genetic material from both CD14+ monocytes and Huh 7.5 cells to produce 
an in vitro model of hepatocyte infection which was grown for varying lengths 
of time prior to real time qPCR measurement of HCV RNA. This approach 
was also used to consolidate the knowledge obtained from previous studies 
which demonstrated establishment of viable HCV in monocytes and 
macrophages of chronic HCV patients. Polymerase chain reaction and 
immunofluorescence microscopy (both confocal and non-confocal) were 
carried out primarily to determine the presence and replication of HCV in the 
fused cells or their progeny.  
4.2. Aims and hypothesis 
The aim of this chapter is to establish a cell-based assay for the in vitro 
study of HCV infection and to determine whether fusing infected monocytes 
from patients with chronic HCV to replication ‘permissive’ liver cell line will 
lead to generation of hybrid cells harbouring viable HCV. We speculate that 
replication can be enhanced in hepatocyte/monocyte fusion model by 
creating an immune deficit environment and that monocytes can be used to 
capture HCV from sera of HCV patients and infect Huh 7.5 cells after 
fusion.  
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4.3. Results 
4.3.1. Insight into initial fusion experiments  
Initially, Huh 7.5 cells and monocytes were fused under different conditions to 
obtain the most favourable settings that would achieve maximum fusion 
between monocytes and Huh 7.5 cells. It was speculated that this 
optimization would achieve higher levels of fusion between cells 
consequently more monocytes and Huh 7.5 cells would fuse maximally to 
form a putative, hybrid (fused) cell line with minimal amounts of single cells in 
culture. This higher degree of fusion would provide more chance of HCV 
being transferred to the replication permissive liver cell line and result into 
establishment of HCV infection by circumventing HCV entry step.  
Different techniques were tried to achieve optimal fusion i.e.; by fusing cells 
at different ratios i.e.; 1:2, 1:1 and 2:1 of monocytes and Huh 7.5 cells 
respectively, by using different incubation times with PEG 1500 ranging from 
one to seven minutes before addition of DMEM (with 10% FCS) for dilution 
and deactivation of PEG and by using PEG 1500 with different pHs to 
determine the ideal pH to gain highest level of fusion.  Moreover, cells were 
examined for 24 hours and it was observed that the fused cells which were 
grown on non-collagen coated plates showed massive cell death in the initial 
days after fusion and empirical experiments with collagen coated plates 
facilitated cell survival. We also tried modifying the fusion reaction volume to 
keep cells closer together for first 24 hours which elucidated that using 500 µl 
DMEM (FCS 10%) in each well of a 12 well plate enabled cells to be in close 
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contact with each other and with the lower surface of the well and helped 
them to adhere and grow at the bottom of the well more effectively. It was 
contemplated that cell-to-cell interaction would play a crucial role in growth, 
development and proliferation of fused cell line. Hence, an optimal balance 
was eventually achieved which gave maximum fusion along with minimum 
cell membrane damage. Below are the details of these optimization 
experiments. 
4.3.2. Determining optimal fusion conditions 
A. Experimental controls  
To generate control cells to monitor fusion we labelled monocytes and Huh 
7.5 cells with different fluorescent dyes (fluorophobes; DiI and DiO 
respectively). The techniques used to label the cells are described in 
Materials and Methods. To determine whether cells were appropriately 
labelled, Dil and DiO vybrant dye stained monocytes and Huh 7.5 cells were 
examined by flow cytometry. Labelled cells were then fused and investigated 
by FACS (fluorescence activated cell sorting) analysis. Figure 4.1 shows 
typical results from a flow cytometry analysis. 
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Figure 4.1:  Controls for flow cytometric (FACS) analysis: A) Dil dye-
labelled monocytes B) DiO dye-labelled Huh 7.5 cells C) DiI labelled 
monocytes and DiO labelled Huh 7.5 cells fused together by PEG 1500 
at 1:1 ratio. Percentage of fused cells was assessed by flow cytometry 
(FACS) analysis.  
 
A B 
C 
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B. Ratios of monocytes and Huh 7.5 cells for fusion 
Dye labelled monocytes and Huh 7.5 cells were fused in different ratios i.e. 
2:1, 1:1 and 1:2 and results analysed through flow cytometry experiments. 
The example shown below demonstrates extent of fusion depending on ratio 
of Huh 7.5 cells and monocytes. Percentage of fused monocytes and Huh 
7.5s was 52.1% when fused in 1:1 ratio (unfused DiI labelled monocytes 
were 3.33% and DiO labelled Huh 7.5 cells were 0.14%). When fused at 2:1 
monocyte to Huh 7.5 cell ratio percentage of fused monocytes and Huh 7.5s 
was 24.6% (unfused DiI labelled monocytes were 57% and DiO labelled Huh 
7.5 cells were 4.82%) whereas percentage of fused monocytes and Huh 7.5s 
was 35.1% when fused in 1:2 monocyte to Huh 7.5 cell ratio (unfused DiI 
labelled monocytes were 2.96% and DiO labelled Huh 7.5 cells were 43.5%). 
Please see figure 4.2 for details. These experiments were performed on 
three separate occasions and although the absolute values differed the trend 
remained consistent and therefore a ratio of 1:1 was selected for subsequent 
experiments. 
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Figure 4.2: Huh 7.5 cells and monocytes fused at different ratios: Dye-
labelled monocytes and Huh 7.5 cells incubated together in PEG 1500 at 
the ratio of 2:1 (A), 1:2 (B) and 1:1 (C), monocytes to Huh 7.5 cells and 
percentage of fused cells was assessed by flow cytometry 
(representative example from 3 separate experiments). 
It was also observed that cell growth was better when fused at 1:1 monocyte 
to Huh 7.5 ratios where as at 2:1 and 1:2 monocyte to Huh 7.5 cell ratios cell 
A B 
C 
271 
 
growth was noted to be poor by direct observation of the culture plate in three 
separate experiments.  
C. Optimal cell number per well 
Having identified 1:1 as the optimal fusion ratio we modified the number of 
cells in a fixed volume of reaction mixture. 0.5x10-6 fused cells were plated 
per well in collagen coated 12 well culture plates after PEG fusion within 500 
µl of medium for the first day. Using larger amounts of medium for the first 
day reduced adhesion with the bottom of the well, perhaps because of lack of 
close approximation to the base of the collagen coated well and reduced cell-
to-cell interactions. These results were derived from gross observations 
under the microscope with greater number of floating (dead) cells (stained 
with trypan blue to check for viability) and lack of cellular confluence at the 
bottom of the well one day after fusion, based on 3 experiments performed 
without formal comparative quantification.  
After 24 hours, when considerable cellular adhesion and growth was 
observed, medium was increased to 1ml in each well and old medium was 
replaced.  This gave cells ample amount of time to recover from PEG 
induced membrane fragility. Since this plating density provided reasonable 
numbers of viable cells, experiments with different cell densities were not 
performed and this cell number was used in subsequent experiments.           
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D. PEG 1500 incubation time 
To determine the optimal PEG incubation time DiO and Dil labelled Huh 7.5 
cells and monocytes were kept in PEG 1500 at different durations and 
percentage of fusion was observed by flow cytometry (FACS analysis). The 
aim of optimising duration of incubation in PEG 1500 is to establish a definite 
time period which not only attains highest degree of fusion but also causes 
minimal cell membrane fragility by achieving limited PEG exposure. It is 
speculated that highest degree of fusion would achieve better HCV 
replication in fused cell culture. 
Figure 4.3 illustrates the findings of experiment to look at degree of fusion 
observed at different durations of PEG incubation. Dye labelled monocytes 
(DiI labelled) and Huh 7.5 cells (DiO labelled) were incubated in PEG for 1 to 
3 minutes and plated for 24 hours according to optimised procedure 
discussed in previous section (Section 4.3.2, part C). After 24 hours cells 
were extracted to determine percentage of fused cells at different PEG 
incubation times through FACS analysis. 
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Figure 4.3: Extent of fusion depending upon the amount of time in PEG 
1500: Percentage of fused cells after incubation in PEG for 1 minute (A), 
2 minutes (B) and 3 minutes (C). Monocytes and Huh 7.5s  were fused at 
1:1 ratio. 
A B 
C 
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According to the experiment above the proportion of fused cells after 1 
minute incubation was 18.4 %, after 2 minutes incubation was 35.3% and 
after 3 minutes incubation was 45.0%, suggesting that increasing the 
duration of fusion increased the proportion of cells that fused. The proportion 
of cells that fused was determined in further experiments by extending PEG 
incubation time to 7 minutes. Figure 4.4 shows representative experiment 
from experiments done on three separate occasions.  
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Figure 4.4: Degree of fusion depending upon the duration in PEG 1500: 
(A) and (B) represent monocyte and Huh 7.5s controls respectively. 
Percentage of fused cells after incubation in PEG for a definite time 
have been shown with 2 minutes (C), 3 minutes (D), 5 minutes (E) and 7 
minutes (F) (Representative example from 3 separate experiments). 
Monocytes and Huh 7.5s were fused at 1:1 ratio. 
The extent of fusion was observed at 2, 3, 5 and 7 minutes and the mean 
percentage of fusion from 3 different experiments was 52.36% at 2 minutes, 
54.1% at 3 minutes, 16.86 % at 5 minutes and 16.61% at 7 minutes. This 
experiment was repeated on three separate occasions and the trend was 
consistent.  
It was observed that cells incubated in PEG 1500 for more than 3 minutes 
showed massive cell death in the next 24 hours possibly because of 
excessive fragility of cell membrane induced due to prolonged period of PEG 
1500 exposure. 
E. Optimal pH conditions for fusion 
DiO and Dil labelled Huh 7.5 cells and monocytes were exposed to PEG 
1500 with pHs of 6, 7 and 8. The percentage of fusion were analysed by 
FACS. Figure 4.5, shows an example of amount of fusion between 
monocytes and Huh 7.5 cells at different pHs of PEG. The duration of the 
fusion was kept constant at 3 minutes in all experiment and ratio of 
monocytes and Huh 7.5 cells was 1:1. 
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Figure 4.5: Relationship between the amount of fusion and the pH of 
PEG 1500: Monocyte (A), huh7.5s (B), PEG pH 6 (C), PEG pH 7 (D), PEG 
pH 8 (E) (Typical example from three separate experiments). Monocytes 
and Huh 7.5s were fused at 1:1 ratio. 
Three separate experiments were done and it was observed that the trend 
was similar among all three. Mean percentage of fusion with PEG with pH of 
6 was 53.61%, pH of 7 was 54% and pH of 8 was 53.6% (n=3).  
F. Longitudinal measurement of fused cell frequency 
After fusing dye labelled cells in the above favourable conditions, i.e. 1:1 
monocytes and Huh 7.5 cell ratio, PEG 1500 with pH of 7, 3 minutes 
incubation in PEG 1500, using a large number of fused cells (0.5x10-6 per 
well) and small amount of DMEM with 10% FCS (500 µl) in each well after 
fusion for first 24 hours, frequency and survival of persistently fused cells was 
observed at various times by growing the cells for several days and 
calculating the percentage of fused cells by flow cytometry at days 0, 3, 7 
and 10. At day 3 cells were not CD14 bead selected as at that time Huh 7.5 
cells do not overgrow fused cells probably because they are still in a state of 
recovery from the PEG 1500 insult. Massive overgrowth of unfused Huh7.5 
cells was noted after day 5 and therefore it was chosen to select ‘fused cells’ 
(likely to contain replicating HCV) by CD14 bead selection (note that the 
primary monocytes which express CD14 do not proliferate in culture and 
therefore are unlikely to make a significant contribution to the expansion of 
CD14 expressing cells). The percentage of fused cells at these days was 
assessed by FACS analysis. It was seen that immediately after fusion fused 
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cells represented 30.7% of cells, at day 3 they were 26.5%, and the 
proportion of fused cells expressing CD14 at day 7 and 10 were 87.6% and 
62.2% respectively after CD14 bead extraction. Please see figures 4.6 and 
4.7 below. 
                     
Figure 4.6:  Frequency of fused cells immediately after fusion (A) and at 
day 3 (B). Monocytes and Huh 7.5s were fused at 1:1 ratio.                                                               
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Figure 4.7: Frequency of fused cells after CD14 microbeads selection at 
day 7 (C) and 10 (D). Monocytes and Huh 7.5s were fused at 1:1 ratio. 
These experiments indicated that significant numbers of fused cells could be 
generated and maintained in culture for at least 10 days using these 
optimised conditions. These experiments were not repeated further as it was 
determined that further optimisation was best performed using detection of 
replicating HCV by the detection methods. Overall using our optimised 
conditions the mean percentage of fused cells assessed immediately after 
fusion with PEG incubation of 3 minutes was 48.25% (Range 35.0% to 
84.1% and n=10). 
4.3.3. HCV expression analysed in fused cell lines by real time 
quantitative polymerase chain reaction  
In order to confirm that HCV retained by monocytes in chronic HCV patients 
contained viable virions, monocytes fused with Huh 7.5 cells were assessed 
further for HCV RNA expressions by real time qPCR. Monocytes from 
chronic HCV patients were used to assess in vitro HCV expression after 
fusion with Huh 7.5 cells and culturing hybrid cell line for varying lengths of 
time. RNA from cells was extracted in trizol and the amount of HCV in the 
cells was quantified after reverse transcription of extracted RNA and real time 
PCR (See Materials and Methods). qPCR results were analysed by two types 
of relative quantification methods. In one method HCV infection was 
expressed as gene expression calibrated to β-actin while the other method 
was delta-delta CT method in which HCV gene expression was calibrated 
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against β-actin and normalized with the positive control (cells containing HCV 
replicon). It was observed that the trend was the same with both the 
methods. Results here are given by the first method and expressed as HCV/ 
β-actin ratio.  Log2 scale was used to show HCV RNA expression in graphs 
unless stated otherwise. 
Replicon cells were used as a positive control while Huh 7.5 cells and water 
were used as negative controls for PCR. Firstly, RNA from cells was 
extracted from fusions for real time PCR analysis in the first week at different 
days, i.e. day 3, 5 and 7. Expression of HCV in unfused monocytes was also 
assessed by real time PCR and was used as a control to be assessed 
against the HCV expression in the fused population.  HCV expression was 
also observed for longer periods of time in later experiments in a few 
patients. 
4.3.3.1. HCV expression in fused cells (days 1 to 7) 
In this section early pilot experiments to evaluate the feasibility of the 
approach are described and an account of fused cell populations, grown for 
different lengths of time till day 7 is given. A total of twenty four patients were 
studied, twelve belonged to genotype 1 and the other twelve were infected 
with the genotype 3 strain of HCV. The details of patients (ages, genotypes 
+/- subtypes, viral loads nearest to the time blood was taken for fusion, 
fibrosis scores if liver biopsy was done) are given in table 4.1 (patients 
infected with genotype 1 strain) and table 4.2 (patients infected with genotype 
3 strain).      
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Patients infected with genotype 1 strain of HCV:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
No 
  
Date blood taken 
 
 
Age 
 
Genotype 
             
             Viral load  
 
Fibrosis 
 
1 
 
29/07/2009 
 
 
56 
 
1a 
 
5.93 log IU, 858376 IU 
 
ND 
 
2 
 
16/10/2009 
 
33 
 
1b 
 
6.89 log IU, 7714335 IU 
 
ND 
 
 
3 
 
27/01/2010 
 
38 
 
 
1b 
 
7.15 log IU, 14287115 IU 
 
3 
 
4 
 
26/04/2010 
 
58 
 
 
1a 
 
7.01 log IU, 10280828 IU 
 
 3 3 
 
5 
 
07/02/2011 
 
61 
 
 
1a 
 
6.46 log IU, 2866058 IU 
 
3-4 
 
6 
 
01/03/2011 
 
56 
 
 
1 
 
5.91 log IU, 815485 IU 
 
1 
 
7 
 
01/03/2011 
 
59 
 
 
1a 
 
5.94 log IU, 870964 IU 
 
ND 
 
8 
 
20/04/2011 
 
42 
 
 
1 
 
5.60 log IU, 396661 IU 
 
2 
 
9 
 
20/04/2011 
 
47 
 
 
1a 
 
6 log IU, 1000000 IU 
 
2 
 
10 
 
 
27/04/2011 
 
53 
 
 
1a 
 
7.20 log IU, 16017910 IU 
 
2 
 
11 
 
 
04/05/2011 
 
55 
 
 
1 
 
6 log IU, 1000000 IU 
 
ND 
 
12 
 
 
11/05/2011 
 
50 
 
 
1b 
 
NA 
 
6 
Table 4.1: Details of genotype 1 patients used in early fusion experiments to 
look at HCV gene expression in fused monocytes and Huh 7.5 cells. The table 
shows age, genotype and subtype (if available), fibrosis score (Ishak scoring) if 
liver biopsy was done, viral load done closest to the time of blood sampling, 
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for each patient. NA= viral load not available at the time the blood sample was 
taken. 
Figure 4.8, shows experiments performed with monocytes extracted from the 
blood samples of patients infected with genotype 1 strain of HCV. Fused 
monocytes and Huh 7.5 cells were selected out on different days particularly 
on days 3, 5 and 7 and HCV RNA expression was studied by using real time 
qPCR and quantified by calibrating HCV gene expression against that of β-
actin. HCV RNA expression in replicon containing cells and monocytes are 
shown for comparison. The mean HCV viral load in these patients was 6.37 
logIU/ml (range: 5.60 to 7.20 logIU/ml).  
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 Figure 4.8: HCV expression in fused cells, using monocytes obtained 
from genotype 1 patients, cultured for varying lengths of time during 
the first week after fusion and extracted for the assessment of HCV 
RNA on different days: HCV infection is expressed as HCV gene 
expression calibrated to β-actin at various time periods in days (day 3 
(n=9), 5 (n=10) and 7 (n=9)). Replicon cells circled in purple on the left 
side acted as the positive control for fusion experiments. HCV 
expression in monocytes from different patients is circled in blue on 
the right side. Each point represents the mean of samples from a single 
patient run in duplicate during real time qPCR. Patient number with 
colour coding is given on the right hand side. 
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Patients infected with genotype 3 strain of HCV:       
 
No 
  
Date blood taken 
 
 
 Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
 
1 
 
28/05/2009 
 
 
66 
 
3 3.02 log IU, 1036 IU 
 
ND 
 
 
2 
 
01/07/2009 
 
 
47 
 
3a 4.77 log IU, 59330 IU 
 
1 
 
 
3 
 
 
05/08/2009 
 
48 
 
3 6.57 log IU, 3720254 IU 
 
1 
 
 
4 
 
02/09/2009 
 
56 
 
3a 
 
6.65 log IU, 4417016 IU 
 
2 
 
 
5 
 
16/09/2009 
 
44 
 
3 
 
4.99 log IU, 98467 IU 
 
2 
 
 
6 
 
02/11/2009 
 
 
35 
 
3a 6.78 log IU, 5968257 IU 
 
5 
 
 
7 
 
19/01/2011 
 
 
30 
 
3a 
 
5.16 log IU, 142918 IU 
 
2 
 
8 
 
 
18/02/2011 
 
57 
 
3a 
 
5.19 log IU, 153103 IU 
 
4 
 
    9 
 
18/05/2011 44 
 
3a 
 
 
6 log IU, 1000000 IU 
 
5 
 
 
   10 
 
18/05/2011 
 
38 
 
3b 
 
6 log IU, 1000000 IU 
 
2 
 
 
   11 
 
 
25/05/2011 
                
57 
 
3a 
 
6.23 log IU, 1699933 IU 
 
ND 
 
 
   12 
 
 
25/05/2011 59 
 
3b 
 
5 log IU, 100000 IU 
 
ND 
 
Table 4.2: Details of genotype 3 patients used in early fusion experiments to 
look at HCV gene expression in fused monocytes and Huh 7.5 cells. The table 
shows age, genotype and subtype (if available), fibrosis score (Ishak scoring) 
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if liver biopsy was done, The viral load test performed at the nearest point in 
time to the biopsy was recorded.  
Figure 4.9, shows experiments performed with monocytes extracted from the 
blood samples of patients infected with genotype 3 strain of HCV. Fused 
monocytes and Huh 7.5 cells were selected out on different days particularly 
day 3, 5 and 7 and HCV RNA expression was studied by using real time 
qPCR and quantified by calibrating HCV gene expression against that of β-
actin. HCV RNA expression in replicon containing cells and monocytes are 
shown for comparison. The mean HCV viral load in these patients was 5.53 
logIU/ml (range: 3.02 to 6.78 logIU/ml).  
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Figure 4.9:  HCV expression in fused cells, using monocytes obtained 
from genotype 3 patients, cultured for varying lengths of time during 
the first week and extracted for assessment of HCV RNA on different 
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days: HCV infection is expressed as HCV gene expression calibrated to 
β-actin at various time periods in days (day 3 (n=10), 5 (n=8) and 7 
(n=8)). Replicon cells circled in purple on the left side is positive control 
for fusion experiments. HCV expression in monocytes from different 
patients is circled in blue on the right side. Each point represents mean 
of sample from a single patient run in duplicate during real time PCR. 
Patient number with colour coding is given on the right hand side. HCV 
expression represents the HCV RNA: β-actin ratio (calculated by the 
relative quantification method). 
The above experiments suggested that 3-7 days after fusion HCV 
expression in fused cells was increased in most fused cell cultures both in 
genotype 1 and 3 compared to expression in monocytes. This suggests the 
presence of HCV replication in fused cell cultures.  
To confirm our initial observations HCV gene expression in monocytes of 19 
patients was compared to HCV RNA in their monocytes fused with Huh 7.5 
cells. The details of patients whose monocytes were compared with fused 
cultures derived by fusing monocytes from same patients with Huh 7.5 cells 
are given in table 4.3 shown below. 
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 No 
  
  Date blood taken 
 
 
 Age 
 
  Genotype 
            
          Viral load  
 
Fibrosis 
 
   1 
 
 
    26/04/2010 
 
 58 
 
 
     1a 
 
 7.01 log IU, 10280828 IU 
 
3 
 
   2 
 
 
    07/02/2011 
 
 61 
 
 
     1a 
 
 6.46 log IU, 2866058 IU 
 
3-4  
 
   3 
 
    01/03/2011 
 
 56 
 
 
     1 
 
 5.91 log IU, 815485 IU 
 
1  
 
   4 
 
 
    01/03/2011 
 
 59 
 
 
     1a 
 
 5.94 log IU, 870964 IU 
 
ND 
 
   5 
 
 
    20/04/2011 
 
 42 
 
 
     1 
 
 5.60 log IU, 396661 IU  
 
2  
 
   6 
 
 
    20/04/2011 
 
 47 
 
 
     1a 
 
  6 log IU, 1000000 IU 
 
2 
 
   7 
 
    27/04/2011 
 
 53 
 
 
     1a 
 
7.20 log IU, 16017910 IU 
 
2  
 
   8 
 
 
    04/05/2011 
 
 55 
 
 
     1 
 
   6 log IU, 1000000 IU 
 
ND 
 
   9 
 
    11/05/2011 
 
 50 
 
 
     1b 
 
             NA 
 
6  
 
  10 
 
 
    28/05/2009 
 
 
 66 
 
     3   3.02 log IU, 1036 IU 
 
ND 
 
 
  11 
 
 
    01/07/2009 
 
 
 47 
 
     3a     4.77 log IU, 59330 IU 
 
1 
 
 
  12 
 
 
    02/09/2009 
 
 56 
 
     3a 
 
 6.65 log IU, 4417016 IU 
 
2 
 
 
  13 
 
 
    16/09/2009 
 
 44 
 
     3 
 
    4.99 log IU, 98467 IU 
 
2 
 
 
  14 
 
 
    19/01/2011 
 
 
  30 
 
     3a 
 
  5.16 log IU, 142918 IU 
 
2 
 
  15 
 
 
    18/05/2011   44 
 
     3a 
 
 
   6 log IU, 1000000 IU 
 
5 
 
 
  16 
 
 
     18/05/2011 
  
  38 
 
    
        3b 
 
    
   6 log IU, 1000000 IU 
 
 
2 
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Table 4.3: Details of patients whose HCV RNA expression in monocytes 
was compared with their fused cells. The table shows age, genotype and 
subtype (if available), fibrosis score (Ishak scoring) if liver biopsy was 
done, viral load done closest to the time of blood sampling from each 
patient. NA = viral load not available at the time blood sample was taken. 
Monocytes from patients were separated into two populations some were 
used in the fusion process and 1x10-6 monocytes were left in culture for 3 
days initially to compare replication in unfused monocytes with replication in 
fused cells. However by day 3 of the culture most (>80% by trypan blue 
exclusion) of the monocytes were dead and thus a comparison of HCV in 
monocytes cultured for 3 days was not possible. We therefore compared 
HCV RNA levels in monocytes immediately after CD14 bead separation and 
RNA was extracted from the cells and used for qPCR analysis. The 
remainder of the isolated monocytes were fused to Huh 7.5 cells. Each 
experiment was performed in duplicate and the mean HCV viral load of these 
patients was 5.73 logIU/ml (range: 3.02 to 7.20 logIU/ml). Figure 4.10 shows 
the results obtained by comparing HCV RNA expression in fused cells with 
the unfused monocytes.   
 
   17 
 
 
    25/05/2011 
     
57 
 
     
 3a 
 
 
6.23 log IU, 1699933 IU 
 
 
ND 
 
 
  18 
 
 
     25/05/2011  59 
 
     3b 
 
   5 log IU, 100000 IU 
 
ND 
 
 
19 
 
 
    18/02/2011 
 
57 
 
     3a 
 
  5.19 log IU, 153103 IU 
 
 4 
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Figure 4.10: Comparison of HCV RNA expression in monocytes and 
fused Cells: HCV expression in monocytes is compared with fused cells 
(each point represents average HCV expression taken from all cultures 
isolated at different days from one patient) (***p=0.0016). HCV 
expression represents the HCV RNA: β-actin ratio (calculated by the 
relative quantification method). 
 
HCV expression was significantly higher in fused cells compared to that in 
the monocytes (p=0.0016). Out of 19 patients, 15 showed a rise in HCV RNA 
expression in fused cells compared to their monocytes. For every patient 
average HCV RNA expression was considered at different days. 
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In order to look at HCV RNA expression separately at different days in 
comparison to monocytes, HCV expression of fused cells isolated on days 3, 
5 and 7 was compared with HCV expression in the monocytes of that  
patient. Some patients' fused cells were isolated from culture for HCV RNA 
qPCR analysis at all 3 days while some were isolated at less than three 
occasions, either for any 2 days or isolated only once on either of the above 
mentioned days. Out of 19 patients 15 patients' fused cells were isolated on 
day 3 and their details are given in table 4.4. 
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No 
  
Date blood taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
   Fold 
Change 
 
1 
 
    26/04/2010 
 
 58 
 
 
     1a 
 
 7.01 log IU, 10280828 IU 
 
3 512 
 
2 
 
    07/02/2011 
 
 61 
 
 
     1a 
 
    6.46 log IU, 2866058  
 
3-4 2.9 
 
3 
 
    20/04/2011 
 
 47 
 
 
     1a 
 
    6 log IU, 1000000 IU 
 
2 11.5 
 
4 
 
    27/04/2011 
 
 53 
 
 
     1a 
 
 7.20 log IU, 16017910 IU 
 
2 18.7 
 
5 
 
    04/05/2011 
 
 55 
 
 
     1 
 
    6 log IU, 1000000 IU 
 
ND 19.00 
 
6 
 
    11/05/2011 
 
 50 
 
 
     1b 
          
               NA 
                   
 
6 246 
 
7 
 
    28/05/2009 
 
 
 66 
 
     3     3.02 log IU, 1036 IU 
 
ND 
 
-2.5 
 
8 
 
    01/07/2009 
 
 
 47 
 
     3a     4.77 log IU, 59330 IU 
 
1 
 
29.6 
 
9 
 
    16/09/2009 
 
 44 
 
     3 
 
    4.99 log IU, 98467 IU 
 
2 
 
4.44 
 
10 
 
    19/01/2011 
 
 30 
 
     3a 
 
    5.16 log IU, 142918 IU 
 
2 
 
1.24 
 
11 
 
    18/05/2011  44 
 
     3a 
 
 
    6 log IU, 1000000 IU 
 
5 
 
3.75 
 
12 
 
 
     18/05/2011  38 
 
     3b 
 
   6 log IU, 1000000 IU 
 
2 
 
65.3 
 
13 
 
     25/05/2011  57 
                   
 
    3a 
 
  6.23 log IU, 1699933 IU 
 
 
ND 
 
-12.7 
 
14 
 
     25/05/2011 
 
 59 
 
     3b 
 
   5 log IU, 100000 IU 
 
ND 
 
-20.65 
 
15 
 
    18/02/2011 
 
 
57 
 
     3a 
 
   5.19 log IU, 153103 IU 
 
4 2.53 
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Table 4.4: Details of patients whose HCV RNA expression in monocytes was 
compared with their fused cells isolated on day 3. The table shows age, genotype 
and subtype (if available), fibrosis score (Ishak scoring) if liver biopsy was done, 
viral load done closest to the time of blood sampling from each patient and fold 
change in HCV RNA after fusion compared to HCV RNA in monocytes. NA = viral 
load not available at the time when blood sample was taken. 
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Figure 4.11: Comparison of HCV RNA expression in monocytes and 
fused cells at day 3. (**p=0.0067 using Wilcoxon matched pair test). 
Monocytes were processed straight after CD14 bead extraction. HCV 
expression represents the HCV RNA: β-actin ratio (calculated by the 
relative quantification method). 
12 patients showed a rise in HCV expression in fused cells compared to their 
monocytes in cells isolated at day 3.  
Out of 19 patients 15 patients' fused cells were isolated on day 5 and their 
details are given in table 4.5. 
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No 
  
Date blood taken 
 
 
Age 
 
 Genotype 
            
          Viral load  
 
Fibrosis 
   Fold 
Change 
 
1 
 
    26/04/2010 
 
 58 
 
 
     1a 
 
 7.01 log IU, 10280828 IU 
 
3 2167 
 
2 
 
    07/02/2011 
 
 61 
 
 
     1a 
 
   6.46 log IU, 2866058  
 
3-4  1.55 
 
3 
 
    01/03/2011 
 
 56 
 
     1 
 
  5.91 log IU, 815485 IU 
 
1  
 
5.26 
 
4 
 
    01/03/2011 
 
 59 
 
 
     1a 
 
  5.94 log IU, 870964 IU 
 
ND -2.7 
 
5 
 
    20/04/2011 
 
 42 
 
 
     1 
 
   5.60 log IU, 396661 IU  
 
2  10.63 
 
6 
 
    20/04/2011 
 
 47 
 
 
     1a 
 
    6 log IU, 1000000 IU 
 
2 -2.22 
 
7 
 
    27/04/2011 
 
 53 
 
 
     1a 
 
 7.20 log IU, 16017910 IU 
 
2  218.5 
 
8 
 
    04/05/2011 
 
 55 
 
 
     1 
 
    6 log IU, 1000000 IU 
 
ND 260 
 
9 
 
    11/05/2011 
 
 50 
 
 
     1b 
 
              NA 
 
6  54.8 
 
10 
 
    19/01/2011 
 
 
 30 
 
     3a 
 
    5.16 log IU, 142918 IU 
 
2 1.32 
 
11 
 
    18/05/2011  44 
 
     3a 
 
 
    6 log IU, 1000000 IU 
 
5 
 
63.5 
 
12 
 
 
    18/05/2011   38 
 
     3b 
 
   6 log IU, 1000000 IU 
 
2 
 
-4.73 
 
13 
 
    25/05/2011 
               
57 
 
3a 
 
  6.23 log IU, 1699933 IU 
 
ND 
 
-3.8 
 
14 
 
 
    25/05/2011 
 
 59 
 
     
    3b 
 
    
   5 log IU, 100000 IU 
 
 
ND 
 
 
-2.7 
 
15 
 
 
    18/02/2011 
 
57 
 
     3a 
 
   5.19 log IU, 153103 IU 
 
 4 1.16 
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Table 4.5: Details of the patients whose HCV RNA expression in monocytes was 
compared with their fused cells isolated on day 5. The table shows age, genotype and 
subtype (if available), fibrosis score (Ishak scoring) if liver biopsy was done, viral load 
done closest to time of the blood sampling from each patient and fold change in HCV 
RNA after fusion compared to HCV RNA in monocytes. NA= not available. 
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Figure 4.12, shows HCV expression in fused cells extracted on day 5 
compared with that in monocytes. Monocytes were processed straight after 
CD14 bead extraction.  
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Figure 4.12: Comparison of HCV expression (HCV/β-actin ratio) in 
monocytes and fused cells at day 5. (*p=0.02 using Wilcoxon 
matched pair test). HCV expression represents the HCV RNA: β-actin 
ratio (calculated by the relative quantification method). 
11 patients showed an increase in HCV gene expression in fused cells 
isolated at day 5, compared to their monocytes 
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Out of 19 patients 14 patients' fused cells were isolated on day 7. Table 4.6 
gives details of these patients. 
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No 
  
Date blood taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
   Fold 
Change 
 
1 
 
    26/04/2010 
 
58 
 
 
     1a 
 
7.01 log IU, 10280828 IU 
 
3 932 
 
2 
 
    07/02/2011 
 
61 
 
 
     1a 
 
    6.46 log IU, 2866058  
 
3-4  29.02 
 
3 
 
    01/03/2011 
 
56 
 
 
     1 
 
    5.91 log IU, 815485 IU 
 
1  -2.62 
 
4 
 
    20/04/2011 
 
42 
 
 
     1 
 
    5.60 log IU, 396661 IU  
 
2  -5.14 
 
5 
 
    20/04/2011 
 
47 
 
 
     1a 
 
    6 log IU, 1000000 IU 
 
2 1194 
 
6 
 
    27/04/2011 
 
53 
 
 
     1a 
 
 7.20 log IU, 16017910 IU 
 
2  93.8 
 
7 
 
    04/05/2011 
 
55 
 
 
     1 
 
    6 log IU, 1000000 IU 
 
ND 386 
 
8 
 
    11/05/2011 
 
50 
 
 
     1b 
 
                  NA 
 
6  17.1 
 
9 
 
    02/09/2009 
 
56 
 
     3a 
 
6.65 log IU, 4417016 IU 
 
2 
 
5.8 
 
10 
 
    19/01/2011 
 
 
30 
 
     3a 
 
  5.16 log IU, 142918 IU 
 
2 -6.9 
 
11 
 
    18/05/2011 44 
 
     3a 
 
 
    6 log IU, 1000000 IU 
 
5 
 
2704 
 
12 
 
 
     18/05/2011 38 
 
      
3b 
 
   
 6 log IU, 1000000 IU 
 
 
2 
 
7.5 
 
13 
 
     25/05/2011 
             
57 
 
     3a 
 
6.23 log IU, 1699933 IU 
 
ND 
 
794.4 
 
14 
 
 
     25/05/2011 59 
 
     3b 
 
   5 log IU, 100000 IU 
 
ND 
 
46.6 
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Table 4.6: Details of the patients whose HCV RNA expression in monocytes was 
compared with their fused cells isolated on day 7. The table shows age, genotype 
and subtype (if available), fibrosis score (Ishak scoring) if liver biopsy was done, 
viral load done closest to the time of blood sampling from each patient and fold 
change in HCV RNA after fusion compared to HCV RNA in monocytes. ND= not 
done, NA= not available.  
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Figure 4.13, shows HCV expression in fused cells extracted on day 7 
compared with that in monocytes. Monocytes were processed straight after 
CD14 bead extraction. 
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Figure 4.13: Comparison of HCV expression in monocytes and fused 
Cells at day 7. (*p=0.01 using Wilcoxon matched pair test). HCV 
expression represents the HCV RNA: β-actin ratio (calculated by the 
relative quantification method). 
11 patients showed an increase in HCV expression in fused cells compared 
to the monocytes when isolated at day 7. 
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The next step was to assess HCV expression in fused cells in patient's 
monocytes cultured for longer than 7 days after fusion with Huh 7.5s. 
4.3.3.2. HCV expression in fused cells cultured for more than 
7 days 
In some patients fused cells were grown for longer than seven days. This 
was to see whether a cell line infected with naturally occurring HCV derived 
from patients’ monocytes could be generated. HCV expression was 
assessed in these patients and compared with HCV expression in fused cells 
cultured for less than seven days. Comparison of HCV expression in cultured 
cells between the 1 to 7 days compared to those isolated between 10-21 
days is shown in figure 4.14. The mean HCV viral load of patients was 
5.25logIU/ml (range: 3.02 to 6.65logIU/ml).  
 
  No 
  
Date blood taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
 
1 
 
28/05/2009 
 
 
66 
 
3 3.02 log IU, 1036 IU 
 
ND 
 
 
2 
 
01/07/2009 
 
 
47 
 
3a 4.77 log IU, 59330 IU 
 
1 
 
 
3 
 
 
05/08/2009 
 
48 
 
3 6.57 log IU, 3720254 IU 
 
1 
 
 
4 
 
02/09/2009 
 
56 
 
3a 
 
6.65 log IU, 4417016 IU 
 
2 
 
Table 4.7: Details of the patients whose monocytes were used in the fusion 
experiments to look at HCV gene expression in fused cells after a longer 
time scale. The table shows age, genotype and subtype (if available), 
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fibrosis score (Ishak scoring) if liver biopsy was done, The viral load test 
performed at the nearest point in time to the biopsy was recorded. ND= not 
done. 
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Figure 4.14: Comparison of HCV expression in fused cells cultured for 
more than 7 Days in four patients: Each point represents HCV 
expressions at a different day. For one patient HCV expression for both 
days 3 and 7 was available (*p=0.02 using Mann Whitney U test). HCV 
expression represents the HCV RNA: β-actin ratio (calculated by the 
relative quantification method). 
These data suggest that fusing monocytes from patients with HCV with Huh 
7.5 cells leads to increased expression of HCV for the first 7 days after fusion 
and a decline in HCV RNA thereafter, indicating HCV RNA replication for the 
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initial 7 days. Therefore, HCV could not be stably expressed in Huh 7.5 cells 
for longer duration in order to establish an HCV infected cell line.  
4.3.4. Indirect immunofluorescence microscopy 
4.3.4.1. Single staining with anti-NS5A 
Hybrid cells obtained after fusion of HCV patients’ monocytes with Huh 7.5 
cells were extracted on 3rd, 5th and 7th days and stained for the HCV encoded 
protein NS5A using polyclonal sheep anti-NS5A ( a kind gift from Professor 
Mark Harris, University of Leeds) as primary antibody while the secondary 
antibody was alexa-fluor 488 nm-conjugated polyclonal IgG (goat anti-
sheep). Replicon cells were stained as positive controls (figure 4.15) and Huh 
7.5 cells were taken as negative controls (figure 4.16). NS5A staining of 
fused cells and their controls are given below. Figure 4.17 shows the fused 
cells stained with NS5A antibody. 
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                                         DAPI/NS5A (Overlay)                NS5A 
                     
 
                 
 
Figure 4.15:  Replicon cells being used as positive control 
for this experiment, are stained with antibody against NS5A, 
using alexa-fluor 488-nm conjugated polyclonal IgG as a 
secondary antibody. On left are the overlays of DAPI and 
NS5A staining while on right are only NS5A stained cells (in 
this case staining positive)  
 
 
 
306 
 
               
           
 
 
               DAPI/NS5A (Overlay)                   NS5A 
  
                                  
   
                    
 
Figure 4.16:  Huh 7.5 cells being used as negative control for 
this experiment, do not stain positive with antibody against 
NS5A, using alexa-fluor 488-nm conjugated polyclonal IgG 
as a secondary antibody. On left are the overlays of DAPI 
stain and NS5A staining while on right are only NS5A 
stained cells (in this case staining negative). 
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                                DAPI/NS5A (Overlay)                   NS5A 
 
        
 
Fusion at Day 3    
                                                                                                                                                                                                                                 
       
 
                  Fusion at Day 3 
 
       
 
Fusion at Day 5  
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                          DAPI/NS5A (Overlay)                  NS5A 
          
 
Fusion at Day 5 
 
                      
Fusion at Day 7 
Figure 4.17: Fused cells extracted on different days from 
different HCV patients and stained with antibody against 
NS5A, using alexa-fluor 488-nm conjugated polyclonal IgG 
as a secondary antibody. On left are the overlays of DAPI 
and NS5A staining while on right are only NS5A stained 
cells (in this case staining positive). (Monocytes in fused 
cells were derived from genotype 1b HCV patient and viral 
load was 6.89logIU/ml at the time when blood was taken, 
derived from genotype 3a HCV patient and viral load was 
6.78logIU/ml at the time when blood was taken). 
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Fused cells stained positive for NS5A protein. NS5A is a non-structural 
phosphoprotein, composed of approximately 447 amino acids and is 
released during processing of viral polyprotein. It is involved in viral 
replication and assembly (He, Staschke et al. 2006). Its exact role in the 
replication process is poorly understood (Huang, Staschke et al. 2007). It 
has also been implicated in modulating cell signalling pathways, interferon 
response and pathogenesis and in regulating apoptosis. Moreover, it is 
thought to have an enzymatic function which is not very clear yet (Yamasaki, 
Arcuri et al. 2012). It is thought that it works by interacting with other HCV 
and host cellular proteins  (He, Staschke et al. 2006, Reed, Xu et al. 1997, 
Macdonald and Harris 2004, Liang, Ye et al. 2007, Love, Brodsky et al. 
2009). NS5A staining represents viral life cycle progression and replication 
process in fused cells.  
4.3.4.2. Double staining with anti-NS5A and anti-albumin 
To determine whether the fused cells that expressed HCV were genuinely 
hepatocytes rather than, for example, fused monocytes, antibodies directed 
against HCV and the liver specific marker albumin were used to stain 
hepatocytes containing loci of HCV replication. Fused cells from one patient 
were stained for NS5A using polyclonal sheep anti-NS5A as primary 
antibody while secondary antibody was alexa-fluor 488 nm-conjugated 
polyclonal IgG (goat anti-sheep). Replicon cells were stained as positive 
controls and Huh 7.5s were taken as negative control.  After that cells were 
stained for albumin, which is a hepatocyte marker, with polyclonal rabbit anti-
albumin (from DAKO, Glostrup, Denmark) to differentiate Huh 7.5s from 
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monocytes. The secondary antibody for anti-albumin was PE-conjugated 
mouse anti-rabbit (from Invitrogen Molecular Probes). Replicon cells and 
Huh 7.5s stained positive for albumin. Fused cells stained positive for both 
albumin and NS5A. 
  
     DAPI Staining                                Albumin Staining            
 
          
 
    NS5A Staining                                 Merged 
 
         
 
  Replicon Cells 
      
Figure 4.18: Dual staining of the replicon cells: Replicon 
cells used as positive control for the experiment, are stained 
with antibody against NS5A, using alexa-fluor 488-nm 
conjugated polyclonal IgG as a secondary antibody and with 
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antibody against albumin using PE-conjugated mouse anti-
rabbit as secondary antibody. 
 
                   DAPI  Staining                                Albumin  Staining     
                        
                   
 
         NS5A Staining                                Merged 
 
                                    
   
                             Huh 7.5 cells    
 
Figure 4.19: Double staining of Huh 7.5 cells: Huh 7.5 cells 
used as negative control for this experiment, do not stain 
positive with antibody against NS5A, using alexa-fluor 488-
nm conjugated polyclonal IgG as a secondary antibody and 
with antibody against albumin using PE-conjugated mouse 
anti-rabbit as secondary antibody. 
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                                   DAPI Staining                                   Albumin Staining 
 
               
  
   NS5A Staining                                  Merged  
 
        
 
                  Fused cells (Day 3) 
Figure 4.20: Double staining of the fused cells: Fused cells 
stained with antibody against NS5A, using alexa-fluor 488-
nm conjugated polyclonal IgG as a secondary antibody and 
with antibody against albumin using PE-conjugated mouse 
anti-rabbit as secondary antibody. 
Indirect immunofluorescence microscopy showed viral NS5A protein co-
localised with albumin (produced by Huh7.5 cells), confirming replication in 
the fused cells. 
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4.3.4.3. Confocal immunofluorescence microscopy  
Confocal microscopy was done to determine whether the NS5A staining of 
Huh 7.5s was due to protein within the cells or due to contamination from 
overlying monocytes. Confocal microscopy provided three dimensional 
images of the cells allowing a better appreciation of the site of the HCV 
proteins. Fused cells were stained at day 3 for NS5A using polyclonal sheep 
anti-NS5A as primary antibody while secondary antibody was alexa-Fluor 
488 nm-conjugated polyclonal IgG (goat anti-sheep). Replicon cells were 
stained as positive controls and Huh 7.5s were taken as negative control.  
After that cells were stained for albumin (used as a hepatocyte marker) with 
polyclonal rabbit anti-albumin from DAKO, UK to differentiate Huh 7.5s from 
monocytes. The secondary antibody was alexa-fluor 565nm-conjugated 
mouse anti-rabbit from Invitrogen Molecular Probes UK. Replicon cells and 
Huh 7.5s stained positive for albumin. Fused cells stained positive for both 
albumin and NS5A, illustrated in figure 4.21. 
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  DAPI staining         NS5A staining          Albumin staining     Merged 
      
 
    Huh 7.5s 
 
     
 
   Replicon Cells 
 
       
 
Fused cells (Day 3) 
Figure 4.21: Confocal microscopy with dual staining: replicon cells, used 
as positive control for this experiment, are stained with antibody against 
NS5A; using alexa-fluor 488-nm conjugated polyclonal IgG as a secondary 
antibody and with antibody against albumin with alexa-fluor 565-nm 
conjugated mouse anti-rabbit as secondary antibody. Huh 7.5 cells, used 
as negative control for this experiment, do not stain positive with antibody 
against NS5A, using alexa-fluor 488-nm conjugated polyclonal IgG as a 
secondary antibody but stains positive with antibody against albumin with 
alexa-fluor 565-nm -conjugated mouse anti-rabbit as secondary antibody. 
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Fused cells stain with antibody against NS5A and with anti-albumin Ab 
showing double stain. 
 
4.3.5. Manifestation of different types of fusions 
Indirect immunofluorescence staining of fused cells showed that the cells 
may fuse in two different ways. In some cells ‘intact monocytes’ were linked 
to hepatocytes while some fused cells were seen as merged Huh 7.5 cells 
and monocytes.  To examine the morphology of fused cells more closely, 
cells were fused after being stained with different fluoroprobes i.e.; DiO 
(wavelength similar to FITC) labelled Huh 7.5 cells and DiI (wavelength 
similar to PE) labelled monocytes were fused together under the previously 
determined optimal conditions and types of fusions were examined more 
closely under confocal immunofluorescence microscope (as discussed in 
Chapter 2: Materials and Methods). Confocal microscopy was used to see 
the position of monocytes relevant to Huh 7.5s in a fused cell. It was 
observed that monocytes fused with Huh 7.5 cells in two different ways. They 
either showed complete fusion with Huh 7.5 cells or fused partially.  
Under the confocal immunofluorescence microscope complete fusion was 
observed as monocytes (IM) fused to Huh 7.5 cells and had irregular 
membrane and in this type of fusion ‘spillage’ of DiI dye was observed into 
Huh 7.5 cell cytoplasm. Partial fusion manifested itself as round monocytes 
(RM) either attached to Huh 7.5 cells or engulfed by Huh 7.5 cells with 
minimal ‘spillage’ of DiI dye into Huh 7.5 cell cytoplasm. Moreover, it was 
observed that monocytes showing more spillage of DiI dye into the cytoplasm 
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had much more irregular shapes than monocytes with lesser spill. It was also 
observed that the irregularity of monocytes coincided with the amount of DiI 
dye spilled into the cytoplasm of fused cell. Hence, there was a positive 
correlation between the amount of cytoplasmic spillage and irregularity of 
monocyte membrane which led to the hypothesis that the amount of 
extrusion of monocytic contents into the fused cells could be related to the 
extent of HCV replication into the Huh 7.5 cell fused with that monocyte. The 
mechanism by which monocytes might fuse in a particular fashion is not 
clear. 
Figure 4.22, illustrates monocytes observed during the two types of fusion 
processes.  
    DiI, red-dye (monocytes)                  DiI, red-dye (monocytes) 
    DiO, green dye (huh 7.5s)                 DiO, green-dye (huh 7.5s) 
 
        
 
           IM (irregular monocytes)                  RM (round monocyte) 
 
Figure 4.22: Types of monocytes in fusion: the two different 
type of monocytes (red stained with vybrant dye DiI) 
observed after fusion with Huh 7.5 cells (green stained with 
IM 
RM 
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vybrant dye DiO) are shown here with irregular monocyte (IM) 
on left hand side and round monocyte (RM) on right hand 
side. 
4.3.5.1. Hepatitis C replication in different types of fusions 
As discussed earlier it was speculated that two different fusion processes 
took place – one involved ‘extrusion’ of monocyte contents and the other 
involved the reconstitution of monocyte membrane and formation of an intact 
monocyte within the hepatocyte. It is possible that one of these fusion 
processes may be more permissive for HCV replication – we speculate that 
immortalisation of intact monocytes by fusion may allow HCV replication OR 
extrusion of monocyte contents may allow delivery of HCV into the 
replication permissive Huh 7.5 cells. To evaluate these possibilities and to 
determine whether to optimise the fusion process for delivery of intact or 
damaged monocytes we examined the level of HCV replication in fused cells 
of differing morphology. 
DiI dye labelled monocytes from two hepatitis C positive patients, fused with 
unlabelled Huh 7.5 cells and stained with primary antibody anti-HCV NS5A 
(secondary antibody is alexa-fluor 488) were used to study amount of HCV 
replication in the above mentioned two types of fusions. Different fields with 
NS5A signals in fused cells were randomly selected under confocal 
fluorescent microscope using 40x magnification, showing the two type of 
fusions i.e.; partial fusion (containing round monocytes-RM) and complete 
fusion (containing monocytes with irregular cell membrane- IM and spillage 
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of cytoplasmic contents into the fused cell). Figure 4.23, shows the imaging 
slides of the two type of fused cells (containing either RM or IM) from two 
patients which were used to analyse HCV replication.  
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NS5A Staining of fused cells containing either round or irregularly 
walled monocyte 
     Fused cells from patient A 
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Figure 4.23: Anti-NS5A staining in irregular (IM) and round monocyte (RM) 
fusions: Monocytes stained with DiI dye (red). Anti-NS5A antibody staining is 
seen as green fluorescnece (secondary antibody is alexa fluor 488). DAPI (blue), 
DiI stained monocytes (red) HCV NS5A staining of fused cells (Green). 
RMs 
RM 
RM 
RM 
DiI dye DAPI NS5A Merge
d  
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4.3.5.2. Quantification of anti-NS5A staining 
Monocytes from the two patients stained with DiI dye and fused with Huh 7.5  
cells and then stained with anti-HCV NS5A antibody (secondary antibocy-
alexa fluor 488) were used to quantify amount of HCV replication in two 
different types of monocyte fusions. We speculated that the mode of fusion 
will effect the replication of HCV in the fused population. If fusion was 
complete it led to spilage of DiI dye from the monocyte into the cytoplasm of 
fused cell with or without the fusion of nucei and had irregular cell membrane 
under the microscope. Confocal microscopy was used to assess the position 
of monocytes in relation to the fused cell from different fields (detail 
discussed in above section) acquired after staining fused cells from two 
patients processed on different days. Image analysis and quantification was 
done as mentioned in materials and methods. Quantification was done in the 
selected population by chosing a region of interest (ROI). Area of selection, 
mean intensity of all pixels and integrated density (the sum of all pixels with 
in selected area) from selected population were noted. Tables 4.8 and 4.9 
show areas, means and integrated densities from fused populations. Each 
table represents fused cells from a sinle patient, IM stands for irregular 
monocytic fusion while RM stands for round monocytic fusion.  
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Quantification of NS5A staining in two different types of 
fused cells from patient A: 
No. Area µm2 Average 
Intensity 
Integrated 
Intensity  
IM-1 60092 45.03723 2706377 
IM-2 40362 44.77967 1807397 
IM-3 54500 84.69046 4615630 
IM-4 16935 47.98264 812586 
IM-5 19396 70.39096 1365303 
IM-6 10357 52.35242 542214 
IM-7 63730 68.59531 4371579 
IM-8 59999 63.13229 3787874 
IM-9 28867 24.72706 713796 
IM-10 15643 32.06636 501614 
RM-1 20495 45.7557 937763 
RM-2 18565 22.80522 423379 
RM-3 16223 25.41725 412344 
RM-4 23511 34.89988 820531 
RM-5 19288 30.9467 596900 
RM-6 15026 25.4063 381755 
RM-7 22948 14.95189 343116 
RM-8 28017 15.67309 439113 
RM-9 12335 33.40859 412095 
RM-10 23507 14.14817 332581 
Table 4.8: Patient A: Areas, means and integrated 
densities in the fused populations stained with anti-
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NS5A: Quantification of HCV replication (NS5A staining) 
was done in the selected population by chosing a region 
of interest (ROI) and measuring area of selection, mean 
intensity of all pixels and integrated density in two types 
of fused cells i.e.; IM (irregular monocytes) and RM 
(round monocytes). 
Quantification of NS5A staining in two different types of 
fused cells from patient B: 
No. Area µm2 Average 
Intensity 
Integrated  
Intensity 
IM-1 29008 45.29578047 1313940 
IM-2 76914 93.45224536 7187786 
IM-3 56089 43.04915402 2414584 
IM-4 21477 101.0451646 2170147 
IM-5 36517 63.41824356 2315844 
IM-6 31019 94.18830394 2921627 
IM-7 35594 40.98151374 1458696 
IM-8 30154 42.73598859 1288661 
IM-9 33954 37.22459799 1263924 
IM-10 16629 74.39755848 1237157 
RM-1 46435 38.61233983 1792964 
RM-2 36062 31.68382231 1142582 
RM-3 39886 39.05565863 1557774 
RM-4 63057 36.82760043 2322238 
RM-5 32191 36.81252524 1185032 
RM-6 52676 41.99500721 2212129 
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RM-7 34361 29.0168796 997049 
RM-8 15123 27.99437942 423359 
RM-9 24103 29.95668589 722046 
RM-10 64442 34.40472052 2217109 
Table 4.9: Patient B: Areas, means and integrated 
densities in the fused populations stained with anti-NS5A: 
Quantification of HCV replication (NS5A staining) was 
done in the selected population by chosing a region of 
interest (ROI) and measuring area of selection, mean 
intensity of all pixels and integrated density in two types 
of fused cells i.e.; IM (irregular monocytes in fused cells) 
and RM (round monocytes in fused cells). 
The mean of NS5A staining area, average intensity and integrated intensity 
from fused cells with both IM and RM (from two patients) were used to 
compare HCV replication in these cells (shown in figure 4.24). Average 
intensity and integrated intensity were normalised to area of ROI. 
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   Mean of area 
 IM 36861.8 µm2 
 RM 30412.55 µm2 
    
 
  Mean of average intensity    
 IM 58.47714754 
 RM 30.48862045 
    
  Mean of integrated intensity  
 IM 2239836.8 
 RM 983592.95 
  
 
Figure 4.24: Mean area, average intensity and integrated 
intensity of HCV NS5A staining compared between IMs and RMs 
from the two patients discussed above.  
In order to compare the HCV replication and intensity of NS5A staining 
between the IM and RM, mean area of ROI, average intensity and integrated 
intensity were compared between the two.  
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Figure 4.25: Quantification of hepatitis C replication from indirect 
immunofluorescent staining of NS5A in two types of fusions. A) Shows 
comparison between area of ROI (NS5A staining) measured in fused 
cells containing IM and RM. B) (p value = 0.0002) and C) (p value = 
0.0023) compare intensity of NS5A staining between IM and RM. (IM-
irregular monocyte fusion and RM-round monocyte fusion). 
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There is a significant difference in both average intensity and integrated 
intensity of NS5A stained area of IM and RM (area of ROI has no significant 
difference between IM and RM). These experiments suggest that different 
types of fusion may modify the replication of HCV in the fused cells and 
suggest that changing the fusion conditions to maximise the proportion of 
‘irregular’ fusion may improve viral replication.  
Time constraints prevented further development of this approach. 
Images for this experiment were taken with the help of Dr Ann Wheeler. In 
order to take images of 10 cells which had intact round monocytes and 10 
irregular monocytes considerable time was spent. Finding these cells was 
considerably on the work intensive side as imaging needed 63x magnification 
to get a sufficiently detailed image to analyse (analysis was carried out along 
with Dr Ann Wheeler) which meant that only 1-2 cells could be taken per 
image. Thus this technique was not carried any further. 
4.3.6. Monocytes fused with Huh 7.5 cells after incubating 
with patient’s serum (capture transfer assay)  
This section described a novel capture-fusion transfer technique using 
patient derived HCV to be 'captured' by monocyte and then used to infect 
hepatocytes  using the cell fusion technique described above. This approach 
was used to extract patient derived HCV from hepatitis C infected serum so 
that eventually all genotypes could be studied without needing very large 
amounts of blood from HCV patients for the extraction of monocytes.  
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To determine whether we could infect cell cultured monocytes of healthy 
donors with HCV from serum of hepatitis C patient we incubated monocytes 
from uninfected volunteers with serum from a patient with chronic HCV. If we 
can transfer virus to monocytes then we speculate that we may be able to 
develop a ‘capture-transfer’ model of HCV replication. This will allow 
generation of infected cells using patient sera rather than patient derived 
monocytes. Monocytes from three healthy donors were incubated with serum 
of HCV patients for one day and fused with Huh 7.5s. Fused cells were then 
cultured for 3 days and stained for NS5A on day 3. This is illustrated in 
Figure 4.26.  
                            Overlay of DAPI and NS5A       NS5A Staining  
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Figure 4.26: 'Capture' of HCV via monocytes and transfer to 
Huh 7.5 cells (n=3): Monocytes from healthy individual 
treated with serum of HCV patient and fused with Huh 7.5 
cells and stained for NS5A to study HCV replication. 
Time constraints prevented any further analysis of this approach. However, 
to extend the utility of this assay additional experiments were carried out by 
Dr Morven Cunningham who used the pre-stimulated monocytic cell line 
THP-1 instead of monocytes from healthy individuals to transfer HCV to Huh 
7.5 cells using fusion technique and demonstrated successful replication for 
5 days by real time qPCR technique and indirect immunofluorescence. 
Further experiments by Dr Morven Cunningham showed a genotypic pattern 
of response when treated with telaprevir which has little effect against 
genotype 3 but potently inhibits genotype 1 infection in clinical studies 
(Foster, Hezode et al. 2011, Jacobson, McHutchison et al. 2011, Zeuzem, 
Andreone et al. 2011). Similarly, alisporivir which shows response in 
genotype 2 and 3 infection compared to genotype 1 and 4 in clinical trials 
(Flisiak, Feinman et al. 2009) also showed a genotypic pattern of response 
when tried using this assay. 
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4.3.7. Fusion with SEAP reporter cell line  
Recent publications suggest that an indicator cell line containing SEAP 
(secreted alkaline phosphatase) linked to a retention sequence via an NS3 
cleavable bond can be used to identify replicating HCV (Iro, Witteveldt et al. 
2009). Huh J20 cells harbouring this NS3/4A protease-based reporter assay 
kindly provided by Dr John McLaughlin, Glasgow. The aim was to determine 
whether this cell line would support replication in our assay and whether this 
detection system would allow easy detection of viral replication. We therefore 
used this liver cell line in our fusion assay. Monocytes from four patients 
(shown in figure 4.27) infected with HCV were used in this experiment. They 
were fused with the SEAP reporter cell line and incubated for 4 days. At days 
1 and 4 medium was removed and used for the detection of alkaline 
phosphatase using a commercial kit (see Methods) as per the manufacturers 
recommendations. Placental alkaline phosphatase was used in 1:100 and 
1:1000 dilutions as a positive control while plain DMEM was used as 
negative control. Luminescence is expressed as relative light units (RLU) 
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Figure 4.27: SEAP assay used to see whether it could detect HCV 
replication in fused monocytes and Huh J20 Cells: Amount of 
luminescence reflects the main principle of SEAP reporter cell line by 
secreting EGFP bound alkaline phosphatase in culture medium after 
being infected with hepatitis C virus because of cleavage at NS3/4A 
serine protease site by the virus. Positive control (placental alkaline 
phosphatase bound with fluorescent protein) is used in 1:100 and 
1:1000 dilutions. Negative control was plain medium. 
 
Two patients’ monocytes were incubated with and without telaprevir at a 
concentration of 10µg/ml (14.7nM) before fusion with Huh J20 cells. 
Experimental controls were untreated monocytes (from similar patients) 
fused with Huh J20.  
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Figure 4.28: Patient A) Drug treatment of fused cells using SEAP assay 
to detect any change: Luminescence released by the fused cells which 
were treated with and without telaprevir along with the positive and 
negative controls is expressed as RLU.   
     
Figure 4.29: Patient B) Drug treatment of fused cells using SEAP assay 
to detect any change: Luminescence released by the fused cells which 
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were treated with and without telaprevir along with the positive and 
negative controls is expressed as RLU. 
These experiments required further work as we did not include a positive 
control for the replicating hepatitis C virus which would cleave at NS3/4A site 
and release alkaline phosphatase in the culture medium. The positive control 
(placental alkaline phosphatase) used in the above experiments was 
provided in the SEAP kit and was already labelled with green fluorescence. It 
is not certain whether the conditions used in this experiment were optimised 
for replication of HCV in Huh J20 cells. Moreover, It is not clear from these 
negative experiments whether Huh J20 cells are permissive to viral 
replication or not. Furthermore, it is not known whether viral replication is 
taking place without protease mediated cleavage of recognition sequence in 
SEAP assay and subsequently stopping alkaline phosphatase release into 
supernatant. JFH-1 has shown to release alkaline phosphatase by 
recognising protease cleavage sequence in previous report by Pan et al. 
(Pan, Lee et al. 2009) which might implicate that SEAP assay is only positive 
with an aberrant HCV strain like JFH-1 which shows 20 fold higher 
transcription of HCV compared to replicon strains developed earlier and did 
not require adaptive mutation to sustain and replicate in infected cells. 
4.3.8. Effect of PIV5-V protein on IFN induced pathway  
The above studies revealed that in HCV fusion model the replication of HCV 
was marginal following fusion, although the amount of replicating virus was 
greater than that seen in isolated monocytes suggesting that there was some 
degree of enhancement in the fused cells. To increase the level of HCV 
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replication in fused cells different ways to enhance viral replication were tried. 
It was speculated that local IFN production may inhibit the replication of the 
fused cells and therefore a Huh7.5 cell line in which response to antiviral 
cytokines (type I, type II and type III interferons) was blocked by active 
deletion of signal transducer and activator of transcription 1 (STAT1) by the 
viral protein PIV5-V (parainfluenza virus 5-V protein) which degrades STAT1 
was tried. In addition to blocking STAT1 it was planned to block other 
putative antiviral pathways that are induced by NFкβ. 
To determine whether inhibiting the cellular response to interferon improved 
the replication of HCV in the fusion model we generated a cell line that lacks 
the ability to respond to Type 1, 2 and 3 IFNs.  A stably transfected cell line 
containing PIV5 which is known to inhibit IFN signalling was generated for 
this purpose (see Methods) and I used this cell line in the fusion model. This 
cell line was obtained after transfecting Huh 7.5 cells by PIV-V.IRES.neo 
plasmid. The figure below shows the bands obtained by gel electrophoresis 
after restriction enzyme digestion of PIV-V.IRES.neo. To further confirm the 
integrity of the plasmid the full nucleotide sequence was verified by Gene 
Service UK (data not shown).  
 
 
341 
 
 
Figure 4.30: The bands obtained by the gel electrophoresis of the 
plasmid PIV-V.IRES.neo after restriction enzyme digestion at various 
points by the restriction endonucleases. 
The predicted sizes of the plasmid digested with NcoI were 1631bp, 854bp 
and 5071bp. The predicted size of the fragment digested with NotI was 
7556bp.  Hence the plasmid restriction fragments are as predicted by the 
sequence. 
After generating the clones of cells, i.e.; Huh 7.5 cells transfected with the 
PIV5-V containing plasmid, the ability of PIV5 to block the activation of IFN 
induced genes (ISGs) in Huh 7.5 cells was examined. The PIV5-V IRES.neo 
containing cells were treated with IFN (1000IU/ml) and tested for the 
expression of Interferon stimulated gene, MxA by real time qPCR after 24 
hour incubation at 37⁰C and 5% CO2. THP-1 cells and Huh 7.5 cells were 
used as positive controls for MxA production secondary to stimulation with 
IFN, illustrated in figure 4.30   
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100bp 
 
      1Kbp 
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Figure 4.31: MxA expression in response to IFN stimulation: THP-1 
cells, Huh 7.5 and PIV5 plasmid containing Huh 7.5 cells were treated 
with 1000 IU/ml IFN for 24 hours and expression of MxA was quantified 
by real time qPCR.  The negative controls were not IFN treated.  
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The cell line containing PIV5 (PIV5 cells) does not show expression of MxA 
after stimulation with IFN while THP-1 and Huh 7.5 cells have high MxA 
expression on treating with IFN.  
The next step was to fuse cells with no response to IFN with monocytes of 
hepatitis C patients and analyse HCV expression. 
4.3.9. HCV expression in Huh 7.5 and PIV5 cells 
Monocytes from patients with high viral load were fused with Huh 7.5 and 
PIV5 cells simultaneously and HCV expression and replication was assessed 
in both types of fused cells by real time qPCR and Immunostaining 
microscopy. 
4.3.9.1. HCV expression through real time qPCR 
Monocytes from seven different patients were fused with Huh 7.5 and PIV5 
cells and HCV expression was assessed using real time qPCR at day 3 
(n=4), day 5 (n=7) and day 7 (n=4). This is illustrated in figure 4.31 which 
shows comparison of HCV expression in both types of cells after fusion. 
 
No 
  
 Date blood taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
 
1 
 
  20/08/2010 
 
 
  48 
 
   2a    5.98 log, 963648 IU 
 
3  
 
 
2 
 
  19/01/2011 
 
     
  30 
 
   3a 
 
   5.16 log, 142918 IU 
 
2  
 
3 
 
  18/02/2011 
 
  57 
 
   3a 
 
   5.19 Log, 153103 IU 
 
4 
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4 
 
   
   07/02/2011 
 
   
  61 
  
  1a 
    
   6.46 log, 2866058 IU 
 
3-4  
 
5 
 
  01/03/2011 
 
  56 
    
   1 
 
   5.91 log, 815485 IU 
 
1  
 
 
6 
 
   01/03/2011 
 
 
  59 
 
   1a 
 
   5.94 log, 870964 IU 
 
ND 
 
7 
 
   20/04/2011 
 
 
  42 
 
   1 
    
   5.60 log, 396661 IU  
 
2  
Table 4.10: Details of the patients whose monocytes were fused with PIV5 
positive Huh 7.5 cells. The table shows age, genotype and subtype (if 
available), fibrosis score (Ishak scoring) if liver biopsy was done, viral load 
done closest to the time of blood sampling from each patient. ND= not 
done. 
 
Figure 4.32: HCV expression in Huh 7.5 cells with and without 
PIV5 plasmid after fusion with patients’ monocytes.  
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There was no significant difference in HCV expression and replication in both 
types of cells after fusion. P value was greater than 0.05 using Wilcoxon 
matched pair test.  
4.3.9.2. Indirect immunofluorescence staining of PIV5 cells 
after fusion 
PIV5 cells were fused with three patients’ monocytes and stained with 
antibody against NS5A. 
     
Isotype Control 
     
PIV5 +ve Huh 7.5/ Monocytes fusion A 
     
PIV5 +ve Huh 7.5/ Monocytes fusion B  
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PIV5 +ve Huh 7.5/ Monocytes fusion C 
Figure 4.33: Indirect immunofluorescence staining of PIV5 
containing Huh 7.5 cells after fusion with HCV patients’ 
monocytes (n=3).  
Taken together these data suggest that inhibiting IFN signal transduction 
does not augment HCV replication in this model. It is unclear whether this is 
because this replication model is insensitive to interferon or because 
interferon is not induced in this model system.  
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4.3.10. Patients used in indirect immunofluorescence 
microscopy experiments  
The data of all patients whose monocytes were used for all the indirect 
immunofluorescence microscopy experiment are given below: 
 
 
No 
 
Age 
 
 Genotype 
            
       Viral load  
 
Fibrosis 
  
Experiment  
 
 
1 
 
57 
 
    2 
 
  
6.65 log, 3650653 IU 
 
  ND 
 
 
 Fused cells 
 
 
2 
 
33 
 
   1b 
 
6.89 log, 7714335 IU 
 
  ND 
 
 
 Fused cells 
 
3 
 
35 
 
 
   3a 6.78 log, 5968257 IU 
 
    5  
 
 
 Fused cells 
 
 
4 
 
 
59 
 
    
    4 
5.94 log, 877674 IU 
 
 
    1  
 
 
 Fused cells 
(confocal 
microscopy) 
 
 
5 
 
58 
 
   1a 
 
 
7.01 Log, 10280828 
IU 
     
           3  
  3 
3 
Fused cells 
(confocal 
microscopy) 
 
 
6 
 
38 
    
   1b 
 
 
7.15 log, 14287115 IU 
 
    3  
Capture-fusion 
 transfer 
 
 
7 
 
48 
 
   2a 5.98 log, 963648 IU 
 
    3  
  
Capture-fusion 
 transfer 
 
 
8 
 
 
30 
 
   3a 
 
 5.16 log, 142918 IU 
 
    2  
Capture-fusion 
 transfer 
 
 
9 
 
 
57 
 
   3a 
 
5.19 Log, 153103 IU 
 
    4 
PIV5 containing 
Fused cells 
 
10 
 
 
61 
 
   1a 
 
6.46 log, 2866058 IU 
 
  3-4  
PIV5 containing 
Fused cells 
 
11 
 
 
56 
     
    1 
 
5.91 LOG, 815485 IU 
 
    1  
PIV5 containing 
Fused cells 
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12 
 
 
59 
 
   
   3b 
 
   
 5 log, 100000 IU 
 
    
 ND 
 
IM vs RM fusion 
(confocal) 
 
13 
 
59 
 
3b 
 
5 log, 100000 IU 
 
ND 
 
IM vs RM fusion 
(confocal) 
Table 4.11: Details of the patients whose HCV RNA expression was 
observed through indirect immunofluorescence microscopy after fusion: 
The table shows age, genotype and subtype (if available), fibrosis score 
(Ishak scoring) if liver biopsy was done, viral load done closest to the 
time of blood sampling from each patient. ND= not done. 
4.3.11. Drug validation of HCV fusion model 
A) Experiments with genotype 1 HCV containing fused cell 
Monocytes from patients infected with genotype 1 strain of HCV were fused 
with Huh 7.5 cells. Equal numbers of cells were separated out with half kept 
as controls and other half were treated with telaprevir at a concentration of 10 
µg/ml (14.7nM), known to inhibit the replication of Genotype 1 HCV. HCV 
expression was observed on days 3, 5 and 7 in both treated and untreated 
cells. Table 4.12 shows patients' data that were included in this study.  
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Table 4.12: Details of genotype 1 infected patients whose HCV RNA expression was 
observed with and without telaprevir treatment: The table shows age, genotype and 
subtype (if available), fibrosis score (Ishak scoring) if liver biopsy was done, viral load 
done closest to the time of blood sampling from each patient and fold change in HCV 
RNA in fused cells from different patients incubated with and without telaprevir. ND= 
not done, NA= not available.  
Figure 4.33, 4.34 and 4.35 show the effect of telaprevir on HCV expression of 
fused cells from genotype 1 strain of HCV on day 3, 5 and 7 respectively and 
HCV expression was assessed by real time qPCR.  Absolute quantification 
technique (using plasmid DNA standards - internal reference standards in 
form of plasmid containing target gene) was used to analyse HCV expression 
in treated and untreated samples. Absolute values were calculated for HCV 
from known standards. A known amount of plasmid was used to construct a 
calibration curve and then unknown samples identified from this and results 
were expressed in absolute terms as the number of copies of HCV RNA.          
 
No 
  
    Date blood  
     was taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
 
Fold Change 
On different days 
  
 
1 
 
20/04/2011 
 
 
 47 
 
 1a 
 
   6 log, 1000000 IU 
 
2 
Day 3:  -1.01 
Day 5:  -188.8 
Day 7:  -1.88 
 
2 
 
27/04/2011 
 
 53 
 
1a 
 
 7.20 Log,16017910 IU 
 
2  
 
Day 3:  -8.80 
Day 5:  -3.07 
Day 7:  -26.2 
 
3 
 
04/05/2011 
 
 
 55 
 
1 
  
   6 log, 1000000 IU 
 
ND 
Day 3:  -98.1 
Day 5:  -277.3 
Day 7:  -22.7 
 
4 
 
11/05/2011 
 
 
 50 
 
1b 
 
               NA 
 
6  
Day 3:  -4.33 
Day 5:  -17.6 
Day 7:  -3.40 
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Figure 4.34: Effect of telaprevir on HCV expression of the fused 
cells from genotype 1 strain of HCV (from four patients) extracted 
on day 3: HCV expression was assessed by real time qPCR. 
Absolute quantification (using plasmid DNA standards) was used to 
analyse HCV expression in treated and untreated samples. Each 
point represents mean HCV expression from a single patient. *p = 
0.0156 (using Wilcoxon matched pair test). Log10 scale is used for 
HCV RNA expression in top figure. 
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Figure 4.35: Effect of telaprevir on HCV expression of the fused 
cells from genotype 1 strain of HCV (from four patients) extracted 
on day 5: HCV expression was assessed by real time qPCR. 
Absolute quantification (using plasmid DNA standards) was used to 
analyse HCV expression in treated and untreated samples. Each 
point represents mean HCV expression from a single patient. **p = 
0.0078 (using Wilcoxon matched pair test). Log10 scale is used for 
HCV RNA expression in top figure. 
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Figure 4.36: Effect of telaprevir on HCV expression of the fused 
cells from genotype 1 strain of HCV (from four patients) extracted 
on day 7: HCV expression was assessed by real-time qPCR. 
Absolute quantification (using DNA standards) was used to analyse 
HCV expression in treated and untreated samples. Each point 
represents mean HCV expression from a single patient. *p = 0.0156 
(using Wilcoxon matched pair test). Log10 scale is used for HCV 
RNA expression in top figure. 
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B) Experiments with genotype 3 HCV containing fused Cell 
Clinical studies in patients infected with genotype 3 HCV show that telaprevir 
is ineffective in this genotype. To determine whether this can be detected in 
our assay we studied monocytes from patients infected with genotype 3 
HCV. Monocytes from 4 patients were fused with Huh 7.5 cells. Equal 
numbers of cells were separated out with half kept as controls and the other 
half were treated with telaprevir. HCV expression was observed on days 3, 5 
and 7 in both treated and untreated cells.  
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Table 4.13: Details of genotype 3 infected patients whose HCV RNA expression 
was observed with and without telaprevir treatment: The table shows age, 
genotype and subtype (if available), fibrosis score (Ishak scoring) if liver biopsy 
was done, viral load done closest to the time of blood sampling from each patient 
and fold change in HCV RNA in fused cells from different patients incubated with 
and without telaprevir.  ND= not done. 
Figure 4.36., 4.37 and 4.38 shows the effect of telaprevir on HCV expression of 
fused cells containing genotype 3 strain of HCV. HCV expression was assessed by 
real time qPCR.  Absolute quantification technique (using plasmid DNA standards) 
was used to analyse results. 
 
 
No 
  
    Date blood  
    was taken 
 
 
Age 
 
Genotype 
            
          Viral load  
 
Fibrosis 
 
Fold Change 
On different days 
 
 
1 
 
18/05/2011 
 
      44 
 
     3a 
 
 6 log, 1000000 IU 
 
5 
 
Day 3:  -2.29 
Day 5:   1.66 
Day 7:  -1.84 
 
2 
 
18/05/2011 
 
      38 
 
     3b 
 
 6 log, 1000000 IU 
 
2  
 
Day 3:  -1.64 
Day 5:  -4.30 
Day 7:  -1.79 
 
3 
 
25/05/2011 
 
 57 
 
     3a 
 
 6.23 log, 1699933 IU  
 
ND 
 
Day 3:   1.35 
Day 5:   3.56 
Day 7:   4.79 
 
4 
 
25/05/2011 
 
      59 
 
     3b 
 
 5 log, 100000 IU 
 
ND 
 
Day 3:   4.34 
Day 5:   5.07 
Day 7:   3.14 
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Figure 4.37: Effect of telaprevir on HCV expression of the fused 
cells from genotype 3 strain of HCV (from four patients) extracted 
on day 3: HCV expression was assessed by real time qPCR. 
Absolute quantification (using plasmid DNA standards) was used to 
analyse HCV expression in treated and untreated samples. Each 
point represents mean HCV expression from a single patient. 
p>0.05 (using Wilcoxon matched pair test). Log10 scale is used for 
HCV RNA expression in top figure. 
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Figure 4.38: Effect of telaprevir on HCV expression of the fused 
cells from genotype 3 strain of HCV (from four patients) extracted 
on day 5: HCV expression was assessed by real time qPCR. 
Absolute quantification (using plasmid DNA standards) was used to 
analyse HCV expression in treated and untreated samples. Each 
point represents mean HCV expression from a single patient. 
p>0.05 (using Wilcoxon matched pair test). Log10 scale is used for 
HCV RNA expression in top figure. 
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Figure 4.39: Effect of telaprevir on HCV expression of the fused 
cells from genotype 3 strain of HCV (from four patients) extracted 
on day 7: HCV expression was assessed by real time qPCR. 
Absolute quantification (using plasmid DNA standards) was used to 
analyse HCV expression in treated and untreated samples. Each 
point represents mean HCV expression from a single patient. 
p>0.05 (using Wilcoxon matched pair test). Log10 scale is used for 
HCV RNA expression in top figure. 
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To compare the effect of telaprevir on genotype 1 and genotype 3 HCV all of 
the data containing CT values from treated and untreated cells from patients 
with genotype 1 and 3 HCV were collated and plotted together. Figure 4.39 
show the summary of all the data (note that this figure includes values from 
different times plotted all together i.e.; 3, 5 and 7 days from different 
experiments). In order to determine the reproducibility of the results reverse 
transcriptase step was done twice for each sample.  
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                                                          Genotype 1                                                                      
                                         
     
 
                                                      Genotype 3 
                             
Figure 4.40: HCV expression shown as CT values comparing differences 
between controls and telaprevir treated in both genotypes 1 (p=<0.0001 
- matched pair test) and 3 (n/s): Each point in the graph shows a CT 
value from the PCR of a different patient at days 3, 5 and 7 – RT 
(reverse transcription) done twice for each patient to look at 
reproducibility of the original result. 
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These data suggest that sensitivity to telaprevir in the fusion assay correlates 
with the clinical response. These initial drug sensitivity testing indicate that 
this assay may be useful to predict individual patient response to telaprevir.  
Dr Morven Cunningham has now extended the work with antiviral drug 
testing of the fused cells from different genotypes and confirmed these 
preliminary findings.  
4.4. Discussion  
Accurate phenotyping of HCV before commencing on antiviral therapy is 
important for determining future response to conventional antiviral drug 
regimens. In recent years newer antiviral drug combinations have emerged. 
Drug combinations confer varying responses in variety of different HCV 
genotypes and subtypes (Zeuzem, Asselah et al. 2011). Cell fusion approach 
has been utilised by one previous group to study extrahepatic HCV 
replication (Frentzen, Huging et al. 2011). We have applied this technique to 
allow an analysis of patient specific HCV strains.  
Fusion data presented in this chapter shows that HCV expression can be 
detected in fused cells during the first few days of fusing monocytes of HCV 
patients with Huh 7.5 cells. The level of replication is low but can be inhibited 
by telaprevir in a genotype specific manner. However, the HCV signal in 
these fused cells is relatively low and our attempts to enhance the signal 
using inhibition of interferon signalling and modified detection techniques 
(SEAP release) were unsuccessful. Further steps need to be taken to 
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enhance current model and market for drug screening for ‘difficult’ genotypes 
(3, 4, 5, 6 etc). 
We have set up an HCV fusion model based on approach recommended by 
Professor Malcolm Alison. Monocytes are one of the non-hepatic sites which 
are known to harbour replicating HCV (discussed in chapter 1 section 1.9.1). 
As discussed above serum derived HCV has not been propagated in 
hepatocytes. Moreover, HCV replicons show significant replication in Huh 7.5 
cells compared to other cell lines. Hence, suggesting that Huh 7.5 cells are 
highly permissive to HCV replication but again they cannot capture HCV from 
patients' sera. It has been proposed that the block might be at the HCV entry 
step. Fusing monocytes with Huh 7.5 cells led to HCV replication within 
hybrids by bypassing this major hurdle.  Furthermore, very low level of HCV 
RNA was detected within monocytes which were not fused and replication 
was much enhanced in fused cells for first few days. However, HCV RNA 
was significantly reduced in cultured fused cells after 1st week which could 
be due to over confluence of non-hybrid single Huh 7.5 cells due to selection 
advantage. This has hampered the formation of a cell line containing 
replicating HCV from individuals for long term drug sensitivity and resistance 
testing. In brief, our fusion technique has led to formation of a potent but 
short-term model which contains HCV obtained from patients. Although this 
model is cell type dependent it is robust and reproducible.  
Real time quantitative PCR was used to detect HCV RNA. It is a sensitive 
assay which can detect very low level viral replication. This thesis relies 
heavily on data generated from real time qPCR reactions. There are many 
advantages of using real time qPCR but despite being described as the gold 
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standard, qPCR faces significant challenges because of variability of RNA 
templates, assay designs and protocols, as well as immense need for data 
normalization and conflicting data analysis. Appropriate standardization is 
required at every step of real time qPCR along with optimal assay design and 
reliable data normalization to obtain decent results. qPCR calls for 
optimisation in all channels of workflow that start with sample collection, 
sample stabilization and nucleic acid purification, and ends with amplification, 
detection and quantification of results.  Apart from technical difficulties which 
include low yield, contamination and unspecific amplification, two major 
factors involved in PCR failure or poor results are; specificity of reaction and 
template secondary structure and factors influencing these two which are 
choice of enzyme, reaction conditions (annealing temperature, etc), primer 
design and template quality. Carefully choosing these factors is significant for 
better PCR quality and results. Due to exceedingly high sensitivity, well 
structured experimental design and a profound understanding of 
normalization techniques are essential for precise results. Variations during 
PCR can be incurred from different sources like assay design, PCR reagents, 
PCR equipments and human error. For example, lack of standardization of 
reverse transcription reaction can lead to variable results. Therefore, it is 
essential to measure intra- and inter-assay variation and also to minimize 
variability.  
Despite the above mentioned challenges this technique can be very effective 
after considerable optimisation. The progress of qPCR reaction is effectively 
monitored as it occurs in real time. The amount of amplicon can be measured 
precisely at each cycle and the result is amazingly broad, 107-fold dynamic 
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range, thus data analysis, including standard curve generation and copy 
number calculation, is performed easily. The amplification and detection is 
combined in a single tube eliminating the use of post-PCR manipulation. 
Post-PCR melt curve analysis is a simple way to check real time qPCR 
reaction for primer dimer artefacts and to ensure reaction specificity as 
different PCR products can be distinguished by their melt curve 
characteristics. It’s easy to check PCR contamination by substituting negative 
control using water instead of a DNA template in one of the reactions. 
Moreover, this technique eliminates the need for post-amplification 
manipulation, significantly reducing the risk of contamination in subsequent 
experiments. Moreover, a well constructed experiment and introducing 
proper controls can make real time qPCR one of the most sensitive, efficient 
and reproducible methods of calculating gene expression. In our experiments 
we used appropriate controls at various stages to monitor the reliability of this 
technique. Considerable steps were taken to eliminate the issues with 
contaminations. Appropriate primers were used during the final amplification 
stage to achieve correct amplicons. 
 
We have used immunofluorescence (IF) microscopy to confirm presence of 
HCV viral protein NS5A in the fused cells which signifies HCV replication. 
From both PCR and IF microscopy results it has been confirmed that 
replication is taking place in fused cells. qPCR results show that replication in 
fused monocytes and Huh 7.5s is significantly enhanced compared to 
monocytes alone. The work in this thesis could not demonstrate release of 
HCV virion in supernatant. However, later experiments by Dr Cunningham 
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using a modification of this assay with a new monocyte cell line (THP-1 cells) 
have shown virus release suggesting that the virus is undergoing complete 
replication. 
In order to amplify replication of HCV in fused cells different techniques were 
tried; initially to enhance fusion between monocytes and Huh 7.5s and by 
modifying fusion process and later by interfering with IFN induced signalling 
and inhibiting response to IFN. It was observed that inhibiting IFN induced 
response in Huh 7.5 cells did not increase replication in fused cells when 
compared with regular Huh 7.5 cells. One of the reasons for this blunted 
response to inhibited IFN signalling may be that Huh 7.5 cells have defected 
RIG-1 signalling which inhibits the production of IFN, thus Huh 7.5 cells are 
already deficient in IFN and hence the reason why they are so permissive to 
HCV infection (discussed in chapter 1 section 1.7.3.1). Our data may confirm 
the previous reports that Huh 7.5 cells are defected in RIG-1 signalling which 
makes them ideal for HCV replication.  
In this chapter I have described preliminary experiments done to set up a 
novel ‘capture-fusion’ assay in which patient derived HCV is ‘captured’ by 
monocytes and then transferred to hepatocytes using cell fusion. This work 
was extended further by Dr Cunningham who showed that this technique 
allows analysis of patient-derived virus and drug sensitivity and treatment 
response can be predicted for a wide spectrum of clinical isolates. It has 
been postulated by Revie et al. that monocytes/macrophages might up-
regulate certain factors which could modify HCV and promote its infection in 
various other cell line or select variants which could have selection 
advantage (discussed in chapter 1 section 1.9.1). Dr Cunningham showed 
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that pre-stimulation of THP-1 cell line by empirically chosen cytokine profile 
led to success of capture transfer assay and without this prior stimulation 
HCV could not be detected in Huh 7.5 cells after incubating monocytes from 
buffy coats with sera of patients and then fusing with Huh 7.5s. My results 
with unstimulated and uninfected monocytes from buffy coats showed HCV 
transfer in fused cells after incubating these monocytes with patient's sera. 
This observation does not coincide with later experiments by Dr Cunningham 
using unstimulated THP-1 cells which showed lack of HCV transfer in fused 
cells. One explanation could be that monocytes/macrophages select out HCV 
variants from patient's sera or they might up-regulate various factors in Huh 
7.5s that increase HCV transfer in their fused cells. Moreover, as cytokine 
expressions in monocytes and THP-1 cells vary following stimulation with 
LPS it is possible that varying results obtained using THP-1 cells in capture-
fusion transfer technique may be due to this difference (Schildberger, 
Rossmanith et al. 2013).  
Telaprevir is a protease inhibitor which inhibits the hepatitis C viral enzyme 
NS3 4A serine protease. It establishes covalent but reversible bond with the 
protease catalytic site in order to inhibit the action of NS3 4A serine protease. 
It is indicated for treatment of genotype 1 HCV infection. We chose to use 
telaprevir for drug validation experiments because its potent, rapidly acting 
and its response varies in different genotypes. Telaprevir efficacy in the 
treatment of genotype 1 hepatitis C infection has been demonstrated in 
numerous clinical trials and after instituting it in the treatment of genotype 1 
infection has improved the response rate. In one study 14 days of therapy 
with telaprevir inhibited HCV replication in replicon based on a genotype 1b 
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HCV strain while introducing interferon and telaprevir in combination led to 
synergistic effect on HCV RNA suppression (Lin, Perni et al. 2006). In 
another similar study using genotype 1a replicon same response was seen 
(Perni, Almquist et al. 2006). Telaprevir is poorly effective in genotype 3 HCV 
and very few patients show some antiviral response (Foster, Hezode et al. 
2011). In our experiments to see in vitro response to telaprevir in genotype 1 
and 3 HCV, it is seen that sensitivity to telaprevir in the fusion assay 
correlates with the clinical response. 
 
In summary, a novel fusion assay permitting in vitro replication of patient-
derived HCV from diverse viral genotypes has been developed which could 
enable antiviral drug sensitivity testing. Genotype-specific responses to a  
novel antiviral drug - telaprevir have been demonstrated in this chapter and 
the assay shows promise for further development.  
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The aim of this thesis was to develop a functional model of HCV replication 
which examines virus derived from infected HCV patients. Hepatitis C is 
globally a major health issue and since its discovery scientists have faced 
difficulty with creating in vitro models. Despite many setbacks Interferon and 
ribavirin have been the standard of care (SOC) treatment for chronic HCV 
infection for almost a decade. However recently there have been 
developments in antiviral therapeutics. Novel direct acting antivirals (DAAs) 
have been instituted in the treatment of HCV and in future might replace 
present SOC therapy (reviewed in De Clercq 2012). Many other direct acting 
antiviral agents are being tested which target the protease NS3/4A, the 
protein NS5A, and the enzyme RNA dependent RNA polymerase 'NS5B'. 
Two of the DAAs already been introduced in the treatment of HCV are 
telaprevir and boceprevir (reviewed in De Clercq 2012).  
The development of novel antiviral therapeutics can potentially be 
streamlined by using patient-derived model systems in which drugs can be 
tested prior to embarking upon clinical trials.  Primary human hepatocyte 
cultures derived from hepatitis C patients have been used previously to study 
viral replication, life cycle, host interactions and to monitor response to 
antiviral medication (Rosenberg, Carpentier et al. 2010). However such 
models have been hampered by difficulties in maintaining primary human 
hepatocytes (PHHs) from infected individuals in culture for a long duration 
(reviewed in Raymond, Selliah et al. 2009) because of reduced cell viability 
and an inability to proliferate after isolation from in vivo environment mainly 
due loss of their differentiated phenotype (Bhatia, Balis et al. 1999, Wu, 
Robotham et al. 2012). Moreover, PHHs from uninfected individuals are 
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inefficiently infected by incubating in the sera of HCV infected patients 
(reviewed in Wu, Robotham et al. 2012). Few studies reported propagation of 
serum derived HCV into cultured PHHs (Rumin, Berthillon et al. 1999, 
Lazaro, Chang et al. 2007, Buck 2008, Molina, Castet et al. 2008) but the 
replication has been marginal and with no reproducibility (Ploss, Khetani et 
al. 2010). Nonetheless, PHHs withstood these barriers and were infected 
with HCVcc when cultivated with supporting cells in specialized 
micropatterned co-cultures. (Khetani and Bhatia 2008, Ploss, Khetani et al. 
2010). However, these co-cultures need specialised substrates (culture-
matrices) and expertise which are not yet widely available (Lindenbach 
2010). Because of considerable difficulty in culturing PHHs researchers have 
attempted infection of immortalized hepatocytes and hepatoma cell lines 
(Ikeda, Kato et al. 1997, Ikeda, Sugiyama et al. 1998) but HCV titres were not 
very high (Ikeda, Sugiyama et al. 1998) and though suitable for evaluating 
antiviral drugs they are not sufficient to study viral life cycle.  
As serum infected cell lines did not produce ample amount of HCV 
replication, studies were carried out to generate cell lines with full-length in 
vitro transcribed viral cRNA (Dash, Halim et al. 1997) or cDNA integrated into 
the chromosomes and thus expressing viral RNA. These clones were found 
to be infectious after intrahepatic inoculation in chimpanzees (Kolykhalov, 
Agapov et al. 1997, Yanagi, Purcell et al. 1997). A breakthrough in this field 
came with the invention of stable replication model of subgenomic HCV RNA 
and a bicistronic HCV replicon was cloned from patient with chronic hepatitis 
C (Lohmann, Korner et al. 1999). This system facilitated the study of different 
aspects of viral life cycle and the antiviral drug testing. It was however 
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noticed that replicon required several adaptive mutations in order to self 
replicate (Blight, Kolykhalov et al. 2000). This replicon system facilitated the 
study of viral life cycle and allowed antiviral drug testing. However the 
drawbacks of this system doesn’t allow replication of the whole HCV making 
it difficult to interpret true response of antiviral drugs and true host-viral 
relationship cannot be assessed by this system (Guha, Lee et al. 2005). 
Moreover, adaptive mutations required for replication in vitro doesn’t allow 
replication in vivo in chimpanzees which makes in vitro response to antiviral 
drugs less predictable (Bukh, Pietschmann et al. 2002).  
It was observed that these conventional replicon systems were not able to 
produce infectious particles in supernatant (Arai, Suzuki et al. 2011) and this 
led to formation of a HCV infectious system by Wakita and his colleagues in 
which full length replicon was developed from genotype 2a infected 
Japanese patient with fulminant hepatitis and was called JFH-1. JFH-1 
replicated efficiently and produced infectious virion in Huh-7 cell lines 
(Wakita, Pietschmann et al. 2005). Later structural region of J6 genotype 2a 
clone was introduced into JFH-1 which increased its infectivity (Lindenbach, 
Evans et al. 2005). Limitations of this system are that it contains HCV 
particles from genotype 2 strain which is less dominant genotype globally and 
was obtained from a fulminant hepatitis patient which is a rare event 
(reviewed in Yi, Villanueva et al. 2006). Infectious particles were also 
released by H77 a genotype 1a variant but infectivity of release particles is 
low compared to JFH-1 (Yi, Villanueva et al. 2006).  
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In order to create a model which could look at individual patient virus in more 
detail in vitro we used surplus tissue fragments of routine biopsy samples 
from patients with HCV to develop an ex vivo system to test antiviral 
compounds like telaprevir and NA808. Telaprevir is a first generation direct 
acting antiviral drug which inhibits viral protease NS3-4A and inhibits 
cleavage of nascent proteins involved in the assembly of nascent virions. In 
clinical trials telaprevir is more sensitive against genotype 1 strain of HCV 
(Reesink, Zeuzem et al. 2006). It is rapid acting and exerts its antiviral effect 
within 2 days of treatment however monotherapy is linked to emergence of 
resistance (Forestier, Reesink et al. 2007). NA808 is an experimental agent 
developed by Chughai Pharmaceutical Co. Ltd which could inhibit HCV 
replication in genotype 1 replicon system within 7 days according to 
experiments performed by Chughai Pharmaceutical Co. Ltd. Although its 
mechanism of action is not very clear it is thought to inhibit serine 
palmitoyltransferase enzyme which is a co-factor involved in sphingolipid 
synthesis pathway. As sphingolipid is involved in assembly of HCV its 
depletion can effect formation of infectious particles.  
This thesis depends mainly on data gathered from real time qPCR reactions. 
The progress of real time qPCR and generation of amplicon can be 
monitored in real time. Apart from relative quantification we have used 
standard curve generation to assess copy numbers of HCV RNA. Due to 
exceedingly high sensitivity, despite being described as the gold standard, 
qPCR calls for appropriate standardization at every step along with optimal 
assay design and reliable data normalization. There is a chance of increased 
variability during qPCR due to assay design, PCR reagents, PCR 
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equipments and human error. It is essential to measure intra- and inter-assay 
variation and also to minimize variability. Hence, a well structured 
experimental design and use of appropriate controls can make real time PCR 
one of the most sensitive, efficient and reproducible methods of evaluating 
gene expression. In addition to qPCR we used indirect immunofluorescence 
to show viral NS5A protein co-localised with albumin which is produced 
specifically by Huh 7.5 cells.  
Experiments to look at the effect of telaprevir on HCV RNA levels in intact 
liver biopsy fragments showed that there was a significant reduction in the 
mean HCV RNA in biopsies belonging to genotype 1 infected patients. 
However, the majority of biopsies showed only minute change in HCV RNA 
expression and the significant effects of telaprevir may have been dominated 
by the substantial changes seen in a few samples. Hence, the changes seen 
in most liver biopsies were modest and broad range of samples need to be 
analysed to examine the effects of the drug and derive a statistically 
significant result. Furthermore, effect of telaprevir on HCV RNA in liver 
biopsies on the whole did not show any significant change in genotype 2 and 
3 infected patients. Thus, considering the effect of telaprevir on liver biopsies 
obtained from aggregated cohort of patients belonging to genotypes 1-3 
show that the results are comparable to those derived from the clinical trials. 
Experiments with NA808 had limited sample size and short incubation period 
compared to previous experiments performed on replicon cells (containing 
genotype 1 strain of HCV) by 'Chugai Pharmaceuticals' in which effect was 
seen after incubation with NA808 for 7 days. Nonetheless, we observed that 
effect on HCV RNA after 24 hours incubation with NA808 was similar to that 
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obtained after 48 hours incubation. Genotype 3 strain infected biopsies 
showed response to NA808 both after 24 and 48 hours incubation. We could 
not however come to any definite conclusion about the effect of this drug on 
genotype 3 HCV RNA because of a very small sample size. Furthermore, It 
did not impart any inhibitory effect on HCV RNA from genotype 1 strain within 
24 and 48 hours. It is not clear whether the lack of response in genotype 1 
patients is due to lack of response to drug or due to longer action of NA808 
which could not be seen in 48 hours. Nonetheless, it was found in later 
experiments on man that it did not cause any inhibitory effect at 
concentrations that were non toxic to humans and was withdrawn from 
further development. 
Moreover, the need for multiple samples and statistical analysis detracts from 
the value of the assay – the data presented above indicate that it will be 
difficult to adapt this assay to determine the drug sensitivity of an individual 
patient. Poor sensitivity of the assay may be related, at least in part, to the 
differences in HCV RNA expression in different fragments taken from the 
same biopsy. Additionally, reduced viability of hepatic cells after isolation 
from in vivo environment may contribute to poor expression of HCV RNA and 
lack of sensitivity.  
In summary, some of the drawbacks of liver biopsy model are high sample to 
sample variability and lack of homogeneity among different biopsy fragments, 
restricted availability of liver biopsies or resected liver tissues, limited 
duration of viability of the hepatic cells in vitro. Furthermore, differences in 
patients' clinical history, methods of isolation and host genetics contribute 
towards the lack of attainment of reproducible results. 
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The viability experiments showed that viability of liver biopsy fragments 
reduced considerably within 48 hours and extracting hepatic cells from the 
surrounding extracellular matrix led to further reduction in the viability of liver 
biopsy cells. The micro-patterning technique used by others groups may 
provide an optimal environment for maintaining hepatocytes in culture (Ploss, 
Khetani et al.2010, Khetani and Bhatia 2008). This micro-pattern co-culturing 
of hepatic cells with embryonic fibroblasts is used to provide a favourable 
microenvironment for adequate cell functioning and to achieve maximum 
benefits by controlling and modulating the degree of contact. This involves a 
miniaturized model with spherical islands of primary human hepatocytes co-
cultivated with 3T3-J2 murine embryonic fibroblasts to induce heterotypic and 
homotypic synergy of cells. This interdependence is vital for preservation of 
the hepatocyte phenotype and function over prolong period as cells make 
polarized layers with optimized dimensions required for maintaining the 
viability and liver specific function. However, the system is technically very 
challenging and has not been reproduced outside the initiators laboratory. 
We used a simpler approach by growing hepatic cells with 3T3 embryonic 
fibroblasts in 1:4 ratio so that simple, easy to use culture conditions could be 
acquired that would maintain differentiated hepatocytes in culture for several 
days to allow studies on HCV replication and antiviral drug testing to be 
completed. In initial experiments comparing pure hepatic cells with co-
cultured hepatic and 3T3 cells, HCV RNA was quantified to assess the 
viability of culture. A definite trend levering towards the side of co-culture was 
observed but antiviral drug testing showed considerable variation between 
duplicate samples and could not provide efficacy of this approach. Growing 
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hepatic cells with embryonic fibroblasts did not increase the value of the 
assay for antiviral drug testing in our liver biopsy studies. Thus this technique 
was abandoned.  
Peripheral blood mononuclear cells harbour HCV and some studies have 
demonstrated HCV replication in these cells. However, there are 
speculations that there is low level replication in them (Cribier, Schmitt et al. 
1995). We used polyethylene glycol mediated fused monocytes (from chronic 
HCV patients) and Huh 7.5 cells to produce a model for the study of HCV 
replication. Significant replication does not occur in Huh 7.5 cells incubated in 
patients' sera, this could be attributed to either a block in the uptake of virus 
or the lack of HCV receptors required for internalisation of the virus or a block 
in replication of HCV which could be subdued by delivery of large amounts of 
HCV by the fusion process to overcome host immune response.  Moreover, 
other factors might play a part and further experimental work is needed to 
elucidate exact mechanism of monocyte/Huh 7.5 cells fusion induced HCV 
replication.  
We determined optimum conditions which would provide maximum degree of 
fused monocytes and hepatocytic cells. Fusion experiments suggest that 
fusing monocytes from infected patients with Huh 7.5 cells leads to increased 
expression of HCV for the first 7 days after fusion and a decline in HCV RNA 
afterwards. HCV could not be stably expressed in Huh 7.5 cells for longer 
duration and establishment of an HCV infected cell line was not possible. 
Telaprevir was used to test validity of this approach because it is potent, fast 
acting and has shown genotype specific response in clinical trials (Foster, 
Hezode et al. 2011). Replication of HCV in fused cells could be inhibited by 
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telaprevir. In our experiments to look at telaprevir sensitivity in different 
genotypes it was demonstrated that response to telaprevir in the fusion assay 
correlates with that observed in clinical trials. Hence, HCV replication can be 
induced by fusion of infected patients' monocytes with Huh 7.5 cells and can 
be inhibited by antiviral compounds. To extend the applicability and 
practicality of the fusion assay we used monocytes from healthy patients to 
capture HCV from serum of chronically infected patients' sera and then fused 
these monocytes with Huh 7.5 cells and studied HCV replication further. As 
there is compartmental distribution of HCV quasispecies HCV from serum 
might vary compared to that harboured in monocytes (Roque-Afonso, 
Ducoulombier et al. 2005). Thus capturing HCV from serum might facilitate 
the direct examination of serum derived HCV after incorporating it into this 
technique. Replication was observed by indirect immunofluorescence 
microscopy in the capture-transfer model. Further analysis was carried out by 
Dr Morven Cunningham who used pre-stimulated monocytic cell line THP-1 
to capture serum derived HCV. However, the issue with fusion approach is 
that the replication is marginal and the attempt to increase HCV replication in 
fused cells by interfering with IFN production (STAT1 degradation by PIV5) 
did not provide enhanced replication. As discussed in Chapter 1, Huh 7.5 
cells are highly permissive to HCV replication in part due to defect in the RIG-
1 molecule which is an important effecter for the downstream production of 
IFN in response to viral RNA.  The failure to enhance HCV replication in 
STAT1 degraded Huh 7.5 cell line could be that the Huh 7.5 cells are already 
deficit in IFN production and hence are highly permissive to HCV replication. 
This is due to the flaw in the RIG-1. STAT1 degradation in Huh 7.5 cells does 
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not increase HCV replication any further because IFN production is already 
defected in Huh 7.5 cells. 
In short, our work demonstrates that HCV replication dies out after 7 days 
and thus a hybrid cell line containing replicating virus from HCV individuals 
for the purpose of long term drug sensitivity and resistance testing could not 
be developed. Nevertheless, our fusion technique has led to the formation of 
an ad hoc, interim model of patient derived HCV which can be used to study 
fast acting antivirals. Although this model is cell type dependent, it is potent 
and robust. 
A large number of direct acting antivirals were developed using HCV 
subgenomic replicon system. However, determining sensitivity of new 
antiviral drugs to diverse viral genotypes often requires patient exposure 
which is not possible through the current HCV models. As the replication of 
patient-derived HCV in the fused cells could be inhibited by antivirals, this 
technique has a potential to be used as an identifier of patient-specific 
responses to antiviral compounds. HCV therapeutics involves the use of 
combination therapy to combat the development of resistance. Moreover, 
antiviral combination effective for one genotype or subtype differs from the 
other. For example, the combination of faldeprevir and non-nucleoside NS5B 
inhibitors is more effective against genotype 1b compared to genotype 1a 
(Kronenberger and Zeuzem 2008). Thus, accurately phenotyping the virus 
before commencing treatment is important. 
We did not notice significant viral replication within monocytes. This could be 
due to either very low levels of HCV replication within monocytes or the virus 
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persists in a non-replicative form. Although the relationship between the 
therapeutic failure and the viral persistence in monocytes remains to be fully 
determined, the presence of replication competent virus in monocytes leads 
to the speculation that these cells may be acting as a 'Trojan horse' 
associated with the reappearance of HCV after therapeutic viral clearance.. 
This thesis has only looked at Huh 7.5 cell line which due to the defect inRIG-
1 is highly permissive to HCV infection. Moreover, Huh 7.5 cells are 
hepatoma derived cells and might not represent PHHs. Moreover, the 
acquisition of PHHs is cumbersome and they lose their differentiated 
phenotype quickly on isolation from the in vivo environment. Additionally, 
their viability reduces rapidly in vitro, there is lot-to-lot variability amongst 
these cells and have low plating efficiency. Furthermore, stem cell technology 
has introduced a valuable alternative to Huh 7.5 cells by introducing the 
pluripotent stem cells, either obtained from embryonic source or induced by 
reprogramming factors like hESCs and iPSC respectively. These cells have 
ability to regenerate and have the potential to differentiate into hepatocyte 
like cells (Ghodsizadeh, Taei et al. 2010, Sullivan, Hay et al. 2010). 
Differentiated human hepatocyte-like cells (DHHs) display hepatic function, 
express hepatic markers and are permissive to HCVcc (Wu, Robotham et al. 
2012, Roelandt, Vanhove et al. 2013). Moreover, the complete life cycle of 
HCV infection starting with viral entry and ending with the virion formation 
and secretion in culture medium has been observed in these cells. Both wild 
type and adaptive mutants were able to replicate in these cells indicating that 
the ability to support HCV infection does not depend upon particular 
mutations or isoforms (reviewed in Wu, Robotham et al. 2012).  
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In a nutshell, we have developed a novel fusion assay which permits 
replication of patient-derived HCV belonging to diverse range of genotypes in 
vitro. Furthermore, it could facilitate testing of patient sensitivities to antiviral 
drugs and genotype-specific response to novel antiviral drug telaprevir has 
been demonstrated. It can be used to predict the development of resistance 
in a chronic HCV patient and could be employed to distinguish poorly 
responsive viral subsets from responsive strains. The capture-fusion assay 
represents a promising new technique which may help identify the most 
appropriate treatment strategy for individual patients with chronic HCV 
infection. Further development is needed to convert this into a clinically 
beneficial assay for drug screening and determining resistance. It can be 
enhanced further to evaluate sensitivity of different patient isolates to 
telaprevir and to compare sensitivity in this model with deep sequencing and 
modified replicon. Moreover this technique could be used further in 
determining whether the transfer of other RNA or DNA viruses was possible 
by this approach or whether we could transfect monocytes with viral RNA or 
DNA and generate infection.  
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Appendix 1 
       Knodell Histology activity index (HAI) 
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Appendix 2 
           The Ishak Modification of the Knodell HAI:  
Architectural Changes, Fibrosis and Cirrhosis 
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Appendix 3  
The Ishak Modification of the Knodell HAI: Grading 
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Abstract 
There is provided a method for replicating HCV virus in vitro which comprises the 
following steps: (i) fusing an HCV-infected white blood cell with a hepatocyte cell to 
produce a fused cell; and (ii) culturing the fused cell so that HCV replication may 
occur. There is also provided a fused cell capable of replicating HCV virus in vitro 
which is made by fusing an HCV-infected white blood cell with a hepatocyte cell, 
and uses of such a fused cell to screen for anti-HCV drugs and assessing patient 
responsiveness to therapy before treatment. 
Claims (OCR text may contain errors) 
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1. A method for replicating HCV virus in vitro which comprises the following steps:  
(i) Fusing an HCV-infected white blood cell with a hepatocyte cell to produce a fused 
cell; and  
(ii) Culturing the fused cell so that HCV replication may occur.  
2. A method according to claim 1, wherein the HCV-infected white blood cell is 
isolated from an HCV patient.  
3. A method according to claim 2, wherein the HCV-infected white blood cell is 
made by infecting a white blood cell with HCV virus in vitro.  
4. A method according to claim 3, wherein the white blood cell is derivable from a 
white blood cell line.  
5. A method according to claim 3 or 4, wherein the white blood cell has been pre-
treated with at least one pro-inflammatory reagent. 6. A method according to any 
preceding claim, wherein the white blood cell is a monocyte.  
7. A method according to any preceding claim, in which white blood cell is infected 
with HCV virus having HCV genotype 2, 3, 4, 5 or 6.  
8. A fused cell capable of replicating HCV virus in vitro which is made by fusing an 
HCV-infected white blood cell with a hepatocyte cell.  
9. A method for making a fused cell according to claim 8, which comprises the step 
of fusing an HCV-infected white blood cell with a hepatocyte cell in vitro.  
10. A method according to claim 9, wherein the HCV-infected white blood cell is 
derived from a HCV patient. 1. A method according to claim 9, wherein the HCV-
infected white blood cell is made by infecting a white blood cell with HCV virus in 
vitro.  
12. A method according to claim 1, which comprises the following steps:  
(i) Culturing a white blood cell in vitro with serum from an HCV patient, so that the 
white blood cell is infected with HCV in the serum; and  
(ii) Fusing the HCV-infected white blood cell with a hepatocyte.  
13. The use of a fused cell according to claim 8 to assess the capacity of a test HCV 
treatment to reduce HCV replication.  
14. A method for screening a test treatment which comprises the step of analysing 
the capacity of the test treatment to reduce HCV replication in a fused cell according 
to claim 7.  
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15. A method according to claim 14, wherein the test treatment is a test compound 
or composition. 16. A method according to claim 15, wherein the test compound or 
composition comprises IFN and/or ribavirin  
17. A method according to claim 14, wherein the capacity of the test treatment is 
tested in a plurality of fused cells according to claim 8, each replicating a different 
strain of HCV virus, in order to analyse whether the effectiveness of the test 
compound or composition is HCV strain-specific.  
18. A method for assessing the likelihood that a HCV patient will respond to a test 
HCV treatment, which comprises the step of analysing the capacity of the treatment 
to reduce HCV replication in vitro in a fused cell according to claim 8, wherein the 
fused cell is made by fusing a hepatocyte cell with a white blood cell which is either:  
(i) Isolated from the HCV patient; or  
(ii) A white blood cell which has been infected with HCV virus from the subject in 
vitro.  
19. A method for selecting a treatment which comprises the step of assessing the 
responsiveness of an HCV patient to a test HCV treatment by a method according to 
claim 18 and selecting a treatment which reduces HCV replication in the fused cell 
in vitro.  
20. A method for assessing the likelihood that a subject will relapse following 
treatment, which comprises the following steps: (i) fusing a white blood cell from the 
subject with a hepatocyte cell to produce a fused cell; and  
(ii) Investigating whether HCV can be detected in the fused cell, wherein a subject is 
determined to be likely to relapse if HCV is detectable in the fused cell.  
21. A method according to claim 20, wherein the presence of HCV is investigated by 
detecting the presence or absence of HCV RNA.  
22. A method for investigating the progression of an HCV treatment which 
comprises the following steps:  
(i) Periodically isolating a white blood cell from the subject;  
(ii) Fusing the white blood cell with a hepatocyte cell to produce a fused cell; and 
(iii) Investigating whether HCV can be detected in the fused cell.  
23. A method for investigating the progression of an HCV treatment which 
comprises the following steps:  
(i) Periodically isolating a serum from the subject;  
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(ii) Culturing a white blood cell in vitro with the serum, so that the white blood cell is 
infected with HCV in the serum; and  
(iii) Fusing the HCV-infected white blood cell with a hepatocyte; and  
(iv) Quantifying HCV RNA in the fused cell.  
24. A method for determining when an HCV treatment may be stopped by 
investigating the progression of the treatment by a method according to claim 22 or 
23 and determining that the treatment may be stopped when a white blood cell or a 
serum sample is isolated which produces a fused cell in which HCV is undetectable.  
     Detailed description of the patent is available at:
http://www.google.com/patents/WO2013064833A1?cl=en&utm_cource=gb-gplus-
sharePatent WO2013064833A1 -  Method for replicating hcv in vitro 
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Development and Validation of a “Capture-Fusion”
Model to Study Drug Sensitivity of Patient-Derived
Hepatitis C
Morven E. Cunningham, Alia Javaid, Jenny Waters, Joseph Davidson-Wright, Joshua L.C. Wong,
Meleri Jones, and Graham R. Foster
Emerging therapies for chronic hepatitis C viral (HCV) infection involve inhibition of viral
enzymes with drug combinations. Natural, or treatment-induced, enzyme polymorphisms
reduce efficacy. We developed a phenotyping assay to aid drug selection based on viral
transfer from monocytes to hepatocytes. We studied HCV in monocytes from infected
patients and developed a model in which patient-derived HCV is “captured” by the cell
line THP-1 and replication assessed after fusion to hepatoma cells. We found that mono-
cytes from HCV-infected patients harbor virus that replicates when cells are fused to hepa-
tocytes. THP-1 cells incubated with infected sera capture HCV, which replicates when
fused to hepatocytes. Inhibitable replication of all HCV genotypes was achieved (42 of 52
isolates). We measured sensitivity of telaprevir (TVR) and alisporivir (AVR) in different
genotypes, and showed differences in 50% inhibitory concentration (IC50) correlating with
clinical response (TVR IC50 for genotype (G)1 was 0.042 6 0.003 vs. 0.117 6 0.015 lM
for G3, whereas AVR IC50 for G1 was 0.139 6 0.013 vs. 0.044 6 0.007 lM for G3). We
tested TVR-resistant viral isolates and identified changes in IC50. One patient with a poor
clinical response to TVR and wild-type viral sequence showed reduced TVR sensitivity in
our assay. We studied samples from a 2-week TVR monotherapy study in which 5 of 8
patients with G3 HCV did not respond whereas 3 of 8 patients did. The “capture-fusion”
assay correctly identified responders. Conclusion: The capture-fusion model represents a
promising new technique that may help identify appropriate treatment strategies for
patients with chronic HCV infection. (HEPATOLOGY 2015;61:1192-1204)
See Editorial on Page 1112
T
herapy for patients infected with hepatitis C
virus (HCV) is rapidly evolving, and inter-
feron (IFN) and ribavirin (RBV) are being
replaced by direct-acting antiviral (DAA) agents.1
Drugs against the viral nonstructural protein 3 of
HCV (NS3) protease (telaprevir [TVR] simeprevir,
and boceprevir) and nonstructural protein 5B of HCV
(NS5B) polymerase (sofosbuvir; SOF) have been
licensed, and new protease, nonstructural protein 5A
of HCV (NS5A), and polymerase inhibitors are in
clinical trials. In combination with IFN, most drugs
increase the proportion of patients who respond. This
has led to attempts to avoid IFN-related side effects by
combining drugs of different classes in IFN-free regi-
mens. Distinct viral strains respond differently, for
Abbreviations: Abs, antibodies; AVR, alisporivir; DAA, direct acting antiviral; DMEM, Dulbecco’s modified Eagle medium; DMSO, dimethyl sulfoxide; FCS,
fetal calf serum; G, genotype; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; JFH-1, Japanese fulminant hepatitis type 1; HCV, hepatitis C virus; IC50, 50%
inhibitory concentration; IF, immunofluorescence; IFN, interferon; IL, interleukin; mRNA, messenger RNA; NS3, nonstructural protein 3 of the hepatitis C virus;
NS5A, nonstructural protein 5A of the hepatitis C virus; NS5B, nonstructural protein 5B of the hepatitis C virus; PBMCs, peripheral blood mononuclear cells;
PEG, polyethylene glycol; Peg-IFN, pegylated IFN; PI3K/Pi4K, phosphatidylinositol 3- and 4-kinase; PMA, phorbol 12-myristate 13-acetate; PS, penicillin/strepto-
mycin; RBV, ribavirin; RT-qPCR, reverse-transcription quantitative polymerase chain reaction; SOF, sofosbuvir; SR-B1, scavenger receptor class B type 1; SVR, sus-
tained virological response; TVR, telaprevir; WT, wild type.
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example, genotype (G)1b strains respond well to prote-
ase inhibitors combined with non-nucleotide polymer-
ase inhibitors or NS5A inhibitors,2,3 but G1a strains
require additional drugs.4 Some G1a strains do
respond to protease plus non-nucleoside drugs,5 but
their characteristics are undefined. IFN-free SOF is
effective for G2 HCV and has some efficacy in G1,
but less so in G3.6
Development of DAAs was facilitated by in vitro
HCV replication systems (the G1 replicon and
replication-permissive G2 strain, Japanese fulminant
hepatitis type 1 [JFH-1])7,8 that allowed high-
throughput screening. Subgenomic replicons based
around G3a and G4a have extended the range of geno-
types that can be studied,9,10 and chimeric variants have
been used to analyze resistance-associated variants.
These systems are of limited value in analysis of a
patient’s viral sensitivity—defining drug sensitivity of a
viral isolate requires subcloning each DAA target gene
and insertion into a replicon. Difficulty in generating
replicons with more than one modified locus precludes
studies of multidrug combinations. In human immuno-
deficiency virus infection, viral phenotyping assays
enabled selection of optimal regimens, although pro-
gress in genotypic resistance testing has reduced their
value. For G1 HCV, some viral motifs associated with
protease inhibitor treatment failure have been identi-
fied,11 but for other genotypes there is no association
between sequence and response,12 indicating that, in the
short term, viral phenotyping assays may be useful in
identifying optimal regimens for less-responsive viral
strains. Although recently presented data indicate that
emerging drug regimens cure over 90% of patients with
G1 HCV,13,14 the proportion of patients who fail may
be higher in practice. To avoid development of
“multidrug-resistant” HCV strains, careful selection of
“second-line” regimens will be required. Identification
of the most effective treatment regimens in this scenario
would be facilitated by phenotyping assays.
Association of HCV with extrahepatic sites, such as
peripheral blood mononuclear cells (PBMCs), is estab-
lished, although extrahepatic viral replication remains
controversial.15-20 Here, we describe a “capture-fusion”
technique in which patient-derived HCV is “captured”
by monocytes and transferred to hepatocytes using cell
fusion. This allows analysis of patient-derived virus
from all genotypes and drug sensitivity and treatment
response can be predicted. This new assay may be
helpful in determining optimal drug combinations and
be of particular value in patients who have failed
“first-line” regimens.
Materials and Methods
Cells, Reagents, and Clinical Material. Huh7.5
cells (kindly provided by C.M. Rice, Rockefeller Insti-
tute, New York, NY) were maintained in Dulbecco’s
modified Eagle medium (DMEM) with glutamine, 10%
fetal calf serum (FCS), and 1% penicillin/streptomycin
(DMEM/10% FCS/PS). THP-1 cells21 were maintained
in RPMI with glutamine, 10% FCS, and 1% PS.
PBMCs and sera were obtained from consenting
patients with chronic HCV infection.
Stimulants/inhibitors used were phorbol 12-
myristate 13-acetate (PMA; Sigma-Aldrich, Dorset,
UK), IFN-c (Invitrogen, Paisley, UK), and wortman-
nin (Sigma-Aldrich).
TVR and alisporivir (AVR) were kindly supplied by
Janssen Virology (Baar, Switzerland) and Novartis
Pharma AG (Basel, Switzerland), respectively. IFN-a-
2a was from Cambridge Bioscience (Cambridge, UK)
and RBV from Sigma-Aldrich. Ethical approval for the
study was given by London-City Research Ethics
Committee, and informed consent obtained from all
patients. The study was conducted in accord with the
Declaration of Helsinki.
Fusion of Patient Monocytes. PBMCs were sepa-
rated from whole blood by centrifugation on Ficoll-
Paque (GE Healthcare, Buckinghamshire, UK). The
PBMC layer was washed twice before positive selection
of CD141 cells by magnetic separation (Milteyi Bio-
tec, Surrey, UK), according to manufacturer’s instruc-
tions. For fusion optimization experiments, CD141
cells were incubated with DiI and Huh7.5 cells with
DiO (Life Technologies, Paisley, UK) before incuba-
tion with polyethylene glycol (PEG) 1500 (Roche
Diagnostics, Burgess Hill, UK). Cells were fixed with
4% paraformaldehyde (PFA) and enumerated by flow
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cytometry (FACSCanto II; BD Biosciences, Oxford,
UK).
For all subsequent fusion experiments, Huh7.5 cells
and CD141 cells (1:1) were incubated with PEG at
37C for 2 minutes, then prewarmed medium
(DMEM) added dropwise and the cells washed by
centrifugation. Fused cells were seeded into six-well
plates (5 3 105 cells/mL) and maintained at 37C.
Stimulation and Infection of THP-1 Cells.
THP-1 cells were seeded into six-well plates (106 cells/
mL) and maintained for 18 hours, with or without
IFN-c (10 ng/mL) and PMA (200 ng/mL). Cells were
washed thrice and medium replaced with RPMI/2%
FCS and patient serum (1 HCV IU/cell). After incu-
bation (37C for 18-24 hours), supernatant was
removed and cells washed. Adherent cells were
removed by scraping and combined with Huh7.5 cells
(1:1). Cell fusion was performed as described above.
Fused cells were seeded into six-well plates (105 cells/
mL) and maintained at 37C with or without drugs
for up to 7 days. In selected experiments, supernatants
were pooled from non-drug-treated wells and concen-
trated by filtration through a 0.45-lm filter, then 10
mL was layered on 4 mL of 20% sucrose. Supernatants
were centrifuged (24,000g) for 2 hours and the pellet
resuspended in 1 mL of RPMI. For capture-fusion
experiments using concentrated supernatant, 1 3 106
prestimulated THP-1 cells were incubated with 1 mL
of concentrated supernatant for 24 hours before
fusion.
Drug Inhibition Assays. Fused cells were rested
overnight before the addition of drugs. TVR and AVR
were diluted from 20-mM stock solutions in dimethyl
sulfoxide (DMSO). Each drug concentration was
tested in quadruplicate. Drug dilution mix alone
(RPMI/2% FCS/0.5% DMSO) was added to control
wells. Media and drug were refreshed at day 3. Viral
RNA was calculated as a percentage of that in
untreated wells. Dose-response curves were constructed
and used to estimate the 50% inhibitory concentration
(IC50) of drug using Prism 4.0 software (GraphPad
Software, Inc., La Jolla, CA).
Cell Viability Assays. Cell viability was measured
using the Cell Titer-Glo assay (Promega, Southamp-
ton, UK) and a FLUOstar Optima plate reader (BMG
Labtech, Aylesbury, UK), according to the manufac-
turer’s instructions.
Quantification of HCV RNA and Gene Expres-
sion. Total RNA was extracted with TRIzol (Invitro-
gen) and quantified using RiboGreen (Invitrogen),
according to the manufacturer’s instructions. Comple-
mentary DNA was synthesised using Moloney murine
leukemia virus reverse transcriptase (Promega) and
diluted (1:10) for amplification by quantitative poly-
merase chain reaction (qPCR; QuantiTect SYBR Green
PCR kit; Qiagen, Hilden, Germany). For primers and
cycling conditions, see the Supporting Information.
Target messenger RNA (mRNA) was normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
or b-actin expression, which were confirmed to be sta-
bly expressed in these experiments (GeNorm; Primer-
Design, Southampton, UK).
For HCV copy number quantification, one-step
reverse-transcription PCR (RT-qPCR) using the Quan-
tiTect Virus Kit (Qiagen) and TaqMan Gene Expres-
sion Assay HCV primer and probe (Applied
Biosystems, Paisley, UK) was performed. Serial dilu-
tions of an RNA standard were included in each PCR
run and results expressed relative to total sample RNA.
Fluorescence-Activated Cell-Sorting Analysis.
Cells were incubated with primary antibody (Ab) or
appropriate isotype control in 1% bovine serum albu-
min/10% FCS for 30 minutes. Alexa Fluor 488 sec-
ondary Abs were used to detect bound primary Ab
and quantified on a FACSCanto II flow cytometer
(BD Biosciences). Data were analyzed using FlowJo
software (TreesStar, Ashland, OR).
Statistical Analysis. Data were tested for normal-
ity using the D’Agostino’s and Pearson’s test. Statistical
analyses used the Student t test for parametric data or
Mann-Whitney’s U test for nonparametric data, with
P < 0.05 considered significant.
Results
Identification of Replication-Competent HCV in
Patient-Derived Monocytes by Fusion With Huh7.5
Cells. We examined CD14(1) monocytes from
patients with chronic HCV infection (N 5 4) and
found low levels of HCV that did not increase during
cell culture (7 days), implying a lack of viral replica-
tion (data not shown). We then fused patient-derived
monocytes with Huh7.5 cells using PEG. Dye-labeled
cells were used to determine optimal fusion conditions.
Fusion of 40% of CD14(1) monocytes with Huh7.5
cells was achieved using optimized conditions (see
Materials and Methods; Fig. 1A). Monocytes from
patients infected with diverse viral genotypes were
fused to Huh7.5 cells and maintained in culture for
up to 21 days. HCV RNA increased progressively up
to 7 days after fusion, but declined thereafter (Fig.
1B). In these preliminary experiments, HCV RNA was
quantified relative to beta-actin expression. To confirm
reliable detection of low-level HCV RNA and quantify
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Fig. 1. Detectable HCV RNA increases after fusion of patient-derived monocytes with Huh7.5 cells, and this can be inhibited with antiviral
drugs. (A) Fluorescence-activated cell-sorting plot showing PEG-mediated fusion of patient monocytes and Huh7.5 cells. Huh7.5 cells were
stained with DiO and CD14(1) monocytes with DiI. After PEG fusion, the percentage of cells expressing both dyes was enumerated by flow
cytometry. Figures refer to percentage of total cells. (B) monocytes from 7 patients with chronic HCV were fused with Huh7.5 and HCV RNA quan-
tified at various times up to 21 days after fusion. Not all time points are available for all samples as a result of limited cell numbers. Results
are expressed as fold change from unfused monocytes and normalized to beta-actin expression. (C) Mean 6 standard error of the mean (SEM)
of five further experiments where monocytes from HCV patients were either fused or cocultured with Huh7.5 cells and HCV RNA quantified up to
7 days after fusion. P 5 0.038 at 3 days and P 5 0.015 at 5 days postfusion for the comparison between fused and unfused cells. (D) Mean
6 SEM of two further experiments where fused patient monocytes were cultured with or without 100 IU/mL of IFN-a-2a. P 5 0.031 for the com-
parison between treated and untreated cells at day 7 postfusion. (E) Mean 6 SEM of three further experiments where fused G1 patient mono-
cytes were cultured with or without TVR 0.5 lM. P 5 0.0001 at 5 days and P 5 0.0002 at 7 days postfusion for the comparison between
treated and untreated cells. (F) Mean 6 SEM of two further experiments where fused patient monocytes were cultured with or without the PI3K/
PI4K inhibitor, wortmannin, 0.5 lM for 5 days after fusion. P 5 0.014 for the comparison between treated and untreated cells. (C-E) HCV cop-
ies/lg total RNA as a percentage of day 0 postfusion to normalize for differences in HCV-RNA yield between individual patient samples. (F) HCV
copies/lg total RNA as a percentage of untreated cells at day 5 postfusion.
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HCV-RNA copy number, a one-step RT-qPCR assay
was employed (see Materials and Methods) with a
quantification range of 10-108 HCV copies per reac-
tion (Supporting Fig. 1). Rather than logarithmic
increases in HCV RNA observed in propagation of
cell-culture HCV strains, we typically observed a 2- to
10-fold increase in viral RNA over 7 days after fusion,
suggesting low-level replication (Fig. 1C). Treatment
of fused cells with antiviral drugs abolished this
increase (Fig. 1D,E). Treatment of fused cells with
wortmannin, a phosphatidylinositol 3- and 4-kinase
(PI3K/PI4K) inhibitor, also reduced replication after
fusion (Fig. 1F). Contamination by laboratory HCV
strains was excluded by viral sequencing (data not
shown). Attempts to demonstrate HCV replication
using less-sensitive techniques (western blotting and
indirect immunofluorescence [IF]) were unsuccessful,
most likely because of the low level of viral replication
(data not shown). Together, these results indicate that
viable HCV is associated with monocytes of patients
with chronic HCV infection. Fusion of infected
monocytes with Huh7.5 cells permits sufficient viral
replication to be detected by a sensitive PCR assay.
Association of Patient-Derived HCV With THP-1
Cells Is Enhanced by PMA and IFN-c, but Is Inde-
pendent of CD81. Patient-derived HCV in fused
cells can be inhibited with antiviral drugs, allowing
identification of patient-specific responses to antiviral
therapies. Given the limitations of working with
patient monocytes, we examined whether cultured
monocytes could be used to capture HCV from
patient serum. After incubation of the monocytic cell
line, THP-1, with patient serum, we found little asso-
ciation of HCV with THP-1 cells. Others report that
PMA and IFN-c pretreatment enhances HCV uptake
into monocytic cell lines.22 Stimulation of THP-1
with PMA/IFN-c enhanced the association of patient-
derived HCV (Fig. 2A), and trypsin treatment of
virus-loaded THP-1 cells after 4 hours reduced viral
levels, indicating that virus was internalized between 1
and 4 hours after infection (Fig. 2B).
HCV entry into hepatocytes is dependent upon
CD81, scavenger receptor class B type 1 (SR-B1),
claudin, and occludin.23 Neither mRNA nor cell-
surface expression of CD81 or SR-B1 was enhanced
by PMA/IFN-c treatment of THP-1 (Supporting Fig.
Fig. 2. Association of patient-derived HCV with THP-1 is enhanced by PMA/IFN-c, but is independent of CD81. (A) THP-1 cells were cultured
for 24 hours with PMA 200 ng/mL, IFN-c 10 ng/mL, PMA 200 ng/mL and IFN-c 10 ng/mL or no stimulants before incubation with patient
serum. HCV RNA was measured 24 hours after infection. P 5 0.026 for the comparison between unstimulated and PMA/IFN-c-stimulated cells.
(B) THP-1 cells prestimulated with PMA/IFN-c were treated with trypsin at various times after incubation with patient sera. P 5 0.029 for the
comparison between trypsin treatment 0 and 24 hours postinfection. (C) PMA/IFNc-stimulated THP-1 cells were incubated in the presence or
absence of anti-CD81 blocking Ab (5 lg/mL) for 1 hour before infection with patient-derived HCV. HCV RNA was quantified after 24 hours.
Graph shows mean 6 standard error of the mean of two independent experiments. P 5 0.09 for the comparison between antibody treated and
untreated cells.
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2). Claudin-1 and occludin were not expressed by
these cells. Blocking Abs to CD81 did not reduce
HCV association with stimulated THP-1 (Fig. 2C),
although JFH-1 entry into Huh7.5 cells was inhibited
(Supporting Fig. 3). These data suggest that HCV
association with THP-1 is independent of CD81 and
other receptors are associated with HCV entry into
hepatocytes.
Accumulation of Patient-Derived HCV Occurs
After Capture Fusion. Accumulation of HCV RNA
was observed after Huh7.5 fusion to PMA/IFN-c-
stimulated, HCV-exposed THP-1 cells, compared to
HCV-exposed, PEG-treated Huh7.5, THP-1, or
Huh7.5 alone (Fig. 3A). HCV-RNA accumulation
after fusion was significantly greater when THP-1 were
prestimulated, particularly when IFN-c was added to
PMA stimulation (Fig. 3B). To examine the potential
antiviral effects of IFN-c, we studied expression of the
IFN-inducible gene MxA. MxA expression was not
induced by cell fusion and was low in fusions with
HCV-infected monocytes, even when the monocytes
had been pretreated with PMA/IFN-c, but could be
up-regulated by subsequent treatment with IFN-a
(Fig. 3C). Priming of Huh7.5 cells with IFN-a signifi-
cantly reduced HCV replication after fusion (Fig. 3D).
Thus, addition of IFN-c increases uptake of virus by
monocytes, but fusing IFN-c-exposed cells does not
lead to induction of antiviral genes in fused cells.
However, direct stimulation of Huh7.5 cells with the
more potent antiviral IFN, IFN-a, does reduce HCV
replication. These data suggest PMA/IFN-c treatment
of THP-1 is important for HCV capture, but does
not trigger induction of innate antiviral responses,
although the cells are still able to induce antiviral
genes.
To establish whether full replication cycles occurred
in the fused cells with release of infectious virus, super-
natants from capture-fusion experiments were col-
lected, concentrated, and applied to Huh7.5 cells or to
stimulated THP-1 cells in a fresh capture-fusion cycle.
HCV RNA accumulated over time in fused cells and
to a much lesser extent in Huh7.5 cells (Fig. 3E).
These data suggest that HCV undergoes replicative
cycles with release of infectious virions in the capture-
fusion model.
HCV RNA Accumulation Occurs After Fusion in
Isolates From All Viral Genotypes and Can Be
Inhibited by Antiviral Drugs. Fifty-two viral isolates
of genotypes 1-6 were tested in this capture-fusion
assay and HCV RNA could be quantified (>10 copies
per reaction) after fusion in 42 (81%). Median viral
yield was 63 copies/lg total RNA (range, 14-354)
equivalent to median 19 HCV copies per fused cell
(range, 4-106). Of the remaining 10 samples, seven
were archival (3-7 years old) and may have degraded
during storage. Three samples produced detectable
HCV RNA below the quantification limit in repeated
experiments. HCV-RNA yield varied between samples,
but did not relate to viral load or disease activity (Sup-
porting Fig. 4), and was consistent in repeated experi-
ments for a given sample (Supporting Fig. 5),
suggesting that replicative fitness in this model is influ-
enced by intrinsic viral characteristics. TVR exposure
after fusion caused a dose-dependent reduction in
HCV RNA in isolates from all genotypes except G3,
known to be poorly TVR sensitive (Fig. 3F). Experi-
ments with alternative inhibitors confirmed that sensi-
tivity of G3 HCV could also be studied (see below).
Drug Sensitivity of Patient-Derived HCV in the
Capture-Fusion Model Reflects Genotypic Patterns of
Response to Antiviral Drugs. We observed that G3
HCV was poorly inhibited by TVR in the capture-
fusion assay (Fig. 3F). TVR inhibits G1, but has little
effect against G3 HCV.24-26 Conversely, the cyclophil-
lin inhibitor, AVR, is more efficacious against G2 and
G3 than G1 and G4.27 THP-1 cells exposed to sera
from G1- and G3-infected donors were fused with
Huh7.5, then treated with TVR or AVR for 5 days
before quantification of HCV RNA. Dose-response
curves were constructed and used to calculate an IC50.
Figure 4 shows pooled results from 14 donors,
normalized to untreated cells. Dose-response curves
were constructed for all isolates which reached quanti-
fiable levels (Supporting Fig. 6 shows absolute values
for representative patients). Drug-induced cytotoxicity
was excluded by measuring cell viability after drug
exposure. TVR had no effect on cell survival. The
minor effects of doses of AVR >0.1 lM were insuffi-
cient to account for the reduction in HCV RNA (Sup-
porting Fig. 7). G1 samples were significantly more
sensitive to TVR and less sensitive to AVR than G3
(Fig. 4A-D). Individual TVR and AVR IC50s for each
sample are shown in Fig. 4E,F. G2 isolates were sensi-
tive to TVR and AVR, whereas G4 strains showed a
similar AVR response to G1 (in keeping with clinical
trial data). Some G4 isolates were poorly sensitive to
TVR, consistent with clinical trial findings.28 However,
other G4 isolates were inhibited by TVR in the assay,
suggesting differing TVR susceptibility amongst G4
strains (Supporting Fig. 8).
Drug Sensitivity in the Capture-Fusion Assay
Reflects Phenotypic Treatment Response. To explore
whether clinical TVR resistance could be detected in
the capture-fusion assay, pretreatment and post-
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Fig. 3. Replication of patient-derived HCV occurs after capture by prestimulated THP-1 and fusion with Huh7.5 cells and can be inhibited by
telaprevir. A. Mean 6 standard error of the mean (SEM) of two independent experiments where HCV RNA was quantified from PMA/IFN-c-stimu-
lated, HCV-exposed THP-1 fused with Huh7.5 cells, from HCV-exposed THP-1 and Huh7.5 cells without fusion, and from HCV-exposed Huh7.5
cells treated with PEG (fusion protocol). P 5 0.019 for the comparison between HCV RNA in fused THP-1/Huh7.5 at days and 5 postfusion.
Results are shown as percentage of HCV RNA in cells at day 0. (B) Representative of two independent experiments where THP-1 cells were cul-
tured with PMA 200 ng/mL, PMA 200 ng/mL and IFN-c 10ng/mL or no stimulants for 24 hours before infection with patient-derived HCV and
fusion with Huh7.5 cells. HCV RNA was quantified up to 5 days after fusion. P 5 0.005 and P 5 0.015 for the comparison between unstimu-
lated and PMA/IFN-c-stimulated THP-1 at days 3 and 5 postfusion, respectively. (C) PMA/IFNc-treated THP-1 fused with Huh7.5 (labeled fused
THP-1/Huh7.5), PMA/IFN-c-treated, HCV-exposed THP-1 fused with Huh7.5 (labeled fused THP-1/Huh7.5 1 HCV), or unfused Huh7.5 (labeled
Huh7.5) were cultured for 5 days in the presence or absence of IFN-a-2a (100 IU/mL). MxA mRNA was quantified by PCR and expressed rela-
tive to GAPDH expression and uninfected, unfused, untreated Huh7.5. Results are shown on a logarithmic scale. (D) Huh7.5 cells were pre-
treated with IFN-a-2a (100 IU/mL) before fusion with prestimulated, HCV-infected THP-1. HCV RNA was quantified up to 5 days after fusion. (E)
Mean 6 SEM of two independent experiments in which supernatant from capture-fusion experiments was applied to PMA/IFN-c-stimulated THP-
1, which were then fused with Huh7.5 in a further round of capture-fusion, or na€ıve Huh7.5 cells. HCV RNA was quantified up to 5 days after
fusion. (F) HCV RNA 5 days after fusion in capture-fusion experiments, with or without TVR 1.0 lM using sera from donors infected with diverse
HCV genotypes. Each point represents mean HCV RNA 6 SEM from at least four biological replicates from a representative patient sample.
Fig. 4. Sensitivity of patient-derived HCV to antiviral drugs can be assayed in the capture-fusion model. HCV derived from serum from 9 G1
and 5 G3 donors was treated with varying concentrations of TVR or AVR in capture-fusion assays and HCV RNA measured after 5 days. G1
patient-derived HCV was more sensitive to TVR than G3 (A and B), but less sensitive to AVR (C and D). Comparison of individual IC50 values
showed TVR IC50 was 0.042 6 0.003 for G1 samples versus 0.117 6 0.015 lM for G3; P 5 0.001 (E). Conversely, AVR IC50 was 0.139 6
0.013 for G1 samples versus 0.044 6 0.007 lM for G3; P 50 .004 (F). Graphs show mean 6 standard error of the mean.
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breakthrough sera were obtained from 2 patients with
G1 HCV who initially responded to TVR, pegylated
IFN (Peg-IFN) and RBV, but experienced virological
breakthrough by treatment week 12. Sequencing of the
first 200 amino acids of viral NS3 to 1% frequency
by pyrosequencing found wild-type (WT) virus at
baseline and TVR resistance-associated mutations
V36M/R155K at breakthrough in the majority of
sequences. TVR sensitivity pre- and postbreakthrough
assessed in the capture-fusion assay demonstrated a
loss of sensitivity in the resistant strains (Fig. 5A). Pre-
and post-treatment serum was obtained from 1 further
patient with G1 HCV with a poor clinical response to
TVR, Peg-IFN, and RBV (circa 1 log10 reduction in
viral load at week 4). No TVR resistance-associated
mutations were identified pretreatment (sequencing to
1% frequency), although V36M/R155K mutations
were present at treatment failure. This strain
demonstrated poor TVR sensitivity in the capture-
fusion assay both before and after exposure (Fig. 5B).
Pretreatment sera from 2 further patients with G1
HCV and a poor clinical response to TVR, Peg-IFN,
and RBV also demonstrated poor TVR sensitivity in
the capture-fusion assay (data not shown). This sug-
gests that phenotypic sensitivity to TVR may be more
predictive of response than genotypic sensitivity.
IFN sensitivity may be a determinant of acquisition
of resistance to direct-acting antiviral drugs. Whether
host or viral factors dominate IFN sensitivity is
unclear. Archived pretreatment sera from 4 patients
who responded to Peg-IFN and RBV (HCV RNA
undetectable at treatment week 4) and 4 patients with
a null response (<2 log10 drop in viral load at treat-
ment week 12) were used to examine IFN sensitivity
Fig. 5. Phenotypic and genotypic drug resistance correlates with drug sensitivity in the capture-fusion assay. Pretreatment and postbreak-
through sera from 2 patients who failed treatment with TVR, Peg-IFN, and RBV demonstrated loss of TVR sensitivity in the capture-fusion assay
after acquisition of genotypic and clinical TVR resistance (A). Pre- and post-treatment serum from a patient with little clinical response to TVR,
Peg-IFN, and RBV showed poor TVR sensitivity both pretreatment and after treatment failure (B). Using archived pretreatment sera from patients
who did or did not respond to Peg-IFN and RBV treatment, HCV strains from patients who responded to treatment (C) were more sensitive to IFN
in the capture-fusion assay than viral strains from patients who did not respond (D). Graphs show mean 6 standard error of the mean.
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in the capture-fusion assay. Pretreatment HCV from
patients who responded to IFN was more sensitive to
IFN in the capture-fusion assay than virus from patients
with a null response (Fig. 5C,D). Patient viral loads
and viral replication achieved in the assay did not differ
significantly between the groups (data not shown).
In contrast to G1, the predominant mode of treat-
ment failure in G3 HCV infection is relapse. Relapse
rates are higher in patients who receive suboptimal
RBV dosing.29,30 Archived pretreatment sera from 10
G3 patients with cirrhosis treated with Peg-IFN and
RBV, 4 with sustained virological response (SVR), and
6 who relapsed were used to study pretreatment IFN
and RBV sensitivity. No difference in IFN sensitivity
was observed, but pretreatment HCV from patients
with SVR was more sensitive to RBV in the assay than
virus from relapsers (Fig. 6).
Sensitivity to TVR in the Capture-Fusion Assay
Correlates With Clinical Response. Although TVR
was poorly effective in G3 HCV, a subgroup of
patients (30%) did respond.26 To establish whether
the capture-fusion assay could identify TVR-sensitive
G3 HCV, pretreatment, blinded sera were obtained
from 8 patients with G3 HCV who had received TVR
monotherapy in a clinical trial.26 TVR sensitivity of
each sample in the capture-fusion assay correlated with
clinical response, whereas a biochemical phenotyping
assay did not12 (Fig. 7). Three samples with the great-
est TVR sensitivity in the capture-fusion assay corre-
sponded to patients who responded clinically to TVR.
These results indicate that the assay may predict
patient responses to TVR.
Discussion
We have developed a capture-fusion technique that
allows drug sensitivity of over 80% of HCV viral
strains to be assessed. We found that resistance to
TVR can be reliably determined, clinical sensitivity to
cyclophilin and protease inhibitors can be identified,
and there is a strong correlation between TVR sensitiv-
ity in our assay and clinical response in patients with
G3 HCV, unlike conventional phenotyping assays.
Cell-fusion techniques have been employed to investi-
gate extrahepatic HCV replication,31 but this is the
first report using cell fusion to facilitate replication of
patient-derived HCV strains.
Emerging therapies for chronic HCV infection
involve combinations of DAAs. Different combina-
tions have differential effects on different viral strains,
for example, faldeprevir with a non-nucleoside NS5B
inhibitor cures most patients with G1b HCV, but only
43% of patients with G1a.2 Accurate phenotyping of
infecting virus before antiviral therapy may be valuable
in determining appropriate drug combinations in
future therapeutic regimens. Although the number of
drug combinations tested in our assay is relatively
small, we have no reason to expect that the assay will
not identify viral sensitivity to a wide range of differ-
ent therapies.
We investigated compounds with clinical trial data
that differ in different genotypes. We found a close
correlation between activity in patients and our assay,
suggesting that the capture-fusion model may be useful
in assessing sensitivity to DAAs. For the protease
inhibitor, TVR, our assay accurately identifies viruses
with known resistant variants, and, of interest, we
identified a single patient with WT protease sequence
and a poor therapeutic response to TVR whose virus
was phenotypically resistant to TVR. These data sug-
gest that novel resistant variants to TVR may exist and
lie outside the classical resistance-associated regions.
Further work will be required to delineate this region
and identify the frequency of these variants.
The clinical response to Peg-IFN and RBV therapy for
HCV is dominated by host (interleukin [IL]28B)32,33
and viral genotype. In an assessment of viral IFN sensi-
tivity in 8 patients with diverse responses, we noted
reduced sensitivity in patients who showed no clinical
response. The archival samples analyzed could not be
correlated with IL28B genotype, and insufficient samples
were available to assess RBV sensitivity. Further studies
will be needed to investigate the complex interactions
between host IL28B genotype, viral IFN sensitivity, and
clinical outcome. We noted a reduced response to RBV
in patients with G3 HCV who relapsed, when compared
to patients who achieved SVR, suggesting that RBV sen-
sitivity may be an important determinant of response in
this genotype. Further studies, including viral sequencing
and phenotyping in chimeric replicons, will be required
to confirm this observation and are underway.
It has long been recognized that monocytes from
patients with HCV contain viral fragments, but it is
unclear whether these cells contain replicating virus.
We find that fusing monocytes from patients with
HCV to replication-permissive hepatocytes allows viral
replication in chimeric cells, indicating that monocytes
contain viable HCV. The role of sequestered virus in
viral persistence and the emerging immune response
remains to be determined.
Interestingly, given the antiviral action of IFN-c, we
found that IFN-c prestimulation of THP-1 was
required, in addition to PMA, to achieve viral replica-
tion after fusion of HCV-exposed THP-1 with
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Huh7.5. Others have observed Fc receptor up-
regulation after PMA/IFN-c treatment of monocyte
cell lines, with enhanced uptake of HCV immune
complexes.22 Certainly, uptake of HCV into THP-1
cells appears independent of the classical HCV entry
receptors, CD81, SR-B1, claudin, and occludin.
Fig. 6. Pre-treatment RBV sensitivity in the capture-fusion assay correlates with treatment response in G3 patients with cirrhosis treated with
IFN/RBV. Using archived pretreatment sera from 10 G3 patients with cirrhosis who relapsed or achieved SVR after Peg-IFN and RBV treatment,
no difference in IFN sensitivity was observed according to treatment outcome (A, B, and E). HCV strains from patients who achieved SVR were
more sensitive to RBV in the capture-fusion assay than viral strains from patients who relapsed (C, D, and F). Graphs show mean 6 standard
error of the mean.
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Significant replication of HCV does not occur in
THP-1 cells, suggesting that fusion with Huh7.5 may
provide access to permissive factors absent in THP-1.
These may include the phosphoinositide kinases, PI3K
or PI4K, given that the PI3K/PI4K inhibitor, wort-
mannin, reduced replication after fusion. Delivery of
HCV to Huh7.5 cells by fusion bypassed MxA induc-
tion, despite retention of IFN-signaling pathways. This
suggests that one mechanism underlying the capture-
fusion process is delivery of virus to hepatocytes with-
out an intracellular innate immune response. However,
other factors are likely to play a role and elucidating
the mechanisms underlying HCV replication after
monocyte-hepatocyte fusion requires further work.
The assay described depends upon detection of low-
level HCV RNA by PCR. Alternate techniques to
detect HCV proteins directly (e.g., western blotting
and IF) were attempted, but the level of viral protein
was too low to allow detection (western blotting) or
was masked by high levels of nonspecific background
staining in fused cells (IF). PCR is a well-validated
technique to detect viral replication, and the robust
responses observed in the assay support the value of
this approach.
In summary, we have developed a capture-fusion
assay that permits replication of patient-derived HCV
of all viral genotypes in vitro and enables testing of
sensitivity to antiviral drugs. Genotype-specific
responses to novel antiviral drugs and detection of
resistant viral strains have been demonstrated. IFN-
responsive or poorly responsive viral strains can be dis-
tinguished, and the assay can identify the subgroup of
patients with G3 HCV who respond to TVR. The
capture-fusion assay represents a promising new tech-
nique that may help identify the most appropriate
treatment strategy for patients with chronic HCV.
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